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Abstract 
Germ cell tumours (GCTs) are clinically and pathologically heterogeneous neoplasms that arise 
at gonadal (testicular/ovarian) and extra-gonadal sites. The chemotherapy burden for patients 
with malignant germ cell tumours (mGCTs) that require treatment results in substantial long-
term side-effects, and, furthermore, poor-risk patients have <50% survival. Consequently, 
identifying common molecular changes and novel therapeutic targets in mGCTs is of major 
clinical importance.  
MicroRNAs are short, non-protein coding RNAs that regulate gene expression. We previously 
showed that miR-99a-5p/-100-5p and miR-125b-5p are among the most frequently under-
expressed microRNAs in mGCTs, regardless of anatomical site, histological type or patient 
age. The present study investigates the upstream causes and downstream consequences of such 
under-expression. 
The mature form of miR-125b-5p is the product of two genomic loci, which form a cluster with 
either miR-99a-5p (on chromosome 21q) or miR-100-5p (on chromosome 11q). MiR-99a-5p/-
100-5p share identical ‘seed’ regions (at nucleotide positions 2-7), which determine their 
mRNA targets. Cross-reactivity experiment revealed that both miR-99a-5p and miR-100-5p 
probes were highly cross-reactive to each other’s target (from 91% to 95%), indicating 
functional overlap. Linear regression analysis of qRT-PCR data reveals a strong positive 
correlation between miR-99a-5p/-100-5p and miR-125b-5p levels (R2=0.989) in mGCTs, 
strongly suggesting co-regulation. 
Primary microRNA transcripts (pri-miR-99a/-100 and pri-miR-125b), and other genes that co-
localise to these miRNA clusters (e.g. BLID on chromosome 11), were quantified by RT-qPCR 
in four representative cell lines - TCam2, 1411H, 2102Ep, and GCT44 - which were derived 
from a range of common histological types of mGCTs. A significant down-regulation 
(p<0.0001) of all primary transcripts was observed, suggesting transcriptional repression of the 
entire cluster regions. Treatment of the cell lines with 5’-azacytidine resulted in significant up-
regulation of all three miRNAs (p<0.002), as well as BLID (p<0.02). The methylation status of 
potential CpG islands at the region of interest on chromosome 11 and chromosome 21 was 
therefore investigated by Pyrosequencing. Significant hyper methylation was found in 2102Ep, 
1411H and GCT44 cell lines, suggesting that the miR-99a-5p/-100-5p and miR-125b-5p 
clusters are likely transcriptionally silenced by DNA methylation. 
To assess the functional relevance of these microRNAs in GCT progression, co-transfection of 
microRNA mimics (8.3 nM miR-99a-5p/-100-5p + 8.3 nM miR-125b-5p) was performed. A 
significant decrease in cell growth was seen in 1411H (p<0.01) and TCam2 (p<0.03) cells. To 
identify the mimics’ downstream mRNA targets, HumanHT-12 v4 Expression Bead Chip 
(Illumina) mRNA arrays were used and data analysed using Sylamer. This analysis showed 
that mimic-treated cells were enriched in downregulated genes involved in pro-proliferative 
mechanisms. 
Among those, further functional characterisation focussed in particular on TRIM71, FGFR3, 
E2F7 and LIN28A. Moreover, restoring miR-99a-5p/-100-5p and miR-125b-5p in TCam2 cells 
also resulted in G0-G1 accumulation, consistent with a cell cycle effect. 
These data support a functionally important role for miR99a-5p/-100-5p and miR-125b-5p in 
GCT progression. They also raise the possibility of a therapeutic replenishment approach for 
treating these, and potentially other, tumours. 
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Chapter 1   Introduction  
 
1.1   Preface 
The work presented in this thesis focuses on better understanding the function that microRNAs 
(miRNAs) have in the development and progression of malignant germ cell tumours (mGCTs). 
Despite their extensive clinical and pathological heterogeneity, all mGCTs are believed to 
originate from primordial germ cells (PGCs) (Teilum, 1965). To date, no one has identified a 
common event, or biological abnormalities, that combines all the different subtypes of mGCTs. 
In 2010, members of the Coleman lab undertook a global miRNA study of mGCTs. 
Interestingly, they observed a remarkable separation between mGCTs and non-malignant 
controls (comprising the benign subtype teratomas and normal gonadal controls) by global 
profiling, regardless of patient age or histological subtype (Palmer et al., 2010). These findings 
offered the potential to be harnessed for prospective future therapies as, for the first time, a 
common biological in malignant GCTs has been found (Palmer et al., 2010). 
GCTs can affect patients of all ages and the most common treatment options depend mainly on 
type and stage of tumour. Stage I GCT patients are treated with surgery, while for stage II-IV 
the only available treatment so far is chemotherapy. The usage of chemotherapy has improved 
cancer survival by almost 70% in the last 30 to 40 years (Einhorn and Williams, 1979). 
However, it has to be taken into consideration that the risks of having long-term and late side 
effects from chemotherapy treatment is almost 50% (Travis et al., 2005). One example of these 
effects comes from the usage of cisplatin as a chemotherapy agent. This chemical compound 
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impairs hearing abilities, especially in children, making the patient at risk of deafness. Other 
late effects due to chemotherapy agents include reproductive and sexual development 
problems, growth and hormone problems, lung and breathing problems. It has been reported 
from the National Health Interview Survey that approximately 1 in 4 cancer survivors reports 
a decrease in quality of life due to physical problems (Weaver et al., 2012). The need for more 
targeted and less toxic therapies is thus critical in maintaining a good quality of life to the 
patient, particularly given the young median age that GCTs affect patients (Murray MJ, Fern 
LA, Stark DP, Eden TO, 2009).  
The discovery of dysregulated miRNAs expression as a potential common biological 
abnormality among GCTs (Palmer et al., 2010; Murray et al., 2013), encouraged us to further 
study them in detail at a molecular level. Needless to say, understanding and extrapolating their 
mechanistic framework could help in utilising them as plausible therapeutics in cancer 
treatment. 
1.2   Overview of germ cell tumours (GCTs) 
Germ cell tumours (GCTs) are a heterogeneous group of benign and malignant tumours that 
vary by clinical presentation, clinical course and tumour histology (Penn, Jenney and 
Nicholson, 2014). GCTs are believed to arise from totipotent PGCs (Teilum, 1965). During 
normal development, PGCs formation is observed in the embryo after implantation and 
gastrulation, when the epiblast, endoderm, mesoderm and ectoderm are first established 
(Matsui and Okamura, 2005). At this point, following molecular signalling received from the 
yolk sac, a small population of pluripotent stem cells are physically set apart from the yolk sac 
of the embryo and germ line specification occurs (Ying et al., 2000). The exact events 
regulating germ line specification remain unclear in humans because of the very limited access 
to early embryonic samples. In normal development, during the first trimester of human 
gestation, germ cells start to migrate through the hindgut and dorsal mesentery to the lateral 
mesoderm where they form gonocytes, oogonia in females or spermatogonia in males, within 
1.2 Overview of germ cell tumours (GCTs) 3 
 
 
the futures ovaries and testes, respectively (Fujimoto, Miyayama and Fuyuta, 1977). During 
this journey, modification or aberrant migration (including migration to the brain, mediastinum 
or other location) of these cells may occur, resulting in the development of GCTs (Figure 1.1).  
 
Figure 1.1: Developmental cycle of mammalian germ cells. Fertilisation of oocytes by sperm, 
promotes the formation of a zygote, which undergoes several events to form a blastocyst. Primordial 
germ cells (PGCs) derive from embryonic stem cells which are contained in the inner cell mass. 
Following normal migrations, oogonia and spermatogonia will develop in ovaries and testis, 
respectively. During this event formation of GCTs can occur. Following abnormal migration, cells that 
will survive to the hostile environment will develop into GCTs. 
 
   Histological heterogeneity of GCTs 
Depending on the location and stage of PGCs differentiation, when the aforementioned 
modifications occur, different subtypes of tumour may arise (Figure 1.2). If a tumour develops 
during the somatic stages of differentiation, a teratoma is formed, which is considered a benign 
form of GCT, certainly in paediatric practice. If a tumour develops during embryonal-like 
differentiation, embryonal carcinoma (EC) arises, while extra-embryonic differentiation leads 
to yolk sac tumour (YST) or choriocarcinoma (CHC), respectively. The latter group of 
tumours, show embryonal differentiation, yolk sac differentiation and trophoblastic/placental-
like differentiation, respectively, and collectively are named non-seminomatous tumour 
(Murray, Nicholson and Coleman, 2015a). Lastly, if PGCs remain undifferentiated when a 
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tumour arises, a germinoma results. The exact terminology of these tumours depends on tumour 
site - seminoma in the testis, dysgerminoma in the ovary and germinoma at other extragonadal 
sites, including the brain (Murray and Nicholson, 2010), and collectively are named seminoma 
tumours (Murray, Nicholson and Coleman, 2015b). 
 
Figure 1.2: Derivation of the various sub-categories of germ cell tumours. Adapted from (Murray 
and Nicholson, 2010). 
 
1.3   Epidemiology of GCTs  
The heterogeneity of GCTs is also demonstrated in the age of onset in which the disease 
develops. GCTs are rare tumours that can present in all age groups - from newborns to late 
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adulthood. GCTs account for 4% of paediatric cancer (patients aged 0 to 14 years), 13.8% of 
early adulthood cancer (patients aged 15 to 24 years) (Murray and Nicholson, 2010; Arora et 
al., 2012; Kaatsch et al., 2015) and 95% of testicular cancer in adults and young adults males 
(M Dror Michaelson, MD, PhD William K Oh, 2018). Interestingly, around 95% of GCTs in 
adults are gonadal, whereas in children gonadal and extragonadal GCTs occur at similar 
frequencies (Murray and Nicholson, 2010).  
 
 
Figure 1.3: Incidence rates of germ cell tumour by anatomical site. Number of cases, per million-
person year, aged 0-79 years in England and Wales, 1995-2003. Taken from (Murray et al., 2009). 
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In children aged <15 years, gonadal GCTs are common in both female [with mGCTs 
developing in the ovaries (30%)] and male [with mGCTs developing in the testes (20%)] 
patients. Among the extragonadal GCTs, the most common location of tumour formation is the 
central nervous system (CNS), in both males and females (20% of extragonadal mGCTs), 
followed by mediastinum and thorax in males and abdomen and pelvis in females (Figure 1.4) 
(Murray and Nicholson, 2010). 
 
 
Figure 1.4: Site distribution and frequency of germ cell tumours in children. The graph shown the 
incidence rate of mGCTs in children depending on their origin, gonadal or extragonadal. Adapted from 
(Murray and Nicholson, 2010). 
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   Demographic differences in the anatomical site and age of formation 
of GCTs.  
The data presented in this section, is divided into two parts. The first one focuses on the 
demographic differences of mGCTs among paediatric patients, while the second part focuses 
on mGCTs patients in on all age groups.   
Data from the National Cancer Institute’s Surveillance, Epidemiology and End Results 
Program (SEER) evaluated trends for GCTs in boys and girls under 19 years old in the United 
States (Poynter, Amatruda and Ross, 2010). An incidence peak was observed before the age 1 
and from the age of 15-19 years among boys and girls. Before the age of 4, extragonadal tumour 
was the only GCT detected in girls, while in boys’ extragonadal and gonadal tumours were 
equally represented. After the age of 10, for both girls and boys, the majority of the tumours 
were localized in the ovaries and testes, respectively (Poynter, Amatruda and Ross, 2010). A 
similar study, conducted in Germany, analysed the incidence rates, time trends and survival for 
1366 GCTs in children aged 0 to 14 years old. An incidence peak was observed in children 
aged <1 year for both girls and boys, confirming the previous data analysis (Kaatsch et al., 
2015). Although, when the range group 10 to 14 years was considered, the data showed a 
dominance in the extragonadal mGCT in males mostly in the central nervous system, not 
previously observed (Kaatsch et al., 2015). 
The former study also looked at mGCTs incidence between Caucasian Americans and Black 
Americans. Among the first group, boys and girls aged <9 had no difference in the incidence 
of GCTs, while between 10 and 19 years, girls had lower incidence than boys. Among the 
second group, black girls had higher incidence of GCT malignancies in both age range when 
compared with black boys. This variance was probably due to the lower incidence of gonadal 
tumours in black boys in the 10-19 age group compared with white boys (Poynter, Amatruda 
and Ross, 2010).  
No differences were found in the overall GCTs incidence by tumour location or histology in 
non-Hispanic vs Hispanic boys’ and girls’ age 0-9. In the age group 10-19, higher incidence of 
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GCTs were noticed in the Hispanic population when compared with non-Hispanic population 
of the same sex. Hispanic girls resulted in higher gonadal incidence of GCTs, while Hispanic 
boys have higher overall GCTs incidence (Figure 1.5) (Poynter, Amatruda and Ross, 2010). 
Incidence rate is calculated as the number of new cases of disease divided by the time that each 
person was observed, totaled for all persons. 
 
Figure 1.5: Incidence of paediatric GCT by tumour location in boys and girls in the SEER registry. 
Taken from (Poynter, Amatruda and Ross, 2010). 
 
The most common GCTs malignancies in adults are gonadal GCTs (95%) -testicular cancer or 
ovarian cancer in males and females, respectively (Slap, Lehmann and Biro, 2008; Patricia M 
Baker, 2009). A recent study has analysed data collected from European population-based 
cancer registries (CRs) (Trama and Berrino, 2017).  mGCTs incidence rate in Europe, was 
found to be equal to 34 cases every 1.000.000 people between 2000 to 2007, with marked 
differences between males (64/1.000.000) and females (4/1.000.000). Similarly, in the USA, 
between 1973 and 2007, the incidence rate for white males was 56/1.000.000 while for females 
was 3.5/1.000.000 (Stang et al., 2012). This high discrepancy in female and male rate, is due 
to the fact that TGCTs are the most commonly occurring malignancy among white males 
between ages 15 and 44 years (McGlynn and Cook, 2009; Ghazarian et al., 2015a). The 
incidence of testicular GCT (TGCT) was monitored between 1992 and 2011 from the SEER 
and racial/ethnicity-based comparison was assessed. Interestingly, the incidence of TGCT was 
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highest among non-Hispanic white men, (69.7 per 1.000.000 man-years) followed by 
American Indian/Alaska Native (46 per 1.000.000 man-years), Hispanic white (41 per 
1.000.000 man-years), Asian/Pacific Islander (19 per 1.000.000 man-years), and black (12 per 
1.000.000 man-years) men (Ghazarian et al., 2015b). 
Understanding the differences observed among age, sex and ethnicity groups, needs further 
investigation. 
   Increasing trend of GCT incidence and possible explanations 
Overall incidence of malignant GCTs, in both children and adults ranged between 0 and 84 
years, underwent an increase from 1979 to 2003 (Arora et al., 2012). Across the patient aged 
0 to 84 years, the increase was detected for germinoma (mainly testicular and central nervous 
system mGCTs) and non-germinoma (mainly ovarian mGCTs) (Arora et al., 2012). No 
difference was detected overall for mGCTs of mediastinum, thorax, abdomen or pelvis with 
only an increase seen for non-germinomas of the abdomen and pelvis in the age group 0 to 9 
years (Arora et al., 2012). Most of this increase was observed for those aged between 10 to 49 
years (Arora et al., 2012). A similar study conducted on mGCTs extragonadal and gonadal in 
Finland found a significant increase in testicular mGCTs in males between 15 and 44 years of 
age, while in females the incidence of ovarian mGCTs remained stable during the time from 
from 1969 and 2008 (Pauniaho et al., 2012), as shown from a previous study on ovarian cancer 
carried out in Osaka, Japan (1975-1998) (Ioka et al., 2003). In agreement with the previous 
study, no differences were noticed in the incidence of non-gonadal mGCTs between 1969 and 
2008 (Pauniaho et al., 2012). 
The highest testicular tumour incidence has been observed in many countries in the 21st century, 
such as western and northern Europe, Australia, New Zealand and USA, while a lower 
incidence has been noted in Asia and Africa (Manecksha and Fitzpatrick, 2009; Rosen et al., 
2011; McGlynn and Trabert, 2012; Ghazarian et al., 2015b). No definitive answer has been 
found yet for this increase. Geographic and ethnic discrepancies suggest that environmental 
and genetic factors might contribute in causing testicular GCTs. Few studies have focused on 
10 Introduction 
 
 
looking at differences in the environment in which males with testicular mGCTs are exposed. 
Interestingly, an interruption in the tumour incidences in the generation of men born during the 
World War II was clearly seen in Nordic countries in the 1940s, and in France and Switzerland 
during the 1930s. This was likely due to changes in the everyday habits mainly of food and 
tobacco consumption (Bergström et al., 1996; Richiardi et al., 2004). Sedentary behavior, 
consumption of fats, milk and dairy products, have all been shown to be associated with 
testicular cancer risk, all of which were not commonly present during World War II. Another 
environmental factor that can differ in time and in geographic locations is pollution. Blood 
screening were undertaken to look for the presence of chemical compounds that could have a 
putative effect on the observed increased incidence (Hardell et al., 2003). No differences were 
found among the patients’ blood. However, when the blood derived from the patients’ mothers 
was tested, they found increased traces of polychlorinated biphenyls (PCBs), 
hexachlorobenzene, and some chlordanes in the blood of cancer patient’s mothers compared 
with the blood of healthy patients’ mothers. Some of these chemicals are endocrine disrupters 
and have been found in the animal kingdom to reverse gonadal sex or create abnormalities of 
reproductive development (Bergeron, Crews and McLachlan, 1994; Guillette et al., 1994). The 
exposure to these chemicals could plausibly be involved in testicular carcinogenesis (Hardell 
et al., 2003).  
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1.4   Classification of GCTs 
The classification of GCTs has been a contentious issue. There are two main classification 
systems used, namely, the World Health Organisation (WHO) and the British Testicular Tumor 
Panel (BTTP). To date, the most prominent classification used is derived from the WHO (97%), 
with only a small minority using the BTTP alone (<1%) or the BTTP in tandem with the WHO 
classification (2%) (Figure 6) (Williamson et al., 2017). 
 
Figure 1.6: 2016 edition of World Health Organisation classification. 
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Unfortunately, these classifications don’t take into consideration the class of GCTs arising in 
childhood, which differs from those arising in adulthood. Currently, the paediatric 
histopathological classification in international clinical use is modified from the original 
description by Dehner (Table 1.1) (Dehner, 1983). The following part of this section will 
further describe, in brief, the general definition, occurrence and diagnosis patterns of the 
tumours classified under Dehner’s system. 
Type Histology Comment 
1 Germinoma a.   Intratubular 
b.   Invasive 
2 Teratoma a.   Mature (MTD) 
b.   Immature  
Grade 1-immature tissue < 1 foci per LPF per slide 
Grade 2-immature tissue 1-3 foci per LPF slide 
Grade 3-immaure tissue ≥ 4 foci per LPF slide 
3 Embryonal carcinoma Malignant teratoma undifferentiated (MTU) or teratocarcinoma 
4 Yolk sac tumour Also termed endodermal sinus tumour 
5 Choriocarcinoma Malignant teratoma trophoblastic (MTT) 
6 Gonadoblastoma Pre-malignant lesion 
7 Mixed malignant GCT Malignant teratoma intermediate (MTI) 
Table 1.1: Histopathological classification of paediatric germ cell tumours. In immature teratoma, 
microfoci of yolk sac tumour, termed Heifetz lesions, are permitted without the tumour being classified 
as malignant (Heifetz et al., 1998). Malignant teratoma refers to a teratoma containing non-germ cell 
malignant component, e.g. sarcoma. LPF = low power field (x4). MTD = malignant teratoma 
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differentiated. MTD, MTU, MTT and MTI are terms used in adult histopathological classifications. 
Adapted and modified from Dehner (Dehner, 1983). 
 
   Germinoma/Seminoma 
Germinoma or seminoma (in females or males, respectively) are undifferentiated tumours that 
maintain features of pluripotency. Seminoma is the most common testicular germ cell tumour, 
representing 50% of the cases and germinoma the second most common ovarian germ cell 
tumour (Hochstetter and Hedinger, 1982; Herrington, 1999). Immunohistochemically, they can 
be distinguished from other subtypes of GCTs by negatively staining for cytokeratin 
(AE1/AE3) and alpha-fetoprotein (AFP) and positively for POU5F1 (OCT3/4) (Looijenga et 
al., 2003). In addition, these tumours are positive for SOX17 and negative for SOX2 staining, 
which assists in distinguishing them from EC cases (Nonaka, 2009). 
   Teratoma  
Teratoma is a GCT that predominantly occurs in the gonads: the testis and the ovaries. They 
account for 95% of ovarian GCT while only 4% represents testicular germ cell tumour 
(Katsube, Berg and Silverberg, 1982). In paediatric patients, teratomas represent 50% of GCTs 
and they are considered benign (Murray and Nicholson, 2010). They may arise in the ovary 
(37% of teratomas), sacrococcyx (SCT; 28%), testis (15%), thorax (7%) and other sites (13%). 
Teratomas are usually composed of multiple cells types derived from at least two germ layers 
(endoderm, ectoderm and/or mesoderm). The cell type in this type of GCT may be well-
differentiated or undifferentiated (Wetherell et al., 2014). They are graded as immature (IT), 
when the teratoma elements are incompletely differentiated and more similar to fetal or 
embryonic tissue, or mature (MT), when the teratoma elements are well differentiated relative 
to the germ cell layers (Murray and Nicholson, 2010; McDougal, 2012). 
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   Embryonal carcinoma (EC) 
EC display early embryonal differentiation and constitute a rare GCT subtype in childhood. In 
adolescence and adulthood, EC may present as a component of mixed malignant GCTs. 
Immunohistochemically, they express POU5F1 (OCT3/4) like germinoma (Poulos et al., 
2006). In addition, they express CD30 (Pallesen and Hamilton-Dutoit, 1988) and SOX2, but 
not SOX17 (de Jong et al., 2008; Nonaka, 2009), which allows them to be distinguished from 
germinoma. 
   Yolk sac tumour (YST) 
YST is the commonest malignant histological subtype of GCT in childhood, secreting AFP and 
displaying extra-embryonic yolk sac differentiation (Murray and Nicholson, 2010). However, 
many different microscopic types are recognised that may cause difficulty in establishing an 
accurate histopathological diagnosis. Glandular, or endometrioid-like, tumours may mimic 
certain carcinomas- hepatoid-like tumours may mimic hepatoblastoma (HB) or hepatocellular 
carcinoma (HCC) and solid patterns of YST may be misinterpreted as germinoma (Ulbright, 
2005). Immunohistochemically, yolk sac tumour can be distinguished from germinoma by 
staining positively for cytokeratin (AE1/AE3) and AFP, and staining negative for POU5F1 
(OCT3/4) (Looijenga et al., 2003; Kao et al., 2012). 
   Choriocarcinoma (CHC) 
CHC is extremely rare in childhood and displays extra-embryonic trophoblastic (i.e. placental-
like) differentiation. Exceptionally, as a consequence of gestational trophoblastic disease due 
to abnormally sited placental tissue, they may arise as pure tumours in infants. CHC are highly 
invasive tumours, often associated with either extensive spontaneous haemorrhage, or 
haemorrhage on initiation of chemotherapy, termed ‘choriocarcinoma syndrome’ and often 
necessitating provision of intensive care to affected patients (Kandori et al., 2010). They are 
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distinguished immunohistochemically by strong HCG staining (Looijenga, 2009) and are 
typically characterised by very high levels of serum HCG (Murray and Nicholson, 2010). 
1.5   Current clinical management of germ cell tumour 
    Initial management 
The management for mature (MT) and immature teratomas (IT) is surgical. Upon recurrence, 
a second surgery might be required (Mann et al., 2008). Chemotherapy is almost never adopted 
for teratoma treatment, unless mGCT arises, usually a YST. In the latter case chemotherapy is 
adopted (Mann et al., 2008).  
Ovarian GCTs can present either as mature or immature forms of teratoma (80% of all ovarian 
GCTs) or as a malignant form, with increasing incidence during adolescence (20% of all 
ovarian GCTs). The presentation of the disease is similar in the two forms, with abdominal 
pain and lower abdominal mass (Cecchetto, 2014). The surgical approach consists of ovarian 
tumour resection with sampling of any peritoneal modules (Cecchetto, 2014; Zhao et al., 2016). 
If nodules are composed purely of mature glial tissue (‘gliomatosis peritonei’, a recognised 
phenomenon associated with ovarian immature teratoma), no active management is required 
(Murray and Nicholson, 2010). 
Testicular GCTs usually present as a painless scrotal mass. Surgical approach consists of 
orchiectomy via inguinal excision (Horwich, Nicol and Huddart, 2013). Recently, partial 
orchiectomy is considered as an initial noninvasive step to preserve the fertility and hormonal 
function of the patient (Saltzman and Cost, 2018). Although, if the pathology from the partial 
orchiectomy returns malignant, a radical orchiectomy is completed (Caldwell, Wilcox and 
Cost, 2017). Pathology is either of a mature teratoma or a malignant GCT - seminoma or non-
seminoma (often with ‘mixed’ malignant components present). 
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   Chemotherapy 
Chemotherapy is reserved for the stages 2-4 of cancer, with stage 1 patients entering follow-
up with an expectant ‘watch-and-wait’ policy, as only ~25% will have a recurrence. The use 
of chemotherapy as treatment for GCTs commenced from 1974, led by Einhorn (Einhorn and 
Williams, 1979). Following the treatment with cisplatin, vinblastine and bleomycin (named 
PVB regime), the rate of the cure of these diseases improved from 5 to 60% (Einhorn and 
Williams, 1979). Unfortunately, in paediatric patients, the use of PVB was shown not to be 
tolerated (Exelby, 1980). Subsequently, this regime was modified to accommodate both adult 
patients who did not respond to the PVB treatment and children. Initially, etoposide was used 
in pre-clinical models instead of vinblastine in a new combinatorial treatment named ‘BEP’ or 
‘PEB’ regime (Schabel et al., 1979). This work demonstrated a remarkable synergism between 
etoposide and cisplatin, showing for the first time that a solid tumour could be cured with 
second-line chemotherapy (Schabel et al., 1979). BEP regime (cisplatin, etoposide, bleomycin) 
is still currently used by many US paediatric groups, with a reduced dose and frequency of 
bleomycin compared with adult BEP schedules. 
Unfortunately, the BEP regimen was found to be accompanied by underlying toxic side-effects, 
which remains a serious problem amongst treated patients. Rabinowits et al. showed that the 
combination of bleomycin and cisplatin gave rise to pulmonary toxicity and renal damage 
(Rabinowits et al., 1990; Kollmannsberger et al., 1999). Studies to diminish the toxicity were 
done by treating GCT patients with four cycles of carboplatin (CBDCA) + etoposide + 
bleomycin (EBC). Lower levels of renal and gastrointestinal toxicity were observed but 
myelosuppression was observed (Motzer et al., 1990). Consequently, adolescents with EC, 
CHC or mixed malignant GCTs should be treated with cisplatin-based chemotherapy, as 
insufficient numbers of patients were treated with carboplatin in the UK CCLG GCII study to 
be confident that outcomes were equivalent to adult schedules (Mann et al., 2000). BEP is, to 
date, the first line of chemotherapy most used in clinical practice (Honecker et al., 2018). 
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Although, studies have shown that the overall survival after chemotherapy treatment in GCTs 
treated patients is highly successful (up to 80% survival rate), at least half of the survivors 
develop toxicity such as ototoxicity (caused by cisplatin and carboplatin) (Haugnes et al., 2010, 
2012), nephrotoxicity (caused by cisplatin) or pulmonary fibrosis (caused by inflammation of 
the lung via the drug) later in their lives (Murray, Nicholson and Coleman, 2015b). The 
remaining 20% of patients have cisplatin-resistant tumours. These patients have very poor 
outcomes and significantly increased risk of solid cancers of the pleura and esophagus, and half 
of them usually succumb to it (Figure 1.7) (Travis et al., 2005; Lorch et al., 2012). Needless to 
say, it is crucial to focus on the therapies and regimens that could minimise these toxic effects 
whilst further improving the cure rates for patients with poor-outcomes. There is an urgent 
requirement to investigate molecular changes that may represent biomarkers and targets for 
novel therapy, in order to achieve this goal (Murray, Nicholson and Coleman, 2015c). 
 
Figure 1.7: Current treatments and outcome of GCT patients.  
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1.6   Molecular biology of germ cell tumours 
The earlier section of this chapter introduced an overview of GCTs and the following section 
will cover the current level of molecular understanding. 
   Genomic abnormalities 
To understand the causes of GCT pathogenesis, genomic studies have previously been 
undertaken to elucidate specific chromosomal regions of gain or loss. The majority of the 
studies were performed on adult malignant testicular GCTs (TGCTs) and identified the 
presence of isochromosome 12p (i12p) (Figure 1.8) (Atkin and Baker, 1982). i12p material is 
found in 80% of adults with TGCTs and more limited i12p is seen invariably in the other 20% 
of the cases (Looijenga et al., 1993; Collinson et al., 2014).  Interestingly, in few earlier studies, 
this gain was not found in tumours in patients <9 years of age (Bussey et al., 2001).  However, 
more recent studies done on a larger scale of paediatric samples revealed 12p gain in 44% of 
cases, with an increasing incidence with age (Palmer et al., 2007).  
 
Figure 1.8: Presence of isochromosome 12p [i(12p)] in adult malignant germ cell tumours. 
Karyograms are shown for 5 patients and the i(12p) formation is indicated by red arrows. Taken from 
(Atkin and Baker, 1982). 
1.6 Molecular biology of germ cell tumours 19 
 
 
These findings suggest that genomic copy number imbalances can distinguish GCT subgroups 
primarily by patient age (Palmer et al., 2007) (Murray, Nicholson and Coleman, 2015a). This 
discovery led to further studies to identify the main gene(s) involved in GCT progression 
(Rodriguez et al., 2003). On chromosome 12, stem cells genes such as NANOG are transcribed. 
NANOG overexpression leads to uncontrolled cell proliferation and consequently tumour 
formation. Interestingly, the TGCT subtypes, EC and seminoma showed NANOG 
overexpression, but other malignant subtypes such as YST, did not (Korkola et al., 2006). Other 
genomic copy number imbalances have been described in GCTs in adult patients. Most 
commonly, gain of chromosomes 1, 7, 8, 12, 21 and X and a loss of chromosomes 4, 5, 11, 13 
are observed (Terashima, Yu, Wing-Yuk T Chow, et al., 2014). Recent genome wide 
association studies (GWAS) have identified 18 main susceptibility gene loci in the 
development of TGCTs in adults, including: activating transcription factor 7 interacting 
protein (ATF7IP), BCL-2 antagonist/killer 1 (BAK1), doublesex and mab-3 related 
transcription factor 1 (DMRT1), KIT ligand (KITLG), sprouty homolog 4 (SPRY4), 
and telomerase reverse transcriptase (TERT) (Koster et al., 2014). 
   Epigenetic abnormalities 
It is also important to take into account the role that epigenetic mechanisms have in the 
initiation and protection of pluripotency, and therefore their potential role in GCT 
pathogenesis. From the early stage of germline development, an intensive epigenetic 
remodelling occurs (Kimmins and Sassone-Corsi, 2005). Deregulation of these tightly 
regulated processes is known to be involved in the formation and progression of many cancers 
(Portela and Esteller, 2010). During normal physiological development, PGC formation and 
maturation is dependent upon epigenetic processes such as histone modification and DNA 
methylation, to alter DNA accessibility and transcription, respectively. The ‘epigenome’ is 
highly dynamic and there is growing evidence that GCTs profoundly differ in their gene 
expression profiles and epigenetic regulation from normal germ cells (Dina G Kristensen et al., 
2013).  
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   Histone modifications 
Looijenga et al. studied genome-wide profiles for histone marks (H3K4me3 and H3K27ac) in 
malignant GCT cell lines [TCam2 (seminoma) and NCCIT (EC)]. H3K4me3 and H3K27ac, 
are associated with promoter activation and enhancer activation  (Rada-Iglesias et al., 2011; 
Clouaire et al., 2012). Depending on the cell line, SOX17 and SOX2 were differentially 
enriched for both H3K4me3 and H3K27ac in TCam2 and NCCIT, respectively (van der Zwan 
et al., 2014). Another study has found a substantial difference in the levels of histone 
modification between mGCT cell lines, with high levels of H3K9me2, H3K27me3, H4/H2A 
R3me2 and low levels of H3K4me1in seminoma compared with EC (Dina G. Kristensen et al., 
2013). Differences in the epigenetic landscape, between seminoma and non-seminomatous 
GCTs, suggests that epigenetic phenomena may alter protein-coding and non-protein-coding 
genes in these tumours. 
   Methylation modifications 
Methylation mechanisms are highly dynamic and crucial during germ cell development. Recent 
studies have analysed human DNA methylation from the PGC migration stage to the gonadal 
stage. They found that the methylation was decreased to 7.8% in the 11-week male PGCs and 
6% in the 10-week female PGCs (Figure 1.9) (Guo et al., 2015). 
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Figure 1.9: DNA methylation dynamics. Methylation of human sperm, oocyte, blastocyst, 
post/implantation embryos, primordial germ cell and gonadal somatic cells. Taken from Fuchou Tang’s 
paper (Guo et al., 2015). 
 
Aberrant DNA methylation is believed to contribute to malignancy in GCTs due to potential 
errors resulting from irregular methylation during their development (Smiraglia et al., 2002). 
Methylation mechanisms might also have a role in explaining the heterogeneity of mGCTs. 
The first global methylation array analysis of gene regulatory regions in mGCTs revealed that 
YSTs have increased methylation at many loci, including silencing of potential tumour-
suppressor genes (TSGs) and those genes associated with apoptosis, such as APC  (Jeyapalan 
et al., 2011) and SFRP2 (Schonberger et al., 2010), are methylated in paediatric YSTs but not 
in germinomas, resulting in activation of the Wnt signalling pathway.  
A second study performed an Illumina GoldenGate Cancer Methylation Panel platform to 
compare DNA methylation in three histological subtypes of paediatric GCTs (germinoma, 
teratoma and YST). Methylation patterns showed hypermethylation in a large number of 
cancer-related genes in YST such as APC, RUNX3 and HIC1 (Amatruda et al., 2013a). Further 
analyses were done using Infinium HumanMethylome450 arrays in cell lines of the major 
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subtypes of GCTs. They studied 7,244 genes and discovered that 147 of them showed 
correlating differential methylation and expression. This study further confirmed that non-
seminoma cells exhibit very high levels of gene methylation as compared with seminoma cells. 
The highest correlation between methylated areas and gene silencing was found in CpG islands 
along the promoter region of the silenced gene (Noor et al., 2016). More recent studies have 
found non-canonical CpG sites (CpA, CpT and CpC, collectively named CpH site) to exhibit 
an extensive methylation in embryonal carcinoma. This pattern was associated with high levels 
of DNMT3A/3B, two well-known de novo DNA methyltransferases (Shen et al., 2018). All 
these studies suggest a model where seminomas, which are the most similar to PGCs based on 
histological appearance, gene expression and methylation profile, are a precursor of embryonal 
carcinoma, which is in turn the precursor of yolk sac tumours (Honecker et al., 2006). 
   Protein coding transcriptome 
The protein-coding transcriptome has predominantly been studied in GCTs from adult patients 
and a distinct segregation has been shown between histological mGCT subtypes. For 
seminoma, this included LZTS1; for EC, DNMT3B, GAL and GPC4; for CHC CGA; and for 
YSTs the genes AFP, APOA2, BMP2, VTN and OTX2 (Alagaratnam et al., 2011). Similarly, 
global mRNA gene expression profiles in paediatric malignant GCTs completely segregate the 
two main histological subtypes, YSTs and germinomas (Palmer et al 20008). Higher 
enrichment was seen for genes associated with pluripotency such as NANOG, POU5F1, 
TFAP2C and UTF for paediatric germinomas while higher enrichment in genes involved in 
differentiation (KRT8, KRT19), lipid metabolism (APOA1, APOA2) and proliferation was 
observed for paediatric YST (Palmer et al., 2008). No difference was detected in tumours with 
the same histology but arising in different anatomical sites (Palmer et al., 2008). Furthermore, 
when adult and paediatric samples were compared, global mRNA profiles robustly segregated 
these two groups, leading to the conclusions that transcriptome profiles segregate both 
histological subtype and then age of tumour onset.  
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1.7   MicroRNAs (miRNAs) 
   MiRNA overview  
   History and importance of miRNAs 
MicroRNAs (miRNAs) are a class of short, non-protein coding RNAs, typically 21-23 
nucleotide (nt) long, that post-transcriptionally regulate the expression of protein-coding genes 
(Farazi et al., 2011; Takahashi, Miyazaki and Ochiya, 2014). The importance of miRNAs is 
underlined by an evolutionary conservation across different species, suggesting a critical role 
during development and growth (Warnefors et al., 2014). After binding to the 3’ Untranslated 
region (3’UTR) region, the miRNA reduces protein levels of its target mRNA via either direct 
degradation (by processing via P-bodies in the cytoplasm), or through translational repression 
(Bartel, 2004a). Novel microRNAs are continuously being identified through next generation 
RNA sequencing and other techniques and therefore miRBase, the online microRNA registry 
(www.miRBase.org/) (Griffiths-Jones et al., 2008), is regularly updated. There are now 48,885 
confirmed human mature microRNAs in the most recent miRBase release (v22; March 2018). 
They were first discovered by Lee, Feinbaum and Ambros, in 1993, by isolating Lin-4 from 
the nematode Caenorhabditis elegans. These studies showed that a specific miRNA, lin-4, was 
essential for the normal temporal regulation of development. They discovered that lin-4 was 
acting by negatively regulating the level of LIN-14 protein. In these organisms, the 
downregulation of LIN-14 protein was found to be essential for the progression from the first 
larval stage (L1) to the second stage (L2) (Lee, Feinbaum and Ambros, 1993). Seven years 
after the finding of the first miRNAs, let-7 was discovered. Equally important, let-7 was needed 
in C.elegans to control the L4-to-adult transition of larval development (Reinhart et al., 2000). 
Soon after the discovery of let-7, a new exciting study looked at the sequence conservation of 
miRNAs among different species. They detected the same miRNA in vertebrate, ascidian, 
hemichordate, mollusc, annelid and arthropod. In addition to having its sequence conserved, 
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its function was also conserved between species, suggesting a critical role in the control of the 
development (Pasquinelli et al., 2000). 
Since then, there has been a dramatic increase in reports identifying roles for miRNAs in 
normal development in humans and other species, almost quadrupling between 2005 and 2008 
and increasing eighteen-fold by 2013 (Casey et al., 2015), highlighting the importance of this 
new emerging field.  
   Current knowledge of miRNAs biogenesis and function 
MiRNAs are transcribed by RNA polymerase II (RNAse II) and III (RNAse III) from either 
‘independent’ miRNA genes or from intronic portions of protein-coding genes, to form primary 
transcripts from DNA, termed pri-microRNAs. Pri-miRNAs, which may be up to a few kilo 
bases (Kb) in length can also be polycistronic, i.e. code for more than one miRNA (Lee et al., 
2002). The pri-miRNA transcript fold into hairpins, which act as substrates for an RNAse III 
family enzyme, DROSHA (Lee et al., 2003). It has been recently estimated that a hairpin stem 
length of 36 nt +/- 3 is optimal for pri-miRNA processing (Roden et al., 2017).  
The product of DROSHA cleavage is a  ̴ 70 nt pre-miRNA, which contain a 2-nt overhang at 
its 3’ end (Lee et al., 2003). 
In addition to the DROSHA-dependent mechanism of miRNA biogenesis, a ‘non-canonical’ 
DROSHA-independent pathway has been identified. Some pre-miRNAs are produced from 
very short introns (mirtrons). Mirtrons are non-canonical miRNAs encoded in introns and 
their biogenesis starts with a splicing event. They are not processed by DROSHA and enter 
the canonical pathway at the Exportin-5 level (Figure 1.10) (Westholm and Lai, 2011). 
Mirtrons are much less evolutionary conserved than canonical miRNAs, and it was 
hypothesised that their non-canonical pathway could have provided an early avenue for the 
emergence of miRNA, prior to the advent of DROSHA (Ruby, Jan and Bartel, 2007). 
Recently, awareness of the significance of mirtron miRNAs is increasing, and their role in 
cancer progression has been established in spinocerebellar ataxia 7 (SCA7), myelodysplastic 
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syndrome (MDS) and in the promotion of new vessel formation in the angiogenesis event 
(Aslan et al., 2016; Curtis et al., 2017; Sakai et al., 2017). 
Once formed in the nucleus, pre-microRNAs or mirtrons are transported into the cytoplasm by 
Exportin 5 (XPO5) (Yi et al., 2003; Bohnsack, Czaplinski and Gorlich, 2004), which is also 
important for the stability of pre-microRNAs as loss of expression results in decreased 
cytoplasmic microRNA levels without an increase in nuclear pre-microRNAs (Melo et al., 
2010) and downregulation of mature miRNA in the cytoplasm (Wu et al., 2018). Once in the 
cytoplasm, the 2 nt 3’ overhang present in the pre-microRNAs is recognised by another RNAse 
III family enzyme (DICER1) which cleaves the molecule to a  ̴ 20 nt miRNA/miRNA* duplex 
(the asterisk denotes the passenger strand) (Bernstein et al., 2001). One strand of this duplex is 
then incorporated into the RNA induced silencing complex (miRISC) (Rivas et al., 2005). 
Finally, the mature miRNA strand incorporated into the RISC complex results in mRNA 
degradation or translational repression (Bartel, 2004a; Lim et al., 2005; Krol, Loedige and 
Filipowicz, 2010).The key components of miRISC complex are argonaute (AGO), which 
directly binds miRNA, and a glycine-tryptophan protein of 182 kDa (GW182), which act as 
downstream effector in the repression (Figure 1.10) (Krol, Loedige and Filipowicz, 2010).  
The remaining strand (passenger strand) from the original microRNA duplex, which is not 
incorporated into RISC, is believed to undergo rapid degradation. 
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Figure 1.10: Schematic diagram of miRNA biogenesis. Both the canonical (DROSHA-dependent) 
and non-canonical (DROSHA-independent, or ‘mirtron’) biogenesis pathways are shown. Taken from 
(Krol, Loedige and Filipowicz, 2010). 
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   Mechanism of miRNA regulation of gene expression 
Upon assembly of the mature miRNA into the miRISC complex (miRNA assembled with 
Argonaute proteins), 3’UTR target recognition occurs through conventional Watson-Crick 
miRNA:mRNA base pairing (Ambros, 2000; Esquela-Kerscher and Slack, 2006). The miRNA 
binding at the 3’UTR of its target mRNA, is predominantly determined by the ‘seed’ region of 
the microRNA, located at nt positions 2-8 at the 5’ end of the microRNA. The 2-7 nt sequence 
represents the ‘core’ component of the seed and this is critical in determining binding 
specificity to mRNA targets (Lewis, Burge and Bartel, 2005a). Consequently, as each seed 
region is short and 3’UTRs of mRNA transcripts are much longer, each microRNA is predicted 
to have hundreds of mRNA targets (Lim et al., 2005). 
The interaction occurs between the 5’ end (seed region) of the miRNA, and the 3’ end 
untranslated region (3’UTR) of the target mRNAs. Thought not only to happen when there is 
absolute complementarity in the seed region but less frequently also when few unperfected 
seed matches occur. It has been found that some interaction can occur with a nucleation bulge 
at position 5-6 (Tay et al., 2008; Chi, Hannon and Darnell, 2012). After binding to the 3’UTR 
region, the miRISC complex reduces protein levels of miRNA target mRNA via either direct 
degradation (by processing via P-bodies in the cytoplasm), or through translational repression 
(Bartel, 2004b; Iwakawa and Tomari, 2015). In mammalian cells, the majority of this negative 
regulation has been shown to occur through mRNA degradation (Baek et al., 2008; Selbach et 
al., 2008; Guo et al., 2010a; Eichhorn et al., 2014). For the degragation to happen, the mRNAs 
are firstly deadenylated by the deadenylase complex (PAN2-PAN3 and CCR4-NOT) (Wahle 
and Winkler, 2013). Once deadenylated, they are decapped by decapping protein 2 (DCP2), 
which in tandem with other cofactors degradate the mRNA (Jonas and Izaurralde, 2013). The 
deadenylase complex, decapping complex, Ago and GW182 all localise in P-bodies, which are 
cytoplasmatic ribonucleoprotein granules primarly composed of translationally repressed 
mRNA and protein related to mRNA decay (Luo, Na and Slavoff, 2018). In addition to mRNA 
degragation, miRNAs can promote translational repression. The question of how miRNAs 
repress translation is controversial. With the introduction of ribosome profiling method, the 
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latter hypotesis could be elucidated. Bartel et al. monitored both mRNA levels and the 
corresponding ribosome density after the introduction of exogenous mimics miRNA (Guo et 
al., 2010b; Kuersten et al., 2013). Reduction in mRNA levels due to mimic miRNAs also 
decreased the levels of ribosome density, giving less credibility to the theory of translational 
repression. 
More recently, new studies have started to re-evaluate the miRNA:mRNA interactions. 
Unconventional miRNA binding sites in the 5’UTRs or coding genes have been successfully 
reported (Lytle, Yario and Steitz, 2007; Cloonan, 2015). No differece in mRNA repression was 
detected when the miRNA binding site was located at the 5ʹ′ or 3ʹ′ to the luciferase open reading 
frame (ORF). Further functional studies have been done of miR-103a-3p, miR-122 and miR-
10a, whose target sites are within 5ʹ′UTR regions of their mRNA target (Ørom, Nielsen and 
Lund, 2008; Roberts, Lewis and Jopling, 2011; Zhou and Rigoutsos, 2014). Coding DNA 
Sequences (CDS) have also been shown to conserve some target sequences. Similar to the 
experiment above, miRNA target sequences have been cloned into the CDS of the luciferase, 
showing a decrease in its activity (Hausser et al., 2013). 
These new ways of miRNA:mRNA interaction opens new avenues in the study of miRNAs 
binding and function. For example, currently most of the target predictions databases are 
tailored in order to predict binding sites in the 3’UTR of a gene, which means that we are 
missing out on other sets of mRNAs that could be equally important in the regulation of our 
cells. Further discoveries and validations on this argument need to be undertaken. 
   MiRNAs role in tumorigenesis  
To experimentally determine the role of miRNAs in tumorigenesis, previous studies have 
looked at the effects of disruption of the miRNA machinery in normal cells. This was done by 
testing short hairpin RNAs (sh-RNAs) against DROSHA, DGC8 and DICER1. As expected, 
an increase in cell proliferation was observed, with a particular increase in the cell percentage 
in S phase and a reduce percentage of cells in G0/G1 phase (Kumar et al., 2007). This in vitro 
study was followed by an in vivo study which confirmed the importance of miRNAs in cancer 
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progression; when Dicer1 was inactivated in murine models the same phenotypic effect was 
observed (Kumar et al., 2007). 
Since then, many studies have aimed to find a role for miRNAs in the control of oncogenes or 
tumour suppressor genes. Mutation or deregulation of these genes are often combined with 
tumour progression (Huebner and Todaro, 1969). 
Together with an enhancement in cell growth, levels of C-MYC, K-RAS and P53 are usually 
observed (Johnson et al., 2005; Hoffman and Liebermann, 2008; Vazquez et al., 2008; 
Campaner and Amati, 2012; Li et al., 2012; Drosten et al., 2014). 
It is important to mention that miRNAs function is cancer-specific and that the same miRNA 
can act differently depending of the context (Banzhaf-Strathmann and Edbauer, 2014). Thus, 
the same miRNA can act as oncogene or tumour suppressor in their own right. For example, 
miR-125b-5p is broadly studied in a variety of tumours such as breast cancer and glioma 
(Akhavantabasi et al., 2012; Li et al., 2018; Yuan et al., 2018), where it acts as tumour 
suppressor, or colorectal cancer or renal cell carcinoma (Mori et al., 2011; Jin et al., 2017; Yu 
et al., 2017), where it acts as oncogene.   
   MiRNAs in the regulation of cell cycle 
The cell cycle is under the strict control of several mechanisms that enforce correct cell 
division. The basic cell cycle in divided into four phases namely, G1, S, G2 and M (Norbury 
and Nurse, 1992). During S and M phases, the cell initially generates a faithful copy of its 
genetic material (S phase) and then it divides it together with all the other cellular components 
into two identical daughter cells (M phase). G1 and G2 phases are a ‘gap period’ in which the 
cell prepares itself for a successful completion of S and M phases. Adult cells are almost all in 
a quiescent state known as G0 phase, meaning that after proliferation, cells exit the cell cycle. 
Quiescent cells may re-enter the cell cycle or remain in their non-proliferative state. Re-
entering the cell cycle requires a regulated process of activation and inactivation of specific 
proteins at specific times (Malumbres and Barbacid, 2001). 
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The transition of the cell from one phase to another is orchestrated by a series of different 
regulators. A major group of regulators are the Cyclin-Dependent Kinases (CDKs). Activity of 
CDKs, as the name suggests, is dependent on the activity of cyclins – a family of regulatory 
subunits. Cyclins are synthesized and degraded at different stages of the cell cycle providing 
temporal regulation of CDKs (Vermeulen, Van Bockstaele and Berneman, 2003). One of the 
first links between miRNAs and the cell cycle was the discovery of the anti-proliferative 
potential of the miR-15a-16-1 cluster, due to targeting of CDKs. This cluster induced arrest in 
G1 phase by targeting CDK1, CDK2 and CDK6 (Linsley et al., 2007; Wang et al., 2009; 
Takeshita et al., 2010). Other regulatory miRNAs were soon discovered - miR-124, miR-34a, 
miR-125b, miR-195 and found to play a role in cell cycle regulation by targeting CDK4 and 
CDK6 (Pierson et al., 2008; Sun et al., 2008; Xu et al., 2009; Shi et al., 2010). CDKs, in turn, 
phosphorylate target proteins and drive the cell sequentially through the different phases of 
growth and division. One example of this regulation is the entry into G1 phase. Entry into G1 
is triggered by the D-type cyclins (CycD1, CycD2, CycD3) that bind CDK4 and CDK6 
eliciting their activity during this phase. Consequently, negative regulators of the cell cycle 
such as the retinoblastoma proteins RB, RBL1 and EBL2 are down-regulated. Its inactivation 
is essential for starting a new cell cycle and to release E2F-dependent transcription of cell cycle 
genes. RB has been shown to be targeted from miR-106a in gastric, prostate and lung tumour 
cancer (Volinia et al., 2006). Levels of E2F were firstly found to be regulated by miR-17-5p 
and miR-20a cluster, together with C-MYC expression. C-MYC regulates the expression of 
miR-17-5p and miR-20a cluster, which, in turn, regulate the expression of E2F1, supporting a 
model in which miR-17-5p and miR-20a limit C-MYC-mediated induction of E2F1 expression, 
preventing uncontrolled reciprocal activation of these gene products (O’Donnell et al., 2005). 
Since then, many more miRNAs have been found to control the cell cycle progression through 
direct or indirect binding of the main effectors of cell cycle progression (Figure 1.11) (Bueno 
and Malumbres, 2011). 
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Figure 1.11: Overview of miRNAs role in the cell cycle progression.  MiRNAs with proliferative 
potential are shown in red whereas anti-proliferative miRNAs are in blue. S, S-phase; M, Mitosis; G1 
and G2 indicate transition phases of the cell cycle whereas G0 indicate quiescent cells. Adapted from 
(Bueno and Malumbres, 2011). 
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   MiRNAs in the regulation of apoptosis, autophagy and necroptosis 
Multicellular organisms have tightly controlled cell division and also cell death (Tyson and 
Novak, 2014). Billions of cells in a healthy human body die from programmed cell death every 
hour in organs such as the bone marrow and the intestine. This programmed cell death is named 
apoptosis, necroptosis (programmed necrosis) and autophagy. Programmed cell death is strictly 
regulated by a multitude of factors of which miRNA seems to have a role (Su et al., 2015). 
Apoptosis is the most common form of programmed cell death (Danial and Korsmeyer, 2004). 
There are two main apoptotic pathways: the extrinsic or death receptor pathway and the 
intrinsic or mitochondrial pathway.  
The intrinsic pathway relies on the formation of a complex termed the apoptosome, composed 
of procaspase-9, apoptotic protease activating factor 1 (APAF-1), and cytochrome c. A series 
of Bcl-2 family members control the release of cytochrome c by regulating mitochondrial 
membrane permeabilisation. When cytochrome c leaks out of the membrane, a series of pro-
apoptotic protein are activated, which terminates with the activation of caspase-3, 6 and 7. 
Many studies have found a connection between deregulated miRNAs expression and 
uncontrolled cell death by the activation of the intrinsic apoptosis pathway such as miR-125b, 
which was found to target Bcl-2 antagonist killer 1 (BAK1) that is essential to induce Taxol-
induced apoptosis. Furthermore, its downregulation confers resistance of breast cancer cells to 
paclitaxel promoting cancer survival (Zhou et al., 2010). BCL-2 has been found to be the target 
of other miRNAs such as miR-204, miR-148a and miR-24-2c (H. Zhang et al., 2011; 
Srivastava et al., 2011; Sacconi et al., 2012).  
The extrinsic pathway is initiated by the binding of death ligand to the death receptors in the 
TNF receptors superfamily. This interaction is then followed by a cascade of events that 
terminates with the activation of caspase-3, 6 and 7 and the induction of apoptosis. MiRNAs 
involved in the extrinsic pathway have been discovered such as miR-20a, miR-146a and miR-
196b, which by targeting FASL death ligand promote cancer cell survival (Z. Li et al., 2011; 
Huang et al., 2012; Guo et al., 2013). 
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In the last few years, autophagy studies have increased our understanding, allowing researchers 
to speculate that this regulatory mechanism is one of the most important pathways in cancer 
progression. In 2016, Yomiuri Shimbun received a Nobel Prize for his contributions in 
understanding the hidden cellular mechanisms of autophagy (Takeshige et al., 1992). 
Autophagy is usually initiated by starvation stimuli (Kroemer, Mariño and Levine, 2010; 
Anding and Baehrecke, 2015), hypoxic and endoplasmic reticulum (ER) stress (Rashid et al., 
2015; Niu et al., 2017) and reactive oxygen species (ROS) (Chen et al., 2017). AMPK-
mTORC1 has been characterized as being at the centre of autophagy regulation in which it 
integrates multiple stimuli to initiate the UNC-51-like kinase (ULK) complex, which is situated 
at the beginning of the autophagy cascade (Kim and Lee, 2014). MiRNA have been shown to 
regulate this complex. For example, miR-20a and miR-106b have been shown to regulate the 
UNC-51-like kinase (ULK) complex (H. Wu et al., 2012), while miR-148b was reported to 
target AMPKα1 to inhibit cell proliferation and invasion and to enhance cancer cell chemo-
sensitivity (H. Wu et al., 2012). Many other miRNAs have been shown to participate in the 
correct autophagy function, giving them a central role in this regulatory pathway as intensely 
reviewed from Gozuacik (Gozuacik et al., 2017). 
Necroptosis is the third mechanism of programmed cell death. Few studies to date have linked 
necroptosis and miRNA expression, as for many years necrosis was considered an unregulated 
form of cell death. Only recently a form of regulated necrosis has been discovered, hence the 
term ‘necroptosis’ (Galluzzi and Kroemer, 2008). The formation of the ‘necrosome’ by 
receptor-interacting protein kinase 1 (RIP1, also known as RIPK1) and RIP3 is the most critical 
event in necroptosis (Holler et al., 2000). Recently, two studies were published on the role that 
miRNAs (miR-223-5p/-3p and miR-21) have in the regulation of necroptosis. MiR-223-5p/-3p 
has been found to promote necroptosis in myocardial ischemia/reperfusion (I/R) through 
suppression of RIP1/RIP3/MLKL pathway (Qin et al., 2016), while miR-21 promotes 
necroptosis in the pancreas through repression of CDK2AP1 (Afonso et al., 2018). Clearly, the 
quest to find the contributions of miRNAs in cellular death is on-going and requires further 
attention.  
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   Deregulation of miRNAs 
Due to the central role of miRNAs in the regulation of normal cellular activities, and their 
tumorigenic role when deregulated, it is now vital to understand how they are controlled. Their 
regulatory pathway has to be well understood for further research to be able to identify potential 
new therapies to control and combat cancer progression. This section will shed some light on 
the deregulation of miRNAs and its consequences.  
   Amplification or deletion of miRNA genes 
Abnormal miRNA expression can be due to alteration in the genomic locus, where the miRNA 
transcript is located. It has been estimated that half of the miRNAs that exist are located in 
regions of high instability due to partial chromosome deletion, loss of heterozygosity (LOH), 
minimal regions of amplification, common breakpoint regions or SNPs (Calin et al., 2004a). 
This was confirmed by interrogating 283 known human miRNA genes by high-resolution 
array-based comparative genomic hybridisation in 227 specimens from human ovarian cancer, 
breast cancer and melanoma (Zhang et al., 2006a).  
The first discovery of aberrant miRNA expression due to genomic instability was the loss of 
miR-15a/-16-1 cluster at chromosome 13q14 observed in B-cell chronic lymphocytic 
leukaemias (B-CLL) (Calin et al., 2002). On the other hand, in lung cancer, the same cluster 
gene was amplified, resulting in an increase in the production of miRNAs, and enhanced 
cellular proliferation (Hayashita et al., 2005). Gain of genetic material was also observed in 
eight cases of diffuse large B-cell lymphoma (DLBCL) (Tagawa and Seto, 2005). 
Another form of genomic alteration can derive from chromosomal translocation (Sax and 
Enzmann, 1939). Chromosomal translocations have also been shown to have a role in the 
overexpression of miRNAs such as miR-125b-5p in acute lymphoblastic leukemia (ALL) in 
children. A juxtaposition of a immunoglobulin heavy chain (IGH) enhancer on chromosome 
11 in front of miR-125b-1 and BLID was found to be the cause of the upregulation of both 
genes (Tassano et al., 2010). 
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   Transcriptional control of miRNAs 
Altered levels of transcription factors (TFs) that bind to promoter or enhancer regions, 
upstream of miRNA loci, may account for dysregulated miRNA expression in malignancy. 
Examples of this deregulation are proteins that are often deregulated in cancer such as C-MYC 
and P53. The proto-oncogene C-MYC encodes for a TF that regulates cell proliferation, growth 
and apoptosis. C-MYC overexpression causes aberrant binding to the promoter region of 
miRNAs, resulting in upregulation of miR-17-92 cluster and repression of miR-26, miR-29, 
miR-30 and let-7 family members (O’Donnell et al., 2005; Chang et al., 2008). Feedback-loops 
have been discovered which may act as possible TF-miRNA regulation mechanisms. An 
interesting example has been shown in c-Myc-miR-122 regulation. C-MYC was shown to 
repress miR-122 expression through binding its promoter region. Mir-122 in turn indirectly 
inhibits the transcription of C-MYC itself by targeting TFDP2 and E2F1. The dysregulation of 
this feedback loop leads to the onset of hepatocellular cancer (Wang et al., 2014). Interestingly, 
in hepatocellular carcinogenesis, they found another feedback-loop mechanism that also 
involves C-MYC and miR-148a-5p/miR-363-3p (Han et al., 2013).  
P53 causes overexpression of miR-34a in CLL through binding its promoter and in turn, miR-
34a promotes P53 expression by targeting SIRT1, a negative regulator of p53 (Yamakuchi and 
Lowenstein, 2009; Hermeking, 2010). In addition to C-MYC and P53, there are other examples 
of TFs that regulate miRNA expression. For instance, CDX2 is a homeobox TF that regulates 
the expression of miR-125b by binding to its promoter region. CDX2 overexpression induces 
miR-125b which inhibits core binding factor β (CBFβ) translation, which is essential for 
myeloid cell differentiation. Its repression promotes leukaemogenesis (Lin et al., 2011). 
   Dysregulated epigenetic changes 
Another well-known feature of cancer development and progression is epigenetic alterations. 
These alterations can be presented as DNA hypomethylation, aberrant hypermethylation of 
tumour suppressor genes and disruption of histone modifications (Gronbaek, Kirsten Hother, 
Christoffer Jones, 2007). 
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MiRNA expression was found to be regulated by epigenetic changes in cancer, for the first 
time, in 2006. Saito and co-workers found that in bladder cancer almost 6% of miRNAs were 
upregulated following treatment with DNA methylation and histone acetylation inhibitors 
(Saito et al., 2006a). Since then, more studies on the importance of methylation have been 
published. For example, the expression of miR-223 has been shown to be epigenetically 
silenced by CpG methylation in primary leukaemic blasts (Fazi et al., 2007) and miR-125b was 
found to be highly downregulated in invasive breast cancer because of hypermethylation of its 
promoter (Y. Zhang et al., 2011a). Other miRNAs more recently have been discovered to be 
modulated by epigenetic regulation in a variety of cancers (Suzuki et al., 2012; Ramassone et 
al., 2018). MiR-34a promoter hypermethylation is responsible for its reduced expression in a 
multitude of cancers, including acute myeloid leukemia (AML), lung cancer and breast cancers 
(Watanabe et al., 2012; Pigazzi et al., 2013; Vrba et al., 2013). Epigenetic regulation of 
miRNAs has been combined into a database called EpimiR, which collated evidence of 1,974 
such regulations, with 19 discrete types of epigenetic modification involving 617 miRNAs 
across seven species, all experimentally validated (Dai et al., 2014). These evidences have 
highlighted the important role of epigenetic in miRNA regulation. Aberrant methylation of 
miRNA could be used as potential prognostic markers or as target for therapeutic intervention 
in cancer. 
   Defects in miRNA biogenesis machinery 
As previously described, miRNAs are strictly regulated during their biogenesis and numerous 
proteins act in tandem to promote their maturation. Therefore, mutations or aberrant expression 
of protein involved in the miRNAs biogenesis machinery can lead to miRNAs dysregulation 
(Hata and Kashima, 2016). For example, DROSHA and DICER1, two of the key component of 
miRNA maturation, have been found to be dysregulated in many tumours (Lu et al., 2005; 
Murray et al., 2014). To demonstrate the functional significance of DROSHA and DICER1, 
knockdown using RNA interference (RNAi) an RNAi approach was done in neuroblastoma 
cell line and an increase of cell growth in vitro was observed (Lin et al., 2010). On the other 
hand, increased levels of DICER1 and DROSHA, appear important in the development of 
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certain cancers such as serious ovarian carcinoma (Vaksman et al., 2012). Recently, a single-
nucleotide substitution/deletion mutation was observed in DGCR8 and DROSHA in patient 
affected from Wilms’ tumours leading to decrease of miR-200 and let-7a (Walz et al., 2015). 
Proteins such as AGO and exportin-5 (XPO5) also have been found to be affected in certain 
tumours. For example, a defect in XPO5 traps pre-miRNA in the nucleus due to a genetic 
mutation of XPO5, which generates a protein without the C-terminal, necessary for the 
formation of the pre-miRNA/XPO5/Ran-GTP ternary complex (Melo et al., 2010). These 
mutations lead to abnormal mature miRNA expression levels and consequently to 
tumorigenesis. 
   MiRNAs in Germ Cell Tumours (GCTs) 
The Coleman group previously investigated whether dysregulation of miRNAs was present 
across the clinical spectrum of GCTs. They profiled 615 miRNAs in paediatric malignant 
GCTs, control and cell lines (48 samples in total) (Palmer et al., 2010). They found that the 
most significant differentially expressed miRNAs in mGCTs were derived from miR-371-373 
and miR-302/367 clusters, which were over-expressed, all with a p value<0.00005. However, 
they found that most of the differentially-expressed miRNAs were down-regulated in mGCTs 
compared with controls and benign tumours (Figure 1.12), consistent with previous findings in 
other epithelial cancers (Lu et al., 2005). 
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Figure 1.12: Heatmap of miRNAs expression in 42 clinical tissue samples. The heatmap is based on 
the most significantly differentially expressed miRNAs (in red we can see an overexpression and in 
blue an underexpression of the different miRNAs). The dendogram completely segregates paediatric 
malignant germ cell tumours (seen in blue for germinoma/seminoma, yellow for yolk sac tumour and 
red for embryonal carcinoma) from benign tumours (teratoma) in brown and normal controls in green. 
Supplementary Figure S2 in Palmer et al. CR 2010 (Palmer et al., 2010). 
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   Downregulated miRNAs 
In view of the aforementioned findings, the Coleman group further investigated the role of 
certain downregulated miRNAs in mGCTS, which represent putative tumour-suppressor 
genes. Initially, they performed an in-depth study to find the potential significance of 
downregulation of the entire let-7 miRNA family in GCTs (Murray et al., 2013), which is a 
known tumour suppressor gene in other cancers that regulates cell proliferation (Takamizawa 
et al., 2004; Johnson et al., 2007). From microarray data, they discovered LIN28 (an RNA 
binding protein and known negative regulator of let-7 biogenesis) was particularly abundant in 
mGCTs. LIN28 acts by blocking the downstream processing of precursor let-7 molecules 
(Viswanathan, Daley and Gregory, 2008). Once LIN28 binds pri-let-7 and pre-let-7, it prevents 
their processing by DROSHA and DICER1 (Viswanathan and Daley, 2010a). The binding 
occurs through a stem loop motif that includes the nucleotide sequence ‘GGAG’ leading to the 
recruitment of a terminal-uridyl-transferase (TUTase), resulting in pre-let-7 uridylation and 
degradation (Heo et al., 2009). In GCTs, LIN28 knockdown (KD) resulted in specific 
upregulation of let-7 family members, confirming a negative regulation of let-7 by LIN28. 
Furthermore, replenishment of let-7 levels in mGCT cell lines using a mimic let-7 molecule 
(namely let-7e) resulted in reduced cell numbers associated with reductions in let-7 targets 
including MYCN. In addition, reductions in LIN28 itself were also observed, demonstrating a 
feedback loop, through a let-7 binding site in the LIN28 3’UTR (Figure 1.13) (Murray et al., 
2013). Moreover, other miRNAs known to be downregulated in GCTs have an SCR in the 
3’UTR of LIN28 (e.g. miR-125b-5p).
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Figure 1.13: Schematic representation of the LIN28/let-7 pathway. This model has been described 
in GCTs. Adapted from (Murray, Nicholson and Coleman, 2015b). 
 
   Other important miRNAs downregulated in mGCTs 
Subsequently, the Coleman group commenced the study of other important downregulated 
miRNAs. The miRNAs with expression levels shown in deep blue in the heat map (Figure 
1.12) are the most significantly downregulated miRNAs (adjusted p-values <1x105). From 
these data, five top-ranking putative tumour suppressor miRNAs were chosen for further 
investigation. These are the five most downregulated miRNAs, ranked by adjusted p-value, 
with at least a mean 4-fold decrease in paediatric mGCTs compared with non-malignant 
samples. These miRNAs are: miR-152-3p, -204-5p, -99a-5p, -100-5p and -125b-5p (in 
descending order of p-value significance) (Table 1.2) (Palmer et al., 2010). 
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Putative tumour 
suppressor miRNAs 
FC Adjusted 
p-value 
Sequence 
miR-152-3p -4.17 5.09 x10-9 UCAGUGCAUGACAGAACUUGG 
miR-204-5p -7.78 2.32 x10-8 UUCCCUUUGUCAUCCUAUGCCU 
miR-99a-5p -11.1 9.25 x10-8 AACCCGUAGAUCCGAUCUUGUG 
miR-100-5p -10.5 1.23 x10-7 AACCCGUAGAUCCGAACUUGUG 
miR-125b-5p -10.9 9.59 x10-7 UCCCUGAGACCCUAACUUGUGA 
Table 1.2: The most downregulated miRNAs in paediatric malignant GCTs. The mean level of this 
downregulation in the tumour subtypes is expressed as a negative log2 fold-change (log2FC) based on 
previous global miRNA profiling in paediatric and adolescent GCTs (Figure 1.12). Fold change (FC) 
is a measure describing how much a quantity changes going from an initial value to a final value.  
 
   MiRNAs as potential therapy 
   MiRNA inhibition therapy 
MiRNAs are of increasing interest in the clinical field, as they may be used as potential 
therapeutic strategies. Considerable strides have been made to develop and study anti-miRNA 
oligonucleotides that bind overexpressed miRNAs in cancer cells. These antagonists of 
miRNAs have been used both in in vitro and in vivo models of breast cancer (Obad et al., 2011), 
B-cell lymphoma (Zhang et al., 2012) and medulloblastoma (Murphy et al., 2013). There is 
also an extended Phase II clinical trial of an inhibitor against miR-122 (Miravirsen) in patients 
with chronic hepatitis C, who are not responding to current therapies, and it has been showing 
very promising early results (Lanford et al., 2010; Lindow and Kauppinen, 2012; van der Ree 
et al., 2016). A more recent clinical trial (LO7) showed that using RG-101 (a hepatocyte 
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targeted carbohydrate conjugated oligonucleotide with potent antagonist activity against miR-
122) resulted in significant reduction of viral load in treated patients (Van Der Ree et al., 2015).  
   MiRNA replacement therapy 
The feasibility of miRNA replacement strategies has been investigated using different delivery 
systems (Höbel and Aigner, 2013; Aigner and Fischer, 2016). Local delivery has been 
performed using different delivery methods – e.g. (i) a cholesterol-conjugated 2’-O-methyl-
modified miR-375 mimics were used in a hepatoma xenograft resulting in suppression of liver 
cancer cell growth (He et al., 2012); (ii) a lentiviral vector was used to deliver let-7 in non-
small cell lung cancer (Trang et al., 2010); and (iii) polyethylenimine (PEI)-mediated delivery 
of unmodified miRNAs was adopted to deliver miR-145 and miR-33a into a mouse model of 
colon carcinoma (Ibrahim et al., 2011). Recently, nanoparticle techniques have been used, such 
as a gold-nanoparticle vehicle to prevent metastasis in breast cancer. MiR-96/miR-182 was 
delivered locally in a breast cancer mouse model and the level of metastasis derived from the 
primary tumour was significantly decreased (Gilam et al., 2016). Systemic delivery has also 
been successfully performed, for example, using adeno-associated viruses containing miR-26a 
in a hepatocellular carcinoma murine model (Kota et al., 2009) or in silica nanoparticle-based 
targeted delivery of miR-34a to neuroblastoma tumours in a murine orthotopic xenograft model 
(Tivnan et al., 2012). The latter method used engineered nanoparticles to specifically target 
cells with high expression of disialoganglioside (GD2) antigen. This antigen is overexpressed 
on the surface of neuroblastoma cancer cells, making the therapy more targeted towards that 
specific subtype of cells (Tivnan et al., 2012). 
In 2013, the first Phase I clinical trial involving miRNA-replacement therapy for cancer in 
humans commenced, utilising a nanoparticle-derived minicell delivery system to replenish 
levels of miR-16 in mesothelioma and non-small cell lung cancer (TargomiRs) (Reid et al., 
2013). This system used mini-cells derived from an asymmetric cell division in bacteria and 
engineered with epidermal growth factor receptor (EGFR)-specific antibodies. Recently, the 
outcome of the clinical trial was published with positive results and an acceptable safety profile, 
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supporting additional studies of miRNA replacement in combination with chemotherapy agents 
(van Zandwijk et al., 2017a) (Figure 1.14). 
 
Figure 1.14: TargomiR treatment of mesothelioma. Computed tomography (CT) scans from patient 
lungs with mesothelioma before (on the left) and after (on the right) TargomiR treatment. The red arrow 
shows the thickness of the lung due to mesothelioma, which disappeared after 8 weeks of treatment. 
Adapted from (Reid et al., 2016). 
 
   MiRNAs in body tissues  
Prior to such further work on therapeutic strategy, it is important to make predictions about the 
tolerance of normal peripheral tissues to exogenously delivered miRNAs. It has been 
demonstrated that the delivery of miRNAs, that are abundant in normal tissues but lost in 
diseased cells, can be successfully replenished with minimal toxicity (Kota et al., 2009). In 
order to interrogate this further, in the case of the miRNAs under current interrogation in 
mGCTs, expression data in most other human tissues was retrieved from the miRNA body map 
project (Mestdagh et al., 2011). Fortunately, this shows high expression of miR-99a-5p, miR-
100-5p, miR-125b-5p, miR-152-3p and miR-204-5p in most body tissues, and provides a good 
predictor for the global therapeutic tolerance of replenishment of these miRNAs (Figure 1.15). 
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Figure 1.15: The miRNA body map of the five downregulated miRNAs relevant to GCTs. High 
level of expression is colored in red, and is confirmed in most normal tissue types. All miRNAs in the 
picture are referred as -5p, except for miR-152 which is referred as -3p. 
1.8   Aims of the project 
The overall aim of this project is to understand the mechanism and functional significance of 
miRNAs downregulated in mGCTs. As the understanding of the biogenesis and mechanisms 
of action of miRNAs has grown in the past two decades, their importance in regulating gene 
expression and essential role in controlling key cellular mechanisms has been highlighted, 
including contributing to cancer progression when deregulated (Peng and Croce, 2016). As 
global miRNA profiling segregates mGCTs from non-malignant controls, new avenues for 
developing miRNA-targeted therapy in the future has been opened for this tumour type. 
However, in order to develop this, first it’s crucial to understand the causes of miRNA 
dysregulation and their effect on mGCT progression. 
 
The investigation was divided into four major parts: 
•   Part I- Providing evidence for the importance of miRNA downregulation in 
mGCTs compared with non-malignant controls. 
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Levels of the most downregulated miRNAs were reanalysed from previous microarray 
expression data performed in the lab (Palmer et al., 2010). From these data, miRNA 
downregulation was compared between clinical samples derived from mGCTs and 
representative mGCT cell lines and non-malignant control samples. Subsequently, the 
relevance of these miRNAs was assessed by looking at the specific seed abundance 
decrease in the mRNA profile of mGCTs. Raw data from the mRNA microarray were 
available in the lab (Palmer et al., 2010). 
 
•   Part II- Elucidating the cellular level where miRNA downregulation occurs 
MiRNA deregulation may occur in a variety of ways (Rupaimoole et al., 2016). A 
multitude of steps need to be tightly regulated for normal miRNA production and 
expression levels. For instance, at the genomic level, an alteration in the copy number 
of specific loci could affect the quantity of miRNA production (Kloosterman and 
Hochstenbach, 2014). Similarly, alterations in the biogenesis pathway of miRNA could 
also affect its maturation (Ha and Kim, 2014).  
In my study, I have focused on the following- 
i)   Genomic DNA copy number analysis was performed to look for evidence 
of copy number loss at these loci in mGCT cell lines as compared with non-
malignant samples. 
ii)   qRT-PCR was used to quantify primary miRNA transcripts (pri-miRNA), -
3p counterpart and host genes, to identify relative contributions of the 
miRNAs and to elucidate the biogenesis stage in which miRNA 
downregulation occurs. 
 
•   Part III- Understanding the contribution of methylation to miRNA 
downregulation. 
Given the importance of DNA methylation in the regulation of miRNAs (Loginov et 
al., 2015), and the role of methylation previously described in mGCTs (Shen et al., 
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2018), studies were conducted to clarify a possible involvement of methylation in the 
control of miRNA expression. 
i)   DNA demethylation experiments were performed using 5-azacytidine 
(5-aza) followed by qRT-PCR to quantify the levels of the 
downregulated miRNAs.  
ii)   Semi-quantitative analysis such as bisulfite conversion was performed 
followed by quantitative analysis such as pyrosequencing to accurately 
quantify the percentage of methylation on CpG islands. 
 
•   Part IV- Evaluation of downstream consequences of the replenishment of these 
putative tumour-suppressor miRNAs in vitro using mGCT cell lines.  
The next part of the study was to understand the effects of miRNAs replenishment in 
vitro on mGCTs to characterize their importance in the progression of cancer. This step 
was essential to set the basis for future in vivo work. 
i)   Phenotypic effects on cancer cell proliferation was assessed, along with 
the miRNA, mRNA target and protein alterations that underpin these 
changes. 
ii)   Further, in order to identify downregulated protein-coding targets 
following replenishment, assessment of global mRNA levels was 
performed using microarray/sequencing technology and systematic 
interrogation using the bioinformatic tool Sylamer (van Dongen, Abreu-
Goodger and Enright, 2008a). 
iii)   Pathway analysis of the putative gene target was analysed using 
different bioinformatic tools and the most significant ones were carried 
forward for further characterisations.  
Part I and Part II of my investigations are presented in Chapter 3 of this thesis, part III is 
presented in Chapter 4 and Part IV in Chapter 5. 
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2.1   Cell culture 
Reagents for Cell Culture  
Reagent Company 
Absolute ethanol 
VWR International Ltd, 
Radnor, PA,USA 
Dulbecco’s Modified Eagle’s Medium (DMEM) with GlutaMAZ-1 
Gibco, Thermo Fisher 
Scientific, Waltham, MA, 
USA 
Dulbecco’s Modified Eagle’s Medium (DMEM) with GlutaMAZ-1, no 
sodium pyruvate 
Opti-MEM Reduced serum media 
10X Trypsin-EDTA: porcine trypsin (5 g/ml) and EDTA (2 g/ml) 
RPMI-1640 medium 
Sigma-Aldrich, 
St. Louis, MO, USA 
Dimethyl sulphoxide (DMSO) 
Penicillin-Streptomycin: 10,000 units’ penicillin + 10 mg 
streptomycin per ml in 0.9% NaCl (100X stock) 
200 mM L-Glutamine (100X stock) 
Dulbecco’s Phosphate Buffered Saline modified without calcium 
chloride and magnesium chloride (PBS) 
USA HI fetal calf serum 
Hyclone; Thermo Fisher 
Scientific, Waltham, MA, 
USA 
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Table 2.1: Reagents used in tissue culture. 
 
2.2   Cell lines 
For in vitro studies, four human malignant germ cell tumours (mGCTs) cell lines were 
selected that reflected the range of malignant GCT histological subtypes commonly observed 
in clinical practice:, namely Embryonic carcinoma (EC) [2102Ep (Damjanov and Andrews 
1983)], yolk sac tumour (YST) [GCT44 (Pera, Blasco Lafita et al. 1987) and 1411H 
(Vogelzang, Bronson et al. 1985)] and seminoma (Sem) [TCam2 (de Jong, Stoop et al. 
2008)]. 
2102Ep and 1411H were provided by Professor Peter Andrews, University of Sheffield, UK. 
GCT44 and TCam2 were provided by Dr. Janet Shipley, Institute of Cancer Research, 
Marsden, Surrey, UK.  
Cells were cultured in their respective media (Table 2.2). All cells were grown in T175 or 
T75 plastic-culture flasks (Corning) at 37°C in an incubator with 5% carbon dioxide (CO2) in 
air. 2102Ep were passaged every 4-5 days when they reached over confluency to maintain 
their embryonal state. TCam2, 1411H and GCT44 were passaged every 3-4 days when 80-
90% confluency was reached. For all cell lines, cell passage was performed by removal of 
supernatant followed by a wash with 10 ml of sterile 1X phosphate buffered saline (PBS,) per 
T175 flask. After the wash, 5 ml of pre-warmed 0.5% trypsin-ethylenediaminetetraacetic acid 
(trypsin-EDTA) was added to the monolayer (Table 2.1). Cells were then incubated at 37°C 
and visually inspected under microscope until they had fully detached from the culture 
surface. The cells were then centrifuged for 5 min at 300 g. The supernatant was aspirated 
FBS Good 
PAN Biotech, Aidenbach, 
Germany 
Trypan blue stain (2X) 0.4% solution for use with Countess cell 
counter 
Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, 
USA 
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and cells resuspended with 6 ml of pre-warmed media, 2 ml of this suspension was added to 
T175 containing 20 ml of pre-warmed medium.  
Cell 
Lines 
Description 
Media 
used 
10% FCS 
Penicillin 
(100 U/ml) 
and 
Streptomycin 
(0.1 mg/ml) 
Reference 
2102Ep 
(EC) 
EC-derived from adult 
teratocarcinoma with 
mixed mGCT (mainly 
EC) 
Dulbecco’s Modified 
Eagle Medium (DMEM) 
(+ 2 mM Glutamine; no 
sodium pyruvate) 
Hyclone Heat-
Inactivated fetal calf 
serum (HI-USA 
FCS) (10X) 
1% 
(Andrews et al., 
1982) 
1411H 
(YST) 
YST–derived from a 
testicular 
teratomacarcinoma 
DMEM+Glut-pyr 
Hyclone Heat-
Inactivated fetal calf 
serum (HI-USA 
FCS) (10X) 
1% 
(Vogelzang et 
al., 1985) 
GCT44 
(YST) 
YST–derived from 
metastatic site: para-
aortic lymph node 
Dulbecco’s Modified 
Eagle Medium (DMEM) 
Standard fetal calf 
serum (FCS) (10X) 
1% 
(Pera, Köberle 
and Masters, 
1995) 
TCam2 
(Sem) 
Sem–derived from 
primary lesion of a left 
testicular seminoma 
RPMI-1640 + Glut 
Standard fetal calf 
serum (FCS) (10X) 
1% 
(Mizuno et al., 
1993) 
Table 2.2: Cell lines with their respective culture methods used. 
 
   Cell counting and seeding for experiments 
For cell counting, the cells were trypsinised and resuspended into pre-warmed medium. 10 µl 
of cells suspension was mixed 1:1 volume with 0.4% trypan blue dye (Thermo Fisher 
Scientific) and 10 µl of the mixed solution was added to each of the counting chambers A and 
B of a Countess automated cell counter (Invitrogen). Trypan blue stains dead cells blue and 
allows distinction between live and dead cells. For transfection experiments, the cells were 
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seeded in 6-well pates; density at which cells were plated differed between cell lines as 
indicated in (Table 2.3). 
 
Cell line Culture dish Growth area (cm2) 
Cell seeding number 
x 105 
Medium volume (ml) 
2102Ep 
24-well plate 1.9 1.5 0.5 
12-well plate 3.8 3 1 
6-well plate 9.6 7.5 2 
1411H 
24-well plate 1.9 0.2 0.5 
12-well plate 3.8 0.4 1 
6-well plate 9.6 1 2 
GCT44 
24-well plate 1.9 0.2 0.5 
12-well plate 3.8 0.4 1 
6-well plate 9.6 1 2 
TCam2 
24-well plate 1.9 0.2 0.5 
12-well plate 3.8 0.4 1 
6-well plate 9.6 1 2 
Table 2.3: Cell culture seeding density and volumes. 
 
   Cell freezing and thawing 
For freezing cells, after trypsinising and counting, the cell suspension was centrifuged at 300 
g for 5 min and the supernatant subsequently removed. The cells were then resuspended in 
freezing medium [90% volume of cell line specific FCS and 10% volume of dimethyl 
sulphoxide (DMSO)] to achieve a concentration of 1x106 cells/ml and aliquoted into cryogenic 
vials (‘cryovials’, Nunc A/S). These vials were placed into a Mr FrostyTM (Thermo Fisher 
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Scientific) container and stored overnight at 80°C to achieve a gradual cooling process. The 
following day the cells were moved to a liquid nitrogen tank. 
 
For thawing cells, the cryovials were first transferred on dry ice from the liquid nitrogen 
container to the tissue culture facility. The cryovials were gently agitated in a water bath at 
37°C until almost no ice was visible. The cell suspension was then poured into a 15 ml tube 
containing 10 ml of pre-warmed culture medium and spun at 300 g for 5 min in a Sorvall 
Legend T centrifuge (Thermo Scientific, Epsom, Surrey, UK). The supernatant was carefully 
aspirated and the cell pellet resuspended in 2 ml of the appropriate pre-warmed medium (Table 
2.1). This suspension was used to seed a 25 cm2 (T25) flask containing a further 4 ml of pre-
warmed medium. Cells were incubated at 37°C in 5% CO2.  
   Cell treatment using mimic transfection 
   Volume of transfection reagents and duration of transfection 
The cell lines 2102Ep, 1411H, GCT44 and TCam2 were seeded in 2 ml of growth medium 
without penicillin-streptomycin (P/S) in 6-well plates (Corning) and allowed to grow to around 
30~40% confluency before being treated in triplicate at day 0 (d0) with the transfection reagent 
Lipofectamine RNAiMAX (Thermo Fisher Scientific, Cat. #13778030). Mimics (mirVana®, 
Thermo Fisher Scientific) were transfected at three different concentrations: 8.3 nM, 16.7 nM 
and 33.3 nM. 8 µl of Lipofectamine RNAiMAX was added to 200 µl of specific OptiMEM® 
transfection media and incubated at room temperature for 20 min. At d0, triplicate wells were 
treated by transfection with 16.7 nM of miR-100-5p (mirVana® miRNA mimic, Cat. 
#4464066), 16.7 nM of miR-125b-5p (mirVana® miRNA mimic, Cat. #4464066), 16.7 nM of 
non-targeting control (NTC) (mirVana® miRNA mimic negative control #1, Cat. #4464058), 
an equal combination of 8.3 nM miR-100-5p mirVana® miRNA mimic and 8.3 nM miR-125b-
5p mirVana® miRNA mimic, a combination of 16.7 nM miR-100-5p mirVana® miRNA mimic 
and 16.7 nM miR-125b-5p mirVana® miRNA mimic or 33.3 nM of NTC (Table 2.4). 
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Mimics used 
Single mimic 
concentration 
Final concentration of 
all mimics 
Lipofectamine 
RNAiMAX 
Opti-
MEM 
miR-100-5p 16.7 nM 16.7 nM 8 µl 200 µl 
miR-125b-5p 16.7 nM 16.7 nM 8 µl 200 µl 
(miR-100-5p+miR-
125b-5p) 
8.3 nM 16.7 nM 8 µl 200 µl 
(miR-100-5p+miR-
125b-5p) 
16.7 nM 33.3 nM 8 µl 200 µl 
NTC 16.7 nM 16.7 nM 8 µl 200 µl 
NTC 33.3 nM 33.3 nM 8 µl 200 µl 
Table 2.4:  Conditions used for mimic experiment.  
 
Two 6 well-plates of untreated cells were used for comparison of cell numbers at day 0 (d0), 
day 2 (d2), day 4 (d4) and day 7 (d7). These studies identified that 8 µl of Lipofectamine 
RNAiMAX was well tolerated, as long as the duration of transfection was adjusted in a cell 
line dependent fashion (8 hrs for 2102Ep and GCT44, 6 hrs for 1411H and 4 hrs for TCam2). 
Transfection was performed using normal media without P/S, as previously described (Murray 
et al., 2013), before a media change, which was repeated daily thereafter. From the second day 
after the transfection, the media included P/S. At d2, d3, d4 and d7, cells were trypsinised and 
RNA extracted. 
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2.3   DNA work 
   DNA sample 
In the first instance, DNA was extracted from four representative mGCT cell lines: 2102Ep, 
TCam2, GCT44, 1411H and from testis of a healthy patient samples as normal gonadal control 
(Genomic DNA – human adult normal tissue: testis, BioChain, Cat. #D1234260).  
   DNA extraction 
For DNA extraction, cells were pelleted in a 15 ml falcon tube and 5 ml of lysis buffer (10 mM 
Tris-Cl pH 8, 10 mM EDTA pH 8, 150 mM NaCl, 0.4% SDS) with 1 mg/ml protease K was 
added. Samples were incubated at 37°C overnight. The next day the adequate digestion of cells 
was confirmed and if not sufficient an extra volume of lysis buffer was added and samples 
were incubated for an extra 4 hrs at 37°C. Equal volumes of phenol-chloroform were 
subsequently added to the solution of lysed cells and phase separation performed by 
centrifugation for 10 min at 1,800 g resulting in a lower organic phase and an upper aqueous 
phase. The upper aqueous phase was carefully removed and two further washes with 
phenol/chloroform performed. The phenol-chloroform combination reduces the partitioning of 
poly(A) and mRNA into the organic phase and reduces the formation of insoluble RNA-protein 
complexes at the interphase. The pH of phenol determines the portioning of DNA and RNA 
into the aqueous and the organic phase, respectively.  
After the third wash with phenol/chloroform, 5 ml of chloroform was added to completely 
remove any phenolic and organic contaminants, the sample was subsequently mixed and 
centrifuged at 1,800 g for 10 min. The top layer was transferred in a clean 15 ml falcon tube 
and 2 volumes of 100% ethanol were added to one volume of the aqueous solution. Finally, 
1/10th of 3 M sodium acetate (pH 5.2) was added to one volume of the aqueous solution and 
samples were stored at -20°C overnight. 
The next day the samples were spun at 4°C, 12,000 g for 10 min to pellet the DNA, supernatant 
was discarded. The pellet was then washed with 70% cold ethanol and centrifuged at 12,000 g 
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for 10 min, supernatant was discarded. Finally, the pellet was air-dried for 15 min, re-
suspended with 20 μl of nuclease free water, and left overnight at 4°C. DNA was subsequently 
quantified using a NanoDrop (Thermo Scientific) spectrophotometer to confirm satisfactory 
purity and obtain the resultant DNA concentration. The samples were diluted if needed and 
stored at -20°C. 
   Primer design 
All primers to assess for genomic loss were designed using the website: ‘Primer3’ 
(http://bioinfo.ut.ee/primer3-0.4.0/primer3/) and subsequently ordered from Sigma Aldrich. 
Genomic sequences were downloaded from the Ensembl Genome Browser 
(http://www.ensembl.org/index.html) according to Human release GRCh38. Forward and 
reverse primers were designed to have a length between 18 and 23 nt (optimal size 20 nt), a 
product size between 80 and 100 nt and a melting temperature between 59°C and 62°C. The 
designed primer pairs were screened using PRIMER BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome). I 
identified primer pairs that were specific to the intended PCR target. This method uses the 
Basic Local Alignment Search Tool (BLAST) and a global alignment algorithm to screen 
primers against a user-selected database in order to avoid primer pairs (all combinations 
including forward-reverse primer pair, forward-forward as well as reverse-reverse pairs) that 
may cause non-specific amplification. The optimal primer pairs for each genomic locus 
(minimum two pairs) were then formally tested by qPCR and assessed for target abundance 
(i.e. Ct value), primer efficiency calculation and melting curve assessment for the presence of 
a single product. 
   Primer efficiency calculator 
Total DNA from the malignant GCT cell line, 1411H was used to calculate the primer 
efficiency for each pair of primers. Primer efficiency is the multiple by which the target DNA 
is amplified per PCR cycle. Under ideal conditions each pair of primers should double the 
amount of DNA target per cycle, giving an optimal primer efficiency of 2. In reality, values 
≥1.80 are considered acceptable. These efficiencies were calculated using a cell line known to 
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express the target gene sufficiently to be detected within 45 PCR cycles. Six different DNA 
dilutions were performed (starting from undiluted DNA at a concentration of 10 ng/µl and then 
having 1:2, 1:4, 1:10, 1:50 and 1:100 dilutions). 
All reactions were performed in triplicate in 96-well plates, using the SYBR green qPCR 
protocol described below and using the Realplex Mastercycler ep-gradient S machine 
(Eppendorf) (PCR conditions described in Table 2.5). 
 
Stage Time (min) Temperature (°C) 
Hold 2:00 95° 
45 cycles 
0:15 95° 
0:20 58° 
0:15 72° 
0:08 76° 
Melting curve 
8:00 78° 
0:15 95° 
0:15 65° 
0:15 95° 
Table 2.5: PCR conditions for primary efficiency calculations. 
 
The raw data derived from the fluorescent calculation was exported in Microsoft Excel (.xls) 
format and the primer efficiency was calculated by using the ‘Primer Efficiency Calculator’ 
program designed by Dr. Ian Roberts (ex-member of Coleman’s lab). This program plots Ct 
values for each reaction versus the log10 (relative amount of target amplicon). Linear regression 
was performed to determine a line of best fit for these data points, and the slope of the line was 
calculated. Primer efficiency was then determined using this equation: 𝑝𝑟𝑖𝑚𝑒𝑟	  𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 	  10× − 1𝑠𝑙𝑜𝑝𝑒 − 1 
 
For each primer pair, target abundance (Ct value), primer efficiency and melting curves (to 
confirm the presence of only one product) were considered in order to choose the most reliable 
pair of primers.  
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   Polymerase chain reaction 
The PCR reactions were conducted using JumpStartä Taq DNA polymerase (Sigma-Aldrich, 
#D9307), to find optimal PCR condition to obtain a suitable concentration of DNA to enable 
sequencing of the fragment of interest and were performed in a MJ Research Tetrad PTC-225 
Peltier Thermal Cycler. The reagent for the PCR were combined in 0.2 ml non-flex PCR tube 
(Starlab) for a total concentration of 25 µl or 50 µl. The reaction components (Table 2.6) and 
the cycling conditions (Table 2.7) are listed below. 
 
Reagent Volume per reaction 
Buffer 10X 2.5 μl 
dNTP (2 μM) 2.5 μl 
Forward primer (2 μM) 2.5 μl 
Reverse primer (2 μM) 2.5 μl 
JumpStart Taq DNA polymerase 0.5 μl 
DNA (12.5 ng/μl) 2 μl 
Nuclease-free water (NFW) 12.5 μl 
Total Volume 25 μl 
Table 2.6: Reagents required for PCR.  
PCR Step Time (min) Temperature (°C) 
Initial Denaturation 2 94° 
40-45 cycles 
Denaturation 0:30 94° 
Annealing 0:30 50-60° 
Extension 1 72° 
Final extention 7 72° 
Table 2.7: PCR reaction conditions. 
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The resultant PCR samples were kept at 4°C until further use. The PCR products were then 
mixed with 1X Orange G tracking dye (SigmaAldrich, Cat. #O3756) and run on a 1% agarose 
gel alongside a 100 bp ladder (New England Biolabs). The resultant gel was visualised using a 
Quantity One UV machine (Bio-Rad). 
   DNA gel extraction 
Specific DNA bands identified were cut out and gel purified in order to isolate the desired DNA 
fragment required for sequencing. Extraction of the DNA from the agarose gel was completed 
using the QIAquickâ Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. 
Briefly, the excised band was placed in a 1.5 ml Eppendorf tube and the mass of the gel 
fragment determined. 3X gel volumes of Buffer QG were added to each tube, where 100 mg = 
100 μl, and the sample incubated at 50°C for 10 min. Once dissolved, 1X gel volume of 
isopropanol was added and mixed. The sample mixture was then applied to a QIAquick column 
in a 2 ml collection tube and centrifuged at 17,900 g for 1 min. The flow through was discarded 
and the column washed with 500 μl Buffer QG followed by 750 μl Buffer PE. The column was 
then placed into a clean microcentrifuge tube and DNA eluted in 30 μl ddH2O. The 
concentration of DNA was then determined using a Thermo Scientific Nanodrop 2000 
Spectrophotometer. The samples were then placed in a -20°C freezer until further use. The 
DNA sequencing was completed by the Department of Biochemistry, University of Cambridge 
according to the specifications of the institute (DNA at 20 ng/100 bp in 10 μl).  
   DNA sequencing analysis 
The resultant sequencing files were viewed using DNA sequencing software ChromasPro 
(Technelysium). Chromatograms were used to assess the quality of the sequence data and the 
alignment tool was used to compare samples as well as to detect any changes to the expected 
sequence.  
When DNA sequencing analysis was used in the biosulfite experiment, DNA sequences were 
compared with look at CpG changes between mGCTs and non-malignant controls. 
58 Materials and Methods 
 
Chromatograms were analysed using ImmageJ and when a double peak was detected, usually 
C and T in a CpG island, the relative contribution of the C or T was calculated by equating the 
two peaks to 100% and then assign a proportion for each nucleotide depending on the peak’s 
height. 
   Quantitative-PCR (qPCR) analysis of gDNA samples 
To determine genomic copy number of chromosome 11 and chromosome 21, primers adjacent 
to the area of miR-100/-125b-1 and miR-99a/-125b-2, were created (Table 2.9). DNA was 
extracted and measured in triplicate in four representative mGCT cell lines: 2102Ep (EC), 
1411H (YST), GCT44 (YST) and TCam2 (Sem) and in a testis patients’ samples as a control. 
Each experiment was performed in triplicate using SYBRâ Green JumpStartä Taq 
ReadyMixä (Sigma-Aldrich, Cat. #S4438) (Table 2.8). Test reactions and non-template 
controls were run in triplicate on a realplex real-time PCR system (Mastercyclerâ Eppendorf). 
QPCR cycle conditions were the same as those used for the primer efficiency assay described 
in Table 2.5.  
 
Reagents used Volume per reaction 
SYBR Green 2.5X 10 µl 
Primer mix (4 µM) 2 µl 
gDNA (25 ng) 8 µl 
Total volume 20 µl 
Table 2.8: Reagents used for qPCR of gDNA. 
 
Realplex qPCR software was used to automatically determine the fluorescence threshold and 
return a cycle threshold number (Ct). Melting curve analyses were obtained after each PCR run 
at 65°C to 90°C and showed a single PCR product, confirming specificity of amplification. 
Expression ratios of the genomic sequences were calculated using the comparative threshold 
cycle (Ct) method described by (Pfaffl, 2001), with normalisation to four reference genes 
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(B2M, GAPDH, 18A and 18B).  18A (at position chr18: 9103147-9103241 of the Ensembl 
version GRCh38) and 18B (at position chr18: 6401843-6401934 of the Ensembl version 
GRCh38) represent two regions known not to be deregulated in GCTs on chromosome 18. Cts 
for each particular DNA sample then referenced to the control samples (Table 2.9).  
CHROMOSOME 11 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
MIR100HG AGACATCTGAGGGGCAACC GCGAGGAAGCCAAGTTTATG 
50Kb upstream miR-100 GTGTATGGGGAAGGCAATGT GCACGAAGGAAGGATGGTAA 
10Kb upstream miR-100 CTAGCCATGTTGCTTGTTTCTTT AGACACCTTTCATTCTACCACCA 
5Kb upstream miR-100 GATAAAACGTGGCACGACAAT TTTGCCAAAAGATCCAATCAC 
miR-100 CCCGTAGATCCGAACTTGTG TATAAGCAAAGCCCCAGGTC 
Let-7a-2 ATGCTCCCAGGTTGAGGTAGTA GTTTAGTGCAAGACCCAAGGAA 
BLID TGCAAGACACATTCCTTCTCA AGCAGCAGCAGAGAGGCTAT 
10Kb upstream miR-
125b-1 CGGCTAGATTGAATGAAAGACC CATAGTTGGGAACTGAGGCAAT 
miR-125b-1 AGAAAACATTGTTGCGCTCCT AGAGCCTAACCCGTGGATTTA 
CHROMOSOME 21 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
MIR99AHG AGAGAAGCCGGCACTCAGAT CAGTTGCGTAGAGTAAAAGTGTGC 
50Kb upstream miR-99a TGAAAACATTGTGTCAGCTTCA TTAATCCGCAGAGGCAATTC 
10Kb upstream miR-99a AAATTGTGAAACGTTCCCTCTTC GCATCTGGCCATTATTGAAAGT 
5Kb upstream miR-99a GATAAAACGTGGCACGACAAT TTTGCCAAAAGATCCAATCAC 
miR-99a CCCGTAGATCCGAACTTGTG TATAAGCAAAGCCCCAGGTC 
Let-7c ATGCTCCCAGGTTGAGGTAGTA GTTTAGTGCAAGACCCAAGGAA 
10Kb upstream miR-
125b-2 CGGCTAGATTGAATGAAAGACC CATAGTTGGGAACTGAGGCAAT 
miR-125b-2 AGAAAACATTGTTGCGCTCCT AGAGCCTAACCCGTGGATTTA 
HOUSE KEEPER GENES 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
GAPDH TTGTCAAGCTCATTTCCTGGT GAATGAGGAACCTCCGGTACA 
B2M CGGCTCTGCTTCCCTTAGACT TCACAGCCAAGCATTCTACAAAC 
18 A GAGGCACCTCTCGTTTCAAG TTCTCCCTAAGCCTTCACGA 
18 B GCAGTAGGGCAAGGGTGTAG TGGAGGTTTGGATTGAGGTC 
Table 2.9: Primers used for genomic copy number assessment in mGCTs cell lines and normal 
testis. 
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2.4   RNA work 
   RNA extraction (miRNA and total RNA) 
MiRNA and total RNA extractions for the various GCT cell lines were performed using 
TriReagent (Sigma-Aldrich, St Louis, Missouri, USA), following the TriZol RNA extraction 
protocol (Rio et al., 2010). Experiments carried out in 6-well plates were directly treated with 
1 ml of TriReagent per well and the resulting suspension transferred to a 1.5 ml Eppendorf 
tube. 200 µl of saturated chloroform was added, left briefly at room temperature and then spun 
at 16,000 g for 40 min. The upper aqueous phase containing RNA was then carefully separated 
from the interphase and pink organic layer into a clean Eppendorf tube. RNA was precipitated 
by adding 2-propanol, left to stand and then spun in a microcentrifuge at 16,000 g for 5 min. 
The supernatant was removed and the resultant pellet washed with ice-cold 75% ethanol, and 
then respun for 5 min at 16,000 g. After removing all liquid with a pipette, the pellet was air-
dried for 5 min, dissolved in nuclease-free water and placed on a heat block set at 55°C for 10 
min. RNA was then quantified using a Nanodrop 2000 Spectrophotometer (Thermo Fisher 
Scientific Inc., Waltham, Massachusetts, USA).   
   cDNA synthesis 
Synthesis of complementary DNA (cDNA) from RNA was done using the QuantiTectâ 
Reverse Transcription Kit (Qiagen, Cat. #205310) according to the manufacturer’s 
instructions. In order to ensure the removal of any contaminating genomic DNA, 1 µg of RNA 
template and 2 µl of Genomic DNA Wipeout buffer were added to an RNase-free 0.2 ml 
microcentrifuge tube together with nuclease-free water up to a final volume of 14 µl. The 
reaction was incubated for 2 min at 42°C and then samples placed immediately on ice. Samples 
underwent the reverse transcription step as per the manufacturer’s instructions (Table 2.10). 
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Reagents Volume per reaction 
Quantiscript RT buffer 4 µl 
RT primer mix (polyT plus random hexamer 
primers) 1 µl 
Quantiscript reverse transcriptase 1 µl 
Total volume 6 µl 
Table 2.10: Reagents used for mRNA cDNA synthesis. 
The mixture was added to 0.2 ml microcentrifuge tubes containing RNA template. The mixture 
was then incubated in a GeneAmp 9700 PCR Thermal Cycler at 42°C for 30 min to generate 
complementary DNA (cDNA), followed by 3 minutes at 95°C to inactivate the enzyme. 
Following the reverse transcription reaction, the synthesised cDNA was diluted 1:80 using 
ddH2O, and was immediately used for qPCR amplification or placed at -20°C for long-term 
storage.  
   RT-qPCR analysis of cDNA samples 
RT-qPCR was used to quantify the level of relative cDNA levels between samples. RT-qPCR 
was performed using SYBRâ Green JumpStartä Taq ReadyMiXä Green Master Mix (Sigma), 
as per manufacturer’s instruction (Table 2.11). 
Table 2.11: Reagents used for mRNA RT-qPCR. 
 
The RT-qPCR reaction was carried out in triplicate for each primer pair in 96-well white PCR 
plates (Starlab) using an Eppendorf Mastercycler ep gradient S realplex2. The cycling 
conditions followed the manufacturer’s instructions (Table 2.12). 
  
Reagents Volume per reaction  
Sigma SYBR Green Buffer  10 µl  
Specific primer pair (4uM)  2 µl  
(5 ng) cDNA (1:80)  8 µl  
Total volume 20 µl  
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Stage Temperature (°C) Time (min) 
Denaturation  95° 2 
Cycle 
(40 Cycles) 
95° 0:15 
58° 0:20 
72° 0:15 
Final extension 76° 8 
Table 2.12: Reaction conditions required for mRNA RT-qPCR. 
 
The primer efficiency of each qRT-PCR primer was determined as previously described. 
Primers sequences are described below (Table 2.13). 
 
Name Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Reference/Supp
lier 
LIN 28A 
GAAGCGCAGATCAAAAGGA
G 
CTGATGCTCTGGCAGAAGTG 
(Murray et al., 
2013) 
H1_ARID 
3A 
CATCATGTACACAGGAGTTC AAGGCAACGAGTTATTTGAG 
Sigma-Aldrich 
KiCqStartä 
H3_ARID 
3B 
TCAACAAGAAGATCTGGAGG CTTTCTTCTCACACTCATAGG 
Sigma-Aldrich 
KiCqStartä 
H1_TRIM 
71 
TGGAAGGTAGAAAAGATCCG TCAAGCTTGTTGAGGTTTTG 
Sigma-Aldrich 
KiCqStartä 
H1_CTDS
PL 
ATGGAAAGAAATGTGTGGTC ACCTGATGTATAGTTCCATCG 
Sigma-Aldrich 
KiCqStartä 
H1_E2F7 CTACAGCTTGATGTTGTTGG 
GTAGTTTTCTCAGTTGACAAG
G 
Sigma-Aldrich 
KiCqStartä 
mTOR ACAGCCCAGGCCGCATTGTC TCCAGGGACTCCGTCAGGCG Persoal design 
2.4 RNA work 63 
 
H1_FGFR
3 
GAAGATGCTGAAAGACGATG GCAGGTTGATGATGTTTTTG 
Sigma-Aldrich 
KiCqStartä 
GAPDH TGCACCACCAACTGCTTAGC 
GGCATGGACTGTGGTCATGA
G 
(Vandesompele et 
al., 2002) 
ACTB CTGGAACGGTGAAGGTGACA 
AAGGGACTTCCTGTAACAAT
GCA 
(Vandesompele et 
al., 2002) 
RPLI13A 
CCTGGAGGAGAAGAGGAAA
GAGA 
TTGAGGACCTCTGTGTATTTG
TCAA 
(Vandesompele et 
al., 2002) 
YWHAZ 
ACTTTTGGTACATTGTGGATT
CAA 
CCGCCAGGACAAACCAGTAT 
(Vandesompele et 
al., 2002) 
 Table 2.13: Primers used for RT-qPCR analysis of cDNA samples. 
 
   Quantification of transcript level changes 
Based on Vandesompele and co-worker’s findings (Vandesompele et al., 2002), a range of 
housekeeping genes were tested for each different experimental condition in order to obtain a 
baseline level of expression for comparative analysis of gene expression. Gene expression 
ratios were calculated using the comparative threshold cycle (Ct) method described by Pfaffl 
(Pfaffl, 2001). The house keeping genes used for normalisation were: GAPDH, YHWAZ, 
RPL13A and ACTB (Table 2.13).  
   Pri-miRNA assay 
Levels of pri-miR-100; pri-miR-99a, pri-miR-125b-1 and pri-miR-125b-2 were quantified in 
quadruplicate. The total RNA extracted from cells firstly underwent treatment with TURBO 
DNA-free kit (Part number AM1907, Ambion, Thermo Fisher Scientific Inc, USA) as per the 
manufacturer’s recommendation. Initially, 100 ng of RNA was used and diluted to a final 
volume of 10 µl with nuclease-free water. However, due to very low abundance of pri-miRNA 
product at this concentration of RNA (Ct threshold values generally >40 cycles or 
undetectable), more RNA input was needed in order to accurately quantify pri-mRNA levels 
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(1000 ng). Briefly, 1 µl of 10X TURBO DNAse (2U) was added to the initial RNA and 2 µl of 
DNase inactivation reagent was subsequently added added at the mix. The sample was then 
incubated for 30 min at 37°C. Subsequently, the samples were incubated for 2 min at room 
temperature and then centrifuged at 12,000 g for 1.5 min and the supernatant containing RNA 
was transferred to a fresh 1.5 ml Eppendorf tube.  
Samples then underwent reverse transcription using Taqman High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Warrington, UK, Cat. #4368814), which is specifically 
designed for low abundance targets, as per the manufacturer’s instructions (Table 2.14). The 
samples were then placed in a GeneAmp 9700 PCR Thermal Cycler with the cycling condition 
listed in (Table 2.15). 
 
Reagents Volume per reaction 
RT buffer 2 µl 
Random primers 2 µl 
Multiscribe reverse transcriptase 1 µl 
Deoxynucleotide triphosphate (dNTP) 0.8 µl 
Nuclease-free water (NFW) 4.2 µl 
TURBO DNase-treated RNA 10 µl 
Table 2.14: Reagents used for pri-miRNA cDNA synthesis. 
 
Temperature (°C) Time (min) 
25° 5 
42° 30 
85° 5 
Table 2.15: Reaction conditions for pri-miRNA cDNA synthesis. 
 
cDNA was then used to quantify the levels of pri-miRNA levels by qRT-PCR using Taqman 
2X Universal primer master mix (No AmpErase UNG) and the relevant pri-miRNAs (pri-miR-
100, pri-miR-99a, pri-miR-125b-1 and pri-miR-125b-2) or housekeeping assays: RPLO, GUS-
B and 18S (Applied Biosystem) (Table 2.18).  
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The necessary mix (Table 2.16) was prepared in half-skirted clear 96-well PCR plates (Axygen 
Biosciences, Union City, California, US), and run on the Realplex Mastercycle ep-gradient S 
machine (Eppendorf) according to the cycling conditions listed below (Table 2.17).  
 
Reagents Volume per reaction 
Taqman 2X Universal mastermix 10 µl 
Relevant pri-miRNA 1 µl 
Nuclease-free water (NFW) 5 µl 
cDNA product 4 µl 
Table 2.16: Reagents required for TaqMan pri-miRNA qRT-PCR. 
 
Stage Temperature (°C) Time (min) 
Hold 95° 10 
Cycle 
(40 Cycles) 
95° 0:15 
60° 1 
Table 2.17: Reaction conditions required for TaqMan pri-miRNA qRT-PCR. 
 
Finally, Ct values were exported in Microsoft Excel (.xls) format from the Realplex 
Mastercycler and the expression ratios was calculated using the comparative Ct method and 
normalised to the three housekeepers. 
 
Taqman assay miRBase accession Assay ID 
hsa-pri-miR-99a MI0000101 Hs03302729_pri 
hsa-pri-miR-100 MI0000102 Hs03302731_pri 
hsa-pri-miR-125b-1 MI0000446 Hs03303095_pri 
hsa-pri-miR-125b-2 MI0000470 Hs03303224_pri 
RPLO N/A Hs99999902_m1 
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GUS-B N/A Hs99999908_m1 
18S N/A Hs99999901_s1 
Table 2.18: Taqman assays used for quantification of pri-miRNA levels. 
 
   Taqman qRT-PCR 
MiRNA expression levels were quantified using Taqman quantitative real-time PCR (qRT-
PCR) assays in two separate steps (Applied Biosystems, Warrington, UK), as per the 
manufacturer’s instructions. The first step was necessary in order to reverse transcribe miRNA 
into single stranded cDNA. Total RNA was quantified and diluted to 5 ng/µl where necessary. 
Reverse transcription (RT) was performed using Taqman microRNA Reverse Transcription 
Kit (Applied Biosystems), adopting specific stem-loop primers for each of the miRNAs tested 
and housekeeping gene (Cat. #4427975 for all assays, Applied Biosystems) (Table 2.23). 
The necessary mix (Table 2.19) was prepared in half-skirted clear 96-well PCR plates (Axygen 
Biosciences, Union City, California, US), and run on a GeneAmp 9700 PCR Thermal Cycler 
(Applied Biosystems) according to the cycling conditions listed below (Table 2.20).  
Reagent Volume per reaction 
dNTP (100 mM) 0.1 μl 
Multi-scribe RT enzyme (50 U/μl) 0.67 μl 
RT buffer (10X) 1 μl 
RNase inhibitor (20 U/μl) 0.13 μl 
Nuclease-free water (NFW) 2.77 μl 
Specific primer 2 μl 
Relevant RNA 3.33 μl 
Total volume 10 μl 
Table 2.19: Reagents required for mature miRNA cDNA synthesis. 
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PCR Step Time (min) Temperature (°C) 
Pre-incubation 30 16° 
Annealing/extension 30 42° 
Enzyme inactivation 5 85° 
Hold ∞ 4° 
Table 2.20: Reaction conditions for miRNA cDNA synthesis. 
 
The second step was undertaken using the TaqMan qPCR kit (Applied Biosystems, 
Warrington, UK) to quantify the cDNA RT products in triplicate on a Starlab 96-well plate. 
Initially the concentration to detect miRNA-5p and miRNA-3p used was 15 ng, but further 
optimisation was necessary to detect miRNA-3p strand as the product at this concentration of 
RNA was undetectable (Ct values > 37 cycles) and the concentration was increased to 100 ng. 
The necessary mix (Table 2.21) was prepared in half-skirted clear 96-well PCR plates (Axygen 
Biosciences, Union City, California, US), and run on a Realplex Mastercycle ep-gradient S 
machine (Eppendorf) according to the cycling conditions listed below (Table 2.22).  
 
Reagent Volume per reaction 
Taqman Universal PCR 2X Master Mix 7.5 μl 
Nuclease-free water (NFW) 5.42 μl 
Specific 20X miRNA assay probe 0.75 μl 
Specific RT product (cDNA) 1.33 μl 
Total volume 15 μl 
Table 2.21: Reagents required for TaqMan miRNA qRT-PCR step. 
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qRT-PCR Step Temperature (°C) Time (min) 
TaqMan activation (Hold) 95° 10 
Denaturation 
X40 
95° 0:15 
Annealing/extension 
X40 
60° 1 
Table 2.22: Reaction conditions for TaqMan miRNA qRT-PCR. 
 
Each of the two steps were run with RT primers and qPCR probes specific to each of miR-99a-5p/3p, -
100-5p/3p, -125b-5p, -125b-1-3p and -125b-2-3p, as well as RNU24, which was previously selected as 
an abundant and stable ‘housekeeping’ gene for specific use in GCT tissues and cell lines (Torres et al., 
2012), and is commonly used as a reference gene for miRNA studies.  
Ct values (calculated automatically by the Realplex Mastercycler) were transferred to 
Microsoft Excel for analysis. Quantification of expression levels of selected miRNAs was 
performed using the ΔΔCt method (Livak and Schmittgen, 2001). Expression levels were 
normalised to RNU24. 
 
Taqman assay miRBase accession Assay ID 
hsa-miR-99a-5p MIMAT0000097 000435 
hsa-miR-99a* (-3p) MIMAT0004511 002141 
hsa-miR-100-5p MIMAT0000098 478224 
hsa-miR-100-3p MIMAT0004512 478619 
hsa-miR-125b-5p MIMAT0000423 477885 
hsa-miR-125b-1-3p MIMAT0004592 478665 
hsa-miR-125b-2-3p MIMAT0004603 478666 
hsa-miR-204-5p MIMAT0000265 000508 
hsa-miR-152-3p MIMAT0000438 000475 
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hsa-miR-26b-3p MIMAT0004500 483077 
hsa-miR-137-3p MIMAT0000429 001129 
hsa-miR-500-3p MIMAT0002871 001046 
hsa-let-7b MIMAT0000063 002619 
hsa-let-7d MIMAT0000065 000380 
hsa-let-7e MIMAT0000066 000381 
RNU24 N/A 001001 
RNU38B N/A 001004 
RNU44 N/A 001094 
Table 2.23: Taqman assays used for quantification of miRNA levels. 
 
2.5   Protein analysis 
   Total protein extraction 
Cells were washed with cold PBS and lysed in cold radioimmunoprecipitation assay (RIPA) 
lysis buffer (Thermo Fisher Scientific) (approximately 80 µl per well of a 6-well plate) 
supplemented with cOmplete™ Protease Inhibitor Cocktail (Roche Diagnostics Ltd., Burgess 
Hill, UK) (1:25 dilution). Cells were then removed from the dish using a cell scraper and were 
transferred into a pre-cooled Eppendorf tube. After 15 min of continuous agitation on a 
vibrating shaking platform at 4°C, cellular debris was removed by centrifugation (15 min, 4°C, 
14,000 g). The supernatant was transferred to a fresh 1.5 ml Eppendorf tube and immediately 
quantified or placed at -80°C for long term storage. 
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   Protein quantification 
Total protein concentration was determined using Pierce bicinchoninic acid (BCA) protein 
assay kit (Thermo Fisher Scientific) according to the manufacturer's instruction with some 
modification. Briefly, protein samples were diluted with PBS (2 µl of protein sample added to 
12 µl of PBS, 1:7 dilution) and 3 µl of diluted sample added to the well of 96-well plate in 
triplicate. The BSA stock standard at 1 mg/ml concentration was used to generate a standard 
curve and was added to each well at 5 different volumes in triplicate: 0 µl (Blank), 1 µl, 3 µl, 
5 µl, 7 µl and 10 µl. The provided Reagent A and Reagent B were mixed together in a ratio of 
1:50 and 200 µl of the mixture was added to each well and incubated for 30 minutes at RT in 
the dark. Absorbance was measured at a wavelength of 570 nm using a Dynex Technologies 
plate reader and Revelation software. Protein concentrations were determined using a standard 
curve (Figure 2.1).  
 
 
Figure 2.1: Example of a standard curve used for BCA assay to determine protein concentration 
based on Absorbance values.  
 
   Protein sample preparation and SDS-PAGE separation 
Quantified protein extract (25 µg) was added to 5 µl of NuPAGEä LDS Sample Buffer and 2 
µl of NuPAGEä Sample Reducing Agent (both from Novex, Thermo Fisher Scientific Cat. 
#NP0008, Cat. #NP0004, respectively) and made up to a final volume of 20 µl with 1X PBS. 
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Samples were denatured for 10 min at 95°C and run immediately on a gel or stored at -20°C. 
Pre-cast 4-12% NuPAGEä Bis-Tris Mini Gels (Thermo Fisher Scientific) were placed in an 
XCell SureLockä Mini-Cell (Thermo Fisher Scientific) and the inner tank filled with 
NuPAGEä MOPS SDS Running Buffer 20X (Thermo Fisher Scientific Cat. #NP0001) 
containing NuPAGEä Antioxidant (Thermo Fisher Scientific, Cat. #NP0005) and the outer 
tank filled to the level of the well base with NuPAGE MOPS SDS Running Buffer without 
Antioxidant. The samples were loaded, along with 10 µl of See Blue molecular weight ladder 
(Novex, Thermo Fisher Scientific, Cat. #LC5625). Proteins were separated by electrophoresis 
at 150 V until the desired protein separation was achieved (approximately 1.5 hrs). 
   Western blotting 
A PVDF membrane (Thermo Fisher Scientific) and two pieces of 3MM Whatman filter paper 
were cut to the size of the SDS-PAGE gel. The PVDF membrane was activated by incubation 
in 100% methanol for 15 sec followed by a 2 min rinse in distilled water (dH2O). The PVDF 
membrane was then transferred to ice-cold Transfer Buffer (Thermo Fisher Scientific) 
(supplemented with 20% methanol and NuPAGE Antioxidant) for at least 5 min to equilibrate.  
The whatman filter paper and four blotting sponges were also pre-soaked in Transfer buffer.  
Following electrophoresis, protein samples separated by SDS-PAGE were transferred to the 
PVDF transfer membrane using the XCell SureLock Mini-Cell and XCell IITM blot module. 
The gel cassette was removed from the mini-cell and the two plates of the cassette separated 
using a gel knife. Wells of the gel were subsequently removed with a gel knife and a piece of 
pre-soaked filter paper was placed on top of the gel. The gel and filter paper were carefully 
peeled away from the cassette and the equilibrated PVDF membrane placed on top of the gel, 
ensuring no air bubbles were present. An additional piece of pre-soaked filter paper was placed 
on top of the membrane.  
Two pre-soaked blotting sponges were placed on top of the cathode core of the XCell IITM 
blot module.  The filter paper – gel – membrane – filter paper ‘sandwich’ was placed on top of 
the sponges and an additional two pre-soaked sponges placed on top of the ‘sandwich’. The lid 
of the blot module was placed on top and the whole assembly inserted into the XCell 
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SureLockTM Mini-Cell. The blot module was filled with Transfer Buffer, and ice-cold dH20 
was added to the outer reservoir.  The protein transfer was performed for 2 hrs at 30 V at 4°C.  
After completion of the transfer, the blot module was dismantled and the PVDF membrane 
stained with Ponceau-S Staining Solution (Sigma-Aldrich) to assess the quality of the protein 
transfer. Membranes were washed first with dH2O, then three times for 5 min with TBS with 
0.5% Tween-20 (TBS-T) and incubated for 1 hour at room temperature with blocking buffer 
(5% skimmed milk in 1% TBS-T). Membranes were incubated at 4°C overnight with primary 
antibodies diluted in antisera buffer (5% skimmed milk in 0.1% TBS-T) (Table 24). The 
following day, the membranes were washed three times for 5 min with TBS-T and incubated 
for 1 hr at room temperature in species specific HRP-conjugated secondary antibodies diluted 
in blocking buffer. Following three further washes with TBS-T, the membrane was developed 
using enhanced standard chemiluminescence (ECL) or ECL prime western blotting detection 
reagents (Amersham, GE Healthcare, Little Chalfont, UK) according to the manufacturer’s 
instructions and exposed to autoradiography films at various time-points. If required, the blots 
were treated with Stripping Buffer (Thermo Fisher Scientific) for 15 min incubation at 37°C in 
the dark; and blots incubated with blocking buffer and re-probed with different primary anti-
bodies. The images were scanned and densitometry analyses were performed using 
FluorChem-9900 imaging system software (Alpha-Innotech, San Leandro, U.S), with 
normalisation to a loading control (Actin β or β Tubulin) and referenced to the chosen control 
samples set to 1. 
A PVDF membrane (Thermo Fisher Scientific) and two pieces of 3MM Whatman filter paper 
were cut to size of the SDS-PAGE gel. The PVDF membrane was activated by incubation in 
100% methanol for 15 sec followed by a 2 min rinse in distilled water (dH2O). The PVDF 
membrane was then placed in ice-cold Transfer Buffer (Thermo Fisher Scientific) 
(supplemented with 20% methanol and NuPAGE Antioxidant) for at least 5 min to equilibrate 
along with the 3MM Whatman paper and 4 sponges. Protein samples separated by SDS-PAGE 
were transferred to the PVDF transfer membrane using the XCell SureLock Mini-Cell and 
XCell IITM blot module. Firstly, XCell SureLock Mini-Cell was dismantled, gel separated 
from one of its plates and top lanes and bottom part of the gel cut away. A sheet of 3MM filter 
paper was then adhered to the gel and gel carefully peeled away from second plate. The 
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equilibrated PVDF membrane was then carefully placed on top of the gel ensuring that no air 
bubbles were present. Another sheet of 3MM filter paper was placed on top of the PVDF 
membrane and the `sandwich' placed on top of two pre-soaked 2 sponges that had been placed 
on top of the cathode core of the XCell IITM blot module. Another 2 pre-soaked sponges were 
then placed on top of the `sandwich', the lid of the blot module placed on top and the whole 
assembly inserted into the XCell SureLockTM Mini-Cell. The blot module was topped up with 
Transfer Buffer, the outer reservoir was filled with ice-cold dH2O and whole device placed in 
a 4°C cold room. The protein transfer was performed for 2 hrs at 30 V. After completion of the 
transfer, the blot module was dismantled and the membranes were stained with Ponceau-S 
Staining Solution (Sigma-Aldrich) to assess the quality of the protein transfer to PVDF 
membranes. Membranes were washed first with dH2O, then three times for 5 min with TBS 
with 0.5% Tween-20 (TBS-T) and incubated for 1 hour at room temperature with blocking 
buffer (5% skimmed milk in TBS-T). Membranes were incubated at 4°C overnight with 
primary antibodies diluted in blocking buffer (Table 2.24). The following day, the membranes 
were washed three times for 5 min with TBS-T and incubated for 1 hr at room temperature in 
species specific HRP-conjugated secondary antibodies diluted in blocking buffer. Following 
three further washes with TBS-T, the membrane was developed using enhanced standard 
chemiluminescence (ECL) or ECL prime western blotting detection reagents (Amersham, GE 
Healthcare, Little Chalfont, UK) according to the manufacturer’s instructions and exposed to 
autoradiography films at various time-points. If required, the blots were stripped with Stripping 
Buffer (15 min incubation at 37°C in the dark; Thermo Fisher Scientific) and blots incubated 
with blocking buffer and re-probed with different primary anti-bodies. The images were 
scanned and densitometry analyses were performed using FluorChem-9900 imaging system 
software (Alpha-Innotech, San Leandro, U.S), with normalisation to a loading control (Actin 
β or β Tubulin) and referenced to the chosen control samples set to 1. 
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Target 
Antibody 
catalog number 
Host species Supplier Dilution 
LIN-28 ab46020 rabbit abcam 1:5000 
LIN-41 (E-1) sc-393352 mouse 
Santa Cruz 
Biotechnology 
1:300 
ARID3A (A-4) sc-398367 mouse 
Santa Cruz 
Biotechnology 
1:300 
CTDSPL NBP1-53169 rabbit Novusbio 1:300 
Caspase-3 #9662 rabbit 
Cell signalling 
Technology 
1:500 
Cleaved caspase-3 
(Asp175) 
#9661 rabbit 
Cell signalling 
Technology 
1:500 
β tubulin ab6046 rabbit abcam 1:10000 
Rabbit P044801 goat Dako 1:2000 
Mouse P044701 goat Dako 1:2000 
Table 2.24: Antibodies used for Western Blotting. 
 
2.6   Methylation experiment 
   Demethylation using 5-azacytidine 
For this work, four GCT cell lines: 1411H (YST), 2102Ep (EC), GCT44 (YST) and TCam2 
(Sem) were used. Cells were seeded at a low concentration (7x104 cells/well) to allow them to 
grow for up to 7 days in triplicate in six-well plates. 48 hrs after seeding, the cells were treated 
with 10 μM of the demethylation reagent 5-azacytidine (5-aza) (Sigma-Aldrich, Cat. #A2385) 
which was previously dissolved at the working concentration in different media depending on 
the cell line treated (Table 2.2). Complete media change was performed daily for four days. 
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Negative controls (appropriate media without 5-aza) were performed in parallel using exactly 
the same conditions as described above. 96 hrs after drug exposure, cells were trypsinised and 
RNA extracted in order to evaluate any changes in miRNA levels and host gene caused by 
demethylation. Levels of miR-99a-5p/-100-5p, miR-125b-5p, MIR100HG, BLID and 
MIR99AHG were evaluated. As a control, levels of miRNAs known not to be deregulated in 
mGCTs were tested. The results were then normalised; for this work three different 
housekeeping genes were used: RNU24, RNU44 and RNU38B. 
   Bisulfite conversion 
For this work, we used DNA derived from four mGCT cell lines: 1411H (YST), 2102Ep (EC), 
GCT44 (YST) and TCam2 (Sem). Due to the lack of cell lines representing normal testis or 
ovaries, DNA from one human adult normal testis tissue (BioChain, Cat. #T1234260), three 
normal cervix cell line (95:14, 95:15 and NCX6), one normal fibroblast cell line (HFF-1) and 
one normal retina cell line (RPE) were used as a control. 
1000 ng of DNA was bisulfite converted as per the manufacturer’s instructions using either 
EpiTec Bisulfite Kit (Qiagen, Hilden, Germany, Cat. #59104) or EZ DNA Methylation kit 
(Zymo research, D5001). In order to obtain bisulfite converted DNA, a 140 µl PCR reaction 
was prepared using the reagents in Table 25 and the samples were then placed in a MJ Research 
Tetrad PTC-225 Peltier Thermal Cycler, which was run according to the cycling conditions 
listed in (Table 2.26) below. 
Reagent Volume per reaction 
DNA solution Variable (max 20 µl) 
RNase-free water Depending on DNA quantity 
Bisulfite Mix 85 µl 
DNA protect Buffer 35 µl 
Total volume 140 µl 
Table 2.25: Reagents used to perform biotin conversion using EpiTec Bisulfite Kit. 
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PCR Step Time (min) Temperature (°C) 
Denaturation 5 95° 
Incubation 25 60° 
Denaturation 5 95° 
Incubation 85 60° 
Denaturation 5 95° 
Incubation 175 60° 
Hold overnight ∞ 20° 
Table 2.26: Reaction conditions to perform biotin conversion using EpiTec Bisulfite Kit. 
 
Unmethylated cytosine residues were deaminated to uracil while methylated cytosine (5-mC) 
residues remained unaffected, enabling PCR amplification to recognize uracils as thymines and 
5-mC as cytosines. 
The subsequent morning the Cleanup of bisulfite converted DNA was performed as per the 
manufacturer’s instructions. Briefly, 560 µl of Buffer BL (all the buffer listed are proprietary 
of Qiagen) was added to the PCR reaction. The sample mixture was then applied to an EpiTect 
spin column and placed in a centrifuge and spun at 17,900 g for 1 min. The flow through was 
discarded and the column washed with 500 µl of Buffer BW followed by 500 µl of Buffer BD 
and incubated for 15 min at room temperature. The column was then spun at 17,900 g for 1 
min and washed twice with 500 µl of Buffer BW. The column was then placed into a clean 
microcentrifuge tube and bisulfite converted DNA eluted in 30 µl ddH2O. The samples were 
then placed in a -20°C freezer until further use.  
   Primer design specific for CpG-rich island 
All primers to assess for CpG enrichment were designed using the website: ‘MethPrimer’ 
(http://www.urogene.org/methprimer/) and subsequently ordered from Sigma Aldrich. 
Genomic sequences were downloaded from the Ensembl Genome Browser 
(http://www.ensembl.org/index.html) according to Human release GRCh38.p12 and bisulfate 
converted manually. Forward and reverse primers were designed in order to have a length of - 
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24 nt a product size of 200-500 nt and a melting temperature of 62-68°C. Additionally, the 
primers were designed in order to give two different melting curve products depending on the 
methylated or unmethylated status of the amplified sequence. 
A range of primers spanning up to 10 kilo bases upstream the area of interest at chromosome 
11 and chromosome 21 were used (Table 2.27). 
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CHROMOSOME 11 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
MIR100H
G UP TO 
10KB #1 
TTTTTTTATTATATGTTAATTTTTTTAG
TT 
AAACACATTCTAATATTCTCTACCATTA
TA 
MIR100H
G UP TO 
10KB #2 
GGTTAGGAGTGGTGGTTGGA TCCTACCTCAACCTTACTAAACAAC 
MIR100H
G UP TO 
10KB #3 
GTTGAGGTAGGAGAATTGTTTGAAT CCACTAAACCCCACTAACTTTAATAAA 
MIR100H
G UP TO 
5KB 
AGAGGGTTGGTTGGTGTATTT TCACTCTCTACCCCTCCTCA 
miR-100 
UP TO 
10KB 
AGGGGTATGGAGAAATGAAGGA ACTCAACTCCCATTTCACTCAA 
miR-100 
UP TO 
5KB 
TTATTTGAAATGAAAAATTTTTTTT TTATAATAAAACAAAATAAACCCAAC 
miR-125b-
1 UP TO 
5KB #1 
GGGGTAGTGTGGTTTAGGAAA CCCCACCTTCAAAACAACTTT 
miR-125b-
1 UP TO 
5KB #2 
TTTATTTTTAGTTTGATGAGGAAAG CACCAAACTATCATTTAATAAACAC 
miR-125b-
1 UP TO 
5KB #3 
GATTTTAGTTAAGTAGTTGATGTAGA AACCTCCTATAACACCATCC 
miR-125b-
1 UP TO 
5KB #4 
GGATGGTGTTATAGGAGGTT CTTTCCTTCACAAAATTAAAATTC 
BLID up 
to 5Kb GGAGTGTAGTGGTGTGATTTTA AACAACATACAAAAAATACATCCTA 
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CHROMOSOME 21 
Name Forward primer (5’ to 3’) Reverse Primer (5’ to 3’) 
MIR99AH
G UP TO 
10KB 
TGGGTATTAGTAGTGGTGGTTGTAG CTACCTCCTCAAATAAATCCCTAAC 
miR-99a 
up to 5Kb TTAAAATTGTTATTGTGAAAATAATA TCTAAAAAAAACATCTAAATAAATC 
miR-99a 
up to 10Kb 
#1 
GGTTGAAATTTGGATATTTTAGGTATTA
G 
AAACCACAATAAAAACAACAACAAA
C 
miR-99a 
up to 10Kb 
#2 
GTTAATGAATGTGTTATTTGTTTT ATTACCCCTTTTCCATATATAAAC 
miR-125b-
2 up to 
5Kb 
TTGTAGTTTAGTAGGTTTGGGAGAG TAACTAACTAACTTTTACCCTCCAC 
Table 2.27: List of primers used for the assessment of CpG rich region on chromosome 11 and 21. 
 
   Pyrosequencing 
Fragments for pyrosequencing were generated by polymerase chain reaction, using the settings 
previously described (Table 2.6, Table 2.7). Primers used were the same as shown in Table 
2.27, but one of the primers (Forward or Reverse) was biotinylated (from biomers.net). 
Fragments from the PCR products were then run on a 1% agarose gel to assess the 
concentration. For purification of biotinylated fragments, 10 to 15 µl of PCR product was added 
to a mix consisting of 2 µl Streptavidin Sepharose HP™ Beads (Amersham Biosciences, 
Freiburg, Germany) and 40 µl binding buffer (Qiagen). The mix was shaken at a maximum 
speed (1,400 rpm) for at least 10 min on a BioShake iQ (Qinstruments). Single-stranded 
fragments were purified using the Vacuum Prep Tool™ (Qiagen). Sepharose beads with the 
single-stranded templates attached were added to a PSQ 96 Plate Low™ (Qiagen, Hilden, 
Germany) containing a mix of 24.25 µl annealing buffer (Qiagen) and 0.75 µl of 10 µM 
pyrosequencing primer (final concentration 0.3 µM/well) (Table 2.28). Pyrosequencing was 
performed in a PyroMark MD™ Q24 System (Qiagen) with the PyroGold Q24™ Reagent Kit 
(Qiagen) containing nucleotides and prepared mixtures with enzymes and substrates, 
respectively. For pyrogram exposure including CpG-site methylation calculation, the 
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PyroMark Q24 Software (Qiagen, version 2.0.8) was applied. Only pyrograms including sharp 
peaks with sufficient height for each injected nucleotide of interest and without background 
controls were considered. 
Island 
Biotinylated 
primer 
Sequence primer 
assay #1 
Sequence primer 
assay #2 
Sequence 
primer 
assay #3 
Sequence 
primer 
assay #4 
Isla#4 
(MIR100
HG.11.4
) 
TGAGGAGGGGTA
GAGAGCGA 
TAAATTTTTAGT
TAGATATAGAA
T 
ATAGAAAAGTTT
TTTAAGTTTTTA
T 
TAATGGTATT
TGTAGTGGG
A 
TGTTTTTTAGT
AGTTTAAAGG 
Isla#4 
(MIR100
HG.11.4
) 
AGAGGGTTGGTT
GGTGTATTT 
ATTTAGAAATC
GAGTTAGTTG 
AGTTAGTTTTAG
AGAGGGGTT 
GTTGAGGAG
GGGTAGAGA
G 
 
Isla#5 
(miR-
100.11.1
) 
TTGAGTGAAATG
GGAGTTGAGT 
GTTAAGTTTGA
AAGATGATGA 
GATTAATGTAGA
AGGTTGG 
GATTAGAAT
ATAAGATGG
A 
 
Isla#8 
(miR-
125b-
1.11.1) 
AAAGTTGTTTTG
AAGGTGGGG 
GTGTGGTTTAG
GAAAATTT 
GATTAAATGTGT
TTTTTAAAG 
AATGGTAAA
AGAGAAAAG
G 
AAGGGAGAGA
AAAAGGAGAG 
Isla#9 
(miR-
125b-
1.11.2) 
GTGTTTATTAAAT
GATAGTTTGGTG 
TTTTTAGTTTGA
TGAGGAAA 
GGTTAAAGGTTT
TAAAGAATT 
  
Isla#16 
(miR-
125b-
2.21.1) 
GTGGAGGGTAAA
AGTTAGTTAGTT
A 
GAGTTAATGTT
AATGATGAG 
GTTTTGAGTTAG
TATTAGAT 
  
Table 2.28: Sequence primers design for pyrosequencing. Depending on the quantity of CpG sites 
embedded in the PCR fragment generated using primers described in Table 2.27, a different number of 
assays was designed in order to cover as many CG as possible. Pyrosequencing design is described in 
detail in the section 4.2.4 of this thesis. 
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2.7   Global mRNA expression profiling 
   Samples used 
Global mRNA profiling was performed on a total of 24 samples treated with miRNA mimic as 
per section 1.1.4.1 at day 7 (Table 2.29): 
•   3 x untreated 
•   3 x treated non-targeting control using a total concentration of 16.7 nM 
•   3 x treated using combination of miR-100-5p + miR-125b-5p for a final concentration 
of 16.7 nM  
Global mRNA profiling was performed on a total of 12 samples treated with miRNA mimic as 
per section 1.1.4.1 at day 2 (Table 2.29): 
•   3 x treated non-targeting control using a total concentration of 16.7 nM 
•   3 x treated using combination of miR-100-5p + miR-125b-5p for a final concentration 
of 16.7 nM  
 
Cell 
Line 
Number of 
Replicates 
Day condition 
Single mimic 
concentration 
Final 
concentration of all 
mimics 
1411H 
3 2 Non targeting control 16.7 nM 16.7 nM 
3 2 
Combination of miR-
100-5p + miR-125b-5p 
8.3 nM 16.7 nM 
Tcam2 
3 2 Non targeting control 16.7 nM 16.7 nM 
3 2 
Combination of miR-
100-5p + miR-125b-5p 
8.3 nM 16.7 nM 
1411H 
3 7 untreated 16.7 nM 16.7 nM 
3 7 Non targeting control 16.7 nM 16.7 nM 
3 7 
Combination of miR-
100-5p + miR-125b-5p 
8.3 nM 16.7 nM 
Tcam2 3 7 untreated 16.7 nM 16.7 nM 
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3 7 Non targeting control 16.7 nM 16.7 nM 
3 7 
Combination of miR-
100-5p + miR-125b-5p 
8.3 nM 16.7 nM 
2101Ep 
3 7 Non targeting control 16.7 nM 16.7 nM 
3 7 
Combination of miR-
100-5p+miR-125b-5p 
8.3 nM 16.7 nM 
Table 2.29: Samples used for Illumina array. The table shows number of replicates and the different 
conditions per cell line used in the array performed at day 2 and day 7. 
 
   mRNA microarray protocol 
RNA was assessed for concentration and quality using a SpectroStar (BMG Labtech, 
Aylesbury, UK) and a Bioanalyser (Agilent Technologies, Cheadle, UK). Microarray 
experiments were performed at Cambridge Genomic Services, University of Cambridge, using 
the HumanHT-12 v4 Expression BeadChip (Illumina, Chesterford, UK) according to the 
manufacturer’s instructions. Briefly, 200 ng of total RNA underwent linear amplification using 
the Illumina TotalPrep RNA Amplification Kit (Life Technologies, Paisley, UK) following the 
manufacturer’s instructions. The concentration, purity and integrity of the resulting cRNA were 
measured by SpectroStar and Bioanalyser. Finally, cRNA was hybridised to the HumanHT-12 
v4 BeadChip overnight followed by washing, staining and scanning using the Bead Array 
Reader (Illumina). 
   Bioinformatics analysis 
Bioinformatics analysis was performed by the Cambridge Genomic Services at University of 
Cambridge. Briefly, the data are loaded in Illumina proprietary software, GenomeStudio. No 
background correction or normalisation is applied at this stage. A "final report" is generated, 
generating a text file containing the sample probe profile and the control probe information. 
The report is then processed in R using the lumi package (Du, Kibbe and Lin, 2008) and the 
limma package (Ritchie et al., 2015). The data are loaded and divided into subsets according 
to the groups being compared; only the samples involved in a given comparison are used. 
Subsets were then filtered to remove any non-expressed probes using the detection p-value 
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from Illumina. Across all samples probes for which the intensity values were not significantly 
different (p>0.01) from the negative controls were removed from the analysis. Following 
filtering the data were transformed using the Variance Stabilization Transformation (VST) 
from lumi and then normalised to remove technical variation between arrays using quantile 
normalisation. Comparisons were performed using the limma package with results corrected 
for multiple testing using False Discovery Rate (FDR) testing. Finally, the quality of the data 
were assed and the correlation of the samples in the groups compared.  
   mRNA microarray data processing using Sylamer 
Sylamer analysis was conducted with Keaan Amin and Dr. Anton Enright, member of the 
Cambridge Genomic Services at University of Cambridge. The Sylamer analysis algorithm 
(http://www.ebi.ac.uk/enright/sylamer/) (van Dongen, Abreu-Goodger and Enright, 2008b) 
was used to assess enrichment and/or depletion of nucleotide words of specific length 
complementary to elements of the seed region (nucleotide positions 1-8) of microRNAs (i.e. 
SCRs) in the 3'UTRs of genes within ranked lists, with significance calculated using 
hypergeometric statistics. The primary aim of Sylamer was to identify whether changes in 
microRNA expression are of biological significance, with the secondary aim of producing lists 
of target genes for further validation. 
   Algorithm details 
For each ranked genelist derived from the mRNA expression data, Sylamer analysis was 
undertaken for the six SCR elements of increasing size: three hexamers (corresponding to 
microRNA seed positions 1-6 nt, 2-7 nt and 3-8 nt); two heptamers (positions 1-7 nt and 2-8 
nt); and one octamer (position 1-8 nt). Due to over-representation of conserved adenosines 
flanking SCRs in mRNAs (Lewis, Burge and Bartel, 2005b), the complementarity criterion 
was discarded for SCR position 8 (seed position 1), where the nucleotide was always set to be 
adenosine, irrespective of the actual nucleotide at that position. For each comparison analysed, 
the mRNA genelist was first ranked from down-regulated (to the left) to up-regulated (to the 
right). For each SCR under consideration, an enrichment/depletion p-value was computed at 
different cut-offs in the ranked gene list. At each cut-off, an SCR was either enriched in the 
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3'UTRs of the genes to the left and accordingly depleted in the 3'UTRs of the genes to the right, 
or conversely depleted on the left and enriched on the right. An event of enrichment on one 
side and corresponding depletion on the other side of the cut-off was associated with a single 
p-value. Varying the cut-off resulted in a set of p-values for each SCR (y-axis) visualised on a 
landscape plot (van Dongen, Abreu-Goodger and Enright, 2008a), in which the log10-
transformed p-values were sign-adjusted and plotted against the ranked genelist (x-axis). Sign-
adjustment depended on the specific enrichment/depletion status of the pertinent SCR. A point 
plotted along the positive y-axis signified that the SCR was enriched in the genes to the left and 
depleted in the genes to the right, whereas a point plotted along the negative y-axis conversely 
signified depletion to the left and enrichment to the right. The displacement along the y-axis 
identified the significance of the joint enrichment/depletion p-value for the SCR at that cut-off, 
according to the sign-adjusted log10 transformation. 
   Single-summed significance score 
The single summed significance score is an integration of Sylamer significant scores and an 
overall evaluation of the enrichment or depletion of nucleotide sequences with enhanced 
sensitivity. The scores were calculated by combining the Sylamer results for one hexamer (2-
7 nt), two heptamers (1-7 nt, 2-8 nt) and the octamer of the miRNA SCR, because the middle 
2- to 7-nucleotide region is critical for the mRNA binding function of miRNAs (Lewis, Burge 
and Bartel, 2005a). Based on the calculation method of single summed significance scores, 
Enright’s lab developed an algorithm to extract Sylamer results for individual nucleotide 
sequences and visualised the single summed significance scores with line charts for the first 
time.  
   Functional enrichment analysis 
Reactome, KEGG and Gene Ontology (GO) are the three major tools used in this project for 
functional enrichment analysis of lists of Ensembl gene IDs produced from the Sylamer and 
Illumina analysis. Reactome is a publicly-available database containing manually curated, 
peer-reviewed information of biological processes and pathways (Fabregat et al., 2018). KEGG 
(Kyoto Encyclopedia of Genes and Genomes) is an integrated database resource consisting of 
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eighteen databases. They are broadly categorized into: systems information, genomic 
information, chemical information and health information, which are distinguished by color 
coding of web pages. The KEGG database has been in development by Kanehisa 
Laboratories since 1995, and is now a prominent reference knowledge base for integration and 
interpretation of large-scale molecular data sets (Kanehisa and Goto, 2000). Gene Ontology 
(GO) performs enrichment analysis on gene sets (Ashburner et al., 2000). We used Reactome, 
KEGG and Gene Onthology website to identify the pathways and functions associated with the 
genes of interest which may imply any changes of gene expression contributing to the initiation 
and progression of tumorigenesis of mGCTs. 
2.8   FACS 
   Cell cycle analysis 
For cell cycle analysis, cells were analysed at d1, d2, d3 and d4 after transfection using Click-
iTä EdU Alexa Fluorä 647 Flow Cytometry Assay Kit (Thermo Fisher Scientific, #C10419). 
Reagents were prepared according to manufacturer’s instructions. A stock solution of 10 mM 
EdU was prepared which was then conserved at -20°C for up to 1 year. EdU was used at a 
working concentration of 10 µM by dilution of the stock solution. Cells were incubated for up 
to 3 hrs with 10 µM of EdU. Cells from the same population not treated with EdU acted as a 
negative controltreated. After the optimal incubation time, cells were washed with 3 ml of 1% 
BSA in PBS, pelleted and supernatant removed. The remaining EdU stained pellet was then 
washed again with 3 ml of 1% BSA, pelleted and supernatant removed. The pellet was then 
dislodged using 100 µl of Click-iTÔ fixative (4% paraformaldehyde in PBS). Cells were 
incubated for 15 min protected from light. Cells subsequently underwent a 1% BSA wash, were 
centrifuged and the supernatant was removed. The cell pellet was resuspended in 100 µl of 1X 
Click-iTÔ saponin-based permeabilisation and wash reagent. 500 µl of Click-iTÔ reaction 
cocktail containing Fluorescent dye azide (Alexa FluorÒ 647 azide, #C10424), reaction buffer 
and copper (II) sulfate (CuSO4) in a 100 mM aqueous solution, were added to the tube and 
samples incubated for 30 min in the dark. Cells were then washed once with 3 ml of 1X Click-
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iTÔ saponin-based permeabilisation and wash reagent, centrifuged and the pellet resuspended 
in 500 µl of Click-iTÔ saponin-based. 1 µl of FxCycleÔ Violet (Thermo Fisher Scientific, 
#F10347) was then added to the mixture to stain the DNA content of the cells and samples 
analysed using flow cytometer BD LSRFortessa machine (BD Biosciences) at the Wellcome-
MRC Cambridge Stem Cell Institute. For the detection of EdU with Alexa Fluor® 647 azide 
633/635 nm excitation with a red emission filter (660/20 nm) was used. Flow cytometer data 
were analysed using FlowJo® (version 10.5.0). 
    Apoptosis analysis 
Cell death and apoptosis was measured using annexin V-FITC (BioLegend, Cat. #640905). 
Cells were washed twice with cold BioLegend cell staining buffer (Cat. #420201) and then 
resuspend in Annexin V Binding Buffer (Cat. #422201) at a concentration of 1x106 cells/ml. 
Cells were then transferred in a 5 ml FACS test tube and 5 µl of FITC Annexin V and 1 µl of 
PI (Cat. #421301) were added. The cells were then incubated for 15 min at 37°C in the dark. 
400 µl of Annexin V Binding Buffer (Cat. #422201) was added to each tube and samples 
analysed by flow cytometry.  
   Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, La 
Jolla, U.S.). For comparisons between groups, an unpaired, two-tailed Students t-test was used. 
P-values <0.05 were considered statistically significant. Data are presented as mean ± SEM.
 Chapter 3   Understanding the origin of the 
upstream regulation of miR99a-5p/-100-5p and miR-
125b-5p 
 
3.1   Introduction 
MiRNAs dysregulation has been shown to affect most of the hallmarks of cancer, including 
continuous proliferative signalling, evasion of growth inhibition, resisting cell death, activating 
invasion and metastasis and inducing angiogenesis (Cimmino et al., 2005; Klein et al., 2010). 
Since their discovery, it has become apparent that dysregulation of miRNAs is complex and 
can occur at different levels. One of the most common mechanism of dysregulation takes place 
at genomic level. Most human miRNAs are encoded in introns of both coding and non-coding 
transcripts although they can also be found in exons. MiRNAs, including some which are 
downregulated in GCTs such as miR-100  ̴ let-7 	  ̴ miR-125b, are often clustered. Although the 
distance between clustered miRNAs is generally less than 1 Kb, larger clusters do exist, and a 
distance as far as 50 Kb between clustered miRNAs has been described (Baskerville and Bartel, 
2005; Yuan et al., 2009). Clustered miRNAs have been shown to be generally transcribed as 
polycistrons and have similar expression patterns. Some miRNAs, especially when they are 
located in introns of genes, are expressed with their host gene, implying that they share the 
same promoter (Baskerville and Bartel, 2005). 
More than half of the human miRNAs are located in genomic regions of high instability – such 
as fragile sites and cancer susceptibility loci – and structural genetic changes have been 
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described in a variety of solid tumours including breast, lung, ovarian, colon, gastric and 
hepatocellular carcinoma as well as in leukemias and lymphomas (Calin et al., 2004b). Genetic 
changes identified, include partial chromosome deletions, loss of heterozygosity (LOH), 
amplification of common minimal region of amplification, and mutations at common 
breakpoint region. Natural sequence variation, such as SNPs, have also been found to affect 
miRNA biogenesis, for example changes in the composition of the sequence recognised by 
Drosha-mediated processing complex can lower the production of a mature miRNA (Kumar 
et al., 2008; Volinia et al., 2010), but tumour specific mutations appear to be infrequent.  
Transcription factor such as p53, MYC, ZEB1 and ZEB2 are important regulators of 
miRNAs expression by their direct binding to the promoter of miRNAs genes. They  induce 
both repression or upregulation of transcription, and their function can also be differential 
in a tissue-specific manner (Kim, Han and Siomi, 2009).  
MiRNAs dysregulation can also occur at post-transcriptional level due to aberrant 
transcription factor activity. For example, MYC mediated activation of LIN28A and B 
results in reduced levels of mature let-7 due to the binding of LIN28A and B to the terminal 
loop of pri- and pre-let-7 which in turn blocks the cleavage by Drosha and Dicer respectively 
needed for miRNA maturation (Murray et al., 2013).  
Recent studies have also found a role for epigenetic mechanisms in miRNAs silencing, due 
to promoter hypermethylation, which is a well-known mechanisms that cancer cells adopt 
to suppress the production of genes (Lopez-Serra and Esteller, 2012). 
Interestingly, dysregulation of miRNAs is seen across the clinical spectrum of mGCTs. This 
was originally established in our group by profiling 615 miRNAs in paediatric mGCTs, control 
tissue and cell lines (48 samples in total) by microarray. It was found that most of the 
differentially-expressed miRNAs were down-regulated in GCTs compared with controls and 
benign tumours, suggesting an overall tumour suppressing role for miRNAs in these tumours 
which is common to other malignancies (Palmer et al., 2010). 
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The five-top-ranking putative tumour suppressor miRNAs identified in this study were then 
chosen for further investigation. The five most downregulated miRNAs, ranked by adjusted p-
value, with at least a mean 4-fold decrease in paediatric GCTs compared with non-malignant 
samples are: miR-152-3p, miR-204-5p, miR-99a-5p, miR-100-5p and miR-125b-5p (in 
descending order of significance). Moreover, a similar pattern of downregulation of miR-99a-
5p/-100-5p and miR-125b-5p, was noticed which might suggest co-regulation of these 
miRNAs. The mechanisms directing the downregulation of miRNAs in these tumours are not 
fully understood and are the subject of work presented in Chapter 4.  
The aim of this work is to further characterise downregulated miRNAs in mGCTs. Firstly, 
reanalysis of the five-top-ranking putative tumour suppressor miRNAs will be performed 
across a panel of mGCT tissue samples and cell lines when compared with control and benign 
samples. Secondly, the importance of each of them will be assessed by studying specific seed 
abundance decrease in mRNA profile available in the lab (Palmer et al., 2010), their genomic 
characteristic and their expression profile derived from the previously published miRNAs 
heatmap (Palmer et al., 2010). Finally, investigation to understand at which level the miRNAs 
dowregulation occur will be evaluated. 
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3.2   Results  
   MiRNA expression in mGCTs 
   MiRNA levels in a panel of tissues from GCTs and representative GCT 
cell lines  
In previous work using microarray, five miRNAs, namely miR-99a-5p, miR-100-5p, miR-
125b-5p, miR-204-5p and miR-152-3p, were identified as the most downregulated miRNAs in 
mGCTs after analysis of expression data for 615 miRNAs in 42 paediatric samples comprising 
12 yolk sac tumours (YST), 13 seminomas (Sem), 3 embryonal carcinomas (EC), 6 teratomas 
(Ter), 8 normal gonadal tissues as well as 6 cell lines derived from adult and paediatric 
teratomas (Tera2, and PA1 respectively), adult embryonal carcinomas (2102Ep), yolk sack cell 
tumours (GCT44, 1411H), and adult seminoma (TCam2)  (Palmer et al., 2010). Analysis of 
the individual values of the negative log2 fold-change (log2FC) for each miRNA demonstrated 
a significant downregulation of miR-99a-5p, miR-100-5p, and miR-125b-5p across all mGCT 
tissue samples and cell lines compared with control and benign samples (teratomas) (Figure 
3.1). In contrast, miR-204-5p and miR-152-3p, appeared to be variably downregulated in the 
mGCT tissue samples, and no significant changes were observed in the representative cell lines, 
making future replenishment strategies in vitro and in vivo models unlikely to be successful. 
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Figure 3.1: Relative expression of five selected miRNAs in GCT tissues. a) hsa-miR-99a-5p, b) hsa-
miR-100-5p, c) hsa-miR-125b-5p, d) hsa-miR-204-5p and e) hsa-miR-152-3p. Samples are colour 
coded as follows: embryonal carcinoma (EC) in red, yolk sac tumour (YST) in yellow, seminoma (Sem) 
in blue, teratoma (Ter) in brown. Normal gonads which were used as a control are shown in green and 
cell lines (CL) in black. The black line indicates the average log2 fold-change (log2FC) for the specific 
miRNA. Data from Palmer et al., 2010. 
 
92 Understanding the origin of the upstream regulation of miR99a-5p/-100-5p and 
miR-125b-5p 
 
   Abundance of miRNAs 2-7 nt seed regions across GCT samples 
In the last ten years, it has become apparent that there is a great deal of redundancy in miRNA 
regulation. In addition to the existence of multiple genomic loci producing the same miRNA, 
many miRNAs are part of miRNA “families,” which target the same seed sequence. Hence, 
there is a great deal of redundancy at the genomic level. Because the seed sequence is small, a 
single miRNA can target a large number of mRNAs. The opposite is also true, that a single 
mRNA can be targeted by numerous miRNAs, including those from different families. The 
miRNAs identified as the most downregulated in mGCT share seed sequences with other 
miRNA but these families comprise no more than 3 members. In detail, the 2-7 nt seed of miR-
99a-5p/-100-5p is identical to that of miR-99b; the same is true for miR-125b-5p and miR-
125a; miR-152-3p and miR-148a and miR-148b; and miR-204-5p and miR-211 and miR-623. 
The small size of these miRNA families suggests that any perturbation of any of the miRNAs 
belonging to the same family is likely to have a significant effect on the relevant overall seed 
abundance and result in a biological effect. Interestingly, miR-99a-5p and miR-100-5p not only 
share the 2-7 nt seed sequence, but their entire mature sequence is almost identical and only 
differs by 1nt towards the 3’ end of the sequence (Table 3.1). 
 
Putative tumour 
suppressor miRNAs 
Sequence 
miR-99a-5p AACCCGUAGAUCCGAUCUUGUG 
miR-100-5p AACCCGUAGAUCCGAACUUGUG 
Table 3.1: Sequences of mature mir-99a-5p and miR-100-5p. The sequences are almost identical, 
underlined is the only nucleotide that is different. 
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In view of the similarity between the two miRNAs, the specificity of the TaqMan qRT-PCR 
detection assays for each individual miRNA was tested in the lab. Briefly, miRNAs were 
reverse transcribed using the primer for a specific assay (e.g. miR-99a-5p or miR-100-5p), and 
then amplified using the correct probe/primer mix for the assay of interest (e.g. miR-99a-5p). 
Reverse transcription with an irrelevant primer (i.e. miR-125b-5p) was included to control for 
aspecific amplification (Figure 3.2). 
  
Figure 3.2: MiR-99a-5p and miR-100-5p cross-reactivity assay. Samples were reverse transcribed 
with primers specific for miR-99a-5p, miR-100-5p and miR-125b-5p (x-axis) and then amplified with 
either a probe/primer mix specific for miR-99a-5p (a) or miR-100-5p (b). Expression is shown relative 
to the matched combination of primer in RT and primer/probe PCR assay. Templates used were a 
reference RNA from human ovarian tissue, a reference RNA from human testis (both from Ambion) 
and the Universal Reference (UR) which is derived from a mix of 14 commonly used cell lines. Headers 
show mean percentage cross-reactivity (CR). Adapted from Christos Panayi’s NST, Part II Pathology 
Project Report, 2014. 
 
These tests demonstrated that the individual assays are not able to discriminate between the 
two miRNAs. Therefore, either assay quantifies both miR-99a-5p and miR100-5p, making the 
individual contribution for each miRNA unquantifiable. These data however suggest that these 
miRNAs are likely to have a complete functional overlap. 
To confirm that not only the individual miRNAs but also the overall ‘family’ seed abundance 
was decreased, a reanalysis of the raw microarray data (Palmer et al., 2010) was performed 
with bioinformatic support (Enright group, Department of Pathology, Cambridge). Individual 
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data from miRNAs that share the same seed sequence, were pooled together and a normalised 
intensity ratio of the seed was calculated (Figure 3.3). 
 
Figure 3.3: Seed abundance in GCT samples. Samples are (left to right): CNTRL (normal gonads, 
control tissue), TER (teratomas, benign GCTs), SEM (germinomas, mGCT), YST (yolk sac tumours, 
mGCTs), EC (embryonal carcinomas, mGCT) and CL (GCT derived cell lines). All miRNAs listed in 
this figure are quantified at the -5p end except miR-152 which is quantified at the -3p end. Data analysed 
with support by Dr Harpreet Saini. 
 
In agreement with the data on the individual miRNAs, this analysis demonstrates that the 2-7 
nt seed sequences of miR-99a-5p/miR-100-5p and miR-125b-5p are substantially decreased in 
both clinical mGCT samples and representative GCT cell lines, compared with non-malignant 
control samples (normal gonadal controls and benign teratomas). Moreover, the 2-7 nt seed 
sequence of miR-152-3p is not as highly downregulated across the cell lines, there is no 
significant downregulation in mGCT samples and cell lines of the 2-7 nt seed of miR-204-5p 
compared with non-malignant control samples. Overall these data suggest a more biologically 
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relevant role for the downregulation of miR-99a-5p/miR-100-5p and miR-125b-5p, than for 
the other two miRNAs originally identified from the array data. 
   Investigation of potential genomic alteration as the reason for 
miRNAs downregulation 
   Genomic context  
As a result of the array data analysis, further work was carried out investigating the effects and 
mechanisms of the downregulation in mGCTs of only three of the putative tumour suppressor 
miRNAs: miR-99a-5p, miR-100-5p and miR-125b-5p. 
Interestingly, the mature form of miR-125b-5p is the product of two genomic loci, each of 
which is physically clustered with either miR-99a-5p or miR-100-5p and a let-7 family 
member. The cluster on chromosome 11q24.1 contains miR-100 and miR-125b-1, while the 
cluster on chromosome 21q21.1 contains miR-99a and miR-125b-2 (Figure 3.4).  
 
Figure 3.4: Genomic view of the two miRNA clusters. Chromosome 11 containing miR-125b-1/-100 
and chromosome 21 containing miR-125b-2/-99a. Taken from (Roush and Slack 2008). 
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Interestingly, the original microarray data (Figure 1.12) showed a very similar pattern of 
expression of these three miRNAs in each tissue examined, which may suggest co-regulation 
(Figure 3.5).  
 
Figure 3.5: MiR-99a-5p/-100-5p and miR-125b-5p microarray data. 
 
Furthermore, linear regression analysis of previous qRT-PCR validation data, revealed a very 
strong positive correlation between miR-99a-5p/-100-5p and miR-125b-5p levels, again 
suggesting co-regulation of the 11q and 21q loci (Figure 3.6). 
 
Figure 3.6: Linear regression analysis of the relative expression of miR-99a-5p/-100-5p (x-axis) 
and miR-125b-5p (y-axis). Adapted from Christos Panayi’s NST, Part II Pathology Project Report, 
2014. 
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Figure 4. Mir-99a/100 and miR-125b cluster co- xpression. Linear regression 
analyses of the relative expression of miR-99 /100 (x-axis) and miR-125b (y-axis),
as quantified by qRT-PCR described in Figure 3, on log10 axes.
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   Identification of potential genomic imbalances 
   Identification of reference genes for genomic copy number quantification 
To study the mechanisms mediating the downregulation of these miRNAs, we investigated 
whether any genomic deletion or insertion might have occurred at genomic level. This was 
carried out using a qPCR method to establish relative copy number of the miRNA genomic 
loci relative to other reference genes, for which copy number is known. 
To identify which genes were suitable for data normalisation, four candidate housekeeper genes 
(HK) were selected from regions known to be copy number neutral in mGCTs, namely, 
GAPDH, B2M, 18A and 18B (Terashima, Yu, Wing-Yuk T. Chow, et al., 2014), and levels 
analysed using q-PCR. This was performed on DNA from four representative GCT cell lines 
and DNA extracted from a normal testis tissue sample. The reliability of the HK genes was 
evaluated using two criteria: the first one considered the standard deviation between treated 
and untreated samples, while the second assessed the consistency of expression of the HK 
genes within individual samples by looking at relative expression of the housekeeping genes 
vs each other. For an HK to be acceptable therefore, the standard deviation ( ) of its expression 
in different samples has to be £1, while its expression ratio to the other HKs has to be similar 
in all samples. The four reference genes, showed small variation in the raw Ct values obtained 
between cell lines (Figure 3.7) and overall an intra cell line deviation standard lower than 1 (
<1), and they all had the same expression ratio across the samples. Therefore, these genes were 
used as reference for further experiments. 
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Figure 3.7: Raw Ct values obtained after amplification of genomic regions of four candidate 
reference genes in four representative GCT cell lines and normal testis tissue samples. Data 
presented as mean ± SEM of n=3 biological replicates. 
 
   Assessment of genomic copy number in mGCT cell lines 
Potential genomic copy number imbalances were assessed by q-PCR for both chromosome 11, 
where the miR-100, let-7a-2 and miR-125b-1 cluster is located, and chromosome 21 where the 
miR-99a, let-7c and miR-125b-2 cluster resides. To this end, seven different primers were used 
to screen the entire region of interest on either chromosome 11 and 21. 
Primers were designed to quantitate areas 50Kb, 10Kb and 5Kb upstream of the miRNAs of 
interest as well as specifically hsa-pri-miR-100 (ch11) and hsa-pri-miR-99a (ch21), let-7a-2 
(ch11) and let-7c (ch21) and hsa-pri-miR-125b-1 (ch11) and hsa-pri-miR-125b-2 (ch21) 
(Figure 3.8). 
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Figure 3.8: Location of primer pairs used for copy number assessment on either chromosome 11 
or 21. Chromosome distribution is not to scale. 
 
Quantification was performed across five different DNA samples obtained from four 
representative GCT cell lines and one normal testis tissue. Normal testis tissue DNA was used 
as genomic diploid reference and copy number for the four cell lines established relative to 
this, after appropriate normalisation to their housekeeper genes. For all cell lines, there was no 
consistent variation in the genomic copy number across the region of interest (ROI) on both 
chromosome 11 and chromosome 21 (Figure 3.9). These values showed significant correlation 
(p<0.05) across all the cell lines. 
 
Figure 3.9: Genomic copy number quantification. Summary genomic copy number quantification for 
the regions of interest on chromosome 11 (left panel) and chromosome 21 (right panel) for four mGCT 
cell lines and control testis tissue DNA. Data presented as mean ± SEM of n=3 biological replicates. 
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   Assessment of pri-miRNA levels 
Having excluded genetic aberration as a potential cause of miRNAs downregulation, we 
investigated at which level of miRNAs biogenesis the downregulation occurred. The first step 
in the biogenesis of miRNAs is the production of primary miRNAs transcripts (pri-miRNAs). 
Importantly, the pri-miRNAs of each individual miRNAs studied is different as it includes not 
only the sequence of the mature miRNA, but also regulatory sequences that are unique to each 
chromosome. This allows the study of each loci separately (Table 3.2). 
 
pri-miRNA 
name 
Sequence 
hsa-pri-miR-100 CCUGUUGCCACAAACCCGUAGAUCCGAACUUGUGGUAUUAGUCCGCACAAG
CUUGUAUCUAUAGGUAUGUGUCUGUUAGG 
hsa-pri-miR-99a CCCAUUGGCAUAAACCCGUAGAUCCGAUCUUGUGGUGAAGUGGACCGCACA
AGCUCGCUUCUAUGGGUCUGUGUCAGUGUG 
hsa-pri-miR-125b-1 UGCGCUCCUCUCAGUCCCUGAGACCCUAACUUGUGAUGUUUACCGUUUAAA
UCCACGGGUUAGGCUCUUGGGAGCUGCGAGUCGUGCU 
hsa-pri-miR-125b-2 ACCAGACUUUUCCUAGUCCCUGAGACCCUAACUUGUGAGGUAUUUUAGUAA
CAUCACAAGUCAGGCUCUUGGGACCUAGGCGGAGGGGA 
Table 3.2: Pri-miRNAs sequences. Nucleotide differences in pri-miR-100 and pri-miR-125b-1 using 
pri-miR-99a and pri-miR-125b-2 respectively as the canonical sequence are underlined. 
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   Optimisation of pri-miRNA experimental conditions 
Various optimisation steps were performed in order to achieve accurate quantification of pri-
miRNA levels. Most importantly optimisation of input was key due to the low abundance of 
these transcripts. Input as high as 1000 ng was eventually established as the optimal amount 
for detection. 
To identify which HK genes were suitable for data normalisation, three candidates from 
previously published work were selected (Murray et al., 2013) and levels analysed using qRT-
PCR (18s, GUSB and RPLO). To ensure these genes were suitable across cell lines, the four 
representative GCT cell lines (2102Ep, 1411H, GCT44 and TCam2) as well as RNA from two 
gonadal control samples (ovary and testis mRNA, Ambion) were tested. 18S was the only HK 
with a higher standard deviation between samples ( =1.23) compared with GUSB ( =0.5) and 
RPLO ( =1). However, 18S maintained the same expression ratio between HKs across all the 
samples and because of the low number of possible HK genes available for the experiment, all 
of the three HKs were used (Figure 3.10). 
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Figure 3.10: Raw Ct values of three candidate housekeeping genes for pri-miRNA analysis in four 
representative GCT cell lines and two controls. AO is Ambion Ovary RNA and AT is Ambion Testis 
RNA. Data presented as mean ± SEM of n=3 biological replicates. 
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   Pri-miRNA expression in mGCTs cell lines 
The level of expression of the pri-miRNAs from each individual chromosome, was normalised 
to the pooled control mRNAs (i.e. testis and ovary gonadal controls) using the three 
housekeeping genes identified and plotted for each individual cell line. While the expression 
of the miRNA was downregulated in a similar manner irrespective of the genomic location in 
the cell line TCam2 (a seminoma cell line), the other cell lines showed a differential 
downregulation from the two chromosomal loci.  In 2102Ep (an EC derived cell line) there was 
greater downregulation of the chromosome 21 derived pri-miR-99a and pri-miR-125b-2 
transcripts, while in 1411H and GCT44 (both cell lines derived from YSTs) there was a greater 
downregulation of the chromosome 11 derived pri-miR-100 and pri-miR-125b-1 (Figure 3.11). 
This suggests that transcription of pri-miRNA from both chromosomes is consistently affected 
in mGCT cell lines, although in some cases there appears to be a preferential choice of which 
transcript is targeted for downregulation. Whether this preference is associated with the subtype 
of tumour is unclear, more cell lines and tissue samples would need to be studied for firmer 
conclusion, but it is interesting to note that both YST derived cell lines studied here showed 
the same pattern and that this pattern was different from that seen in other GCT subtypes. 
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Figure 3.11: Expression of pri-miRNAs in different GCT cell lines. Pink bars represent contributions 
from chromosome 11, where miR-100 and miR-125b-1 are located, while orange bars represent 
chromosome 21 contributions, where miR-99a and miR-125b-2 are located. Data presented as mean ± 
SEM of n=3 biological replicates. 
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   Correlation of the expression of pri-miRNA on chromosome 11 and 21 
To assess if expression of the pri-miRNA showed intra-chromosomal correlation (i.e to 
establish if pri-miR-125b-1 transcription correlated to pri-miR-100 transcription and pri-miR-
125b-2 transcription correlated to pri-miR-99a transcription) expression levels were compared 
in four different mGCTs cell line and two normal gonadal controls. Significant correlation was 
found (p-values: 0.0015 and 0.0006, respectively) suggesting that both transcripts on the same 
chromosome are similarly expressed (Figure 3.12).  
 
Figure 3.12: Correlation of expression of pri-miRNAs located on the same chromosome. Four 
different mGCTs cell line were used: in red 2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H 
and GCT44 (both Yolk Sac Tumour) and in green two normal gonadal control (ovaries and testis). 
  
106 Understanding the origin of the upstream regulation of miR99a-5p/-100-5p and 
miR-125b-5p 
 
Correlation between expression from the two chromosomes was also assessed (Figure 13). 
High level of correlation was found (p-values: <0.0001), suggesting a co-regulation in the 
mechanism of downregulation.   
 
Figure 3.13: Correlation of expression of pri-miRNAs located on the different chromosome. Four 
different mGCTs cell line were used: in red 2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H 
and GCT44 (both Yolk Sac Tumour) and in green two normal gonadal control (ovaries and testis). The 
different symbols represent different correlations. The circle symbolises the correlation between pri-
miR-100 and pri-miR-99a, the rhombus symbolises the correlation between pri-miR-125b-1 and pri-
miR-99a, the triangle symbolises the correlation between pri-miR-100 and pri-miR-125b-2 and the 
square symbolises the correlation between pri-miR-125b-1 and pri-miR-125b-2. 
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   Assessment of miRNA -3p abundance 
Pri-miRNAs are further processed to a miRNA:miRNA* duplex, an immature miRNA which 
is found in the cytoplasm. This immature miRNA is formed by two strands, the guide strand, 
which will become the mature miRNA and as such is loaded into the miRNA-induced silencing 
complex, and the passenger strand or miRNA*. Whether the -5p strand or the -3p strand 
becomes the mature miRNA is generally depended on which of the strands is more stable. In 
the case of miR-99, miR-100, and miR-125b the mature miRNAs are the -5’ strand. To further 
investigate the relative contributions to overall miRNA abundance from the two loci on 
chromosomes 11 and 21, the -3p strands of the four miRNAs were quantified (Table 3.3). This 
is due to the fact that the -3p strands of each miRNA are unique because their sequence depends 
on whether the miRNA is derived from Chromosome 11 or 21. Indirectly this makes possible 
to further study the relevant contribution from the two different loci. 
 
miRNA name Sequence 
hsa-miR-99a-3p CAAGCUCGCUUCUAUGGGUCUG 
hsa-miR-100-3p CAAGCUUGUAUCUAUAGGUAUG 
hsa-miR-125b-1-3p ACGGGUUAGGCUCUUGGGAGCU 
hsa-miR-125b-2-3p UCACAAGUCAGGCUCUUGGGAC 
Table 3.3: MiRNAs-3p sequences for the miRNA of interest. Nucleotide differences in miR-99a-3p 
and miR-125b-1-3p using miR-100-3p and miR-125b-2-3p respectively as the canonical sequence are 
underlined. 
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RNU24, was used as HK gene to normalise expression level of -3p strand of the miRNAs of 
interest. -3p strands are present in the cells in low abundance, making their detection difficult 
(Anglesio et al., 2013). Optimisation were undertaken as later described in the paragraph 
3.2.5.1. Because of this reason, when RT-qPCR was performed, the input of RNA was higher 
for mGCTs and universal reference (UR, UR derived from a mix of 14 commonly used cell 
lines and one of the used cell lines in a mGCTs, for this reason in this experiment the amount 
of UR RNA used was the same as the one used for mGCTs), than non-malignant control and 
as a result, RNU24 showed a high standard deviation ( =1.3) when compared among all of the 
sample. When standard deviation was assessed only among mGCTs cell lines and UR or among 
non-malignant control (normal ovaries and testis) the standard deviation become acceptable (
=0.4) (Figure 3.14).  
 
Figure 3.14: Raw Ct values of the housekeeping gene RNU24 in four representative GCT cell lines. 
AO is Ambion Ovary RNA, AT is Ambion Testis RNA and UR is Universal Reference. Data presented 
as mean ± SEM of n=3 biological replicates. 
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   Expression of miRNA-3p in Germ Cell Tumour cell lines 
As for the pri-miRNA quantitation, some optimisation had to be carried out to be able to 
quantitate the -3p miRNAs. Consistent with the fact that -3p strand miRNAs are generally 
found at much lower abundance in cells than their -5p counterparts (Anglesio et al., 2013), the 
input RNA had to be increased from the standard 15 ng to 100 ng, to detect reliably in the GCT 
cell lines the -3p strands using Taqman miRNA assays (Figure 3.15).  
 
Figure 3.15: Expression of -3p strand miRNAs in different GCT cell lines. Pink bars represent 
contributions from chromosome 11, where miR-100 and miR-125b-1 are located, while orange bars 
represent chromosome 21 contributions, where miR-99a and miR-125b-2 are located. Data presented 
as mean ± SEM of n=3 biological replicates. 
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The level of expression of the -3p miRNAs from each individual chromosome, was normalised 
to the pooled control mRNAs (i.e. testis and ovary gonadal controls) using RNU24 as 
housekeeping gene and plotted for each individual cell line. Universal reference control (UR) 
was excluded in this analysis. UR is a pool of 14 cancer cell lines and one of these is mGCT cell 
line, hence it cannot be used as a negative control.  
Consistent with the differential expression of pri-miRNA described in 3.2.4.2, the seminoma 
cell line TCam2 showed a similar level of downregulation of the miRNAs located on 
chromosomes 11 and 21, whereas the other cell lines showed differential regulation. In 2102Ep 
(the EC derived cell line) there was greater downregulation of the chromosome 21 derived 
miR-99a-3p and miR-125b-2-3p transcripts, while 1411H and GCT44 cells (both cell lines 
derived from YSTs) showed a greater downregulation of the chromosome 11 derived miR-100-
3p and 125b-1-3p (Figure 3.15). 
These results are consistent with the observation made during the analysis of pri-miRNA 
expression that transcription of -3p miRNAs from both chromosomes is consistently affected 
in mGCT cell lines, and that in some cases there appears to be a preferential choice of which 
transcript is targeted for downregulation. These observations support the idea that this 
preference is associated with the subtype of tumour, as observed with pri-miRNA expression 
described earlier, but more cell lines and tissue samples would need to be studied. 
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   Correlation of the expression of miRNA-3p on chromosome 11 and 21 
Post-transcriptional mechanisms inhibiting the maturation of miRNA have been shown 
(Gulyaeva and Kushlinskiy, 2016), therefore correlation between the expression of -3p strands 
derived miRNAs from each chromosome was determined. Significant correlation in the 
expression of -3p transcripts from within the same chromosome, as assessed in four different 
mGCTs cell line, two normal gonadal controls, and the Universal RNA Reference (Ambion), 
was found (p-values: 0.0032 and 0.0028, respectively) (Figure 3.16).  
 
Figure 3.16: Correlation of expression of -3p miRNAs located on the same chromosome. Four 
different mGCTs cell line were used: in red 2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H 
and GCT44 (both Yolk Sac Tumour). In green two normal gonadal control (ovaries and testis) and in 
grey the Universal RNA Reference. 
 
As for the pri-miRNA experiments, correlation between chromosomes was also assessed. 
Again, significant correlation was found (p-values: <0.0001), in agreement with the potential 
co-regulation suggested for the pri-miRNAs (Figure 3.17).   
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Figure 3.17: Correlation of expression of -3p miRNAs located on the different chromosome. Four 
different mGCTs cell line were used: in red 2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H 
and GCT44 (both Yolk Sac Tumour). In green two normal gonadal control (ovaries and testis) and in 
grey the Universal RNA Reference. The different symbols represent different correlations. The circle 
symbolises the correlation between miR-100-3p and miR-99a-3p, the rhombus symbolises the 
correlation between miR-125b-1-3p and miR-99a-3p, the triangle symbolises the correlation between 
miR-100-3p and miR-125b-2-3p and the square symbolises the correlation between miR-125b-1-3p and 
miR-125b-2-3p. 
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   Assessment of miRNAs host genes abundance 
MiR-125b-1 and miR-100 are encoded in the intron of a large polycistronic transcript derived 
from Chromosome 11, the long non-coding RNA (lincRNA) MIR100HG. Similarly, miR-
125b-2 and miR-99a are encoded in the intron of another large polycistronic transcript derived 
from Chromosome 21, MIR99AHG (LINC00478). In order to better understand the regulation 
of transcription across the whole region where the two families of miRNA are located, the 
expression of the lincRNAs MIR100HG and MIR99AHG were also determined. Moreover, 
the expression of a coding gene, BLID (BH3-like motif-containing cell death inducer), a 
positive regulator of caspase activity which is located within the region on Chromosome 11 
was also studied. 
   MiRNAs host genes detection 
Four housekeeping genes, RPL13, HMBS, ACTb and YWHAZ were tested to determine the 
most consistent ones to use for normalisation of the expression data. HMBS transcription had 
a high standard deviation between samples ( =1.46), and the expression ratio between HMBS 
and the others HK genes varied across all the samples. This HK gene was discarded for 
subsequent data normalisation. The other HK genes had a lower variability ( =0.85, 0.88 and 
0.85, respectively), and were chosen as they all had the same expression ratio between HKs 
across the samples (Figure 3.18).  
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Figure 3.18: Raw Ct values of four housekeeping genes in four representative GCT cell lines. Data 
presented as mean ± SEM of n=3 biological replicates. 
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The level of expression of lincRNA MIR100HG, and BLID, and lincRNA MIR99AHG from 
each individual chromosome, was normalised to the pooled control mRNAs (i.e. testis and 
ovary gonadal controls) using the three housekeeping genes to normalise expression of both 
coding and miRNAs host transcripts and plotted for each individual cell line (Figure 3.19). 
 
Figure 3.19: Expression of lincRNAs and BLID gene in different GCT cell lines. Pink bars represent 
contributions from chromosome 11, where miR-100 and miR-125b-1 are located, while orange bars 
represent chromosome 21 contributions, where miR-99a and miR-125b-2 are located. Data presented 
as mean ± SEM of n=3 biological replicates.  
 
Consistent with previous results both chromosomal sites showed downregulation of lincRNA 
transcripts. Moreover, the data is consistent with the differential expression of pri-miRNA and 
-3p miRNA described in 3.2.4.2, and 3.2.5.1 respectively, the seminoma cell line TCam2 
showed a similar level of downregulation of the lincRNAs located on chromosomes 11 and 21, 
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whereas the other cell lines showed differential regulation. In 2102Ep (the EC derived cell line) 
there was greater downregulation of the chromosome 21 lincRNA MIR99AHG transcripts, 
while 1411H and GCT44 cells (both cell lines derived from YSTs) showed a greater 
downregulation of the chromosome 11 derived lincRNA MIR100HG. Furthermore, the 
transcripts for the coding gene BLID were downregulated similarly to the lincRNA 
MIR100HG, which is transcribed independently from an overlapping region, with the 
exception of the GCT44 cell line where this transcript appear to be slightly more downregulated 
than the corresponding lincRNA. These data suggest that similar mechanisms of transcriptional 
regulation may occur across the whole area on both chromosomes. 
   Correlation of expression of pri-miRNA, miRNA-3p/-5p and 
MIR100HG host gene in chromosome 11 
The data shown is consistent with similar regulation occurring on lincRNAs, pri-miRNAs and 
individual miRNAs, both -3p, and -5p as well as on the coding gene BLID, which is located in 
the same area but transcribed independently. To further investigate this transcriptional 
regulation, correlation between expression of MIR100HG and pri-miRNA, miRNA-3p, -5p 
and BLID gene, were analysed. The -5p data were previously presented in the Figure 3.6. 
MIR100HG expression significantly correlated with expression of miR-100 and miR-125b-1 
throughout the different stages of miRNA biogenesis studied. Expression of both primary 
transcripts pri-miR-100 and pri-miR-125b-1 showed significant correlation to MIR100HG 
expression (p-value: 0.0005 and <0.0001, respectively) (Figure 3.20 panel a). A similar 
significant correlation was seen for MIR100HG and miRNA -3p strands expression (p-value: 
0.0009 and 0.0005, respectively) and MIR100HG and miRNA -5p strands (p-value: 0.0002 
and <0.0001, respectively), (Figure 3.20 panels b and c respectively). Interestingly, the 
correlation between MIR100HG and BLID gene expression also appeared to be significant (p-
value: <0.0001) (Figure 3.20 panel d). 
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Figure 3.20: Correlation of expression of various transcripts within chromosome 11. Four different 
mGCTs cell lines were used: in red 2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H and 
GCT44 (both Yolk Sac Tumour) and in green two normal gonadal control (ovaries and testis).  
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   Correlation of expression of pri-miRNA, miRNA-3p/-5p with 
MIR099AHG host gene on chromosome 21 
As for the chromosome 11 locus, the data shown for chromosome 21 loci is consistent with 
similar regulation occurring on lincRNAs, pri-miRNAs and individual miRNAs. To further 
investigate the transcriptional regulation on chromosome 21, correlation between expression 
of MIR99AHG and primary transcripts, miRNA-3p, -5p encoded at this locus were analysed. 
The -5p data were previously presented in the Figure 3.6. 
MIR99AHG expression significantly correlated with expression of miR-99a and miR-125b-2 
throughout the different stages of miRNA biogenesis studied. Expression of both primary 
transcripts pri-miR-99a and pri-miR-125b-2 showed significant correlation to MIR99AHG 
expression (p-value: 0.0003 and 0.0002, respectively) (Figure 3.21 panel a). A similar 
significant correlation was seen for MIR99AHG and miRNA -3p strands expression (p-value: 
0.037 and 0.0005, respectively), however MIR99AHG and miRNA -5p strands did not 
correlate significantly (p-value: 0.07 and 0.137, respectively), probably due to a slightly higher 
level of MIR99AHG transcription in GCT44 cell line (Figure 3.21 panels b and c respectively).
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Figure 3.21: Correlation of expression of various transcripts within chromosome 21. Four different 
mGCTs cell line were used: in red 2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H and 
GCT44 (both Yolk Sac Tumour) and in green two normal gonadal control (ovaries and testis). 
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   Correlation between lincRNAs transcribed from two chromosomal 
loci 
Having better clarified the regulation of transcription on each individual chromosome, the 
interplay between the two loci in different chromosomes was then explored. 
The correlation between transcription of genes from the two chromosomes resulted to be 
significant, with a p-value of 0.005 (Figure 3.22). 
 
Figure 3.22: Correlation of transcription across the regions encoding for the downregulated 
miRNAs on chromosome 11 or chromosome 21. Four different mGCTs cell lines were used: in red 
2102Ep (EC), in blue TCam2 (Seminoma), in yellow 1411H and GCT44 (both Yolk Sac Tumour) and 
in green two normal gonadal control (ovaries and testis). The different symbols represent different 
correlations. The circle symbolises the correlation between MIR100HG and MIR99AHG while the 
triangle symbolises the correlation between BLID and MIR99AHG. 
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All together these data point to an intra-chromosomal and inter-chromosomal co-regulation of 
the expression of these miRNA, the origins of which we investigated in further work presented 
in chapter 5. 
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3.3   Discussion 
Microarray analysis of the expression of 246 miRNAs from RNA extracted from 42 paediatric 
mGCTs samples and compared with normal samples, demonstrated that the most 
downregulated miRNAs (adjusted p-values<1x105) were: miR-125b-5p, miR-100-5p, miR-
99a-5p, miR-204-5p and miR-152-3p. Further confirmation of the importance of these 
miRNAs in GCT malignancy was shown by the analysis of the overall seed abundance in the 
3’UTR of deregulated mRNA from mGCT samples and cell lines compared with non-
malignant control samples (normal gonadal controls and benign teratomas) (Palmer et al., 
2010). 
These data demonstrated that the 2-7 nt seed sequences of miR-99a-5p/-100-5p and miR-125b-
5p are substantially decreased in both clinical mGCT samples and representative mGCT cell 
lines, compared with non-malignant control samples. These data also suggest that the observed 
downregulation of miR-99a-5p/-100-5p and miR-125b-5p is likely to have a significant 
functional effect in mGCTs. 
Analysis of the microarray data showed downregulation of transcription of miR-204-5p and 
miR-152-3p in both mGCTs and benign GCTs tissue samples. This result is consistent with the 
reduction in seed abundance shown for miR-204-5p, which seems to be the same across all the 
samples and cell lines. The abundance of the seed of miR-152-3p is more significantly 
downregulated across the mGCT clinical samples compared with the normal control and the 
benign form of GCTs, but this downregulation is not mirrored in the cell lines we studied. 
Although it is probable that the downregulation of these miRNAs has a role in mGCTs, the cell 
lines we have available to study these malignancies in vitro would not be the best model to use. 
Consequently, further work was focussed on miRNAs miR-99a-5p, miR-100-5p and miR-
125b-5p. 
Additionally, a similar pattern of downregulation for miR-99a-5p/-100-5p and miR-125b-5p, 
was observed in the original microarray data, which may suggest that these miRNAs are 
potentially coregulated. 
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The mature form of miR-125b-5p can be derived from either miR-125b-1, which is transcribed 
from a locus on chromosome 11 or miR-125b-2, which is transcribed from a locus on 
chromosome 21. Interestingly, miR-100-5p cluster together with miR-125b-1 on chromosome 
11 and miR-99a-5p cluster together with miR-125b-2 on chromosome 21 and these two 
miRNAs (miR-99a-5p and miR-100-5p) have a high level of homology, with an identical seed 
region shared by the -5p mature strands and differing only by one nucleotide towards the 3’ 
end of the miRNAs. Cross-reactivity experiment also revealed that miR-99a-5p and miR-100-
5p are indistinguishable using the most selective available qPCR detection system (Taqman 
miRNA assays), and it is therefore impossible to separate these transcripts from each other.  
Previous studies investigating the role of the individual miRNA of the miR-100/-125b-1 and 
miR-99a/-125b-2 clusters, demonstrated conflicting functions. For example, miR-125b-5p 
overexpression has been linked to poor prognosis in HER2-positive patients with either gastric 
or breast cancer (Luo et al., 2017; Sui et al., 2017), but conversely in breast cancer, miR-125b-
5p was reported down-regulated in biopsy specimens and as tumour suppressors (Iorio et al., 
2005; Mattie et al., 2006) by mediating the ERBB2 and ERBB3 pathway (Scott et al., 2007) 
or by targeting the ETS1 gene (Y. Zhang et al., 2011b). Similarly, miR-99a-5p/-100-5p has 
been associated with a tumour suppressing or a tumour promoter role in cancer. For example, 
miR-100-5p overexpression was correlated with progression of renal cell carcinoma, acute 
myeloid leukaemia and epithelium-derived gastric cancer cell (Gu et al., 2015; Qin, Huang and 
Wang, 2015; Yang et al., 2015), but contrarily in gastric cancer, ovarian cancer and breast 
cancer miR-100 was acting as tumour suppressor, by targeting CXCR7 or by inhibiting Wnt/b-
catenin signalling pathway (Jiang et al., 2016; Cao et al., 2018). However, there is a high 
phylogenetic conservation of the miR-99a/miR-100/miR-125b cluster, and it is thought that 
within the cluster there may be co-regulation in either the tumour suppressive or oncogenic 
role. 
The results obtained with the microarray analysis of expression in mGCTs, demonstrated an 
almost identical pattern of downregulation of miR-99a-5p/-100-5p and miR-125b-5p. 
Furthermore, the genomic redundancy of the clusters suggests that the expression of the 
individual miRNA may be contributed to by one chromosome alone (11 or 21) or by the 
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simultaneous expression from both chromosomes (11 and 21), which are then potentially 
regulated by the same mechanisms. 
MiRNAs dysregulation occurs in several ways, but the detailed mechanisms causing this 
inaccurate expression are still largely uncharacterised. Chromosomal alteration and genomic 
abnormalities have been shown to cause miRNAs dysregulation in ovarian cancer (37.1% of 
the overall cases), breast cancer (72.8%) and melanoma (85.9%) (Zhang et al., 2006b). In light 
of this evidences, potential copy number changes at the miRNAs miR-100 and miR-125b-1 
cluster locus on chromosome 11 (chr11 q24.1), and at the miR-99a and miR-125b-2 locus on 
chromosome 21, (chr21 q21.1) were investigated by qPCR analysis on genomic DNA.  
In mammals, promoter regions, enhancers, repressors or single nucleotide polymorphisms 
(SNPs) many kilobases (Kb) away from the transcription start site can affect the subsequent 
transcription of genes (Dobi and Winston, 2007), therefore primers for the analysis of potential 
genomic imbalances were designed up to 50Kb upstream of both loci. 
Frequent chromosomal aberration have been previously reported in mGCTs, in particular copy 
number gains of chromosomes 1, 7, 8, 17, 21, X and copy number loss of chromosomes 4, 5, 
11, 13, 18 and Y (Kraggerud et al., 2002; McIntyre et al., 2007). Consistent with these findings, 
our data showed copy number loss of chromosome 11 in some of the mGCTs cell lines 
(particularly in 1411H and TCam2) compared with normal tissue from testis, and copy number 
gains for chromosome 21 in mGCTs cell lines (in particular 1411H, GCT44 and 2102Ep) when 
compared with normal tissue from testis. However, no significant further change in 
chromosomal copy number was detected in the region of chromosome 11 up to 50Kb upstream 
of miR-100 and in the region of chromosome 21 up to 50Kb upstream of miR-99a in mGCTs 
cell lines, suggesting this is not the mechanism by which miRNA dysregulation is occurring. 
Therefore, expression of the genes throughout the biogenesis of the miR-99a-5p/-100-5p and 
miR-125b-5p miRNA was further investigated with particular focus in identifying the relative 
contributions to transcription of the chromosome 11 and 21 loci.  
The first step in miRNA biogenesis is the production of a primary transcript (pri-miRNA) from 
introns or exons of non-coding or coding protein genes. This process takes place in the nucleus 
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and is highly controlled and complex. Pri-miRNAs are difficult to quantify as they can be easily 
degraded, unless they have been modified by capping (polyadenylated cap) and are protected 
by the proteins complexes of the microprocessor (where the core components DROSHA and 
DGCR8 cleave the pri-miRNA into the precursor miRNA (pre-miRNA) (Cai, Hagedorn and 
Cullen, 2004). It is also crucial that DNA is removed prior to quantification, as the pri-miRNAs 
specific primers can also target gDNA sequences. 
Specific primers were used to detect the appropriate pri-miRNA and RNA input optimised to 
allow detection. Pri-miR-99a/-miR-100/-miR-125b-1/-miR-125b-2 expression was quantified 
in mGCT cell lines and compared with gonadal control. Overall expression of pri-miRNAs was 
downregulated for all mGCTs cell lines. As downregulation of pri-miRNA can be due to 
several mechanisms, including downregulation of protein involved in their stabilization or 
maturation, transcription factor or epigenetic mechanisms which regulates their expression (Ha 
and Kim, 2014), we used data from mRNA microarrays that were performed at the same time 
of the miRNA microarrays discussed earlier in the chapter using the same tissue samples, cell 
lines and controls, to identify potential changes that may suggest potential mechanisms. 
Comparison of the expression of genes involved in the maturation and processing of pri-
miRNA such as PRL1, important for pri-miRNA stabilization, DROSHA or DGCR8, the main 
regulators of pri-miRNA maturation in mGCT samples and control tissues suggested that the 
lower expression of pri-miRNAs was unlikely to be due to deregulated expression of members 
of the microprocessor complex as no differences in the expression of the transcripts encoding 
the proteins involved in these processes were detected (data not shown). It cannot be excluded 
however, that post-transcriptional regulation may have an effect on the composition of these 
complexes.  
Interestingly, although all mGCT cell lines demonstrated downregulation of pri-miRNAs 
derived from both chromosomes 11 or 21, there appears to be differential contribution from 
each chromosome in different cell lines. For instance, in 1411H and GCT44, both yolk sac 
tumours derived cell lines, transcription of pri-miR-100 and pri-miR-125b-1 was more reduced 
than transcription of pri-miR-99a and pri-miR-125b-2, perhaps reflecting the detection of a 
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lower copy number across chromosome 11 in these cells. On the other hand, the TCam2 cell 
line showed similar level of downregulation on both chromosomes, whereas in 2102Ep 
expression from chromosome 21 appeared less abundant than from chromosome 11. These 
results suggest that there is no individual chromosome that contributes to the downregulation 
of miR-99a-5p/miR-100-5p and miR-125b-5p, but that both are downregulated, though at 
different levels in different cell lines. 
The significant correlation between pri-miRNAs derived from the same chromosome (pri-miR-
100/-miR-125b-1 on chromosome 11 and pri-miR-99a/-miR-125b-2 on chromosome 21) is in 
agreement with the transcription of the single polycistronic sequence from which both miRNAs 
are derived.  However, the significant correlation between the expression of the pri- transcripts 
from the two chromosomal loci (pri-miR-99a/-miR-125b-2 with pri-miR-100/-miR-125b-1 
also implies a common regulatory mechanism of regulation for both chromosomes.  
To further verify the contribution of both chromosomes 11 and 21 to the miRNA production 
and downregulation, and the possible common mechanisms of regulation of miRNAs 
expression on both chromosomes, the expression of the -3p passenger strand for each of the 
miRNAs of interest was studied. Since the passenger stands derived from each chromosomal 
site are different in sequence, this allowed the dissection of the contribution of each 
chromosome which could not be carried out if the -5p guide strand of the mature miRNAs 
under investigation alone was investigated, as these are identical between chromosomes, 
Not dissimilarly from the pri-miRNA, the passenger strand is usually quickly degraded, and it 
is difficult to quantitate. Optimisation was required but, using 10 times the normal amount of 
RNA used to detect guide strands, miR-99a-3p/-100-3p/-125b-1-3p/-125b-2-3p were 
quantitated in both mGCT cell lines and normal controls. All -3p miRNAs tested were 
downregulated, when compared with gonadal control. Moreover -3p miRNA exhibited in the 
different cell lines the same downregulation pattern seen for their respective pri-miRNAs.  
For instance, in 1411H and GCT44, both yolk sac tumours derived cell lines, transcription of 
miR-100-3p and miR-125b-1-3p was more reduced than transcription of miR-99a-3p and miR-
125b-2-3p. On the other hand, the TCam2 cell line showed similar level of downregulation on 
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both chromosomes, whereas in 2102Ep transcripts appeared to origin less form chromosome 
21 than from chromosome 11.  
The differences observed between the patterns of transcription in the different cell lines could 
be linked to the tumour subtype the cell lines were derived from. Accordingly, both yolk sac 
tumour derived cell lines, GCT44 and 1411H, have the same pattern of regulation, while 
2102Ep and TCam2 derived from embryonal carcinoma and seminoma respectively, appear to 
have their own different characteristic regulation. However, further subtype specific cell lines 
or tumour samples would have to be tested to produce conclusive data about subtype specific 
chromosomal regulation. In time and if confirmed such differences may be exploited to 
differentiate between mGCT subtypes, for example, for diagnostic purposes.  
Significant correlation between expression of -3p miRNAs derived from the same chromosome 
(miR-100-3p/-125b-1-3p on chromosome 11 and miR-99a-3p/-125b-2-3p on chromosome 21) 
was seen, as well as between expression from the different chromosomal loci (miR-99a-3p/-
125b-2-3p with miR-100-3p/-125b-1-3p). These significant correlations again suggest that 
each cluster is transcribed as a single transcript and that both chromosomal loci may be 
regulated by a common regulatory mechanism.  
These findings together, strongly support the hypothesis that both chromosomes contribute to 
the deregulation of the miRNAs of interest and that this downregulation has an origin at the 
transcriptional level. This mechanism is therefore different to the post-transcriptional block, 
previously described by our group and mediated by LIN28, which regulates the expression of 
let-7a, another miRNA transcribed from the same two chromosomal loci (Murray et al., 2013). 
A differential regulation for let-7a and miR-100/-125b-1 has also been described recently in 
response to TGF-β signalling. In this setting, miR-100/-125b-1 are upregulated through 
SMAD2/3, whereas let-7a remains unchanged, due to the fact that TGF-β also induces 
LIN28B, consequently inhibiting let-7a maturation (Ottaviani et al., 2018). 
MiR-99a/-125b-2 and miR-100/-125b-1 are embedded in the introns of a long non-protein 
coding genes (lincRNA) called MIR99AHG (LIN00478), and MIR100HG, respectively. A few 
recent papers have showed that the expression level of MIR99AH (LINC00478) and 
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MIR100HG were similar to the one of the mature form of miR-99a-5p/-100-5p and miR-125b-
5p, suggesting that the miRNA of chromosome 11 and 21 were produced from a single primary 
transcript together with their host lincRNAs (Emmrich, Rasche, et al., 2014; Emmrich, 
Streltsov, et al., 2014; Lu et al., 2017; Ottaviani et al., 2018).  
In agreement with these data, expression of the two lincRNAs was downregulated in all the 
four mGCT cell lines when compared with gonadal control. Significant levels of correlation 
were seen between the lincRNA (MIR99AHG or MIR100HG) with pri-miRNA, miRNA-3p 
and miRNA-5p originating from the same chromosomal locus, strongly suggesting that the 
miRNAs are transcribed all together with their host gene as a single transcript. Furthermore, 
the significant correlation between the expression of lincRNA MIR99AHG on chromosome 21 
and the expression of lincRNA MIR100HG on chromosome 11 points once more towards a 
common mechanism of transcriptional downregulation acting on both chromosomal loci. 
Finally, the analysis of the expression of BLID, a protein coding gene transcribed separately 
from the miRNAs at the same loci on chromosome 11, showed downregulation of the 
expression of this gene. This suggest that the whole region is downregulated in a similar 
manner and with a process that is not specific to miRNA biogenesis.	  
The findings presented in this chapter therefore point to three conclusions: first, the 
downregulation of the expression is most likely to occur at the transcriptional level, second, 
the miRNAs within a cluster are transcribed as a single transcript and third, there is likely to 
be a common mechanism of regulation between the two miRNA clusters chromosomal loci. 
The precise mechanism by which the downregulation of transcription occurs, is still unclear. It 
cannot be excluded that deregulation of proteins involved in pri-miRNAs processing may also 
have a role in the control of miRNAs transcription. However, the fact that this mechanism 
appears to control transcription of both coding and non-coding transcripts, suggest that the 
mechanism is unlikely to involve processes specific for miRNA biogenesis, and that further 
studies should focus on a process potentially resulting on broader changes, such as epigenetic 
modulation of transcription. The conclusions presented in this chapter formed the basis for the 
work presented in the following chapter.  
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 Chapter 4   Investigation of the role of genomic 
methylation on the regulation of the expression of 
miRNA in mGCTs cell lines 
 
4.1   Introduction  
The data presented in the previous chapter suggested that the downregulation of miR-99a-
5p/-100-5p and miR-125b-5p occurs at a transcriptional level. Interestingly, half of the 
miRNAs found in humans have been identified to be closely associated with CpG islands 
(Weber et al., 2007), specific areas in which, in mammalian species, DNA methylation occurs 
(McCabe, Brandes and Vertino, 2009; Jones, 2012). Epigenetic mechanisms, such as promoter 
methylation or histone modifications, are one of the most common mechanisms of miRNA 
regulation (Saito and Jones, 2006; Suzuki et al., 2012). In human cancer, CpG island promoter 
hypermethylation has been identified as one of the causes of miRNA loss of expression (Saito 
et al., 2006b; Lujambio et al., 2007; Toyota et al., 2008). 
Both miR-125b-5p and miR-100-5p have been previously described to be dysregulated by 
epigenetic mechanisms: silencing of miR-125b-5p was shown to be related to promoter 
hypermethylation in invasive breast cancer (Y. Zhang et al., 2011a) and in colorectal cancer 
(Chen and Xu, 2015). Similarly, miR-100 has been shown to be downregulated due to 
hypermethylation of his host gene MIR100HG (Chen et al., 2014). 
Furthermore, methylation mechanisms of regulation play an important role in mGCT 
transformation, differentiation and treatment response (Koul et al., 2002). Numerous studies, 
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have shown global methylation of GCTs, but also a substantial difference between GCT 
subtypes, with seminomas being overall less methylated than non-seminomas (Jeyapalan et al., 
2011; Amatruda et al., 2013b; Shen et al., 2018). Many key regulators genes of methylation 
(such as DNMT3B) have been found to be increasingly expressed in non-seminomas cell lines 
and paediatric samples compared with seminoma, providing a possible explanation for this 
difference (Palmer et al., 2008). 
Due to the known importance of methylation as a regulatory mechanism in mGCTs, and its 
role in miRNA deregulation, this chapter aims to investigate whether aberrant methylation in 
the promoter region or in areas upstream to the miRNAs of interest is a credible mechanism 
by which the expression of miRNA miR-99a-5p/-100-5p and miR-125b-5p is downregulated 
in mGCTs.  
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4.2   Results  
   Effects of treatment with 5-azacytidine on miRNAs 
To investigate whether methylation played a role in the downregulation of miR-99a-5p/-100-
5p and miR-125b-5p, I assessed the effects of DNA demethylation on the expression of these 
miRNAs. 2102Ep (derived from an embryonal carcinoma) and 1411H (derived from a yolk sac 
tumour) cell lines, were treated with 5-azacytidine (5-aza). Cell lines were treated for 4 days 
with 10 µM of 5-aza, without replenishment of the media, and miRNA expression measured 
on day 4 (d4). 
Three housekeeping (HK) genes - RNU24, RNU38B and RNU44 - were assessed to ensure 
that their expression did not change as a result of the treatment. These snRNA (small nuclear 
RNA) were chosen as they have been shown by others to be stably and homogeneously 
expressed in malignant and normal tissue samples and cell lines (Palmer et al., 2010; Genovesi 
et al., 2012; Schwarzenbach et al., 2015). Reliability of the HK genes was evaluated using two 
criteria: the first one considered the standard deviation between treated and untreated samples, 
while the second assessed the consistency of expression of the HK genes within individual 
samples by looking at relative expression of the housekeeping genes vs each other. For an HK 
to be acceptable therefore, the standard deviation ( ) of its expression in different samples had 
to be £1, while its expression ratio to the other HKs had to be similar in all samples. 
RNU38B, did not meet either criteria, since had a standard deviation between treated and 
untreated 2102Ep cells of =1.18 and its expression ratio vs the other HKs was smaller in the 
treated than in the control samples. Therefore, this gene was discarded for subsequent data 
normalisation. The other two HK genes had a low standard deviation between untreated and 
treated samples in both cell lines (RNU24 = 0.21 and 0.11 for 2102Ep and 1411H 
respectively and RNU44 = 0.46 and 0.14 for 2102Ep and 1411H respectively) and consistent 
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expression ratios, and were therefore used to normalise the expression levels of the miRNAs 
(Figure 4.1). 
 
Figure 4.1: Raw Ct values showing expression levels of three candidate housekeeping genes 
(RNU24 in red, RNU44 in green and RNU38B in blue). The samples analysed were 2102Ep and 1411H 
cells in normal conditions and after treatment with 5-aza treatment for 4 days, are shown on the x axis. 
Data presented as mean ± SEM of n=3 biological replicates.  
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The potential effects of treatment with 5-aza on miR-99a-5p/-100-5p, miR-125b-5p and on a 
panel of non-differentially expressed miRNAs (miR-26b-3p, miR-500-3p and miR-137-3p) 
was then assessed (Figure 4.2). These non-differentially expressed miRNAs have previously 
been shown to have equal expression in both mGCT tissue samples and cell lines, and non-
malignant control [gonadal controls and benign GCTs (i.e. teratomas)] (Palmer et al., 2010). 
 
Figure 4.2: Expression of miR-99a-5p/-100-5p (red bars), miR-125b-5p (green bars) in 2102Ep 
and 1411H cell lines following 5-aza treatment for 4 days. Grey bars represent the average expression 
of non-differentially expressed miRNAs in mGCT cell lines under the same conditions. Expression was 
normalised to housekeeping genes and referenced the respective untreated control. Data presented as 
mean ± SEM of n=3 biological replicates. * p<0.05, **p<0.01, *** p<0.005 and **** p<0.001. 
 
A significant upregulation of miR-99a-5p/-100-5p was seen after 5-aza treatment in both 
2102Ep (p-value: 0.0001) and 1411H (p-value: 0.0001) cell lines. However, no significant 
difference in the expression of miR-125b-5p was detected in either 2102Ep or 1411H cells. 
  
*** 
*** 
n/s 
n/s 
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   Effects of multiple treatment with 5-azacytidine on 2102Ep cells 
To confirm whether transcription of miR-125b-5p was unchanged following treatment with 5-
aza, the experiment was repeated with one cell line, 2102Ep, using a modified protocol.   
Briefly, 2102Ep cells were treated with 10 µM of 5-aza, but the media containing fresh 5-aza 
was replenished every day. Quantification of miRNAs expression quantification was then 
performed on day 1, 2, 3 and 4 of treatment.  
RNU24 expression was analysed to ensure that there was no effect of the adjusted 5-aza 
treatment throughout the time-course as previously described in the section 4.2.1. RNU24 was 
shown to be consistent across all the samples at all timepoints ( = 0.4). RNU24 was therefore 
utilised as the housekeeping gene (Figure 4.3). 
 
 
Figure 4.3: Raw Ct values showing average expression levels of RNU24 housekeeping gene in 
normal conditions (in green) and after treatment (in red) with 5-aza treatment for 4 days. Data 
presented as mean ± SEM of n=3 biological replicates.  
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The potential effects of treatment with 5-aza on miR-99a-5p/-100-5p, miR-125b-5p and the 
panel of non-differentially expressed miRNAs (miR-26b-3p, miR-500-3p and miR-137-3p) 
were then assessed (Figure 4.4) over a 4 days time-course. 
 
Figure 4.4: Expression of miR-99a-5p/-100-5p (red bars), miR-125b-5p (green bars) in 2102Ep 
cells following 5-aza treatment for 4 days. Grey bars represent the average expression of non-
differentially expressed miRNAs in mGCTs cell lines under the same conditions. Expression was 
normalised to the respective day matched untreated control. Data presented as mean ± SEM of n=3 
biological replicates. * p<0.05, **p<0.01, *** p<0.005 and **** p<0.001. 
 
No significant difference in expression levels was detected for either miRNA at day 1 or 2 of 
treatment. A significant upregulation of miR-99a-5p/-100-5p after 5-aza treatment in 2102Ep 
compared with untreated control was seen at day 3 (p-value: 0.03), but no significant difference 
was detected for miR-125b-5p. 
Differently from the previous experiment, a significant upregulation of both miR-99a-5p/-100-
5p and miR-125b-5p was seen at d4 compared with untreated control (p-value: 0.0001 and 
0.003, respectively). However, the levels of upregulation in this experiment for miR-99a-5p/-
100-5p were lower than seen in the earlier experiment. 
*** 
** * 
n/s 
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   Assessment of lincRNAs levels 
MiR-99a/-125b-2 and miR-100/-125b-1 are embedded in the introns of two long non-protein 
coding genes (lincRNAs), MIR99AHG (LIN00478) on chromosome 21, and MIR100HG on 
chromosome 11. Data presented in Chapter 3, (sections 3.2.7 to 3.2.8) show that there is a 
strong correlation between the expression of the mature miR-99a-5p, miR-100-5 and miR-
125b-5p and their host lincRNAs. Consequently, the expression levels of these host genes were 
also assessed. 
To identify which housekeeping genes were suitable for data normalisation, four housekeeping 
genes - ACTb, RPL13A, YWHAZ and HMBS - were assessed to ensure that they were not 
affected by treatment with 5-aza. All HK genes had a low standard deviation between treated 
and untreated samples for each day ( <1), and they had similar expression ratio across all the 
samples. These four HK genes were therefore utilised for normalisation purposes (Figure 4.5).  
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Figure 4.5: Raw Ct values showing expression levels of four candidate housekeeping genes under 
normal conditions and after treatment of 2102Ep cells with 5-aza treatment for 4 days. Data 
presented as mean ± SEM of n=3 biological replicates.  
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Analysis of the expression level of the host genes on chromosome 11 (MIR100HG) and 
chromosome 21 MIR99AHG (LINC00478) is shown in Figure 4.6.
 
Figure 4.6: Expression of MIR100HG and MIR99AHG (LINC00478) in 2102Ep treated with 5-
aza. Each day has been normalised individually with its respective untreated control. Data presented as 
mean ± SEM of n=3 biological replicates. * p<0.05, **p<0.01, *** p<0.005 and **** p<0.001. 
 
Interestingly, levels of MIR100HG and MIR99AHG appeared significant elevated even after 
one day of 5-aza treatment (p-value: 0.0207 and 0.0162, respectively). Overall, MIR100HG 
and MIR99AHG levels were elevated across the 4 days, with significant upregulation for 
MIR100HG at day 2 and 4 of treatment (p-value: 0.0406 and 0.0326, respectively), and for 
MIR99AHG at day 4 (p-value: 0.0199).  
In view of the changes in the level of expression of both miRNAs and their host genes after 
treatment with 5-aza, it was concluded that hypermethylation may potentially be the regulatory 
mechanism causing the downregulation of the expression of miR-99a-5p/-100-5p and miR-
125b. Therefore, studies were carried out to identify more specifically the areas of this potential 
hypermethylation. 
n/s n/s 
n/s 
* * 
* * 
* 
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   Methylation profiles identified using bisulfite conversion 
Further experiments were done to identify the potential areas of hypermethylation that could 
be involved in miRNA regulation. Ideally, methylation profiles of genomic DNA from mGCTs 
cell lines would have been compared with normal gonadal cell lines. However, no cell lines 
derived from normal gonads are currently available, making the comparison between mGCT 
cell lines and appropriate controls challenging. Consequently, four cell lines derived from 
normal cervix tissue (NCX6, 95:14, 95:15 and 95:42), one primary fibroblast cell line (HFF-1) 
and one cell line derived from normal retinal pigmented epithelial cells (RPE) were used as 
controls. One control tissue derived from normal testis was also used together with four mGCT 
cell lines, namely 2102Ep, TCam2, 1411H, and GCT44. 
   Primer design and validation 
DNA methylation can be studied by exploiting the ability of 5-methylcytosines to resist 
conversion by bisulfites to uracil as described in Figure 4.7. 
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Figure 4.7: Differential response to bisulfite conversion in methylated and unmethylated cytosines. 
Unmethylated cytosines are converted to uracil by exposure to sodium bisulfite and can then be 
amplified to thymidine by PCR (right panel). The ability of 5-methylcytosines to resist conversion, 
which results in amplification by PCR as unchanged cytosines (left panel), allows evaluation of the 
thymidine vs cytosine relative ratio and can therefore be used therefore to quantify levels of methylation 
at each potential methylation site.   
 
Little is known about the location of the potential areas of methylation in the genomic 
sequences upstream of the miR-99a/-125b-2 and miR-100/-125b-1. DNA methylation 
upstream of genes is most frequently found in areas which are rich in CpG (i.e. CpG islands) 
(McCabe, Brandes and Vertino, 2009; Jones, 2012), therefore I postulated that these may be 
areas of interest in my study. 
Many bioinformatics tools are available to help identify CpG rich regions. For this analysis, I 
used MethPrimer, a free online tool that as well as predicting potential CpG islands in DNA 
sequences, designs bisulfite-converted DNA specific primers within or flanking the CpG island 
(Li and Dahiya, 2002) (Figure 4.8). Briefly, the sequence of interest is submitted via a menu, 
which also allows the definition of the minimal length required to define the CpG island (100 
nt by default), as well as the CG percentage needed to identify a region as CG rich (50% by 
default). The program returns a visual representation of the characteristics of the sequence 
analysed, including the location of all CpG, the location of the potential CpG islands identified 
and primers for the analysis of such regions. The primers are designed by the program to avoid 
potential methylation sites, and therefore to be able to amplify both methylated and 
unmethylated templates and are matched in length and primer melting temperatures. Moreover, 
further refinement of the research parameters is also available, such as location, length and 
melting temperature. In this study, I also added the additional parameter of the melting 
temperature of the amplicon as one of the important criteria to identify primer sets. This was 
crucial as I assessed whether methylation was present using melting curve analysis, a technique 
first described by Ririe to differentiate between desired and undesired products of a PCR (Ririe, 
Rasmussen and Wittwer, 1997) and then adapted to become a method to quantify methylation 
(Ririe, Rasmussen and Wittwer, 1997; Wittwer et al., 2003; Wojdacz and Dobrovic, 2007). 
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Briefly, the temperature at which dsDNA melts is determined by factors such as nucleotide 
sequence, length and GC/AT ratio. A methylated sequence of DNA, following bisulfite 
modification, will maintain a higher GC/AT ratio and so melting at a higher temperature than 
its unmethylated equivalent. Melting curve analysis can detect a single base difference but 
requires quite a bit of optimisation to give quantitative information on the composition of the 
amplicons. Rather than quantify the amount of methylation present, I used this approach to 
identify areas of interest based on differences in the melting curve of amplicons from mGCT 
cells DNA compared with DNA from normal cells.  
 
 
 
 
 
Figure 4.8: Example of MethPrimer output. The unconverted sequence of interest (max length 5Kb) 
is submitted, and CpG rich areas identified, using a 50% CG content as the cut-off. The sequence is 
then converted by the programme to that resulting from bisulfite conversion and primers are designed 
on the converted sequence in the area of interest. 
 
For this approach to succeed, it was crucial that primers were designed to amplify regions 
(amplicons) that could be sufficiently different in their melting characteristic if they were 
methylated or not. Therefore, the melting temperature of amplicons derived from a 100% 
methylated DNA template versus that of amplicons derived from a 100% unmethylated 
template were calculated using the online program uMelt, which predicts the melting 
temperature of a PCR product based on its sequence. Primer pairs identified by MethPrimer 
were chosen if the difference between the predicted melting temperature of fully methylated 
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and fully unmethylated amplicon was >1°C wherever possible. Where necessary, primers were 
modified to fulfil this criterion. 
The presence of CpG islands was searched for in an area up to 10Kb upstream of the 
transcriptional start of the lincRNAs transcripts on either chromosome. For reference, 
MIR100HG is located at the position nt 122,028,327-122,556,721 (GRCh38/hg38) on the 
minus strand of chromosome 11 while MIR99AHG (LINC00478) is located at the position nt 
15,928,296-16,627,397 (GRCh38/hg38) on the plus strand of chromosome 21. Similarly, the 
presence of CpG islands was searched for up to 10Kb upstream of the transcriptional start of 
the individual microRNA. For reference miR-100 is located at the position nt 122,152,229-
122,152,308, and miR-125b-1 is located at the position nt 122,099,757-122,099,844 on the 
minus strand of chromosome 11, whereas miR-99a is located at the position nt 16,539,089-
16,539,169, and miR-125b-2 is located at the position nt 16,590,237-16,590,325 on the plus 
strand of chromosome 21. 
Using the criteria listed above, I identified 11 areas on chromosome 11, and 5 areas on 
chromosome 21 that could be identified as CpG islands and were suitable for analysis by 
melting curve analysis. The characteristics of these areas are listed on Table 4.1 and Table 4.2. 
PCR conditions were then optimised for each primer set identified by standard gradient PCR. 
Once the optimal annealing temperature was identified, Sybr green qPCR was run for each 
primer set using as templates the different cell lines (mGCTs vs non-malignant controls). The 
potential difference in the melting temperature of mGCT samples amplicons vs control 
amplicons was assessed to decide which areas may be differentially methylated. Where 
differences in melting curves and temperatures between mGCT and non-malignant control 
amplicons were detected, the qPCR product was purified and sent for Sanger sequencing. The 
chromatograms obtained by the sequencing process were then semi-quantitatively analysed 
using ImageJ as described in the Materials and Methods section 2.3.7, in order to determine 
methylation levels at each CpG sequenced. Finally established CpG methylation levels were 
compared between mGCT cell lines and non-malignant controls to detect any difference in 
methylation that may be significant. This process is summarised in Figure 4.9. 
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Chromosome 11 
Area 
Isla#01 
(MIR100HG.11.1) 
Isla#02 
(MIR100HG.11.2) 
Isla#03 
(MIR100HG.11.3) 
Isla#04 
(MIR100HG.11.4) 
10Kb upstream 
MIR100HG 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
77 76 83 81 77.5 77 88 83.5 
4 CpG 9 CpG 6 CpG 30 CpG 
Length: 231 nt Length: 262 nt Length: 213 nt Length: 425 nt 
Area 
Isla#05 
(miR-100.11.1) 
Isla#06 
(miR-100.11.2) 
 
10Kb upstream 
miR-100 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
91.8 90 80.5 79.5 
7 CpG 6 CpG 
Length: 440 nt Length: 218 nt 
Area 
Isla#07 
(BLID.11.1) 
 
BLID Tm° CG 
Tm° 
TG 
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82 80.5 
6 CpG 
Length: 227 nt 
Area 
Isla#08 
(miR-125b-1.11.1) 
Isla#09 
(miR-125b-1.11.2) 
Isla#10 
(miR-125b-1.11.3) 
Isla#11 
(miR-125b-1.11.4) 
5Kb upstream miR-
125b-1 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
Tm° CG 
Tm° 
TG 
81.7 80.4 84.5 82 79 77 80.5 78.5 
6 CpG 8 CpG 14 CpG 17 CpG 
Length: 374 nt Length: 161 nt Length: 344 nt Length: 415 nt 
Table 4.1: Areas identified by MethPrimer on chromosome 11. For each area identified, the melting 
temperature of fully methylated amplicons (Tm° CG) and fully unmethylated amplicons (Tm° TG), the 
number of CpG identified and the length of the amplicon is reported. The name of the areas identified, 
correspond to the name of the primer pair and it will be used throughout this work. 
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Chromosome 21 
Area 
Isla#12 
(MIR99AHG.21.1) 
 
10Kb upstream MIR99AHG 
Tm° CG Tm° TG 
85 83.5 
5 CpG 
Length: 143 nt 
Area 
Isla#13 
(miR-99a.21.1) 
Isla#14 
(miR-99a.21.2) 
Isla#15 
(miR-99a.21.3) 
10Kb upstream miR-99a 
Tm° CG Tm° TG Tm° CG Tm° TG Tm° CG Tm° TG 
80 78 89.6 88.7 78 77 
4 CpG 3 CpG 5 CpG 
Length: 170 nt Length: 200 nt Length: 401 nt 
Area 
Isla#16 
(miR-125b-2.21.1) 
 
5Kb upstream miR-125b-1 
Tm° CG Tm° TG 
82.5 81 
15 CpG 
Length: 202 nt 
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Table 4.2: Areas identified by MethPrimer on chromosome 21. For each area identified, the melting 
temperature of fully methylated amplicons (Tm° CG) and fully unmethylated amplicons (Tm° TG), the 
number of CpG identified and the length of the amplicon is reported. The name of the areas identified, 
correspond to the name of the primer pair and it will be used throughout this work. 
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Figure 4.9: Workflow of the approach used to detect CpG islands and methylation status on 
chromosomes 11 and 21. 
A summary of the results obtained is shown in (Figure 4.10). Briefly, panel a) describes results 
for chromosome 11 and panel b) those for chromosome 21. The top row of both panels a) and 
b) shows the position of the methylation specific primers designed by MethPrimers (adjusted 
wherever needed) indicating the area of analysis. The following two rows indicate with a traffic 
light system whether differerences were seen between mGCT cell lines and normal controls, 
with green indicating clear differences, yellow uncertain differences and red no differences 
seen. The upper part of this results section refers to data obtained with the melting curves 
analysis, the lower to the results obtained from the analysis of the chromatograms obtained by 
Sanger sequencing. Overall, of all the potential regions identified as CpG islands by 
MethPrimers, 16 regions could be optimally amplified by PCR. Of these, seven showed 
obvious differences in the melting curves of products obtained from mGCT cell lines versus 
control cell lines, four more showed minor differences and where therefore considered 
uncertain, and five showed no differences. The 11 regions showing potential difference were 
further analysed by Sanger sequencing. For these regions, methylation at each individual 
potential methylation site was quantified by looking at relative C/T peak height in the 
chromatograms, and five regions showed us clear differences in CpG content between mGCTs 
and non-malignant controls. These five regions were used to quantify by pyrosequencing the 
amount of methylation at individual sites of relevance. 
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Figure 4.10: Summary of the results obtained at each step of the process carried out to identify 
areas where methylation may occur. Panel a) describes results for chromosome 11 and panel b) for 
chromosome 21. For both panels, the primer pair position is shown at the top, followed by differences 
in melting curves between mGCT and control DNA (middle) and results from the analysis of peak 
height in Sanger Sequencing chromatograms (bottom). Due to the length of the sequence examined 
(538,395 and 709,102bp on chromosome 11 and 21, respectively), the position of each primer pair is 
indicated relative to the gene or miRNA it is closest to. Each gene or miRNA and associated primer 
pairs is identified with a different colour. A red dot indicates that no differences were detected, a green 
dot indicates that differences were detected, and a yellow dot indicates uncertain results. The top panel 
represents chromosome 11 and in the lower panel is chromosome 21. 
 
   Semi-quantitative analysis of CpG rich regions analysed on chromosome 
11 
Following the process outlined above, semi-quantitative analysis of methylation was carried 
out for five regions (Figure 4.11).  
 
Figure 4.11: CpG rich region selection in chromosome 11. CpG rich islands analysed by semi-
quantitative method and their location on chromosome 11 with reference to the miRNA they are 
upstream of – chromosome distribution is not to scale. 
 
Four of these regions are located on chromosome 11 and were Isla#04 (MIR100HG.11.4) at 
position nt 122,557,193-122,556,721 on the reverse strand, in front of the lincRNA 
MIR100HG, Isla#05 (miR-100.11.1) at position nt 122,159,946-122,159,506 in front if miR-
100 on the reverse strand, Isla#08 (miR-125b-1.11.1) at position nt 122,101,829-122,101,434 
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and Isla#09 (miR-125b-1.11.2) at position nt 122,101,148-122,100,987 on the reverse strand, 
both in front of miR-125-b-1 (Table 4.1). 
In Figure 4.12, Figure 4.13 and Figure 4.14, the average percentage of CpG methylation of the 
mGCT cell lines and non-malignant controls for Isla#4, Isla#5 and Isla#8, are presented. This 
is assessed in a semi-quantitative manner from Sanger sequence chromatograms using the 
relative height of C/T peaks to determine the percentage of methylation in mGCT cell lines and 
non-malignant controls. Table 4.3, 4.4 and 4.5 show the percentage of CpG methylation for 
Isla#04, Isla#05, and Isla#08 in each of the mGCT cell lines and non-malignant controls. It 
should be noted that many returned sequences were of insufficient technical quality to be 
consistently quantified, despite repeat optimisations, which resulted in absence of semi-
quantification for Isla#09. 
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Analysis of Isla#04 (Figure 4.12 and Table 4.3), initially suggested that this area may be 
regulated by methylation as there are many CpG sites (30 in total) which are significantly 
methylated in mGCTs cell lines compared with non-malignant controls (Figure 4.12). 
 
Figure 4.12: Cumulative levels of endogenous CpG DNA methylation in the area Isla#04 
(MIR100HG.11.4). The graph represents in each colour the average percentage of methylation per CpG 
site (30 CpGs in total) in all the mGCT cell lines, and the non-malignant controls. The percentage of 
methylation at each CpG site can range from 0 (no methylation), to 100% (fully methylated). 
Consequently, if each of the 30 CpG sites was fully methylated (100%), the cumulative value would be 
3000. * p<0.05, **p<0.01, *** p<0.005 and **** p<0.001. 
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Observing the specific methylation contribution of each mGCT cell lines and non-malignant 
control is important for an adequate interpretation of the data (Table 4.3). Isla#4 is highly 
methylated in 2012Ep cells and is unmethylated in normal cervix cell lines and normal testis 
tissue DNA. However, there appear to be a similar level and pattern of methylation on DNA 
from the cell line RPE (from CpG9 to CpG21), suggesting that this methylation pattern may 
not be specific to mGCT. Unfortunately, technical issues prevented further semi-quantitative 
analysis, and thus interpretation of these results in necessarily limited. 
Isla#04 
(MIR100H
G.11.4) 
Isla#
04 
CpG
1 
Isla#
04 
CpG
2 
Isla#
04 
CpG
3 
Isla#
04 
CpG
4 
Isla#
04 
CpG
5 
Isla#
04 
CpG
6 
Isla#
04 
CpG
7 
Isla#
04 
CpG
8 
Isla#
04 
CpG
9 
Isla#
04 
CpG
10 
Isla#
04 
CpG
11 
Isla#
04 
CpG
12 
Isla#
04 
CpG
13 
Isla#
04 
CpG
14 
Isla#
04 
CpG
15 
TCam2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
2102Ep 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
≥75
% 
≥75
% 
25-
75% 
25-
75% 
0% 
≥75
% 
25-
75% 
≥75
% 
25-
75% 
GCT44 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
1411H n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Normal 
testis 
n/a n/a n/a 
25-
75% 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
NCX6 
cervix 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a 
95:14 cervix n/a n/a n/a 
25-
75% 
25-
75% 
25-
75% 
0% 0% 0% 0% 0% 0% 0% 0% 0% 
95:15 cervix n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
95:42 cervix n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
RPE 0% 0% 0% 0% 0% 0% 0% 0% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
25-
75% 
HFF-1 0% 0% 0% 0% 0% 0% 0% 
≥75
% 
≥75
% 
≥75
% 
n/a n/a n/a n/a n/a 
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Isla#04 
(MIR100H
G.11.4) 
Isla#
04 
CpG
16 
Isla#
04 
CpG
17 
Isla#
04 
CpG
18 
Isla#
04 
CpG
19 
Isla#
04 
CpG
20 
Isla#
04 
CpG
21 
Isla#
04 
CpG
22 
Isla#
04 
CpG
23 
Isla#
04 
CpG
24 
Isla#
04 
CpG
25 
Isla#
04 
CpG
26 
Isla#
04 
CpG
27 
Isla#
04 
CpG
28 
Isla#
04 
CpG
29 
Isla#
04 
CpG
30 
TCam2 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
2102Ep 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
≤25
% 
≥75
% 
25-
75% 
25-
75% 
25-
75% 
n/a n/a n/a n/a 
GCT44 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
1411H n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Normal 
testis 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% n/a n/a n/a n/a 
NCX6 
cervix 
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
95:14 cervix 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
95:15 cervix n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
95:42 cervix n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
RPE 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
25-
75% 
n/a n/a n/a n/a n/a n/a n/a n/a n/a 
HFF-1 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Table 4.3: Semi-quantitative assessment of percentage of CpG methylation. The table show the area 
upstream of the lincRNA MIR100HG [Isla#04 (MIR100HG.11.4)] in mGCT cell lines and a panel of 
control samples, including both tissue and cell lines. Methylation above 75% is colour coded with red, 
methylation levels between 25 and 75% are shown in orange and low (≤25%) or no methylation in pale 
yellow. A large proportion of the Sanger sequencing performed was not able to be quantitated, despite 
multiple attempts to improve sequence quality, and are therefore labelled n/a. 
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Analysis of Isla#05, (Figure 4.13 and Table 4.4) upstream of miR-100, showed full methylation 
of all the CpG sites (7 in total) in mGCT cell lines compared with non-malignant controls 
(Figure 4.13). 
 
Figure 4.13: Cumulative levels of endogenous CpG DNA methylation in the area Isla#5 (miR-
100.11.1). The graph represents in each colour the average percentage of methylation per CpG site 
(seven CpGs in total) in all the mGCTs cell lines, and the non-malignant controls. The percentage of 
methylation at each CpG site can range from 0 (no methylation), to 100% (fully methylated). If each of 
the seven CpG sites were fully methylated (100%), the cumulative value would be 700. * p<0.05, 
**p<0.01, *** p<0.005 and **** p<0.001. 
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Isla#05 was fully methylated in 2012Ep cells, but unfortunately, no other mGCT cell line could 
be analysed for this region due to technical issues (Table 4.4). This region appeared to be 
generally unmethylated in normal cell lines, with occasional low to medium methylated CpGs 
and could therefore potentially be regulated by methylation in mGCTs. DNA from testicular 
tissue showed a somewhat more methylated region, but overall a much lower level of 
methylation compared with 2102Ep cells. Taken together, the data for this region point to a 
potential difference in the level of methylation in this region in mGCT derived cell lines versus 
normal cell lines and tissue. 
 
Isla#05 
(miR-
100.11.1) 
Isla#05 
CpG1 
Isla#05 
CpG2 
Isla#05 
CpG3 
Isla#05 
CpG4 
Isla#05 
CpG5 
Isla#05 
CpG6 
Isla#05 
CpG7 
TCam2 n/a n/a n/a n/a n/a n/a n/a 
2102Ep ≥75% ≥75% ≥75% ≥75% ≥75% ≥75% ≥75% 
GCT44 n/a n/a n/a n/a n/a n/a n/a 
1411H n/a n/a n/a n/a n/a n/a n/a 
Normal 
testis 
10% 25-75% 25-75% 25-75% 25-75% ≥75% 25-75% 
NCX6 
cervix 
0% 0% 0% 0% 0% 0% 10% 
95:14 cervix n/a n/a n/a n/a n/a n/a n/a 
95:15 cervix 0% 0% 25-75% 0% 0% 0% 0% 
95:42 cervix 0% 0% ≤25% ≤25% 25-75% 0% 25-75% 
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RPE n/a n/a n/a n/a n/a n/a n/a 
HFF-1 0% 0% 0% 0% 0% 0% ≤25% 
Table 4.4: Semi-quantitative assessment of percentage of CpG methylation. The table show the area 
upstream of miR-100 [Isla#05 (miR-100.11.1)] in mGCTs cell lines and a panel of control samples, 
including both tissue and cell lines. Methylation above 75% is colour coded with red, methylation levels 
between 25 and 75% are shown in orange and low (≤25%) or no methylation in pale yellow. A large 
proportion of the Sanger sequencing performed could not be quantitated, despite multiple attempts to 
improve sequence quality, and are therefore labelled n/a. 
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Analysis of Isla#08, (Figure 4.14 and Table 4.5) upstream of miR-125b-1, showed significant 
methylation of the CpG sites (six in total) in mGCTs cell lines compared with non-malignant 
controls (Figure 4.14). 
 
Figure 4.14: Cumulative levels of endogenous CpG DNA methylation in the area Isla#8 (miR-
125b-1.11.1). The graph represents in each colour the average percentage of methylation per CpG site 
(six CpGs in total) in all the mGCT cell lines and the non-malignant controls. The percentage of 
methylation at each CpG site can range from 0 (no methylation), to 100% (fully methylated). If each of 
the six CpG sites were fully methylated (100%), the cumulative value would be 600. * p<0.05, 
**p<0.01, *** p<0.005 and **** p<0.001. 
 
When individual contributions were analysed, I observed a 100% methylation in three mGCT 
cell lines at the Isla#8 CpG4 and Isla#8 CpG5, which could not be seen in any of the four 
normal cell lines and tissue DNAs analysed (Table 4.5). However, no methylation was 
observed at these CpGs in the GCT44 cell line, suggesting perhaps that this cell line may be 
regulated differently at this locus. Taken together, the data suggest that there may be two CpG 
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that are utilised in mGCT to regulate this area in a manner different from normal cells/tissue, 
but that this may not be a ubiquitous mechanism. 
Isla#8 
(miR-
125b-
1.11.1) 
Isla#07 
CpG1 
Isla#07 
CpG2 
Isla#07 
CpG3 
Isla#07 
CpG4 
Isla#07 
CpG5 
Isla#07 
CpG6 
TCam2 n/a 0% 0% ≥75% ≥75% 0% 
2102Ep n/a 0% 0% ≥75% ≥75% 0% 
GCT44 n/a 0% 0% 0% 0% n/a 
1411H n/a 0% 0% ≥75% ≥75% n/a 
Normal 
testis 
n/a 0% 0% ≤25% ≤25% n/a 
NCX6 
cervix 
n/a 0% 0% 0% 0% n/a 
95:14 
cervix 
n/a n/a n/a n/a n/a n/a 
95:15 
cervix 
n/a n/a n/a n/a n/a n/a 
95:42 
cervix 
n/a 0% 0% 0% 25-75% 0% 
RPE n/a 0% 0% 0% 0% 0% 
HFF-1 n/a 0% 0% 0% 0% 0% 
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Table 4.5: Semi-quantitative assessment of percentage of CpG methylation. The table show the area 
upstream of miR-125b-1 [Isla#08 (miR-125b-1.11.1)] in mGCT cell lines and a panel of control 
samples, including both tissue and cell lines. Methylation above 75% is colour coded with red, 
methylation levels between 25 and 75% are shown in orange and low (≤25%) or no methylation in pale 
yellow. A large proportion of the Sanger sequencing performed could not be quantitated, despite 
multiple attempts were made to improve sequence quality, and are therefore labelled n/a. 
 
   Semi-quantitative analysis of CpG rich regions analysed on chromosome 
21 
Only one region was selected on chromosome 21, Isla#16 (miR-125b.21.1) at position 
16,582,169-16,582,372 on the forward strand in front on miR-125b-2 (Table 4.2). 
 
 
Figure 4.15: CpG rich region selection in chromosome 21. CpG rich islands analysed by semi-
quantitative method and their location on chromosome 11 with reference to the miRNA they are 
upstream of – chromosome distribution is not to scale. 
 
Analysis of Isla#16, (Figure 4.16 and Table 4.6) upstream of miR-125b-2, assessed in a semi-
quantitative manner from Sanger sequence chromatograms using the relative height of C/T 
peaks to determine the percentage of methylation, suggests that this area may be regulated by 
methylation as there are many CpG sites (14 in total) which are significantly methylated in 
mGCT cell lines compared with non-malignant controls (Figure 4.16).  
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Figure 4.16: Cumulative levels of endogenous CpG DNA methylation in the area Isla#16 (miR-
125b-2.21.1). The graph represents in each colour the average percentage of methylation per CpG site 
(14 CpGs in total) in all the mGCTs cell lines, and the non-malignant controls. The percentage of 
methylation at each CpG site can range from 0 (no methylation), to 100% (fully methylated). If each of 
the 14 CpG site were fully methylated (100%), the cumulative value would be 1400. * p<0.05, 
**p<0.01, *** p<0.005 and **** p<0.001. 
 
Table 4.6 shows in detail the percentage of CpG methylation for each mGCTs cell lines and 
non-malignant control, for Isla#16. All normal cell lines showed no methylation in this region, 
whereas three mGCT cell lines showed medium to high levels of methylation for the same 
CpGs. This suggested that this area may be targeted by methylation to regulate expression on 
miR-125b-2 in mGCT cell lines in a manner that is different from normal cells/tissue.  
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Isla#16 
(miR-
125b-
2.21.1) 
Isla#
16 
CpG 
1 
Isla#
16 
CpG 
2 
Isla#
16 
CpG 
3 
Isla#
16 
CpG 
4 
Isla#
16 
CpG 
5 
Isla#
16 
CpG 
6 
Isla#
16 
CpG 
7 
Isla#
16 
CpG 
8 
Isla#
16 
CpG 
9 
Isla#
16 
CpG 
10 
Isla#
16 
CpG 
11 
Isla#
16 
CpG 
12 
Isla#
16 
CpG 
13 
Isla#
16 
CpG 
14 
TCam2 n/a n/a n/a n/a 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
n/a n/a n/a n/a n/a 
2102Ep 
25-
75
% 
25-
75
% 
0% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
25-
75
% 
≥75
% 
≥75
% 
GCT44 n/a n/a n/a n/a 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
≥75
% 
1411H n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Normal 
testis 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
NCX6 
cervix 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
95:14 
cervix 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
95:15 
cervix 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
95:42 
cervix 
0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
RPE 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
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HFF-1 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 
 
Table 4.6: Semi-quantitative assessment of percentage of CpG methylation. The table show the area 
upstream of miR-125b-1 [Isla#16 (miR-125b-2.21.1)] in mGCTs cell lines and a panel of control 
samples, including both tissue and cell lines. Methylation above 75% is colour coded with red, 
methylation levels between 25 and 75% are shown in orange and low (≤25%) or no methylation in pale 
yellow. A large proportion of the Sanger sequencing performed could not be quantitated, despite 
multiple attempts to improve sequence quality, and are therefore labelled n/a. 
 
Taken together, the data presented in sections 4.2.3.2 and 4.2.3.3 suggests a differential 
methylation in mGCT cell lines compared with normal cells/tissues.  
   Quantitative analysis of methylation by pyrosequencing 
The semi-quantitative analysis of methylation in putative CpG islands on both chromosomes 
11 and 21 points to differential methylation in mGCT cell lines that could contribute to the 
downregulation of the miRNAs miR-99a-5p, miR-100-5p and miR-125b-5p. However, the 
data obtained by the semi-quantitative method relies on the quality of chromatograms, and it 
was frequently difficult to derive consistent data, which resulted in an incomplete analysis. The 
issues experienced in this kind of analysis can be overcome by utilising a quantitative method 
such as pyrosequencing.  
What distinguishes pyrosequencing from other traditional DNA sequencing methods such as 
Sanger sequencing, is the use of a chemical light reaction to detect the incorporation of dNTPs 
into the synthesising strand. The light generated is directly proportional to the amount of 
incorporated nucleotide and can be used to indirectly quantify incorporation. Moreover, 
pyrosequencing uses a sequencing-by-synthesis system in which nucleotides are dispensed one 
at a time, incorporated into the extending strand and degraded prior to the next nucleotide 
dispensation, making the pyrosequencing DNA sequence more accurate as well as quantitative. 
There are various applications for pyrosequencing, including SNP identification and 
quantification. In methylation analysis, the relative peak height of T versus C at a particular 
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CpG site in bisulfite converted DNA is measured to give percent methylation. (Harrington et 
al., 2013). However, because of the nature of the methodology, only small regions up to 60 nt 
can be analysed at a time and knowledge of areas of interest are key for this methodology to 
be successful. The work carried out with the screening and semi-quantitative methods enabled 
the selection of such areas of interest and made possible the utilisation of this quantitative 
method.  
   Experimental design and optimisation 
Optimisation of pyrosequencing is not trivial; therefore, this technology is used primarily in 
already well characterised assays for screening purposes, and less commonly in investigative 
assays. A workflow of the steps used for this study is described in Figure 4.17. 
To prepare the template for pyrosequencing, the same combination of primers used for the 
semi-quantitative work were utilised, but one of the primers was substituted with a biotinylated 
one, so that the template could be immobilised for sequencing. 
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Figure 4.17: Workflow for the detection of CpG methylation using pyrosequencing. 
 
The PCR products obtained after amplification with the biotinylated primer were then run on a 
gel, to make sure that the amplification was successful, and purified. 
The sequencing assays were then designed. Briefly, sequencing primers are designed 
complementary to the DNA strand containing the biotinylated primer. For methylation 
analysis, these sequencing primers are designed upstream of the CpGs to analyse and 
depending on the template composition, each assay may cover one or more CpGs of interest. 
The number of primers designed depends primarily on the sequence of the template, in 
particular on the distribution of the CpG.   As only short sequences up to 60 nt can be quantified 
in each assay, CpG that are close together may only require one assay and hence a sequencing 
primer, whereas separate single CpG may need to be quantified on their own assay and primer.  
For each of the five CpG islands analysed by pyrosequencing several sequencing primers were 
utilised. Details are listed in Table 4.7: 
Island analysed # of assay designed # of CpG analysed # of sample 
Isla#4  
(MIR100HG.11.4) 
7 11 
4 mGCT 
2 non-malignant control 
Isla#5 
(miR-100.11.1) 
3 5 
4 mGCT 
3 non-malignant control 
Isla#8 
(miR-125b-1.11.1) 
4 4 
4 mGCT 
4 non-malignant control 
Isla#9 
(miR-125b-1.11.2) 
2 5 
4 mGCT 
4 non-malignant control 
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Isla#16 
(miR-125b-2.21.1) 
2 12 
4 mGCT 
4 non-malignant control 
Table 4.7: Details of the pyrosequencing assays. The table shows in detail, the islands analysed, the 
number of assays designed per island, the number of CpG analysed and the number of samples used per 
assay.  
 
Finally, specific assays were designed for each sequencing primer using the PyroMark Q24 
software. As well as investigating the level of C and T incorporation at a specific CpG site, the 
assays have to fulfil other requirements, primarily the presence of a series of appropriate 
controls including assay controls (e.g. normalisation of single peak and repeated nucleotides 
peak height, baseline light emission, to mention a few) and target specific controls (e.g. for 
methylation studies bisulfite conversion efficiency). The programme helps with the design, but 
further optimisation is generally required. Once the assay and relative conditions are set up, the 
assays can be run multiple times: the output will consist of percent methylation readouts 
calculated automatically using the relative C/T peaks and referenced to the inserted controls 
(Figure 13). 
   Quantification of Methylation by Pyrosequencing   
For each of the five CpG islands, where differential methylation was either seen or suggested 
by the semi-quantitative data analysis, pyrosequencing was performed. The CpG islands 
studied were: Isla#04 (MIR100HG.11.4) at position nt 122,557,193-122,556,721 on the reverse 
strand, in front of the lincRNA MIR100HG, Isla#05 (miR-100.11.1) at position nt 
122,159,946-122,159,506 in front if miR-100 on the reverse strand, Isla#08 (miR-125b-1.11.1) 
at position nt 122,101,829-122,101,434 and Isla#09 (miR-125b-1.11.2) at position nt 
122,101,148-122,100,987 on the reverse strand, both in front of miR-125-b-1, all located on 
chromosome 11 (Table 4.1). Isla#16 (miR-125b-2.21.1) at position nt 16,582,169-16,582,372 
on the forward strand in front on miR-125b-2 on chromosome 21 (Table 4.2).  
Figure 4.18 shows a diagram summarising the quantitative data obtained after analysis of the 
Isla#04 (MIR100HG.11.4). The data were initially collected using seven individual assays that 
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overall cover 30 CpGs, however, due to technical issues due to the pyrosequencing technique, 
data from only 11 CpG sites are reliable in four mGCTs cell lines and 2 non-malignant controls 
(namely normal tissue testis  and HFF-1). 
 
 
Figure 4.18: Schematic representing levels of methylation on Isla#04 (MIR100HG.11.4) located on 
chromosome 11 upstream of the lincRNA MIR100HG. CpGs are indicated as circles across the area. 
Black circles indicate full methylation, white circles indicate no methylation. A half white and half 
black circle indicates partial methylation (< 50%) and three quarters black circle indicates the CpG is 
mostly methylated (>50%). The four GCT cell lines, and the normal testis sample represent data from 
each individual listed sample, whereas normal cell lines shows the percentage of methylation 
established averaging data from five individual normal cell lines. 
 
The data showed a region of full methylation spanning CpGs #4.6 to #4.16 in three of the 
mGCT cell lines. Such region of methylation is not seen in the remaining mGCT cell line 
(TCam2) nor in normal testicular tissue. Partial methylation in this region was seen in the 
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normal cell line control, primarily in the HFF-1 cell lines, whereas no methylation was 
detected. 
Data obtained after analysis of the Isla#05 (miR-100.11.1), 7702bp to 7263bp upstream of 
miR-100 transcription start site is shown in Figure 4.19. The data were collected using three 
individual assays that overall cover seven CpGs. As for Isla#04, technical issues made possible 
the analysis of five CpG sites in four mGCTs cell lines and three non-malignant control (normal 
tissue testis, HFF-1 and NCX6) (Figure 4.19). 
 
Figure 4.19: Schematic representing levels of methylation on Isla#05 (miR-100.11.1) located on 
chromosome 11 upstream of miR-100. CpGs are indicated as circles across the area. Black circles 
indicate full methylation, white circles indicate no methylation. A half white and half black circle 
indicates partial methylation (< 50%) and three quarters black circle indicates the CpG is mostly 
methylated (>50%). The four GCT cell lines, and the normal testis sample represent data from each 
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individual listed sample, whereas normal cell lines shows the percentage of methylation established 
averaging data from five individual normal cell lines. 
 
Analysis of this region confirmed the full methylation of CpGs #5.3 to #5.7 in 2012Ep cells 
seen by Sanger sequencing. The same region appears to be partially methylated in 1411H and 
GCT44 cells and more heavily methylated in TCam2 cells. Partial methylation is also seen in 
normal testis tissue, whereas the normal cell lines have little methylation in this area. 
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Figure 4.20, shows a diagram summarising the quantitative data obtained after analysis of the 
two CpG islands identified on chromosome 11 upstream of miR-125b-1,  Isla#08 (miR-125b-
1.11.1) and Isla#09 (miR-125b-1.11.2) which are located 1-2Kb upstream of miR-125b-1 
transcription start site), The data were collected using different amplicons and for each 
amplicons individual assays were designed to respectively cover six plus eight CpGs. From the 
Isla#8 (miR-125b-1.11.1), data from four CpGs sites were obtained from four mGCTs and four 
non-malignant controls (normal tissue testis, HFF-1, NCX6 and RPE). From the Isla#9 (miR-
125b-1.11.2), data from five CpGs sites were obtained from four mGCTs cell lines and four 
non-malignant control (normal tissue testis, HFF-1, NCX6 and RPE).  
 
Figure 4.20: Schematic representing levels of methylation on Isla#08 (miR-125b.11.1) and Isla#09 
(miR-125b.11.2) located on chromosome 11 upstream of miR-125-b. CpGs are indicated as circles 
across the area. Black circles indicate full methylation, white circles indicate no methylation. A half 
white and half black circle indicates partial methylation (< 50%) and three quarters black circle indicates 
the CpG is mostly methylated (>50%). The four GCT cell lines, and the normal testis sample represent 
data from each individual listed sample, whereas normal cell lines shows the percentage of methylation 
established averaging data from five individual normal cell lines. 
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The data showed significant or full methylation of CpGs #8.4 to #8.5 in three of the mGCT cell 
lines. Methylation is not seen in the remaining mGCT cell line (GCT44) nor in normal 
testicular tissue and cell lines. Partial methylation of CpGs #9.4 to #9.8 was seen in three of 
the mGCT cell lines, whereas there was no methylation on the fourth mGCT cell line (1411H). 
Interestingly, 1411H DNA was fully methylated on the CpGs #8.4 to #8.5, whereas GCT44 
DNA, which was not methylated at these CpGs was fully methylated at CpGs #9.4 to #9.8.   No 
methylation was detected in normal testicular tissue and cell lines.  
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Finally, data obtained after analysis of the Isla#16 (miR-125-b-2.21.1), located 1-2Kb upstream 
of miR-125-b transcription start site on chromosome 21 is shown in Figure 4.21. The data were 
collected using two individual assays that overall cover 12 CpGs. As for the other datasets, the 
data were derived from four mGCTs cell lines and four non-malignant control (normal tissue 
testis, HFF-1, NCX6 and RPE). 
 
Figure 4.21: Schematic representing levels of methylation on Isla#16 (miR-125b-2.21.1) located on 
chromosome 21 upstream of miR-125-b-2. CpGs are indicated as circles across the area. Black circles 
indicate full methylation, white circles indicate no methylation. A half white and half black circle 
indicates partial methylation (< 50%) and three quarters black circle indicates the CpG is mostly 
methylated (>50%). The four GCT cell lines, and the normal testis sample represent data from each 
individual listed sample, whereas normal cell lines shows the percentage of methylation established 
averaging data from five individual normal cell lines. 
The data showed full methylation of the region spanning CpGs #14.4 to #14.14 in three of the 
mGCT cell lines. Methylation is not seen in the remaining mGCT cell line (TCam2) nor in 
normal testicular tissue and cell lines. 
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   Analysis of methylation by pyrosequencing: summary 
The individual contribution of a single methylation site can be important for transcription, but 
in some cases the overall methylation of a region is more important than methylation at a 
specific site. The data shown in 4.2.4.2 suggests a certain degree of variability in the 
methylation profiles of the mGCT cell lines studied. Therefore, overall methylation of the 
region encoding for the miRNAs of interest was also assessed. To assess overall methylation 
in the samples studied, all mGCT cell lines and controls were split into two groups and 
individual methylation contributions added. Figure 4.22 shows cumulative CpG methylation 
in mGCT cell lines versus normal controls, both loci together (panel a) and each individual 
chromosome (panels b and c for chromosomes 11 and 21, respectively). The data shows a 
significant difference in cumulative methylation for mGCT vs normal controls both overall and 
when each individual chromosome is analysed (p<2x10-16 for all comparisons).  
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Figure 4.22: Cumulative levels of endogenous CpG DNA methylation in mGCTs vs non-malignant 
control. The graph represents in each colour the average percentage of methylation per CpG site in a) 
both chromosomes (11 and 21 for a total of 35 CpGs sites), b) only chromosome 11 (for a total of 23 
CpGs sites) and c) only chromosome 21 (for a total of 12 CpGs sites). The percentage of methylation 
at each CpG site can range from 0 (no methylation), to 100% (fully methylated). If each CpG site was 
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fully methylated (100%), the cumulative value would be a) 3500, b) 2300 and c) 1200. * p<0.05, 
**p<0.01, *** p<0.005 and **** p<0.001. 
 
Individual mGCT cell lines were analysed (Figure 4.23), both chromosomes together (panel a) 
and as individual chromosomes (panels b and c). The data showed a significant difference in 
cumulative methylation between 2102Ep, 1411H and GCT44 cells compared with testis tissue 
and normal cell lines. TCam2 cells showed overall a lower level of methylation at the loci 
analysed. This is due to the fact that in some areas, such as Isla#08 (miR-125b-1.11.1) and 
Isla#09 (miR-125b-1.11.2), the methylation pattern on TCam2 cells was in line with mGCT 
cells, but in others such as Isla#16 (miR-125b-2.21.1), the same methylation pattern was seen 
as in normal controls. 
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Figure 4.23: Cumulative levels of endogenous CpG DNA methylation. The graph represents in each 
colour the average percentage of methylation per CpG site in a) both chromosomes (11 and 21 for a 
total of 35 CpGs sites), b) only chromosome 11 (for a total of 23 CpGs sites) and c) only chromosome 
21 (for a total of 12 CpGs sites). The percentage of methylation at each CpG site can range from 0 (no 
methylation), to 100% (fully methylated). If each CpG site was fully methylated (100%), the cumulative 
value would be a) 3500, b) 2300 and c) 1200. * p<0.05, **p<0.01, *** p<0.005 and **** p<0.001. 
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Together, the data presented here show a clear differential methylation between mGCT cell 
lines and normal controls in areas (CpG islands) that are likely to be of importance in the 
transcriptional regulation of miRNAs, providing an insight on the potential mechanisms for the 
downregulation of these transcripts in mGCTs. 
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4.3   Discussion 
While it is clear that dysregulated miRNA expression contributes to the initiation and 
progression of human cancers, the mechanism underlying it is not yet fully understood. MiRNA 
dysregulation, like the dysregulation of oncogenes and tumour suppressor genes, can be caused 
by multiple mechanisms such as deletion, amplification, mutation, transcriptional 
dysregulation, epigenetic changes, etc (Iorio and Croce, 2012). As shown in Chapter 3, the 
downregulation of miR-99a-5p/-100-5p and miR-125b-5p in mGCTs cells is not genetically 
driven, occurs at early stages of their biogenesis and is not associated with the miRNA 
processing and maturation processes.  
Aberrant expression of miRNAs located near CpG island, has suggested that methylation may 
have a role in tumour progression resulting from miRNA dysregulation (Brueckner et al., 
2007). Methylation mechanisms are highly dynamic during germ cell development and 
aberrant DNA methylation has been suggested to be the cause of the mGCT pathogenesis. This 
is thought to be linked to potential errors in methylation control occurring during germ cell 
development  (Lind, Skotheim and Lothe, 2007; Cheung et al., 2009). It is possible that 
dysregulation of miRNA expression may be associated with these potential errors in 
methylation control that specifically occur in mGCTs.  
Importantly, silencing of miR-125b-5p was shown to be related to promoter 
hypermethylation in invasive breast cancer and in TGCT (Y. Zhang et al., 2011a; Batool et 
al., 2018) and in colorectal cancer (Chen and Xu, 2015), while miR-100 has been shown to 
be downregulated due to hypermethylation of his host gene MIR100HG (Chen et al., 2014). 
Taken together, it seems plausible that aberrant methylation in the promoter region or in areas 
upstream to the miRNAs of interest may be the mechanism by which the expression of 
miRNA miR-99a-5p/-100-5p and miR-125b-5p is downregulated in mGCT.  
To test this hypothesis, mGCT cell lines were treated with 5-azacytidine (5-aza). This is a well-
established method to remove the inhibitory effects of methylation on gene transcription. When 
5-aza, which is a cytidine nucleotide analogue, is incorporated into DNA instead of cytidine, 
methylation of the newly synthesised DNA is inhibited, as 5-aza blocks the activity of DNA 
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methyltransferases (Stresemann and Lyko, 2008). Therefore, transcription of genes 
downregulated by methylation would increase following treatment with this compound. 
Initially, cells in culture were treated with 10 µM of 5-aza in the media for four days without 
any media change. Changes in miR-99a-5p/-100-5p expression were clearly noticeable, though 
a lesser effect was seen on expression of miR-125b-5p. This experimental set up was further 
optimised by changing the media daily, therefore replenishing the 5-aza every 24 hrs. With this 
condition, a significant change in expression was seen for both miR-125b-5p and miR-99a-5p/-
100-5p. Different cell lines respond to 5-aza treatment differently, and others have described 
the need of replenishing the media frequently. For examples studies with embryonal carcinoma 
cell lines found that the best results were obtained by treating the cells for 3 days with drug 
replenishment each day (Albany et al., 2017). 
The changes detected in miR-99a-5p/-100-5p and miR-125b-5p transcription levels were 
significant after 3 and 4 days of 5-aza exposure. Interestingly, changes in expression detected 
for the host gene lincRNAs, MIR100HG (host gene of miR-100 and miR-125b-1) and 
MIR99AHG (host gene of miR-99a and miR-125b-2), were also significant only at 4 days of 
treatment, confirming the correlation already seen between the miRNAs and their host genes 
and described in Chapter 3. 
These experiments suggested that methylation had a role in the regulation of miR-99a-5p/-100-
5p and miR-125b-5p expression. Attempts to find information that would help identify areas 
of potential methylation were carried out by accessing data produced by other groups but 
publicly available. For instance, online data on genome wide DNA methylation profiles of 
germ cell tumours were analysed. These studies used the array Infinium 
HumanMethylation450 BeadChip which covers 450K methylation sites located mainly in 
promoter areas. Because long non-protein coding genes and miRNA do not have well 
characterised promoters, it was not possible to find any information about areas of potential 
interest in the database (Rijlaarsdam et al., 2015). 
Because of this lack of information about the specific location of the promoter regions of 
miRNAs, DNA sequences up to 10Kb upstream the starting site of the host genes (MIR100HG 
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and MIR99AHG) were analysed to detect any significant enrichment in CpG dinucleotides. 
The majority of methylation involved in gene silencing occurs where there is a high frequency 
of CpG dinucleotides clustered together, in areas known as CpG islands. The accepted 
definition of a CpG island is a region of DNA greater than 200 bp, with guanine/cytosine 
content above 0.5. MethPrimer, an online tool designed to identify CpG islands, was utilised 
to identify areas that fitted the definition of CpG islands (Li and Dahiya, 2002). Several areas 
of interest containing high density of CpG dinucleotides and showing the characteristics of a 
CpG island were identified in this manner. Once the areas of interest were identified, primers 
that would enable the analysis of several CpG were designed. 
Bisulfite conversion-based PCR is to date the most commonly used technique for methylation 
mapping. Primers spanning CpG rich areas that could amplify both methylated and 
unmethylated bisulfite converted DNA, were designed and tested. A series of optimisation 
steps designed to help identify potential areas on methylation were carried out. The first step 
assessed whether methylation was present using melting curve analysis, a method used to 
quantify methylation (Ririe, Rasmussen and Wittwer, 1997; Wittwer et al., 2003; Wojdacz and 
Dobrovic, 2007). This method exploits the fact that the temperature at which dsDNA melts is 
determined by factors such as nucleotide sequence, length and GC/AT ratio. Following 
bisulfite modification, a methylated sequence of DNA will maintain a higher GC/AT ratio and 
will have a melting temperature higher than its unmethylated equivalent. The analysis of the 
melting curve of an amplified products can give therefore information on the methylation status 
of a specific area (Lorente et al., 2008). 
Of all the PCR products analysed, five products corresponding to a region on chromosome 11 
and one PCR fragment amplified from chromosome 21 had very different melting profiles 
when the product amplified from DNA derived from normal cells was compared with that 
amplified from the DNA of GCT cells. Three products amplified from chromosome 11 and one 
product amplified from chromosome 21 gave uncertain results. These 10 PCR products were 
therefore purified and sequenced to look for evidence of potential methylation. When a 
difference in CG or TG composition was detected, the chromatogram was analysed semi-
quantitatively to determine the CG percentage composition between samples. 
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On chromosome 11, four areas (one in front of MIR100HG, one in front of miR-100 and two 
in front of miR-125b-1) had differential methylation in mGCT DNA compared with non-
malignant controld, and three areas gave uncertain results. On chromosome 21, only one area 
(just upstream of miR-125b-2) showed differences in CpG abundance between mGCTs and 
non-malignant controls. 
This initial screening gave strong evidence supporting the relationship between miRNA 
downregulation and a methylation mechanism of repression in mGCT. It also showed that the 
two chromosomal sites where the clusters of miRNAs were found are very different in terms 
of methylation density. However, the semi-quantitative nature of this analysis raised some 
uncertainty, and therefore a quantitative method was then utilised to measure precisely the level 
of methylation that could be found in these areas. 
With the use of pyrosequencing, quantitative data on the level of methylation present at each 
CpG site identified was acquired and compared between PCR fragments amplified from mGCT 
cell lines, a normal testis tissue sample and a panel of normal control cell line. This analysis 
did not find consistent differences at specific CpG sites, but rather identified an overall different 
methylation profile between cancer and normal DNA across all the areas analysed. When 
overall methylation is analysed across these areas by plotting cumulative CpG DNA 
methylation, a strikingly significant difference was seen between malignant and non-malignant 
samples (Figure 5.22 panel A). This difference existed whether both chromosomal loci were 
analysed together (Figure 5.22 panel A) or separately (Figure 5.22 panel B and C for 
chromosome 11 and 21 respectively). Furthermore, when malignant cell lines were separated 
and looked at independently, again a striking difference was seen between each malignant cell 
line and the average of the non-malignant samples. Again, these differences were highly 
significant when both chromosomal loci were studied together (Figure 5.23 panel A) or 
separately (Figure 5.23 panel B and C for chromosome 11 and 21 respectively). 
Interestingly, not all mGCT cell lines showed the same degree of methylation: in particular the 
embryonal carcinoma cell line (2102Ep) and yolk sac tumour cell lines (1411H and GCT44) 
were overall heavily methylated at the loci analysed, whereas the seminoma cell line (TCam2) 
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was more heavily methylated than normal controls, but to a much lesser extent than the other 
mGCT cell lines. In particular, at some loci, the methylation pattern on TCam2 cells resembled 
that of normal cells, where in others it resembled that of the other mGCT cell lines. Again, this 
was true whether both chromosomal loci are examined together or separately. These results are 
consistent with several studies that have investigated global methylation of paediatric GCTs, 
and have identified substantial difference between GCT subtypes, with seminomas being 
described as having overall a less methylated genome compared with non-seminomas 
(Smiraglia et al., 2002; Smith-Sørensen et al., 2002; Honorio et al., 2003; Wermann et al., 
2010; Jeyapalan et al., 2011; Amatruda et al., 2013b; Noor et al., 2016; Shen et al., 2018). This 
different pattern of methylation is thought to derive from the fact that mGCTs originate from 
germ cells at different developmental stages and inherit their methylation profile from their 
ancestors (Sievers et al., 2005). The zygote is the only totipotent cell of the organism because 
it will give rise to all cells of the embryo. However, male and female gametes in mammals 
originate from embryonic cells marked with their own landscape of DNA methylation and 
histone modifications. For the zygote to be totipotent, these pre-existing epigenetic marks must 
be reset during germ-cell specification and new ones established. This ‘reset’ process is termed 
epigenetic reprogramming (Chaganti and Houldsworth, 2000; Bastien, Smallwood and Kelsey, 
2011), and takes place during migration and maturation of the primordial germ cells (PGCs). 
It occurs in two stages: a first phase of global DNA CpG demethylation takes place during the 
early phases of migration. However, specific areas like imprinted regions remain methylated 
until the PGCs arrive in the developing gonads where imprinting is subsequently gradually 
erased. After these maturing gonadal germ cells reach mitotic (male) or meiotic (female) arrest, 
de novo methylation is initiated, and uniparental sex specific imprinting is acquired.  
Regarding partial methylation of TCam2 cells, it has been shown that certain genes can be 
downregulated to the same extent even though only partial methylation of a regulatory region 
has occurred. For example, SOX17 is underexpressed in non-seminomatous tumour cells to the 
same level that it is in yolk sac tumour cells, despite the level of methylation in the promoter 
region of embryonal carcinoma and teratoma cells being not as high as in a yolk sac tumour 
cell line (Noor et al., 2016). Moreover, as the methylation mediated suppression of 
transcription appears to be linked to overall methylation of an area rather than to single CpG, 
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it cannot be excluded that adjacent areas that were not identified as methylated in the screening 
process described here may be methylated only in TCam2 cells and have the same suppressive 
function and ultimately mediate downregulation of the expression of the miRNAs. It is also 
possible that more than a mechanism is responsible for the downregulation of the expression 
of miRNAs in these seminoma cells.  
In this context, it is important to mention the role of the genomic redundancy of miR-99a-5p/-
100-5p and miR-125b-5p. Genomic redundancy is a mechanism that the genome has evolved 
as a strategy to ensure that important functions are regulated (Krakauer and Plotkin, 2002). 
Different strategies for the downregulation of the two chromosomes might have evolved as an 
extra control for their regulation. One different method of downregulation could derive from 
transcription factor binding upstream miRNAs or lincRNAs as many evidence have suggested 
this method to control the expression of miRNAs (Fazi et al., 2005; Fontana et al., 2007; Rosa 
et al., 2007). 
Next, bioinformatic studies to look for transcription factor binding sites (TFBS) were 
performed in proximity to the miRNAs, in order to see if transcription factors could putatively 
bind to the methylated areas. Only one TFBS on chromosome 11 was found, upstream of miR-
100, which binds a factor called FOXJ2, while five TFBS were found on chromosome 21 for 
the following transcription factors:  CUX1 (one binding site in front of MIR99AHG), 
POUF3F2 (one binding site in front of miR-99a), Oct1 (two binding sites upstream miR-99a 
and miR-125b-2) and FOXJ2 (one binding site in front of miR-99a). Further work to assess 
and confirm the potential role of transcription factors on the regulation of the expression of 
miR-99a-5p/-100-5p and miR-125b-5p will be required to elucidate this further. 
To conclude, the data presented in this chapter supports methylation as a mechanism of down-
regulation of gene expression of miR-99a-5p/-100-5p and miR-125b-5p, in the studied mGCT 
cells. As no individual consistent sites of methylation were identified, it is unlikely that 
methylation regulated expression of the miRNAs per se is utilising individual or specific CpG 
sites. The overall mechanism appears instead to be linked to the presence of methylation over 
large parts of a CpG island. It is possible that this widespread methylation may give rise to a 
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repressive environment via the recruitment of histone modifiers and the consequent presence 
repressive heterochromatin, but further work is required to confirm this potential mechanism.

 
 
 Chapter 5   Investigation into the downstream 
consequences of miR-99-5p/miR-100-5p and miR-
125b-5p downregulation 
 
5.1   Introduction  
MiR-99a-5p/-100-5p and miR-125b-5p have been identified as the most downregulated 
miRNAs in mGCTs. Data presented in Chapter 3 has shown that these two miRNAs are located 
in two clusters on chromosome 11 and 21. Despite being in two locations, the expression of 
these miRNAs is coordinated. Similarly, the processes that have resulted in the downregulation 
of these miRNAs have affected both chromosomal loci. In particular, it was shown in Chapter 
4 that methylation at GpC sites, and consequent chromatin condensation, are responsible for 
the downregulation of these miRNAs. Having studied the upstream mechanisms which are 
responsible for the under-expression of miR-99a-5p/-100-5p and miR-125b-5p, in this Chapter 
the consequences of such deregulation will be explored, with particular focus to mechanisms 
that may be of relevance in mGCTs cancer progression.  
MiR-99a-5p/-100-5p and miR-125b-5p have been shown to regulate different aspect of cancer 
progression and different biological function in the cells in different settings. For example in 
breast cancer, low expression of miR-125b-5p increases cell motility while in metastatic 
colorectal cancer tissues (CRC), the levels of miR-100-5p and miR-125b-5p were significantly 
lower than in CRC tissues without metastases (Akhavantabasi et al., 2012; Fujino et al., 2017). 
MiR-99a-5p/-100-5p have also been shown to be involved in cell cycle progression in renal 
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cell carcinoma via targeting of mTOR and miR-125b-5p plays an important role in regulating 
the proliferation of glioma stem cells by targeting E2F2 (Cui et al., 2012; N. Wu et al., 2012). 
Due to the important role that miR-99a-5p/-100-5p and miR-125b-5p have in cancer, we 
wanted to evaluate whether the replenishment of these putative tumour-suppressor miRNAs in 
mGCT cell lines had phenotypic effects such as cancer cell invasion, migration and 
proliferation in vitro.  
MiRNA replenishment using mimics is the most common way of miRNAs reintroduction in a 
biological system. Many studies have looked at different ways to optimise delivery by 
assessing transfection conditions as well as mimic concentration and composition. Single 
strand mimics are much less efficient than double strand mimics, as their purpose is to exactly 
mimic the function of mature miRNAs. Proteins involved in the processing of miRNAs such 
as DICER and AGO, only recognise double stranded miRNAs. Duplex unwinding is followed 
by RISC complex activation and subsequent target recognition (Chorn et al., 2012). Therefore, 
if the mimic is presented as a single strand, it will have lower probabilities of being recognised 
from the maturation complex. 
Many studies have focused on optimising the concentration of mimic to be used in 
transfections. It was shown that specific effects on the target mRNA could be achieved using 
low concentrations of mimics (1 nM) (Jin et al., 2015) while at high concentrations (up to 100 
nM) high molecular weight RNA complexes were forming intracellularly in the transfected 
cells. Therefore, the use of low concentrations of mimics was found to be more effective. 
MiRNAs replenishment has become of increasing interest in the clinical field, as they may be 
used as potential therapeutic strategies. In 2014, the first clinical trial involving miRNA-
replacement therapy for cancer in humans commenced. Phase I trials, utilising a nanoparticle-
derived minicell delivery system to replenish levels of miR-16 in mesothelioma and non-small 
cell lung cancer have now been completed and Phase II trials are ready to start (van Zandwijk 
et al., 2017b).  
In this chapter, miRNAs replenishment in mGCTs cell lines will be performed to look at any 
phenotypic change that they may induce. Following the restoration of miR-99a-5p/-100-5p and 
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miR-125b-5p, global mRNA levels will be assessed using microarray technology. Systematic 
interrogation using the bioinformatic tool Sylamer will then be utilised, to identify specific 
protein-coding targets altered following replenishment of the miRNAs. Sylamer will also be 
used to detect miRNA specific target genes which will be consequently used for pathway 
analysis to fully comprehend the biological relevance of miR-99a-5p/-100-5p and miR-125b-
5p in mGCTs progression (van Dongen, Abreu-Goodger and Enright, 2008b). 
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5.2   Results 
As discussed in Chapters 3 and 4, the downregulation of miR-99a-5p/-100-5p and miR-125b-
5p is consistent across all mGCT subtypes, and mGCT cell lines, and is therefore a 
characteristic feature in these tumours (Figure in the first result chapter). Consequently, it is 
important to understand the biological changes which are mediated by their deregulation in 
mGCTs. 
   Relative contribution of each miRNA to the overall downregulation 
As both families of miRNAs share almost identical seed region and are therefore predicted to 
interact with many common targets, it was important to determine the relative miRNA 
contribution to the overall downregulation mediated by each miRNA family. To this end, each 
miRNA was initially quantified using qRT-PCR. Subsequently, the RNU24-normalised Ct 
values derived from miR-99a-5p/-100-5p and miR-125b-5p was equated to 100% and a 
proportion for each miRNA, was assigned based on Ct values (Figure 5.1). 
 
 
Figure 5.1: Expression of each downregulated miRNA in 3 representative mGCTs cell lines. In 
purple is the contribution derived from miR-125b-5p, while in orange is the contribution derived from 
miR-99a-5p/-100-5p. 
 
The data shows that miR-99a-5p/-100-5p and miR-125-5p are expressed in equal levels in 
1411H cells (miR-99a-5p/-100-5p: 51%, miR-125b-5p: 49%), whereas, in 2102Ep and TCam2 
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cells, miR-99a-5p/-100-5p have a slightly higher expression (52.6% and 52.8%, respectively) 
compared with miR-125b-5p (47.4% and 47.2%, respectively). 
   Replenishment of miRNA with synthetic mimics 
A common approach to determine the effects of a downregulated miRNA is to reintroduce it 
and analyse the consequence of this renewed expression. Such experiments give insight on the 
pathways the miRNA is involved in, this may vary in different contexts, as a single miRNA 
can target numerous transcripts for degradation and the specific target have been shown to vary 
in different tissues (Preusse, Theis and Mueller, 2016). To further study the impact that these 
miRNAs have on mGCTs progression, the reintroduction of the miR-99a-5p/-100-5p and miR-
125b-5p in representative mGCT cell lines was achieved by transfecting the cells with synthetic 
miRNA mimics. As miR-99a-5p and miR-100-5p mature sequences are almost identical (there 
is only a nucleotide mismatch and not in the seed region), it is impossible to distinguish one 
from the other by qPCR methods (as shown in Chapter 3.2.1.1). Therefore, a single mimic was 
utilised to replenish the members of this miRNA family, namely the miR-100-5p mimic. 
Furthermore, data presented in Chapter 3 points strongly to the fact that both families of 
miRNA are co-regulated in these tumours, and together with the fact that miR-99a-5p/-100-5p 
have equal contribution in the overall downregulation as miR-125b-5p, the reintroduction of 
both miRNA mimics at the same time (called Combo in the experimental setup) was studied 
primarily, as well as separately. 
   Optimisation of miRNA mimics transfection 
To optimise the experimental conditions of the reintroduction of miR-100-5p and miR-125b-
5p, transfection with different concentrations of combined miR-100-5p and miR-125b-5p 
mimics were tested. Furthermore, single mimics were also used to quantify any additive or 
synergistic effects. This work was initially performed on three mGCT cell lines; 2102Ep 
(originally derived from an embryonal carcinoma or EC), 1411H (originally derived from a 
yolk sac tumour or YST) and TCam2 (originally derived from a seminoma or Sem). 
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For each cell line, therefore three different concentrations of mimics were tested both singly 
(miR-100-5p or miR-125b-5p) or in combination (miR-100-5p + miR-125b-5p - identified 
from now on throughout the text as Combo) (Table 5.1). 
 
Transfection 16.7 nM total 
concentration 
33.3 nM total 
concentration 
66.6 nM total 
concentration 
Single mimic (either 
miR-100-5p or miR-
125b-5p) 
16.7 nM 33.3 nM 66.6 nM 
Combo (miR-100-5p + 
miR-125b-5p) 8.3 nM + 8.3 nM 16.7 nM + 16.7 nM 33.3 nM + 33.3 nM 
MNC (Mimic Non-
targeting Control) 16.7 nM 33.3 nM 66.6 nM 
Table 5.1: Detailed description of the conditions used for mimics’ transfection. 
 
Cells were seeded at different densities (1x105 cells/well for 1411H and TCam2 cells, and 
7.5x105 cells/well for 2012Ep cells, all in technical triplicate in a 6 well plate) to compensate 
for their growth rates, so that all would reach the same level of confluence by day 7. 
Cells were transfected with the relevant mimic singly or in combination at day 0 (d0) and then 
counted on day 7 (d7) to assess any phenotypic effect on cell growth. In both 1411H and 
TCam2 cells a reduction of the total number of cells as compared with the Mimic Non-targeting 
Control (MNC) was seen at day 7 after transfection of the Combo at a final concentration of 
16.7 nM and 33.3 nM (Figure 5.2). 2102Ep cells were transfected with Combo combinations 
up to 66.6 nM, however no significant effect on cell growth was seen in any of the tests (data 
shown in the Appendix 1).   
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Figure 5.2: Average cell number per well at day 7 after transfection of mimics in 1411H and 
TCam2. Cell number is expressed as percentage of the untreated control. Transfection using a single 
mimic was performed only at 16.7 nM, whereas MNC treated cells and cell receiving a combination of 
mimics (Combo) were transfected at 16.7 nM, 33.3 nM and 66.6 nM. The MNC matched the total 
amount of mimic used in the Combo. Data presented as mean ± SEM of n=3 biological replicates. * 
p<0.05, **p<0.01, *** p<0.005 and **** p<0.001. For statistical analysis, Student’s t-test was used to 
calculate significance. 
 
Representative images of 1411H and TCam2 cells at day 7 after transfection are shown in 
Figure 5.3, illustrating the results reported in Figure 5.2. Transfection with MNC at the lowest 
dose of mimic tested (i.e. 16.7 nM) indicated that the transfection itself had some intrinsic 
effect on cell viability, as the average number of cells in MNC treated wells decreased to almost 
80% of the untreated wells in TCam2. While the reduction of cell number following 
transfection with MNC was statistically significantly for TCam2 (p-value: 0.05), changes in 
the number of 1411H cells did not reach statistical significance compared with the untreated 
control. This difference is likely due to the increased sensitivity of TCam2 cells to the 
lipofectamine reagent used for the transfection. There was no significant decrease in cell 
numbers in 1411H cells transfected with a single 16.7 nM miRNA mimic as compared with 
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cells transfected with the MNC. In TCam2, while transfection with miR-100-5p did not result 
in a decrease in the total number of cells at day 7, replenishing miR-125b-5p had an effect on 
cell proliferation, but this was not statistically significant.  The transfection of both mimics 
(miR-100-5p + miR-125b-5p) at a combined concentration of 16.7 nM resulted in a significant 
decrease in cell number compared with the MNC treated cells in both cell lines (p-value: 0.008 
and 0.01 for 1411H and TCam2, respectively). No additional phenotypic effect on cell growth 
was seen using the combination of mimics Combo at higher doses, therefore 16.7 nM was 
chosen as the optimal concentration of mimics to be used for subsequent replenishing 
experiments.  
 
Figure 5.3: Images of 1411H and TCam2 cell lines taken at day7. Untreated cells were grown for 7 
days in standard conditions while MNC or the Combo (miR-100-5p + miR-125b-5p) were transfected 
with 16.7 nM of the appropriate mimic/combination. 
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   Effects of miRNA miR-100-5p and miR-125b-5p replenishment  
   Characterisation of cells where miR-100-5p and miR-125b-5p are 
replenished 
Having shown that replenishing miR-100-5p and miR-125b-5p in combination resulted in a 
statistically significant decrease in the number of cells per well after seven days, a detailed 
assessment of the growth of the cells after transfection of the mimics was carried out. As no 
significant phenotypic effect was observed in cells transfected with the mimic individually, 
only the combination of mimics was utilised for these experiments.   
Three cell lines, 1411H, TCam2 and 2102Ep, were transfected with MNC or the Combo at a 
final concentration of 16.7 nM and their growth was followed at d2, d4 and d7 after transfection 
(Figure 5.4 panels a, c and e for 1411H, TCam2 and 2102Ep, respectively). To inform on the 
level of the replenishment and its kinetics, intracellular miR-100-5p and miR-125b-5p were 
quantified at d2, d4 and d7 after transfection (Figure 5.4 panels b, d and f). Although 
replenishment in 2102Ep cells did not give rise to a phenotypic effect on growth, even at the 
highest concentrations of mimics used (66.6 nM), this cell line was included in this experiments 
to further characterise this apparent lack of response.  
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Figure 5.4: Growth curves over 7 days of 1411H (panel a), TCam2 (panel c), and 2102Ep (panel 
e). Growth was assessed after replenishing miR-100-5p and miR-125b-5p, and the levels of intracellular 
mimics found at the same timepoints (1411H, TCam2 and 2102Ep in panel b, panel d and panel f 
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respectively). Data presented as mean ± SEM of n=3 biological replicates. * p<0.05, **p<0.01, *** 
p<0.005 and **** p<0.001. For statistical analysis, Student’s t-test was used to calculate significance. 
 
Consistently with the optimisation experiment, these experiments showed that transfection 
resulted in a sight, but not statistically significant reduction in the viability of the cells, with 
the exception of TCam2 cells where the effect was statistically significant at day 7 (Figure 5.4, 
panel c). Replenishing miR-100-5p and miR-125b-5p in TCam2 and 1411H cell lines resulted 
in a statistically significant decrease in the number of cells at day 7, as previously observed, 
whereas no difference was seen again for 2102Ep cells (Figure 5.4, panel e). Interestingly, the 
growth effect could only be seen at day 7, in 1411H cells, suggesting that only a minority of 
cells are affected by the treatment, whereas in TCam2 cells a reduction in total cell number per 
well can be seen also at day 4. This is probably due to the toxic effect of the lipofectamine 
reagent, as the number of cells in MNC and Combo were the same. The level of replenishment 
of the mimics in 1411H compared with untreated control cells (Figure 5.4, panel b), appears to 
be higher at day 2 than in TCam2 (Figure 5.4, panel d), but no changes were seen in the 
phenotypic effect among these cell lines. This is in line with the lower level of pri-miR-100-5p 
and pri-miR-125b-5p seen in 1411H cells compared with TCam2 as shown in Chapter 3 section 
3.2.4.2, which resulted in lower levels of the mature form of these miRNAs (Chapter 3 section 
3.2.5.1). Consistently with the absence of a phenotypic effect on cell growth, in 2012Ep cells 
the replenishment of the miRNAs was less efficient and levels of mimics at 2 days post 
transfection were 100 to 200-fold lower than in the other two cell lines. Moreover, the level of 
intracellular mimics appeared to decrease more quickly in 2012Ep cells, suggesting that 
perhaps the turnover of the mimics is faster in these cells. 
All together this data further confirmed the initial observation that replenishing miR-100-5p 
and miR-125b-5p results in a reduced growth in both 1411H and TCam2 cell lines. It also 
suggests that these effects are proportional to the level of mimics reintroduced in the cell line, 
as 2012Ep cells, where the levels of replenished were much lower, show no phenotypic effect 
on cell growth.  
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   Identification of expression changes by microarray 
Having shown that replenishing miR-100-5p and miR-125b-5p in combination resulted in a 
statistically significant decrease in the number of cells after seven days, we then investigated 
whether this phenotypic effect was associated with a change in gene expression. To start with, 
gene expression changes were investigated at day 7 post replenishment of the miRNA, to help 
identify the pathways that had been affected, rather than the individual genes. 
To this aim, three cell lines, 1411H, TCam2 and 2102Ep, were transfected with MNC or the 
Combo at a final concentration of 16.7 nM and cells were collected at day 7, followed by RNA 
extraction. Quality and concentration of RNA extracted from cells was assessed with 
SpectroStar (BMG Labtech, Aylesbury, UK) and a Bioanalyser (Agilent Technologies, 
Cheadle, UK). Matching replicates were chosen on the basis of their quality and further used 
for gene expression microarray experiments. Library preparation and the hybridisation to 
microarrays, HumanHT-12 v4 Expression BeadChip (Illumina, Chesterford, UK), as well as 
data collection were performed at Cambridge Genomic Services, University of Cambridge. 
Ultimately, arrays using material obtained from treatment of TCam2 and 1411H cell lines were 
run with 3 biological replicates of untreated cells (Untreated), 3 biological replicates of cells 
treated with the Mimic Non-targeting Control (MNC) and 3 biological replicates of cells treated 
with miR-100-5p and miR-125b-5p together (Combo). For the 2102Ep cell line only 3 
biological replicates of MNC and Combo were used (no untreated cells). 
All raw data obtained passed quality control checks and was put through the standard pipeline 
of data processing and normalisation. Initially, the normalised microarray expression data were 
utilised to generate volcano plots for all samples. A volcano plot (Figure 5.5 panels a, c and e) 
is used to quickly identify changes in large data sets composed of replicate data. It combines a 
measure of statistical significance from a statistical test with the magnitude of the change, 
enabling quick visual identification of those data-points (i.e. genes) that display large 
magnitude changes that are also statistically significant. Degree of significance can be made 
more obvious by choosing a different colour for genes with significance above a certain 
threshold, as in the data presented here where differential expression with an adjusted -log10(p-
value)>0.05 is marked in red. As seen in Figure 5.5 a number of significantly differentially 
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expressed genes were identified at day 7 in both 1411H and TCam2 cells (221 and 2,938 
differentially expressed genes, respectively). More genes were identified as significantly 
differentially expressed genes in TCam2 cells than in 1411H cells when MNC and Combo 
where compared, however more changes were also identified in the comparison between MNC 
and untreated samples for this cell line, perhaps suggesting a technical rather than a biological 
reason for this difference. Consistent with the lack of effects on proliferation seen in 2012Ep 
cells following miRNA replenishment, no significantly differentially expressed genes were 
identified by comparing expression in cells treated with either MNC or Combo. 
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Figure 5.5: Volcano plots showing differential gene expression. a) 1411H cells untreated vs treated 
with MNC, b) 1411H cells treated with MNC vs treated with Combo, c) TCam2 cells untreated vs 
treated with MNC, d) TCam2 cells treated with MNC vs treated with Combo, and e) 2102Ep cells 
treated with MNC vs treated with Combo. Combo is equimolar combination of mimics for miR-100-5p 
and miR-125b-5p. RNA samples were extracted 7 days after mimic transfection. Level of change (fold 
change in log2 scale) is shown on the x axis while the y axis denotes significance (p-value) in log10. 
 
Subsequent hierarchical clustering analysis was carried out with the normalised microarray 
expression data. This type of clustering is based on the core idea of objects being more related 
to nearby objects than to objects further away and are therefore based on distance. A cluster 
can be described largely by the maximum distance needed to connect parts of the cluster. At 
different distances, different clusters will form, which can then be represented using a 
dendrogram, which illustrates the hierarchy of clusters that merge with each other. In a 
dendrogram, the y-axis marks the distance at which the clusters merge, while the samples are 
placed along the x-axis such that the clusters don't mix.  
This analysis is useful to get an overview of the levels of changes and their significance (Figure 
5.6). Two dendrograms per cell line were generated by this analysis, one containing the control 
untreated group (untreated) vs the sample treated with Mimic Non-targeting Control (MNC) 
and a second containing the MNC vs the Combo treated group. The untreated vs MNC control 
dendrogram showed some differences, particularly for TCam2 cells, however more obvious 
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differences were seen in both cell lines when the MNC was compared with the Combo treated 
group. 
For the 2102Ep cell line only one dendrogram was produced, the one containing the MNC vs 
the Combo treated group. As expected, no obvious differences were visible between the 
samples from 2102Ep cells treated with the non-targeting control (MNC) vs the Combo treated 
group. 
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Figure 5.6: Heatmaps showing hierarchical clustering. a) 1411H cells untreated vs treated with MNC, 
b) 1411H cells treated with MNC vs treated with Combo, c) TCam2 cells untreated vs treated with 
MNC, d) TCam2 cells treated with MNC vs treated with Combo, and e) 2102Ep cells treated with MNC 
vs treated with Combo. Combo is equimolar combination of mimics for miR-100-5p and miR-125b-5p. 
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RNA samples were extracted 7 days after mimic transfection. The heatmaps display level of expression 
for both groups in the comparison as a colour map for the top differentially expressed 50 genes. 
 
   Analysis of expression using Sylamer 
Although the preliminary analysis gave us an indication that differential expression of genes 
was occurring after treatment with mimics replenishing miR-100-5p and miR-125b-5p 
compared with a MNC control, this analysis was not sufficient to give insight on the genes 
specifically targeted by the miRNAs. This is due to the fact that the primary targets of the 
miRNA are likely to themselves have further downstream targets which would be differentially 
expressed by day 7 after replenishment. Discriminating between these two classes of genes (i.e. 
directly affected vs indirectly affected) is impossible with conventional analysis. 
Therefore, a different type of analysis, using a programme called Sylamer was performed. 
Sylamer is a system for finding significantly over or under-represented ‘words’ in sequences 
according to a sorted gene list. An example of such a ‘word’ could be the complementary region 
to the seed sequence of a miRNA (Seed Complementary Region or SCR). Sylamer is hence 
typically used to find significant enrichment or depletion of microRNA or siRNA seed 
sequences from microarray expression data by selectively looking for the sequence 
complementary to the miRNA seed region in the 3’UTR region of the mRNA transcript. 
Results are plotted in terms of a significance landscape plot, which displays significance 
profiles for each individual all ‘word’ studied across the sorted genelist. The most significant 
‘words’ are highlighted, alternatively specific ‘words’ can also be looked at. In a successful 
replenishment experiment where the mimic has had an effect on its targets, the replenished 
miRNA would be expected to be pulled out as most significant. Importantly, the programme 
can also be used to produce a list of all the genes differentially expressed that contain such 
‘word’, ranked according to how significant the differential expression is. This would allow 
the identification of the genes directly affected by the replenishment of miR-100-5p and miR-
125b-5p and, consequently, the identification of pathways deregulated due to the under-
expression of these miRNAs. 
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Analysis with Sylamer was carried out on mRNA gene lists ranked according to differential 
gene expression obtained from the comparisons between untreated samples vs MNC and MNC 
vs Combo treated cells. Significance landscape plots for 1411H, TCam2 and 2102Ep cells 
produced from differential gene lists from MNC vs Combo treated cells are shown in Figure 
5.7, 5.8 and 5.9, respectively. 
These Sylamer plots, constructed from day 7 post replenishment expression data, consider 
‘words’ corresponding to six SCR sequences relative to miR-99a-5p/-100-5p and miR-125b-
5p, namely sequences corresponding to three seed hexamers (1-6 nt, 2-7 nt, 3-8 nt), two 
heptamers (1-7 nt, 2-8 nt), and one octamer (1-8 nt) for each miRNA. Both miRNAs are 
represented on the plot, and in total six hexamers, four heptamers and 2 octamers curves are 
shown per graph per cell line. 
5.2 Results 209 
 
 
210 Investigation into the downstream consequences of miR-99-5p/miR-100-5p and 
miR-125b-5p downregulation 
 
Figure 5.7: Sylamer plots derived from analysis of differential expression data for 1411H treated 
with MNC vs Combo. a) significance landscape plots were produced searching for 6-mers (a), 7-mers 
(b) and 8-mers (c). Highlighted are the significance curves for the seed complementary regions (SCR) 
for miR-99a-5p/-100-5p and miR-125b-5p. The differentially expressed genes are plotted on the x-axis 
left to right, from the most downregulated to the most upregulated. The y-axis represents the SCR 
abundance in the 3’UTR of the genes. 
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Figure 5.8: Sylamer plots derived from analysis of differential expression data for TCam2 treated 
with MNC vs Combo. a) significance landscape plots were produced searching for 6-mers (a), 7-mers 
(b) and 8-mers (c). Highlighted are the significance curves for the seed complementary regions (SCR) 
for miR-99a-5p/-100-5p and miR-125b-5p. The differentially expressed genes are plotted on the x-axis 
left to right, from the most downregulated to the most upregulated. The y-axis represents the SCR 
abundance in the 3’UTR of the genes.  
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Figure 5.9: Sylamer plots derived from analysis of differential expression data for 2102Ep treated 
with MNC vs Combo. a) significance landscape plots were produced searching for 6-mers (a), 7-mers 
(b) and 8-mers (c). Highlighted are the significance curves for the seed complementary regions (SCR) 
for miR-99a-5p/-100-5p and miR-125b-5p. The differentially expressed genes are plotted on the x-axis 
left to right, from the most downregulated to the most upregulated. The y-axis represents the SCR 
abundance in the 3’UTR of the genes.  
 
This analysis showed inconsistent results for the various cell lines and seeds. This is unusual 
for true differentially expressed miRNAs where the SCR element is expected to be the most 
significant. Moreover, plots of overlapping SCR elements typically follow a coordinated 
pattern (van Dongen, Abreu-Goodger and Enright, 2008c), which was not seen in this instance. 
The effects of all SCR elements of interest (i.e. six hexamers, four heptamers and 2 octamers) 
were therefore considered simultaneously (in a process called Single-Sum Significance 
Sylamer analysis or SSS) and the graphical representation of the data is shown in Figure 5.10 
panel a for 1411H, panel b for TCam2 and panel c for 2102Ep. For this analysis genes were 
grouped together in bins of 200 genes ranked from the most down-regulated (to the left) to the 
most up-regulated (to the right). An arbitrary cut off was chosen depending on the mean of the 
two peaks generated for miR-100-5p and miR-125b-5p. 
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Figure 5.10: SSS plots derived from analysis of differential expression data. The graphs show (a) 
1411H, (b) TCam2 and (c) 2102Ep cell lines treated with MNC vs Combo. Highlighted are the 
significance curves for miR-99a-5p/-100-5p (red line) and miR-125b-5p (blue line). The differentially 
expressed genes are plotted on the x-axis left to right, from the most downregulated to the most 
upregulated, each bin corresponds to 200 genes. The black vertical line corresponds to the assigned cut-
off and the circle on its left underlines the genes that were used for further pathway analysis. 
 
   Pathway analysis following miRNA replenishment  
From the Significant Single-Sum Sylamer plots, an appropriate cut off for each cell line was 
determined, and the most differentially expressed genes identified as containing the miR-99a-
5p/-100-5p and miR-125b-5p seed complementary region above the threshold were utilised to 
determine the pathways regulated by these miRNAs. 400 genes were identified in 1411H cells 
and 400 genes were identified in TCam2 cells as for both cell lines the threshold was set at the 
second 200 genes bin in the Single-Sum Significance Sylamer graph. As well as these genes, 
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pathways analysis of the most differentially expressed genes as determined by the initial 
analysis of the microarray data were also carried out to investigate the downstream effect of 
the miRNA targeted genes. Genes differentially expressed in TCam2 treated cells showing 0.5 
fold or larger expression changes and with a minimum p-value of 0.05 were included in this 
analysis. For genes differentially expressed in 1411H treated cells a 0.3 fold or larger 
expression change, with a minimum p-value of 0.05 were considered. Different thresholds were 
set in the two cell lines to ensure that a sufficient number of genes were included in the analysis. 
This was required as a lower number of gene changes were seen in the experiments with 1411H 
cells as shown in Figure 5.5 panel b) and panel d). A single gene list containing both the genes 
identified by the Sylamer analysis and the genes identified by the differential expression 
analysis was generated. Gene duplication, due to genes being identified in both analyses, was 
eliminated before further pathway analysis was performed. As no significant enrichment of 
genes containing miR-99a-5p/-100-5p and miR-125b-5p complementary seed regions was 
found by Sylamer analysis and very few differentially expressed genes were identified for 
2102Ep cells, no further analysis was carried out for these samples. 
Pathway analysis using KEGG (Kyoto Encyclopedia of Genes and Genomes), gene onthology 
(GO) and reactome were carried out. The analysis was executed as follows. Firstly, each 
database was used individually and only pathways enriched for three or more genes were taken 
into account. Secondly, these resultant pathways found were compared among the three 
different bioinformatical systems. Finally, only the pathways found to be commonly enriched 
among the three approaches were further investigated. Significance of a particular pathway was 
then utilised to graphically represent the results obtained for 1411H (Figure 5.11 panel a) and 
TCam2 (Figure 5.11 panel b) cells.  
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Figure 5.11: Pathway analysis. The most significant pathways affected by the replenishment of miR-
100-5p and miR-125b-5p and identified in 1411H (panel a) and TCam2 (panel b) cells are shown. The 
size of each quadrant is relative to the significance of the pathway analysed. 
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The analysis of the pathways affected at day 7 post miRNA replenishment illustrates the 
potential mechanisms involved in the phenotypic effect seen in 1411H and TCam2 cells. For 
both cell lines a quarter of the genes differentially expressed at day 7 following replenishment 
of the miRNA code for proteins involved in the regulation of cell cycle and apoptotic process 
which is consistent with the observed phenotypic changes on cell growth seen. However, the 
vast majority of differentially expressed genes appeared to be involved in cell line specific 
pathways. For instance, a high percentage of genes are involved in metabolic processes in 
1411H cells, while in TCam2 the most deregulated genes were involved in the transport of 
small molecules. Moreover, in the TCam2 cell line, genes involved in the PIK3-AKT pathway 
were highly represented (p-value: 0.0000129) in the list of most downregulated differentially 
expressed genes.  
Ultimately, this data outlines the common changes in the regulation of cell cycle occurring 
within both 1411H and Tcam2 cell lines that are likely to be responsible for the phenotypic 
effects observed. Due to the time elapsed from the replenishment, direct targets affected by the 
mimics showed changes of low significance and magnitude, which would be difficult to 
validate experimentally by RT-qPCR and more importantly, by Western blot. Therefore, 
further studies aimed to assess earlier events were then performed. 
   Differential gene expression at earlier times after miRNA 
replenishment  
Having shown (Figure 5.4) a phenotypic effect after replenishing miR-100-5p and miR-125b-
5p in mGCTs cell lines and seeing an association between the changes in gene expression 
detected 7 days post replenishment and the regulation of the cell cycle, earlier changes in gene 
expression were studied. It has been shown by other groups that changes in the regulation of 
miRNA targeted transcripts are often seen more significantly two days post replenishment 
(Bhutra et al., 2014). For this reason, differential gene expression was investigated by 
microarray with samples collected two days after replenishment with either a mimic non-
targeting control or the combination of miR-100-5p and miR-125b-5p mimics (Combo) in the 
same conditions used previously. The experiments were carried out in 1411H and TCam2 cell 
lines alone, as the cell line 2102Ep cell line was excluded from these investigations due to the 
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low differential effects seen seven days post replenishment and the lack of a detectable 
phenotypic effect. As the differences seen between untreated cells and cells treated with MNC 
at day 7 did not warrant the inclusion of these samples, untreated controls were also not 
included in these further investigations. 
All raw data obtained passed quality control checks and were put through the standard pipeline 
of data processing and normalisation, as previously described. The normalised microarray 
expression data were then utilised to generate volcano plots for all samples (Figure 5.12). A 
number of significantly differentially expressed genes were identified at day 2 in both 1411H 
and TCam2 cells. As seen at day 7, more genes were identified as significantly differentially 
expressed in TCam2 cells (1,738 genes at p-value: 0.05) cells than in 1411H cells (99 genes at 
p-value: 0.05) cells when MNC and Combo where compared. Hierarchical clustering analysis 
was also performed and heatmaps obtained are shown in Figure 5.13. One dendrogram per cell 
line was generated by this analysis, containing the samples treated with Mimic Non-targeting 
Control (MNC) in three biological replicates vs the Combo treated group, again in three 
biological replicates. As per day 7, obvious differences were seen in both cell lines at day 2 
post treatment, which are consistent with a mimic mediated effect on the cells at this early 
timepoint. These analyses gave an overview of the levels of changes and their significance, but 
as per the data obtained at day 7, it was important to determine the specific targets modulated 
by the mimics, as secondary targets (i.e. genes regulated by the miRNAs target genes 
themselves) are potentially differentially modulated even at the early timepoint. 
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Figure 5.12: Volcano plots showing differential gene expression. The graphs show in a) 1411H cells 
treated with MNC vs treated with Combo, and in b) TCam2 cells treated with MNC vs treated with 
Combo. Combo is equimolar combination of mimics for miR-100-5p and miR-125b-5p. RNA samples 
were extracted 2 days after mimic transfection. Level of change (fold change in log2 scale) is shown on 
the x axis while the y axis denotes significance (p-value) in log10. 
 
Figure 5.13: Heatmaps showing hierarchical clustering. The graphs show in a) 1411H cells treated 
with MNC vs treated with Combo, b) TCam2 cells treated with MNC vs treated with Combo. Combo 
is equimolar combination of mimics for miR-100-5p and miR-125b-5p. RNA samples were extracted 
two days after mimic transfection. The heatmaps display level of expression for both groups in the 
comparison as a colour map for the top differentially expressed 50 genes. 
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   MiRNA target genes at early timepoints after replenishment of 
miRNAs  
As mentioned in 5.2.3.2, the preliminary analysis was useful to demonstrate that differential 
expression of genes occurred after treatment with mimics replenishing miR-100-5p and miR-
125b-5p compared with a MNC control two days after transfection, but further analysis had to 
be carried out to give insight on the genes specifically targeted by the miRNAs. Analysis of 
the differentially expressed genes was therefore further analysed using Sylamer and the 
significance landscape plots obtained for 1411H and TCam2 are shown in Figure 5.14 and 
Figure 5.15 respectively.  
Consistent with the analysis of the data generated at day 7 post-transfection, these Sylamer 
plots originated from day 2 post replenishment expression data, consider ‘words’ 
corresponding to six Seed Complementary Regions sequences relative to miR-99a-5p/-100-5p 
and miR-125b-5p, namely sequences corresponding to three seed hexamers (1-6 nt, 2-7 nt, 3-
8 nt), two heptamers (1-7 nt, 2-8 nt), and one octamer (1-8 nt) for each miRNA. Both miRNAs 
are represented on the plot, and all together six hexamers, four heptamers and 2 octamers curves 
are shown per graph per cell line.  
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Figure 5.14: Sylamer plots derived from analysis of differential expression data for 1411H treated 
with MNC vs Combo. a) significance landscape plots were produced searching for 6-mers (a), 7-mers 
(b) and 8-mers (c). Highlighted are the significance curves for the seed complementary regions (SCR) 
for miR-99a-5p/-100-5p and miR-125b-5p. The differentially expressed genes are plotted on the x-axis 
left to right, from the most downregulated to the most upregulated. The y-axis represents the SCR 
abundance in the 3’UTR of the genes. 
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Figure 5.15: Sylamer plots derived from analysis of differential expression data for TCam2 treated 
with MNC vs Combo. a) significance landscape plots were produced searching for 6-mers (a), 7-mers 
(b) and 8-mers (c). Highlighted are the significance curves for the seed complementary regions (SCR) 
for miR-99a-5p/-100-5p and miR-125b-5p. The differentially expressed genes are plotted on the x-axis 
left to right, from the most downregulated to the most upregulated. The y-axis represents the SCR 
abundance in the 3’UTR of the genes.  
 
Sylamer analysis showed significant curves for SCRs relative to miR-99a-5p/-100-5p and miR-
125b-5p in plots derived from the differential expression gene list created by the analysis of 
the samples treated with MNC vs samples treated with Combo in both cell lines. Moreover, 
plots of overlapping SCR elements followed a coordinated pattern as expected for truly 
differentially expressed miRNAs. The effects of all SCR elements of interest (i.e. six hexamers, 
four heptamers and 2 octamers) were also considered simultaneously by Single-Sum 
Significance Sylamer analysis and the graphical representation of the data is shown in Figure 
5.16 panel a) for 1411H, and panel b) for TCam2. For this analysis genes were grouped together 
in bins of 200 genes showing similar differential expression. The mRNA gene list was ranked 
left to right from most down-regulated to most up-regulated. 
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Figure 5.16: SSS plots derived from analysis of differential expression data. The graphs show in (a) 
1411H, and (b) TCam2 cell lines treated with MNC vs Combo. Highlighted are the significance curves 
for miR-99a-5p/-100-5p (red line) and miR-125b-5p (blue line). The differentially expressed genes are 
plotted on the x-axis left to right, from the most downregulated to the most upregulated, each bin 
corresponds to 200 genes. The black vertical line corresponds to the assigned cut-off and the circle on 
its left underlines the genes that were used for further pathway analysis. 
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Significant Single-Sum curves were seen in both 1411H and TCam2 cells. Interestingly, in 
both 1411H and TCam2 cells downregulation of genes containing miRNA seed 
complementary regions for either miRNA appeared to have the same level of significance. This 
is in contrast to the data for the same analysis performed at day 7 post replenishment that 
showed significance only for genes containing the miR-125b-5p seed complementary region. 
The data suggests that at earlier timepoints both miRNAs mediate the downregulation of their 
target genes at similar levels, while at later timepoints miR-125b-5b is able to downregulate its 
targets more efficiently than miR-100-5p. For each cell line the peak of the SSS curve for miR-
125b-5p and miR-100-5p was set as threshold for the identification of significant genes to take 
into consideration for further analysis.  
   Pathway analysis at an early timepoint after miRNA replenishment 
From the Significant Single-Sum Sylamer plots, an appropriate cut off for each cell line was 
determined, and the most differentially expressed genes identified as containing the miR-125b-
5p and miR-100-5p seed complementary regions above the threshold were utilised to determine 
the pathways regulated by the replenishment of miR-100-5p and miR-125b-5p. 400 genes were 
identified in 1411H cells (second bin) and 600 genes (third bin) were identified in TCam2 cells.  
Pathway analysis using KEGG (Kyoto Encyclopedia of Genes and Genomes), gene onthology 
(GO) and reactome were carried out. The analysis was executed as follows. Firstly, each 
database was used individually and only pathways enriched for three or more genes were taken 
into account. Secondly, these resultant pathways found were compared among the three 
different bioinformatical systems. Finally, only the pathways found to be commonly enriched 
among the three approaches were further investigated. Significance of a particular pathway was 
then utilised to represent graphically the results obtained for 1411H (Figure 5.17 panel a) and 
TCam2 (Figure 5.17 panel b) cells. 
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Figure 5.17: Pathway analysis. The most significant pathways affected by the replenishment of miR-
100-5p and miR-125b-5p and identified in 1411H (panel a) and TCam2 (panel b) cells are shown. The 
size of each quadrant is relative to the significance of the pathway analysed. 
 
The analysis of the pathways affected at day 2 post miRNA replenishment showed a much 
more consistent picture between cell lines than the one seen at day 7. For both cell lines the 
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majority of the genes differentially expressed at day 2 following replenishment of the miRNA 
code for proteins involved in similar processes, such as the regulation of cell cycle, apoptosis 
and immune system related processes. The regulation of cell cycle and apoptosis was also 
identified at day 7 and is consistent with the observed phenotypic changes on cell growth seen. 
Some differentially expressed genes appeared to be involved in cell line specific pathways, but 
this was only a minor proportion of the genes affected by the miRNAs replenishment. 
Genes that were deregulated in both cell lines were then investigateded at in more details. 62 
genes were found to be differentially regulated in both cell lines after replenishment with 
mimics of miR-100-5p and miR-125b-5p. These genes are of particular interest as they 
highlight common pathways of miRNA regulation in tumours that are otherwise highly 
heterogeneous, characterised by histologically different subtypes and occurring at varied 
anatomical site. Moreover, it puts forward the tantalising suggestion that miR-100-5p and miR-
125b-5p, which are dysregulated in all mGCT, could be used as an all-encompassing potential 
therapeutic target.  
The 62 differentially expressed genes which are affected by miR-100-5p and miR-125b-5p 
replenishment in both 1411H and TCam2 were then utilised for pathway analysis to investigate 
potential common mechanisms of miRNAs regulation (Figure 5.18).  
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Figure 5.18: Pathway analysis. 62 differentially expressed genes were found to be affected by miRNA 
replenishment in both 1411H and TCam2 cell lines. The communal pathways identified are represented 
in the table. The size of each quadrant is relative to the significance of the pathway analysed. Pathway 
analyses were performed using Reactome and Gene Onthology (GO). 
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Pathways analysis with the 62 communal genes identified all the pathways that were initially 
identified in each cell line separately, and again immune system related processes, cell cycle 
regulation and apoptosis were the main area of gene involvement, in agreement with the 
phenotypic changes observed in the replenishment experiments. Further work was therefore 
carried out to validate these findings by RT-qPCR and western blotting. 
   Validation of genes involved in cell cycle regulation 
Having correlated a role in the regulation of the cell cycle to some of the genes identified as 
containing seed complementary sequences in their 3’ UTR to miR-99a-5p/-100-5p and/or miR-
125b-5p and being significantly under-expressed in both 1411H and TCam2 cells, a panel of 
eight genes fulfilling these criteria was selected for validation. Of these, five, were targeted by 
both miR-99a-5p/-100-5p and miR-125b-5p (ARID 3A, E2F7, TRIM71, FGFR3, and 
CTDSPL); one was targeted by miR-99a-5p/-100-5p only (mTOR) and two genes were 
targeted by miR-125b-5p only (ARID 3B and LIN28). 
   Expression of selected genes in tissue 
To assess if the genes identified were deregulated in mGCT tissues, data from The Cancer 
Genome Atlas (TCGA) combined with Genotype-Tissue Expression (GTEx) data via GEPIA, 
an online tool, was analysed. 137 samples derived from TGCT patients were compared with 
165 normal samples. The results are shown in a Log2 scale and the different colours represent 
the degree of expression (dark green being over-expressed and light green being under-
expressed). Interestingly, some of the genes of interest were upregulated in TGCT tissue 
compared with normal tissue, suggesting that such genes may contribute to malignancy (Figure 
5.19).  
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Figure 5.19: Gene expression in tumour tissue (T) vs normal tissue (N). The data were acquired from 
GEPIA, an online platform that integrates data from TCGA and GTEx. Overexpression is shown in 
dark green, underexpression is shown in light green. 
 
   Validation of miRNA gene targets via RT-qPCR and Western blot 
To validate the results obtained by microarray analysis and also to study the potential 
contribution of the replenishment of the individual miRNAs to the observed changes of genes 
involved in the regulation of the cell cycle, cells were treated with either the single miRNA 
(miR-100-5p or miR-125b-5p) at two different concentration: 8.3 nM, and 16.7 nM or with the 
combination (Combo) of the two miRNAs (miR-100-5p + miR-125b-5p) at 16.7 nM. As 
reference, cells treated using mimic non-targeting control (MNC) at the appropriate matched 
concentration were used (Figure 5.20, Figure 5.21, Figure 5.22, Figure 5.23). 
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Figure 5.20: Effects of miRNA replenishment on TRIM71 in 1411H and TCam2 cells. a) gene 
expression as determined by RT-qPCR: TRIM71 expression levels were examined at day 1, day 2 and 
day 3 post transfection. Different shades of the same colour illustrate different concentrations of mimics 
in the same condition (single or combination of mimics), as described in the key. Replenishment of 
miR-100-5p is shown in red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-
125b-5p) in blue. Data presented as mean ± SEM of n=3 biological replicates. Relative gene expression 
was normalised using three housekeeping genes (RPL13A, YWAHZ and ACTb) and independently 
calculated expression ratios were then averaged. b) Western blot analysis of protein expression at day 
2 and day 3 post replenishment with 16.7 nM mimics. Shown are representative blots, the experiment 
was performed twice with similar results. 
 
RT-qPCR analysis of TRIM71 expression confirmed the microarray data, as this gene was 
downregulated 2 days post Combo transfection in both cell lines. Interestingly, expression of 
TRIM71 was modulated by the combination of mimics with different kinetics in the two cell 
lines. In 1411H cells, the downregulation of TRIM71 after replenishment of both miRNAs 
peaked at day 1, and then decreased with time, so that it was lost by day 3, whereas in TCam2 
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cells the maximum downregulation was seen at day 2, with both day 1 and day 3 showing 
similar levels of downregulation (Figure 5.20, panel a). When comparing the effects of the 
mimics on their own to the Combo, the results obtained again differ between the two cell lines. 
In 1411H cells the combination appeared to have an effect equivalent to the sum of the effects 
seen for each mimic (at 8.3 nM), while the relationship between the effects seen with each 
mimic individually and the Combo was more variable in TCam2 cell. For example, at day 1 
post transfection there did not appear to be any difference in the ability of the mimics either 
individually or in combination to downregulate the expression of TRIM71, whereas at day 2 
the combination was significantly more efficient than the mimics alone (p-value: 0.002). 
Furthermore, the data suggested that doubling the dose of either individual mimic, did not result 
in the same effects on transcription shown by their combination at least at days 1 and 2 post 
transfection. The data at day 3 was more complex, as in both cell lines the effects of miR-100-
5p replenishment on TRIM71 seemed to disappear more rapidly than those induced by miR-
125b-5p replenishment. This could potentially explain the rapid reduction in TRIM71 
downregulation seen also with the Combo. Analysis of protein levels following miRNA 
replenishment by Western blotting showed a downregulation of TRIM71 protein induced by 
either each mimic alone or in combination in both cell lines, both at day 2 and 3 after 
transfection. However, all miRNAs replenishment was carried out using 16.7 nM mimics either 
alone or in combination, and, in agreement with the RT-qPCR data, the combination of both 
mimics together always appeared more effective than a single mimic at the equivalent dose. 
Moreover, the downregulation appeared more prominent at day 3, particularly in TCam2 cells.  
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Figure 5.21: Effects of miRNA replenishment on ARID 3A in 1411H and TCam2 cells. a) gene 
expression as determined by RT-qPCR: ARID 3A expression levels were examined at day 1, day 2 and 
day 3 post transfection. Different shades of the same colour illustrate different concentrations of mimics 
in the same condition (single or combination of mimics), as described in the key. Replenishment of 
miR-100-5p is shown in red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-
125b-5p) in blue. Data presented as mean ± SEM of n=3 biological replicates. Relative gene expression 
was normalised using three housekeeping genes (RPL13A, YWAHZ and ACTb) and independently 
calculated expression ratios were then averaged. b) Western blot analysis of protein expression at day 
2 and day 3 post replenishment with 16.7 nM mimics. Shown are representative blots, the experiment 
was performed twice with similar results. 
 
RT-qPCR analysis of ARID 3A expression also confirmed the microarray data, as this gene 
was downregulated 2 days post Combo transfection in both cell lines. Expression of ARID 3A 
was modulated by the combination of mimics with similar kinetics in the two cell lines and the 
maximum downregulation was seen at day 2, with both day 1 and day 3 showing similar levels 
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of downregulation. When comparing the effects of the mimics on their own to the Combo, the 
results obtained were consistent between the two cell lines. In both cell lines replenishment of 
miR-100-5p alone did not downregulate the transcription of ARID 3A at any of the doses 
tested: upregulation of these transcripts was in fact seen at day 2 and day 3 post transfection 
both with 8.3 nM and 16.7 nM mimics. On the other hand, replenishment of miR-125b-5ps 
alone did resulted in downregulation of ARID 3A transcription, however, the relationship 
between the effects of this mimic alone and the effects seen with the Combo were sometimes 
conflicting. Although in some cases the effects seen by the Combo were similar to those seen 
with miR-125b-5p alone (for example in 1411H cells at day 2 and in TCam2 cells at day 1) 
(Figure 5.21, panel a), the combination at other times appeared to have an effect statistically 
greater than seen with the mimic alone, for instance in 1411H cells at day 3 (p-value: 0.02) and 
in TCam2 cells at day 2 (p-value=0.006). Furthermore, the data suggested that doubling the 
dose of the miR-125b-5p mimic on its own did not result in the same effects on transcription 
shown by their combination: differently from TRIM71, doubling the dose of miR-125b-5p had 
a much greater effect than the Combo of mimics, suggesting that in this instance the two mimics 
acted in an antagonistic manner.  
Analysis of protein levels following miRNA replenishment by Western blotting showed a 
downregulation of ARID 3A protein induced by miR-125b-5p alone or in combination in both 
cell lines, both at day 2 and 3 after transfection when replenishment was carried out using 16.7 
nM mimics either alone or in combination. Consistently with the RT-qPCR data, no effect was 
seen on protein levels using the mimic for miR-100-5p alone. 
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Figure 5.22: Effects of miRNA replenishment on CTDSPL in 1411H and TCam2 cells. a) gene 
expression as determined by RT-qPCR: CTDSPL expression levels were examined at day 1, day 2 and 
day 3 post transfection. Different shades of the same colour illustrate different concentrations of mimics 
in the same condition (single or combination of mimics), as described in the key. Replenishment of 
miR-100-5p is shown in red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-
125b-5p) in blue. Data presented as mean ± SEM of n=3 biological replicates. Relative gene expression 
was normalised using three housekeeping genes (RPL13A, YWAHZ and ACTb) and independently 
calculated expression ratios were then averaged. b) Western blot analysis of protein expression at day 
2 and day 3 post replenishment with 16.7 nM mimics. Shown are representative blots, the experiment 
was performed twice with similar results. 
 
RT-qPCR analysis of CTDSPL expression confirmed the microarray data, as this gene was 
downregulated 2 days post Combo transfection in both cell lines. Expression of CTDSPL was 
modulated by the combination of mimics with different kinetics in the two cell lines. In 1411H 
cells, the downregulation of CTDSPL after replenishment of both miRNAs in combination, 
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increased with time and peaked at day 3, whereas in TCam2 cells the maximum downregulation 
was seen at day 2, with both day 1 and day 3 showing similar levels of downregulation.  When 
comparing the effects of the mimics on their own to the Combo, the results obtained were 
consistent between the two cell lines. In both cell lines replenishment of miR-125b-5p alone 
did not downregulate the transcription of CTDSPL at any of the doses tested: upregulation of 
these transcripts was in fact seen at day 1, day 2 and day 3 post transfection both with 8.3 nM 
and 16.7 nM mimics. On the other hand, replenishment of miR-100-5ps alone did result in 
downregulation of CTDSPL transcription, however, in a manner parallel to ARID 3A, the 
relationship between the effects of this mimic alone and the effects seen with the Combo were 
sometimes conflicting. Although in some cases the effects seen by the Combo were similar to 
those seen with miR-100-5p alone (for example in 1411H cells at day 2), the combination at 
other times appeared to have an effect statistically greater than seen with the mimic alone, for 
instance in 1411H cells at day 3 (p-value: 0.0002) and in TCam2 cells at day 2 (p-value: 0.001). 
Furthermore, the data suggested that doubling the dose of miR-100-5p, had similar effects on 
transcription to the combination: with the exception of day 2 in TCam2 cells where doubling 
the dose of miR-100-5p had a much smaller effect than the Combo of mimics on CTDSPL 
transcription.  
Analysis protein levels following miRNA replenishment by Western blotting, showed a 
downregulation of CTDSPL protein induced by miR-100-5p alone or in combination in TCam2 
cells, at day 3 after transfection when replenishment was carried out using 16.7 nM mimics. In 
1411H no changes were detected by Western blot (data not shown). 
   Seed Complementary Region length influences regulation of gene 
expression 
ARID 3A and CTDSPL were identified as targets of both miR-100-5p and miR-125b-5p by 
Sylamer analysis. However, the data presented above suggested that these genes are regulated 
differently from each other. ARID 3A transcription was not affected by the mimic for miR-
100-5p alone while it was affected by the mimic for miR-125b-5p or the combination of the 
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two mimics. On the other hand, CTDSPL transcription was not affected by the mimic for miR-
125b-5p alone, while it was affected by the mimic for miR-100-5p or the Combo.  
To identify the reasons for this differential regulation the number of potential binding sites for 
each individual miRNA in the 3’UTR of the target gene was assessed. A correlation between 
the numbers of 6-mers, 7-mers and 8-mers SCR for either miR-100-5p or miR-125b-5p on the 
3’UTR of the target gene and the level of its downregulation was found (Table 5.2).  
 
Table 5.2: SCR sites specific for miR-100-5p and miR-125b-5p in the 3’UTR of ARID 3A and 
CTDSPL transcripts. 
 
Six SCR binding sites for miR-125b-5p were found in the 3’UTR of ARID 3A, one of which 
was complementary to the miRNA for a stretch of 8 nucleotides. In the same area only one 
SCR for miR-100-5p was identified, with the maximal length of complementarity of 7 nt. 
Conversely, four SCR binding sites for miR-100-5p were found in the 3’UTR of CTDSPL, two 
of which were complementary to miR-100-5p for a stretch of 8 nucleotides, while only two 
SCR for miR-125b-5p were identified, with the maximal length of complementarity of 7 nt. It 
is therefore possible therefore that the specific regulation of the transcription of these genes by 
either of these miRNAs is a result of the differential number of SCR sites and the length of the 
SCR sites themselves. 
Gene 
name 
6-mers 7-mers 8-mers 
miR-100-
5p 
miR-125b-
5p 
miR-100-
5p 
miR-125b-
5p 
miR-100-
5p 
miR-125b-
5p 
ARID 
3A 
1 6 1 6 0 1 
CTDSPL 2 4 4 2 2 0 
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Figure 5.23: Effects of miRNA replenishment on a) E2F7 and b) FGFR3 in 1411H and TCam2 
cells. Gene expression was determined by RT-qPCR at day 1, day 2 and day 3 post transfection. 
Different shades of the same colour illustrate different concentrations of mimics in the same condition 
(single or combination of mimics), as described in the legend. Replenishment of miR-100-5p is shown 
in red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-125b-5p) in blue. Data 
presented as mean ± SEM of n=3 biological replicates. Relative gene expression was normalised using 
three housekeeping genes (RPL13A, YWAHZ and ACTb) and independently calculated expression 
ratios were then averaged.  
 
Two more genes identified to be regulated by miR-100-5p and miR-125b-5p were validated by 
RT-qPCR. Both E2F7 and FGFR3 were shown to be downregulated at day 2 post transfection 
of the Combo mix of mimics in both 1411H and TCam2 cells by RT-qPCR, confirming the 
microarray data.  
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Expression of E2F7 was modulated by the combination of mimics with similar kinetics in the 
two cell lines, with the maximum downregulation seen at day 2.  This consistency between cell 
lines was also seen when comparing the effects of the mimics on their own to the Combo. In 
both cell lines replenishment of miR-100-5p or miR-125b-5p alone downregulated the 
transcription of E2F7 both with 8.3 nM and 16.7 nM mimics. Although in some cases the 
effects seen by the Combo were similar to those seen with a mimic alone (for example in 
TCam2 cells at day 3), the combination at all other times appeared to have an effect greater 
than seen with the mimic alone. Furthermore, the data suggested that doubling the dose of miR-
100-5p, or miR-125b-5p had less effects on transcription than the combination. These 
observations were also true for FGFR3, and overall the two genes behaved very similarly.  
E2F7 is fundamental to the control of several different steps of the cell cycle and it is hence 
differentially regulated at various stages of it. For this reason, it was difficult to have a 
consistent evaluation of its protein levels in culture, particularly as the cells were not 
synchronised.  
As mentioned earlier, some of the genes discovered using Sylamer and chosen for validation 
are targeted by either miR-100-5p or miR-125b-5p alone (Figure 5.24). The effects of the 
replenishment of the miRNAs either on their own or in combination (Combo) on the 
transcription of these genes were tested by RT-qPCR. 
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Figure 5.24: Effects of miRNA replenishment on a) mTOR and b) ARID 3B in 1411H and TCam2 
cells. Gene expression was determined by RT-qPCR at day 1, day 2 and day 3 post transfection. 
Different shades of the same colour illustrate different concentrations of mimics in the same condition 
(single or combination of mimics), as described in the legend. Replenishment of miR-100-5p is shown 
in red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-125b-5p) in blue. Data 
presented as mean ± SEM of n=3 biological replicates. Relative gene expression was normalised using 
three housekeeping genes (RPL13A, YWAHZ and ACTb) and independently calculated expression 
ratios were then averaged.  
 
mTOR is targeted only by miR-100-5p. RT-qPCR analysis of mTOR expression confirmed the 
microarray data, as this gene was downregulated 2 days post Combo transfection in both cell 
lines (Figure 5.24, panel a). Expression of mTOR was modulated by the combination of mimics 
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with similar kinetics in the two cell lines and the maximum downregulation was seen at day 2, 
with both day 1 and day 3 showing lower levels of downregulation. When comparing the effects 
of the mimics on their own to the Combo, the results obtained were consistent between the two 
cell lines. As predicted, in both cell lines replenishment of miR-125b-5p alone did not 
downregulate the transcription of mTOR at any of the doses tested, and some minor 
upregulation of these transcripts was in fact seen. On the other hand, replenishment of miR-
100-5ps alone did result in downregulation of mTOR transcription, but generally at lower level 
than the corresponding Combo treatment. Furthermore, as seen for other genes, the data 
suggested that doubling the dose of the miR-100-5p mimic on its own, did not result in the 
same effects on transcription shown by their combination. 
ARID 3B is targeted only from miR-125b-5p. RT-qPCR analysis of ARID 3B expression 
confirmed the microarray data, as this gene was also downregulated 2 days post Combo 
transfection in both cell lines (Figure 5.24, panel b). As for mTOR, expression of ARID 3B 
was modulated by the combination of mimics with similar kinetics in the two cell lines and the 
maximum downregulation was seen at day 2, with both day 1 and day 3 showing lower levels 
of downregulation. Moreover, when comparing the effects of the mimics on their own to the 
Combo, the results obtained were consistent between the two cell lines. As predicted, in both 
cell lines replenishment of miR-100-5p alone did not downregulate the transcription of ARID 
3B at any of the doses tested, and some minor upregulation of these transcripts was in fact seen. 
On the other hand, replenishment of miR-125b-5ps alone did result in downregulation of ARID 
3B transcription, but generally at lower level than the corresponding Combo treatment. 
Furthermore, the data suggested that doubling the dose of the miR-125b-5p mimic on its own, 
results in the more prominent effects on transcription than shown by the combination of the 
two mimics.  
 All together these data confirm the selective nature of the downregulation of the expression of 
some genes, as identified by Sylamer analysis.  
   LIN28A is specifically targeted by miR-125b-5p 
LIN28A is one of the gene identified using Sylamer and chosen for validation. The effects of 
the replenishment of the miRNAs either on their own or in combination (Combo) on the 
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transcription of this gene was therefore tested by RT-qPCR. This gene is of particular interest 
because previous work carried out in our lab had shown that LIN28 downregulation by siRNA 
resulted in an increase of the levels of let-7 (Figure 5.25). Interestingly, a let-7 sequence is 
present at both chromosomal sites where miR-125b-5p and mir-100-5p are located but is 
regulated differently from the other miRNAs in the same cluster. In particular, let-7 has been 
shown to be downregulated by posttranscriptional mechanisms involving LIN28, while LIN28 
levels are regulated by let-7 via direct downregulation of its transcription. 
This mechanism of regulation has been shown in several contexts and let-7 is thought to have 
a role in a variety of cancers, including mGCTs.  
 
 
 
 
 
 
Figure 5.25: LIN28A let-7 feedback. a) Depletion of LIN28 protein levels after treatment with siRNAs 
for LIN28. Shown are protein levels at day 3 to 5. b) Levels of let-7e and c) levels of let-7d, both 
established by RT-qPCR. Figure adapted from Murray et al, CR, 2013. 
 
As shown in Figure 5.25, the levels of let-7 family members start to rise from day 4 following 
LIN28 knock-down, implying a double-negative feedback loop mechanism regulating the 
expression of these two proteins. Importantly, LIN28 was identified as a target of miR-125b-
5p by the Sylamer analysis (Figure 5.26). 
a) c) b) 
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Figure 5.26: Effects of miRNA replenishment on LIN28A in 1411H and TCam2 cells. a) gene 
expression as determined by RT-qPCR: LIN28A expression levels were examined at day 1, day 2 and 
day 3 post transfection. Different shades of the same colour illustrate different concentrations of mimics 
in the same condition (single or combination of mimics), as described in the legend. Replenishment of 
miR-100-5p is shown in red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-
125b-5p) in blue. Data presented as mean ± SEM of n=3 biological replicates. Relative gene expression 
was normalised using three housekeeping genes (RPLI13A, YWAHZ and ACTb) and independently 
calculated expression ratios were then averaged. b) Western blot analysis of protein expression at day 
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2 and day 3 post replenishment with 16.7 nM mimics. Shown are representative blots, the experiment 
was performed twice with similar results. 
 
RT-qPCR analysis of LIN28 expression confirmed the microarray data; this gene was 
downregulated 2 days post Combo transfection in both cell lines. Expression of LIN28 was 
modulated by the combination of mimics with similar kinetics in the two cell lines and the 
maximum downregulation was seen at day 2, with both day 1 and day 3 showing similar levels 
of downregulation. In both cell lines replenishment of miR-100-5p alone did not downregulate 
the transcription of LIN28 at any of the doses tested: upregulation of these transcripts was in 
fact consistently seen at all analysed times post transfection both with 8.3 nM and 16.7 nM 
mimics, probably due to secondary effects. On the other hand, replenishment of miR-125b-5ps 
alone did result in downregulation of LIN28 transcription. In most cases the effects seen after 
the transfection of the Combo were similar to those seen with miR-125b-5p alone. 
Analysis of protein levels following miRNA replenishment by Western blotting showed a 
downregulation of LIN28 protein induced by miR-125b-5p alone or in combination in TCam2 
cells, mostly at day 3 after transfection when replenishment was carried out using 16.7 nM 
mimics either alone or in combination. Consistently with the RT-qPCR data, no effect was seen 
on protein levels using the mimic for miR-100-5p alone in TCam2 cells, and minimal effect 
was seen on 1411h cells at both time points. 
   Regulation of the expression of LIN28A, let-7 and miR-125b-5p  
To further dissect out the role of miR-125b-5p on the regulation of LIN8 and let-7 family 
members further studies were carried out. 
Firstly, the effect of replenishing miR-125b-5p was studied over a longer time frame, 
particularly in view of the lack of change in protein levels seen at d3 post transfection with the 
Combo treatment. This suggested that at day 3 post transfection, the upregulation of LIN28 
induced by the presence of miR-100-5p in the Combo has an antagonistic effect on the 
downregulation of LIN28 induced by miR-125b-5p. Therefore, I tested whether effects 
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mediated by miR-125b-5p were more significant than the effects mediated by miR-100-5p at 
later timepoints (Figure 5.27). 
 
Figure 5.27: Western blot of LIN 28A. Levels of LIN 28A in TCam2 cell lines were tested at day 2, 4 
and 7 post transfections with Combo or MNC.  
 
As shown in Figure 5.27, the effects of the transfection of the mimic combination on LIN28 is 
greater at day 7 than at earlier timepoints. The effects of the mimics alone or in combination 
on transcription of LIN28 was therefore further investigated.  
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   Level of let-7 after miR-125b-5p transfection 
To further study the potential contribution of miR-125b-5p to the let-7 / LIN28 feedback loop, 
cells were treated with mimics either alone or in combination and levels of transcription of let-
7 family members assessed over the course of six days (Figure 5.28).  
 
Figure 5.28: Effects of miRNA replenishment on of let-7 family members in TCam2 and 1411H 
cells. Gene expression was determined by RT-qPCR. a) let-7b and b) let-7e expression levels were 
examined at day 1, day 2 day 3 and day 6 post transfection. Replenishment of miR-100-5p is shown in 
red, miR-125b-5p in green and the Combo (combination of miR-100-5p+miR-125b-5p) in blue. 
Relative gene expression was normalised using RNU24 and independently calculated expression ratios 
were then averaged. Data presented as mean ± SEM of n=3 biological replicates. 
 
The levels of two let-7 family members (let-7b and let7-e, Figure 5.28 a and b, respectively) 
were shown to be upregulated at day 6 following replenishment of miR-125b-5p alone. This 
suggests that the decrease in the amount of available LIN28 at day 7 post replenishment of 
miRNAs in GCT cell lines may be mediated by upregulation of let-7 transcription. All together 
the data presented here suggest a role for miR-125b-5p in the regulation of the levels of let-7 
that may in turn influence the levels of LIN28. More broadly, the data presented has also shown 
that the transcription of a variety of genes involved in the regulation of the cell cycle are indeed 
affected by the replenishment of the miRNAs of interest, suggesting a potential role for these 
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genes in the phenotypic change in cell growth observed after transfection of the Combo in 
mGCT cell lines.  
   FACS analysis of cell cycle arrest 
As a number of genes shown to be deregulated by the replenishment of miR-100-5p and miR-
125b-5p are involved in the cell cycle, further experiments were carried out to determine 
whether cell cycle arrest could be the potential cause of reduced cell growth following 
transfection of the Combo in mGCT cell lines. In particular, I aimed to determine at which 
stage of the cell cycle a potential arrest was occurring. Incorporation of EdU (5-ethynyl-2’-
deoxyuridine) into newly synthesised DNA was utilised to obtain information about the cellular 
DNA content that was then used to decipher the particular stage of the cell cycle (G1, S, and 
G2/M) cell were at, with the hypothesis that a block at a particular stage would have increased 
the percentage of population found at that stage itself.  
EdU is a thymidine analogue that is incorporated into DNA during the synthesis phase (S 
phase) and has a high intracellular penetration capability due to its small size.  It is added 
directly to the media of cells in culture, but conditions need to be optimised for different cell 
lines. A time course was utilised to establish the optimal time of exposure and concentration 
of this reagent for mGCT cell lines. In optimised experiments, incorporation of EdU occurred 
at a concentration of 10 µM, over a 2 hrs period, which is the time required for the EdU to be 
incorporated into the DNA during active DNA synthesis (Figure 5.29).  
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Figure 5.29: EdU incorporation. Example of EdU incorporation at three different time points in 
TCam2 cell line, showing the different populations that can be identified by this method. The x-axis 
shows the Fx-Cycle Violet used to detect DNA content, while the y-axis shows the EdU incorporation. 
 
Further optimisation was carried out to determine the best way to select (i.e. gate) the cells of 
interest. In particular cell were selected as ‘alive’ and in a single cell suspension. This is 
particularly important to avoid misjudging the amount of intracellular DNA (Figure 5.30). 
 
 
Figure 5.30: Examples of cell selection (i.e. gating) needed before cell cycle analysis. a) Along the 
X-axis is the FSC (Forward SCatter) parameter. This parameter is a measurement of the amount of the 
laser beam that passes around the cell. This gives a relative size for the cell. Along the Y-axis is the 
SSC (Side SCatter) parameter. This parameter is a measurement of the amount of the laser beam that 
bounces off the particulates inside of the cell. This gives information about the granularity. Cellular 
debris are usually low in the FSC parameters and dead cells have high SSC parameters. The graphs 
show a gated ‘alive’ population that fulfils the requirements for further analysis b) Doublets 
discrimination graph. Doublets can be distinguished from single cells by plotting FSC height vs FCS 
area. Doublets have increased area whilst similar height to single cells. The gate shows a typical single 
cells population that fulfils the requirement for analysis. 
 
a) b) 
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Once cells were appropriately gated, further analysis was carried out by FACS. TCam2 cells 
were collected for analysis at day 1 (Figure 5.31), day 2 (Figure 5.32), day 3 (Figure 5.33) and 
day 4 (Figure 5.34) after miRNA replenishment. For these experiments two concentrations of 
mimics were utilised, 16.7 nM and 33 nM. This was done to test whether a greater dose of 
mimic may result in a larger proportion of cells showing phenotypic changes. 
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Figure 5.31: FACS analysis of TCam2 cells one day after transfection with miRNAs mimics. Cells 
were either untreated or treated with mimic non-targeting control (MNC) or the combination of miR-
100-5p and miR-125b-5p (Combo) at two different concentration (16.7 nM and 33.3 nM). a) schematic 
view of the different stages of the cell cycle: G1/G0 phase is shown in red, S phase in blue and G2/M 
phase in green. b) FACS acquisitions defining different stages of the cell cycle. Fx-Cycle Violet 
emission used to detect DNA content is shown on the x-axis while EdU incorporation is shown on the 
y-axis c) histogram showing DNA content. The experiments were repeated 3 times, a representative 
example is shown. The numbers relate to ‘alive population’ (parent). 
 
At day 1 after miRNA replenishment, no differences were seen between MNC and Combo at 
both the concentration. A small decrease in the percentage of cells in S phase was seen in cells 
treated with MNC or Combo, compared with untreated control cells, probably due to toxicity 
associated to the transfection procedure which utilises Lipofectamine RNAiMAX reagent. 
Cells usually recover one day after transfection (data not shown).  
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Figure 5.32: FACS analysis of TCam2 cells two days after transfection with miRNAs mimics. Cells 
were either untreated or treated with mimic non-targeting control (MNC) or the combination of miR-
100-5p and miR-125b-5p (Combo) at two different concentration (16.7 nM and 33.3 nM). a) schematic 
view of the different stages of the cell cycle: G1/G0 phase is shown in red, S phase in blue and G2/M 
phase in green. b) FACS acquisitions defining different stages of the cell cycle. Fx-Cycle Violet 
emission used to detect DNA content is shown on the x-axis while EdU incorporation is shown on the 
y-axis c) histogram showing DNA content. The experiments were repeated 3 times, a representative 
example is shown. The numbers relate to ‘alive population’ (parent). 
 
At day 2 after miRNA replenishment, no significant differences were seen between untreated 
cells and cells treated with MNC at either 16.7 nM or 33.3 nM, suggesting that cells had 
recovered from the slight toxicity associated with the transfection procedure. An 8.1% increase 
in G0/G1 and a corresponding 7.9% decrease in S phase populations was seen in cells treated 
with Combo 16.7 nM compared to MNC 16.7 nM. A similar 7% increase in G0/G1 and a 7.8% 
decrease in S phase was obtained in cells treated with Combo 33.3 nM compared with MNC 
33.3 nM. No significant difference was seen in G2/M phase fractions between MNC and 
Combo. 
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Figure 5.33: FACS analysis of TCam2 cells three days after transfection with miRNAs mimics. 
Cells were either untreated or treated with mimic non-targeting control (MNC) or the combination of 
miR-100-5p and miR-125b-5p (Combo) at two different concentration (16.7 nM and 33.3 nM). a) 
schematic view of the different stages of the cell cycle: G1/G0 phase is shown in red, S phase in blue 
and G2/M phase in green. b) FACS acquisitions defining different stages of the cell cycle. Fx-Cycle 
Violet emission used to detect DNA content is shown on the x-axis while EdU incorporation is shown 
on the y-axis c) histogram showing DNA content. The experiments were repeated 3 times, a 
representative example is shown. The numbers relate to ‘alive population’ (parent). 
 
At day 3 after miRNA replenishment, no significant differences were seen between untreated 
cells and cells treated with MNC at either 16.7 nM or 33.3 nM. An 11.8% increase in G0/G1 
cellular fraction and 12.3% decrease in S phase population was oserved in cells treated with 
Combo 16.7 nM compared with MNC 16.7 nM. A similar 10.2% increase in G0/G1 fraction 
and a 9.5% decrease in S phase population was seen in cells treated with Combo 33.3 nM 
compared with MNC 33.3 nM. No significant differences were seen in the G2/M phase fraction 
when comparing MNC and Combo. 
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Figure 5.34: FACS analysis of TCam2 cells four days after transfection with miRNAs mimics. 
Cells were either untreated or treated with mimic non-targeting control (MNC) or the combination of 
miR-100-5p and miR-125b-5p (Combo) at two different concentration (16.7 nM and 33.3 nM). a) 
schematic view of the different stages of the cell cycle: G1/G0 phase is shown in red, S phase in blue 
and G2/M phase in green. b) FACS acquisitions defining different stages of the cell cycle. Fx-Cycle 
Violet emission used to detect DNA content is shown on the x-axis while EdU incorporation is shown 
on the y-axis c) histogram showing DNA content. The experiments were repeated 3 times, a 
representative example is shown. The numbers relate to ‘alive population’ (parent). 
 
At day 4 after miRNA replenishment, no significant differences were seen between untreated 
cells and cells treated with MNC at either 16.7 nM or 33.3 nM. A 6.2% increase in G0/G1 
population, an 11.4% decrease in S phase fraction and a 5.1% increase in G2/M populations 
was observed in cells treated with Combo 16.7 nM compared with MNC 16.7 nM. A similar 
9% increase in G0/G1 fraction, an 11.8% decrease in S phase population and a 2.7% increase 
in G2/M were seen in cells treated with Combo 33.3 nM compared with MNC 33.3 nM. 
All together the data presented here suggest that the phenotypic effect seen on cell growth in 
TCam2 cells after replenishment of miRNAs is indeed associated with a small but significant 
decrease in the S phase at day 3 (p-value: 0.05). This primarily results in the accumulation of 
cells in G0/G1 phase, however, a small proportion of cells also rests in G2/M phase. It is unclear 
from this data if cells are temporarily arrested in these phases and then resume cycling, or 
whether these blocks result in the induction of apoptosis or other processes that ultimately lead 
to cell death. 
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5.3   Discussion 
In the present study, we aimed to investigate the contribution of miR-99a-5p/-100-5p and miR-
125b-5p in the progression of mGCTs. Replenishment of  miR-99a-5p/-100-5p and miR-125b-
5p alone or in combination, have been previously shown to reduce tumour proliferation in 
breast cancer, hepatocellular carcinoma, oral squamous cell carcinoma and colorectal cancer 
(Henson et al., 2009; Akhavantabasi et al., 2012; Jia et al., 2012; Wang et al., 2018). However, 
their role in mGCTs is still unknown.  
Data presented in Chapter 3, points strongly to the fact that both families of miRNAs are 
coregulated in these tumours. Furthermore, overall expression of miR-99a-5p/-100-5p and 
miR-125b-5p was similar in three representative cancer cell lines, suggesting equal 
contribution of these miRNAs in the overall downregulation. From these studies, we 
hypothesised that miR-99a-5p and miR-100-5p work together and in tandem with miR-125b-
5p and the reintroduction of both miRNA mimics at the same time (named Combo) was 
achieved. 
These miRNAs were then replenished in several mGCTs cell lines and the effect of such 
replenishment analysed. Results showed that restoration of miRNAs levels using both miRNAs 
mimics at the same time (Combo) resulted in a more pronounced phenotypic effect compared 
with transfection of single miRNAs. In particular, no significant phenotypic change on cell 
growth was observed following transfection with mimics for miR-100-5p alone or miR-125b-
5p alone at 16.7 nM each, whereas, when both mimics were transfected individually at lower 
doses (8.3 nM + 8.3 nM each) to achieve a final concentration of 16.7 nM a significant 
phenotypic change on cell growth was observed. This observation has implications for the 
potential use of mimic combination to replenish downregulated miRNAs as a therapeutic 
approach, as lower doses are generally beneficial to reduce off-target toxicity. However, in 
view of the redundancy between these miRNAs, it cannot be excluded that the combination of 
the miRNA mimics may have additional off-target effects, in a manner similar to their 
enhanced activity. Further studies assessing potential additive or synergistic effects of these 
mimics’ combinations in a detailed manner would have to be carried out to draw firmer 
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conclusions. Interestingly, when higher miRNA concentrations were used (up to a final 
concentration of 66.6 nM), additional phenotypic effects were not achieved. I then decided to 
continue my experiments using 16.7 nM of total concentration as adding high concentration of 
mimics can resulted in off-target effect and presence of high molecular weight RNA (Jin et al., 
2015). 
In TCam2 and 1411H cell lines, which were derived from a testicular seminoma and yolk sac 
tumour respectively, replenishment of the miRNA resulted in a phenotypic effect on cell 
growth at day 7 (Bian et al., 2012), while in 2102Ep cells, which were derived from an 
embryonal carcinoma, no changes in growth were seen, even at higher transfection 
concentration.  
Embryonal carcinomas are known to be the most aggressive and the most undifferentiated of 
the non-seminomatous mGCTs. Seminomas, which are only of one histological type and are 
considered to be relatively undifferentiated, are associated with a better clinical prognosis and 
are highly sensitive to chemotherapy. In contrast, non-seminomatous GCTs have a worse 
prognosis and in general are thought to be more resistant to systemic chemotherapy and are 
therefore treated more aggressively. 
In order to understand the reason why 2102Ep cells were resistant to the mimic treatment, 
different experiments were performed. First of all, labelled mimic was utilised to visually 
examine mimic uptake by the cells. In the first few hours following transfection, 2102Ep cells 
incorporated the labelled mimic with similar efficiency to TCam2 or 1411H cells. Interestingly, 
after 12 hrs, it appeared that almost all labelled mimic disappeared from 2102Ep cells (data not 
shown). This was not observed in the other two cell lines. These initial findings indicated that 
the mimic may be actively transported out of 2102Ep cells. Recently, a number of studies have 
highlighted the importance of exosomes in drug-resistance (Zhang et al., 2015; Samuel et al., 
2018), so, accordingly, I investigated the potential involvement of exosomes in the GCT 
system. The first step was to measure the levels of the miRNAs mimics packages into exosomes 
(Appendix 1). I noticed that when 2102Ep cells were transfected, only a small proportion of 
the mimic remained inside the cells; almost all of the remaining mimic was found inside the 
cells’ exosomes from day 1 post transfection. By comparing TCam2 and 1411H with 2102Ep 
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cells I could see a significant difference between the level of mimics packaged into 2102Ep 
exosomes compared with TCam2 and 1411H exosomes. This preliminary result gave me more 
confidence to study exosome involvement in drug resistant more extensively. Unsuccessful 
attempts to knock-out genes involved in the production of exosomes (nSMase and RAB27A), 
using CRISPR/Cas9 and small interfering RNA (siRNA), were performed on 2102Ep cells 
(Alexander et al., 2017; Menck et al., 2017) (Appendix 1). 2102Ep cell lines are highly 
undifferentiated; to maintain this state of undifferentiation cells have to be grown in their 
optimal condition. These cells have little cytoplasm and large nuclei and grow in tight clusters.  
Their undifferentiated state could only be maintained when cells were seeded at a density of at 
least 5x106 per 75 cm2 flask. At lower densities the larger, flatter cells began to appear and the 
cells start to lose their undifferentiated state (Andrews et al., 1982). For this reason, it was hard, 
if not impossible, to select single clones necessary to perform CRISPR/Cas9. A heterogeneous 
population was initially selected due to the loss of genomic nSMase gene, but after a few 
passages the gene reappeared and the protein levels of nSMase increased.  Due to these 
challenges, future studies should focus on drugs that inhibit exosome production.  
To elucidate the mechanisms that led to the phenotypic effect on cell growth seen in the mGCT 
cell lines studied, gene expression was quantified using mRNA isolated at day 7 post miRNAs 
replenishment on Illumina mRNA microarrays. Three cell lines - TCam2, 1411H and 2102Ep 
– untreated or treated with a mimic non-targeting control (MNC) or the combination of miR-
100-5p and miR-125b-5p mimics (Combo) were studied. 
As expected, no gene expression changes were seen after replenishment with the Combo 
compared with MNC in 2102Ep cells. On the other hand, TCam2 and 1411H treated with the 
Combo showed differential gene expression when compared with MNC. Fold change analysis 
showed significant differentially expressed genes for both TCam2 and 1411H. Fewer 
differentially expressed genes were found when untreated cells were compared with MNC, but 
these changes were smaller with much lower significance (p-value). These analyses informed 
on the magnitude of the changes in expression resulting from the replenishment of miRNAs. 
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Further analysis carried out using Sylamer aimed to identify genes with Seed Complementary 
Regions in their 3’UTR corresponding to miR-99a-5p/-100-5p and miR-125b-5p that were 
differentially expressed. When examined independently, no significant curve was seen for the 
hexamers, heptamers and the octamer representing the SCRs of interests, for either 1411H or 
TCam2. However, if all SCR permutations complementary to a specific microRNA were tested 
together, a stronger significance was seen, particularly for genes containing SCRs to miR-
125b-5p. Genes containing SCR to miR-100-5p did not appear to be amongst the most 
downregulated genes. This is interesting as the quantification of the intracellular mimics 
suggest that both miRNAs were replenished to a similar level, with miR-125b-5p being slightly 
less abundant at day 7 in 1411H cells. On the other hand, at day 7 post transfection, the effects 
of miR-100-5p and miR-125b-5p on target genes is lower than at earlier time points, as the 
amount of intracellular mimic decreased with time and the majority of the deregulated genes 
are likely to be downstream of the direct miRNAs’ targets. It is likely that this differential 
significance is an artefact of this late timepoint and bears no biological significance. 
An arbitrary cut-off corresponding approximately to the highest peak of downregulation of 
genes targeted by miR-125b-5p (and miR-100-5p, although the peak for these genes did not 
reach significance) was selected. The genes on the left of the peak were the most significantly 
downregulated and consequently were considered the most significant genes in terms of 
biological effects. As mentioned above, at day 7 the genes deregulated would probably be 
downstream the genes directly targeted by miR-125b-5p and miR-100-5p, therefore pathway 
analysis was carried out using the gene list derived from Sylamer analysis as well as the ranked 
gene list derived from the differential expression analysis of the microarray data using as 
baseline 0.5 fold change with a p-value of 0.05 for TCam2 cells and 0.3 fold change with a p-
value of 0.05 in 1411H cells. Different baselines (or cut-offs) were applied to the two cell lines 
as the number of differentially expressed genes was lower in 1411H than TCam2 cells and this 
allowed the analysis of a sufficient number of genes to be able to deduce pathways of 
importance. Similar pathways were identified in both cell lines, such as cell cycle regulation, 
and apoptotic process. These pathways are consistent with the phenotypic changes seen in the 
cell lines after replenishment of the miRNAs. Others, such as transport of small molecules were 
found only TCam2 cells and may be more relevant to this particular mGCT subtype. 
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Unfortunately, the level of deregulation was very low, and it was impossible to validate these 
findings experimentally by RT-qPCR and western blotting. 
Having elucidated some of the pathways influenced by the replenishment of miR-125b-5p and 
miR-100-5p seven days post transfection, it then was important to narrow down the genes that 
were the initial source of the observed changes. These were partially identified by the day 7 
arrays, however, identification of direct targets of these miRNAs was challenging as their 
targets may in turn have instigated downstream signalling. Moreover, a reduction of the amount 
of mimic present intracellularly at this timepoint would have reduced interactions observed 
between these miRNAs and their targets. Therefore, a second set of arrays were utilised to 
study differential regulation of genes by the replenished miRNAs at a much earlier timepoint 
after transfection (day 2). The 2102Ep cell line was not included in this second study, as no 
phenotypic effect or significant gene expression changes were identified in this cell line at day 
7. Moreover, as untreated control and cells treated with the mimic non-targeting control showed 
some minor phenotypic differences 7 days post transfection but no significant transcriptional 
changes and did not shown any phenotypic differences at this early timepoint, the untreated 
control was also excluded from the experiment. 
The resulting analysis identified numerous differentially expressed genes at day 2 post 
transfection in both TCam2 and 1411H cells treated with the mimics’ combination (Combo). 
In both 1411H and TCam2 cells, downregulation of genes containing miRNA seed 
complementary regions of variable length (hexamers, heptamers or octamer) for either miRNA 
was significant. When the effect of all SCR elements was considered simultaneously, a higher 
significance was demonstrated. The peak of significance for both miRNAs mimics was utilised 
as cut-off, and the genes on the left were used for pathway analysis using the online browsers: 
KEGG, gene ontology (GO) and reactome. More target genes were significantly enriched in 
the SCR of miR-99a-5p/-100-5p and miR-125b-5p at day 2 post treatment than at day 7. 
Pathways involved in cell cycle regulation, apoptotic processes, metabolic processes and 
immune system were identified as significantly affected by the miRNAs replenishment. 
Multiple genes involved in cell cycle regulation were identified as downregulated in both 
1411H and TCam2 gene lists. To further validate the importance of these genes in clinical 
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setting, data from GEPIA (Gene Expression Profiling Interactive Analysis) was utilised. 
GEPIA is a web-based tool that combines TCGA and GTEx data (Tang et al., 2017) and can 
be used to study gene expression in mGCTs clinical samples and compared with normal tissue. 
The genes identified as regulators of the cell cycle which were downregulated in both TCam2 
and 1411H cells were therefore investigated in this database. Interestingly, the vast majority of 
the genes identified by Sylamer analysis were found to be upregulated in tumour samples 
compared with normal controls. This suggests that the mechanisms observed in vitro may also 
be relevant in clinical settings, irrespective of tumour subtype. The discovery of genes that are 
commonly deregulated in different mGCT cell lines and in tissue samples from a variety of 
mGCTs suggest that a common mechanism of deregulation may exist in these tumours and 
opens the possibility of a single therapeutic approach for these highly heterogeneous cancers. 
To validate the pathways and genes identified by microarray gene expression analysis, genes 
deregulated in both cell lines after transfection with miR-100-5p and miR-125b-5p and 
identified as having a role in the regulation of the cell cycle were further investigated.  In 
particular ARID 3A, E2F7, TRIM71, FGFR3 and CTDSPL were identified by Sylamer analysis 
as being regulated by both miRNAs in TCam2 and 1411H cells and were also shown to be 
overexpressed in mGCTs compared with normal tissue. These five genes have been described 
as important regulator of the G1/G0 to S transition in the cell cycle. 
ARID 3A has already been identified as a gene targeted by miR-125b-5p in B-cell acute 
lymphoblastic leukemia (B-ALL). It has also been shown to have a role in cancer progression 
and apoptosis (Puissegur et al., 2012). Similarly, CTDSPL has been identified as a target of 
miR-99b-5p, although this gene is generally thought to be a tumour suppressor gene (Zheng et 
al., 2012). However, overexpression of CTDSPL was shown to lead to changes in expression 
of ribosomal genes and genes involved in cellular migration and metabolism (Winans et al., 
2017). Importantly, a truncated transcript of CTDSPL found in virus induced B-cell 
lymphomas promoted immortalization when overexpressed in primary cell culture (Winans et 
al., 2017). 
FGFR3 is another known target of miR-100. It has been shown to be upregulated in bladder 
cancer and in oral squamous cell carcinoma (OSCC) as a consequence of the downregulation 
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of miR-100-5p (Henson et al., 2009; Song et al., 2010). FGFR3 is one of four members of the 
FGFR family of receptor tyrosine kinases that serve as cell surface receptors for the FGF 
ligands. Signalling by the FGFRs leads to the activation of multiple intracellular signalling 
pathways including the extracellular signalling-regulated kinase/mitogen-activated protein 
kinase (ERK/MAPK) cascade and PI3K signalling, which in turn play important roles in 
various biological processes including embryogenesis, differentiation, angiogenesis, cell 
proliferation, migration, and apoptosis (Bi, Jing and Cao, 2015). 
TRIM71 has been shown to associate with 3ʹ′UTRs of many mRNAs and this association 
represses protein synthesis, accompanied by the decrease in mRNA abundance due to 
accelerated mRNA decay (Loedige et al., 2013). In some instances, TRIM71 acts together with 
miRNAs to achieve this mRNA decay. For example, TRIM71 functions with the miR-290 and 
miR-302 families to repress Cdkn1a expression in embryonic stem cells (ESCs) (Chang et al., 
2012). Cdkn1a is the key inhibitor of the cyclin E-Cdk2 complex whose constitutive activity 
allows progression through the G1–S phase in ESCs. The repression of Cdkn1a expression in 
ESCs is thought to be key in the maintenance of their rapid proliferation. Interestingly, the 
miR-302 family of miRNAs which partners TRIM71 in this regulation of Cdkn1a is highly 
overexpressed in mGCTs. 
The family of E2F transcription factors are known to be important regulator of the cell cycle. 
E2F7 is thought to be important in the deactivation of cell cycle-regulated genes. E2F7 is highly 
expressed during mid to late S-phase, occupies promoters of G1/S-regulated genes and 
represses their transcription. In particular, together with E2F8, E2F7 directly repress directly 
E2F1 with consequent anti-proliferative properties (Carvajal et al., 2012). However, its ability 
to inhibit E2F1 also mediates the block of E2F1-induced apoptosis in response to DNA 
damage. These pro-survival actions of E2F7 suggest that, under certain circumstances, E2F7 
may be oncogenic. Consistent with this idea, E2F7 has been reported to be selectively 
expressed in proliferation-competent keratinocytes and to be overexpressed in cutaneous 
squamous cell carcinoma (CSCC) (Endo-Munoz et al., 2009). 
5.3 Discussion 269 
 
Interestingly, while these 8 genes were all identified by Sylamer analysis to be targets of both 
miRNAs, not all of these genes were downregulated equally by miR-100-5p and miR125b-5p. 
TRIM71, E2F7 and FGFR3 were affected by the replenishment of both miRNAs, but ARID 
3A was affected only by the replenishment of miR-125b-5p, while CTDSPL was affected only 
by the replenishment of miR-100-5p. Analysis of the 3’UTR sequences of ARID 3A and 
CTDSPL identified a different number of seed complementary regions to each individual 
miRNA in these regions. Interestingly, the miRNA with more SCR was indeed the one that the 
genes appeared to be regulated by. Moreover, alongside the higher number of SCRs for a 
particular miRNA, one or more of these SCRs would be characterised by a longer stretch of 
homology. It therefore appeared that as abundance and length of the seed complementary 
region for a specific miRNA (i.e. the mRNA binding site) increased, so did the extent of 
downregulation of the gene by that miRNA. A number of studies have looked at the 
relationship between miRNA binding sites in 3’UTRs and the effects on their target genes, as 
this is fundamental to understanding how miRNAs carry out their function. Unfortunately, 
some of this process is still poorly understood. Many tools are available to predict potential 
seed complementary regions, and most of them – such as such as PicTar, EIMMO or PACMIT 
- search primarily for seeds seven or eight nucleotides long, giving 8-mer SCRs more statistical 
weight (Ellwanger et al., 2011). On the other hand, a recent study on colorectal cancer has 
shown that the length of the SCR does not influence the level of downregulation mediated by 
the miRNA, as no additional downregulation was achieved in this system when a longer SCR 
was introduced (Mullany et al., 2016). The observation that despite the presence of binding 
sites for both miRNAs, greater transcript downregulation was achieved using the miRNA with 
a longer SCR sequence suggests that this may be a relevant factor. Manipulation of the SCRs 
to change miRNA affinity would be needed to strengthen this observation. The use of Sylamer 
to predict specific miRNAs target genes is more flexible than other available platforms as it 
allows the interrogation of SCRs of variable length (6-mers, 7-mers and 8-mers). Moreover, it 
allows analysis using both miRNA and mRNA expression data from matched samples, 
something that other platforms do not provide.  
Reassuringly, the genes that were thought to be targeted by only one miRNA only responded 
to miRNA replenishment in the expected manner, supporting the validity of the Sylamer 
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analysis. mTOR, which is a well-known target of miR-100-5p in a variety of cancers such as 
ovarian cancer, responded only to replenishment with miR-100-5p mimics while ARID 3B and 
LIN28A which are targeted by miR-125b-5p (Nagaraja et al., 2010; Bobbs et al., 2015; Balzeau 
et al., 2017) responded only to replenishment with mimics of the latter. 
Of interest was the investigation of the effects of the replenishment of miR-125b-5p (or the use 
of the Combo), on the expression of LIN28. The reason for this is that the upregulation of the 
expression of LIN28 (an RNA binding protein and known negative regulator of let-7 
biogenesis) in mGCT tissue samples was originally identified in the lab by microarray. LIN28 
acts by blocking the process of maturation of precursor let-7 molecules (Viswanathan, Daley 
and Gregory, 2008). Once LIN28 binds pri-let-7 and pre-let-7, it prevents their processing by 
DROSHA and DICER1 (Viswanathan and Daley, 2010b). This interaction occurs due to a stem 
loop motif that includes the nucleotide sequence ‘GGAG’ and that in turn leads to the 
recruitment of a terminal-uridyl-transferase (TUTase), so that pre-let-7 undergoes uridylation 
and degradation (Heo et al., 2009). In GCTs cell lines, LIN28 knockdown (KD) by siRNA 
results in a specific upregulation of let-7 family members, suggesting that LIN28 and let-7 
regulate each other via a negative feedback loop. Furthermore, replenishment of let-7 levels in 
mGCT cell lines using a mimic let-7 molecule (namely let-7e) resulted in reduced cell growth 
(as established by total cell number counts) associated with reductions in the levels of let-7 
targets such as MYCN. In addition, a reduction in LIN28 expression itself were also observed, 
demonstrating again a feedback loop, mediated by the presence of a let-7 binding site in the 
LIN28 3’UTR (Murray et al., 2013). The observation that miR-125b-5p alone can partially 
restore let-7 levels has potential clinical implications. Due to the regulatory loops described, 
the replenishment of a downregulated miRNA (miR-125b-5p), also has the additional benefit 
of restoring the level of another downregulated miRNA (let-7). The low LIN28A protein level 
found at day 7 can be explained by this additional effect of let-7 to that of miR-125b-5p. 
To further confirm that the phenotypic effects on cell growth seen after replenishment of miR-
100-5p and miR-125b-5p were mediated by a modulation of the cell cycle, FACS analysis was 
performed. These experiments demonstrated that the replenishment of miR-100-5p and miR-
125b-5p indeed resulted in changes in cell cycle, the most significant of which was seen at day 
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3 post mimic transfection. At this timepoint, an increase of approximately 12% in the number 
of cells in G0/G1 phase and a 12% decrease in the number of cells in S phase was seen. This 
increase of the G0/G1 population is likely to be due to failure to pass the G1 checkpoint that 
monitors the DNA integrity and cell machinery. Cells that fail the G1 checkpoint due to DNA 
damage can initiate a process of DNA repair or initiate apoptosis. Cells can also fail the G1 
checkpoint due to limited nutrients or extracellular signalling, in which case they can enter the 
G0 phase of the cell cycle, which describes a state of quiescence. A similar checkpoint is found 
in G2/M phase. 
Interestingly, no further accumulation in G1/S was seen by doubling the number of mimics 
replenished. This was unexpected, however further work would be needed to investigate this 
lack of additional effect. It is in fact unclear if the additional mimic was indeed delivered 
intracellularly as no quantification of the intracellular mimics was performed.  
Unfortunately, it was technically impossible to obtain reliable data on the cell cycle at 
timepoints later than day 5. This was due to the fact that GCT cell lines cannot be seeded 
sparsely and therefore by day 5 cells became too overconfluent (this was particularly true of 
untreated cells and those treated with MNC). Consequently, these cells started to show 
abnormal cell cycle distribution due to the fact that they were responding to inhibition by 
contact. Therefore, almost no cells in these control samples were seen in G2/M phase, whereas 
a large fraction of the population was blocked in the G1/G0 phase. Attempts were made to 
synchronise cells to see if this would improve the ability to determine where cells were blocked, 
however this was never successfully achieved, despite trying different methods including: 
serum starvation, double thymidine block and nocodazole. Taken together the cell cycle data 
shows that following replenishment with miR-100-5p and miR-125b-5p, TCam2 could no 
longer overcome the block in G1/G0. This is in agreement with the suggestion that the genes 
regulated by these miRNAs have an important role in the control of the cell cycle and that this 
is circumvented in these cancer cells by the removal of the miRNA mediated control of these 
genes. 
Ideally the data on cell cycle regulation shown for TCam2 cells would have been confirmed 
using another cell line. Attempts were made to use the 1411H cells, which were extensively 
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utilised for other parts of this work. Unfortunately, while various attempts were made to 
optimise the protocol with these cells, none produced conclusive data. For reference data is 
shown in the Appendix 2. In particular EdU was not incorporated in the cellular DNA after 
treatment of 1411H cells. Different concentrations of EdU and different length of treatment 
were tested, but no sufficient EdU incorporation was achieved. It is possible that these cells do 
not express a pyrimidine salvage pathway that is key for the incorporation of EdU to occur. A 
salvage pathway is the pathway in which nucleotides are synthesized from intermediates in the 
degradative pathway for nucleotides. Without this pathway, the EdU is not phosphorylated 
intracellularly, a step essential for incorporation into replicating DNA to happen. Alternatively, 
it is possible that the permeabilisation step was insufficient to allow staining of the EdU. The 
kit that was utilised for this experiment (Click-iT EdU) only requires a mild detergent 
permeabilisation because of the size of the reagent, but it is possible, although unlikely, that a 
harsher permeabilisation was required.  
Future work will be undertaken to look into the role of apoptosis and the immune system in 
mGCTs cell lines after miRNAs replenishment, as suggested from the pathway analysis data. 
 

 Chapter 6   Concluding discussion and future work 
 
All malignant GCTs are thought to arise from the same progenitors (PGCs), however, until 
recently, no common biological abnormality present in these tumours independently of patient 
age (paediatric or adult), histological subtype (YST, germinoma/seminoma or EC) or 
anatomical site (gonadal or extragonadal) had been identified. Members of the Coleman lab, 
have identified that mGCTs could be segregated from non-malignant controls by their miRNA 
expression profile, thus identifying for the first time a biological abnormality shared by all 
mGCTs (Palmer et al., 2010).  
This doctoral thesis originates from these findings and aimed to investigate the mechanism and 
functional significance of the downregulation of miRNA expression in mGCTs. This presented 
work covers cell biological studies to understand the upstream regulation of miRNA 
expression, and the identification of mechanisms underlying the malignant effects of miRNA 
downregulation in mGCTs by testing the consequence of miRNA replenishment in vitro. 
Ultimately, a better understanding of miRNA dysregulation in mGCTs may provide insight to 
therapeutic approaches targeting miRNAs in the future. 
The material described and discussed in Chapter 3 can be divided into two sections.  
In the first section, data from the microarray previously performed in the lab (Palmer et al., 
2010) was utilised to analyse the individual expression data for each of the five most 
downregulated miRNA (miR-125b-5p, miR-100-5p, miR-99a-5p, miR-204-5p and miR-152-
3p) in mGCT samples and representative cell lines, and compare it to expression in non-
malignant controls (gonadal controls and benign teratomas) (Palmer et al., 2010). This analysis 
showed that miR-99a-5p/-100-5p and miR-125b-5p were the only miRNAs likely to have a 
significant functional effect in mGCTs as their expression level was consistently 
downregulated across all mGCT samples and representative cell lines. Moreover, the 2-7 nt 
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seed sequences of miR-99a-5p/-100-5p and miR-125b-5p was also substantially decreased in 
both clinical malignant GCT samples and representative GCT cell lines, compared with non-
malignant control samples. Once the downregulation of miR-99a-5p/-100-5p and miR-125b-
5p in mGCTs was validated using the array data and seed abundance analysis, the chapter 
moved to a second section that aimed to understand the mechanism by which this 
downregulation occurs. The microarray data suggested that miR-99a-5p/-100-5p and miR-
125b-5p are co-regulated as implied by their similar pattern of downregulation. Additionally, 
miR-99a-5p/-100-5p and miR-125b-5p are physically linked at genomic level. MiR-125b-5p 
is the product of two genomic loci, each of which is clustered with either miR-99a-5p or miR-
100-5p. The cluster on chromosome 11q24.1 contains miR-100 and miR-125b-1, while the 
cluster on chromosome 21q21.1 contains miR-99a and miR-125b-2. The similar pattern of 
regulation and location of these miRNAs suggested a co-regulation in their expression, which 
was further explored in Chapter 3.  
This second section of the Chapter 3 reported three main findings. Firstly, the lower level of 
primary transcripts (pri-miR-99a/-miR-100 and pri-miR-125b-2/-miR-125b-1) and host genes 
(MIR99AHG and MIR100HG) found in mGCTs, compared with non-malignant control, 
indicated that miRNA downregulation occurs at the transcriptional level. Secondly, both 
chromosomes were shown to have a role in miRNAs downregulation. These studies used 
differences in the primary (pri-miRNAs) and the -3p strands (miRNA-3p) transcripts which 
made them specific to a chromosomal site to define the relative contribution of each 
chromosome to the downregulation of the common mature miRNA-5p. To further confirm this 
point, levels of the host genes, MIR99AHG and MIR100HG, were also assessed. The 
assessment of the transcription of BLID, a gene embedded in chromosome 11 between miR-
100 and miR-125b-1, brought another interesting finding. This gene has its own promoter and 
its transcription is separate from the miRNAs’, however its expression was found to be also 
low in mGCTs, suggesting that the mechanism underlying the downregulation of the miRNAs 
was unlikely to be miRNA specific. These two points together brought us to the third and last 
point discussed in Chapter 3. The strong correlation that was observed within chromosomes 
and between the two chromosomal loci by assessing primary miRNA, mature miRNA-5p, 
mature miRNAs-3p and lincRNA transcripts suggests that both miR-99a, miR-125b-2 on 
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chromosome 21, and miR-100, miR-125b-1 on chromosome 11, are regulated at the same time 
by a common process which results in broader changes in transcription. 
The work presented in Chapter 4 of this thesis sought to identify the common mechanism 
through which miR-99a, miR-125b-2 on chromosome 21, and miR-100, miR-125b-1 on 
chromosome 11, are regulated. Chapter 4 focused on DNA methylation as a possible regulator 
of miRNAs expression in mGCTs. Initial experiments showed that miR-99a/-100-5p and miR-
125b-5p expression increased in 2102Ep and 1411H cell lines upon treatment with a de-
methylating agent - 5-azacytidine. This suggested that methylation had a suppressive role on 
the transcription of the miRNAs. Specific regulatory regions differentially methylated in 
mGCTs compared with non-malignant control were then identified using bisulfite conversion. 
Four mGCT cell lines, six normal cell lines and one normal tissue sample derived from the 
testis on a healthy patient were interrogated. Using a semi-quantitative analysis, five CpG 
islands (4 on chromosome 11 and 1 on chromosome 21) were shown to be statistically 
differentially methylated in mGCTs compared with non-malignant controls. Pyrosequencing 
was then used to quantify methylation at each individual CpG dinucleotide. No single CpG 
was identified as selectively methylated in mGCT samples however an overall increase in CpG 
island methylation was observed in mGCTs compared with non-malignant controls, suggesting 
an involvement of methylation in miRNAs downregulation. This overall increased methylation 
as illustrated by cumulative methylation graphs was seen on both chromosomes 11 and 21 and 
could cause the downregulation of the miRNAs transcription by potentially affecting the local 
chromatin structure, making it more condensed and hardly accessible. It is becoming apparent 
that DNA methylation and histone modification are dependent on one another and that this 
crosstalk can lead to changes in chromatin conformation (Cedar and Bergman, 2009). Other 
studies have shown that DNA methylation works together with histone methylation during 
replication to ensure that a correct methylation pattern is passed to the daughter cells (Sarraf 
and Stancheva, 2004). Moreover, the establishment of DNA methylation has been shown to be 
dependent on the H3K9 histone-methyl-transferase dim-5 in a silencing pathway utilized by 
Neurospora crassa, (Tamaru and Selker, 2001). More recent studies are showing a direct link 
between DNA methylation and the histone lysine methylation system (Rose and Klose, 2014). 
Some of the proteins involved in CpG methylation belong to the MBD family. These proteins 
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are also associated with different chromatin-modifying enzymes including histone deacetylases 
and histone lysine methyl-transferases (Fuks et al., 2003). Another important class of proteins 
essential for DNA methylation of CpG sites is the family of DNA methyl-transferases 
(DNMTs). In mammals, there are three DNMTs: Dnmt1, a maintenance methyl-transferase and 
Dnmt3a/b, which are involved in de novo methylation. Several studies have linked H3K9 and 
H3K36 with de novo DNA methylation either through direct domain binding, such as the 
binding of H3K36 to the PWWP domain on the DNMT3a/b or indirect binding such is the case 
of H3K9 (Li et al., 2006; Ooi et al., 2007; Dhayalan et al., 2010; Sasidharan Nair et al., 2018). 
H3K9 and H3K36 are histone modification that regulate the structure of chromatin. H3K9 tri-
methylation is used as a marker of epigenetic silencing and constitutive heterocromatin 
(Schotta et al., 2004; Stewart, Li and Wong, 2005). H3K36 comprises three states of 
methylation and was shown to be required for the formation of the highly condensed chromatin 
structure (Matsuda et al., 2015; Suzuki, Murakami and Takahata, 2017). 
As part of future work, it will be important to investigate the relationship between the observed 
methylation and chromatine structure in mGCT cell lines. Chromatin immunoprecipitation 
(ChIP) is a well-established technique for in vitro detection of histone modifications (Milne, 
Zhao and Hess, 2009). It aims to determine which specific histone modifications are associated 
with specific genomic regions, informing on the transcriptional landscape of the genomic area. 
Performing ChIP analysis to characterise the area surrounding the region where the host genes 
and miRNAs are located will help elucidate the nature of the aforementioned repression. 
Antibodies specific for a variety of markers should be used to evaluate the relative presence of 
markers of active transcription (such as acetylated histone H3 and trimethylated lysine 4 of 
histone H3) versus those of transcriptional repression (dimethylated lysine 9 of histone H3 and 
dimethylated lysine 27 of histone H3).   
Two main issues still need to be addressed with regards to the studies presented in Chapter 4. 
Firstly, concerns have been raised over using cell lines for methylation studies because cancer 
cell lines can develop aberrant methylation profiles as a consequence of the tissue culture 
process (Smiraglia et al., 2001). This concern is valid, and the findings here reported should be 
validated on clinical material, reassuring that the data presented, is in line with observations 
made on tissue samples. Secondly, the unbalanced methylation density between the two 
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chromosomes raises reservations about the hypothesised common mechanism of regulation. 
The area surrounding miR-99a/-125b-2 is more than 50Kb long, and not all CpG islands have 
been tested, it is possible that methylation is occurring in areas that have not been looked at. 
This hypothesis seems likely, as the area upstream the starting site of miR-125b-2 was heavily 
methylated. More importantly, downregulation of the pri-transcripts was very similar in both 
chromosomal loci, which again suggest that both loci are regulated in similar manner. ChIP 
analysis as previously mentioned will help to further elucidate this mechanism on chromosome 
21. It cannot be excluded that other additional mechanism are responsible for the 
downregulation of the transcription of miR-99a-5p/-100-5p and miR-125b-5p. It is also 
possible that there may be chromosome specific additional regulatory pathways. The two loci 
are structurally similar and are likely to have arisen by gene duplication. During species 
evolution, different strategies for the regulation of these two clusters might have evolved. As 
an extra control to dictate their expression, not only epigenetic mechanisms, but also 
transcription factors, might be important. However, more needs to be done to locate the 
promoter of the miRNAs before studies looking at differential regulation by transcription 
factors can be carried out. 
The work presented in Chapter 5 of this thesis explored and discussed the effect of miR-99a-
5p/-100-5p and miR-125b-5p replenishment in mGCTs cell lines. MiR-99a-5p/-100-5p and 
miR-125b-5p replenishment caused the repression of multiple tumour suppressor genes such 
as ARID 3A, ARID 3B, E2F7, TRIM71, FGFR3, CTDSPL, mTOR and LIN28, resulting in cell 
cycle arrest in G0/G1. Most importantly, these deregulated genes have been shown to be 
upregulated in mGCTs patients, as reported from TCGA data combined with GTEx data, 
highlighting the importance of miRNA regulation as potential therapeutic agent for mGCTs 
patients. 
Some of the genes listed and other identified by pathway analysis suggest that replenishment 
of miR-99a-5p/-100-5p and miR-125b-5p in mGCTs may also have pro-apoptotic effects. 
Unfortunately, though many experimental attempts were undertaken to demonstrate the 
possible activation of apoptotic pathways none of the data obtained was informative. As part 
of future work, different assays could be used. For example, Click-iT TUNEL Alexa Fluor, is 
an apoptosis assay based on the identification of fragmented DNA. It uses the same modified 
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nucleotides as the Click-iT reaction used for cell cycle detection. Since the cell cycle assay 
could be used with our cells, an apoptosis assay using the same chemical procedure is likely to 
work well. Alternatively, mitochondrial permeability based-assays could be used. These assays 
use of a dye that accumulates in healthy mitochondria and aggregates there as a multimer. Upon 
disruption of the mitochondrial membrane, the dye is released, changing colour due to 
monomerization as it spreads through the cytoplasm. These assays will be investigated in our 
system to further explore the potential role of apoptosis in mGCT cells where downregulated 
miRNAs have been replenished. 
Another interesting effect obtained by the replenishment of miR-99a-5p/-100-5p and miR-
125b-5p, was to change the level of expression of some members of the let-7 family, another 
class of downregulated miRNAs in mGCTs. Briefly, replenishment of miR-125b-5p, by 
targeting LIN28 and suppressing its expression, resulted in increased levels of let-7, which in 
turns is downregulated by LIN28 (Murray et al., 2013). The replenishment of miR-125b-5p, 
has an indirect effect on the level of expression of another deregulated tumour suppressor 
miRNA (let-7), helping the cell reverting its tumorigenic behaviour. This model is presented 
in the Figure 6.1. This result opens a new prospective for clinical practice, where one can 
envisage a more successful treatment using a carefully chosen miRNA targeting multiple 
downregulated pathways, some directly and some via another downregulated miRNA. 
 
Figure 6.1: Model of miRNAs regulation. MiRNAs post-trascriptionally regulate the expression of 
protein-coding genes by directly bind to the 3’UTR region of mRNAs. A single miRNA can suppress 
the production of a multitude of mRNA. The targeted mRNA can then regulate other miRNAs, as seen 
from the miR-125b-5p-LIN28A-let-7 system described in Chapter 5. In mGCTs the downregulation of 
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miR-99a-5p/-100-5p and miR-125b-5p leads to cell cycle deregulation and uncontrolled cell 
proliferation, due to the up-regulation of their pro-proliferative target mRNA.  
 
As part of the future work, which has already commenced in the lab, an in vivo system will 
now be utilized. Injection of TCam2 cell lines in CD1 nude mice in three different locations 
(in the flank, testicles and brain) has been previously shown to generate tumour (Nettersheim 
et al., 2012). Depending on the location of injection, tumour were generated with a seminoma 
or embryonal carcinoma-like phenotype (Nettersheim et al., 2012). Experiments to establish 
subcutaneous and lung models using TCam2 and 2102Ep cell lines in CD1-Foxn1nu nude 
mouse (Charles River) are currently undergoing in the lab. Once the tumour model is being 
undertaken, a delivery system for the miRNAs needs to be selected. As a proof of principle, 
the first step could be to transfect TCam2 and 2102Ep cells in vitro, using the combination of 
mimics (Combo) and the mimic non-targeting control (MNC), inject the transfected cells into 
the flank of the mouse and follow their growth. However, this method is unlikely to give 
significant results as the effect of the mimics is short lived compared with the length of time 
needed to establish tumours. Delivery of mimics in vivo is problematic, and requires the use of 
high doses, which could result in toxicity. To overcome this problem transfection of TCam2 
and 2102Ep using an inducible lentiviral system would be preferable and will be used in our 
studies. In detail, a Tet-inducible system (Tet-pLKO-neo) lentiviral plasmid will be used 
(Wiederschain et al., 2009). Primary sequence of miR-100 and miR-125b-1 will be cloned into 
the plasmid using restriction enzymes. A non-targeting control plasmid will also be created by 
cloning a non-human pri-miRNA sequence. A lentiviral vector will be generated in 293T cells 
using the cloned plasmid together with a packaging and envelope vector (named psPAX2 and 
pMD2.G, respectively). The formed lentiviral vector will then be used to transduce TCam2 and 
2102Ep cell lines. The expression of the miRNA will be induced by antibiotic treatment of the 
animals after tumour establishment, mimicking the activity of small molecule inhibitor in the 
clinical setting. To activate the plasmid, administration of doxycycline will be performed either 
by oral gavage or in drinking water. 
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The findings presented in this doctoral thesis further our understanding of the mechanisms and 
functions of downregulated miRNAs in mGCTs. This study contributed to identify a possible 
regulatory mechanism of miR-99a-5p/-100-5p and miR-125b-5p downregulation, which 
opened a new avenue in mGCTs studies. From the clinical perspective, the presented findings 
created the basis for an in vivo study, which hopefully will be brought forward in the future in 
clinical trials as targeted therapy. Taken together, these results might set the basis for the 
development of a targeted therapy which could reduce the toxicity effect due to chemotherapy 
treatment.  
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Figure 7.1: Possible involvement of exosome in 2102Ep transfection failure. The left panel shows 
data from 2102Ep cell lines, while the right panel shows 1411H data. a) Growth curve of untransfected 
cells, transfected Combo (2102Ep with 66.6 nM and 1411H with 16.7 nM) and non-targeting control 
(MNC) (2102Ep with 66.6 nM and 1411H with 16.7 nM). b) Level of miRNAs expression in the 
exosomes compared with cells by normalising the data to RNU24. c) Levels of miR-100-5p and miR-
125b-5p in the cells and in the exosomes at day 1 after Combo transfection and d) at day 2 after Combo 
transfection. 
 
 
Figure 7.2: Creation of CRISP-Cas9 plasmid for nSMase2 knock-out. The Cas9-D10A vector was 
kindly provided by Professor Stephen Jackson (Chiang et al 2016). Two gRNAs were inserted into the 
plasmid in two different restriction enzyme points: BsaI site and BbsI site. 
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Figure 7.3: QPCR gel to detect genomic level of nSMase2 after CRISP transfection. From left to 
right: nSMase2 (2102Ep KO and 2102Ep), ENTPD3 (2102Ep KO and 2102Ep), ARHGEF17 (2102Ep 
KO and 2102Ep), ZSWIM2 (2102Ep KO and 2102Ep) and FAM99A (2102Ep KO and 2102Ep). The 
other 4 genes have been assessed as they had high risk of being targeted by the CRISP-Cas9 plasmid 
due to similarity of their sequence with the gRNA used for knocking-out nSMase2. 
 
 
Figure 7.4: Level of miR-100-5p and miR-125b-5p after combo transfection in 2102Ep cell line. 
nSMase2 KO cells and 2102Ep CRISP empty plasmid were transfected using Combo and level of miR-
100-5p and miR-125b-5p were tested. nSMase2 KO cells were compared with 2102Ep CRISP empty 
plasmid and normalised to RNU24. No significant differences were noticed. Data presented as mean ± 
SEM n=3.
 Chapter 8   Appendix 2 
  
Figure 8.1:  Cell cycle analysis of 1411H cells using NC3000. 1411H cells were analysed at day 1, 2, 
3,4 and 5 after treatment. Row a) untreated cells, row b) non-targeting control (MNC) and row c) Combo 
treated cell.  
 References 
 
Afonso, M. B., Rodrigues, P. M., Simão, A. L., Gaspar, M. M., Carvalho, T., Borralho, P., … 
Rodrigues, C. M. P. (2018). miRNA-21 ablation protects against liver injury and 
necroptosis in cholestasis. Cell Death & Differentiation, 25(5), 857–872. 
https://doi.org/10.1038/s41418-017-0019-x 
Aigner, A., & Fischer, D. (2016). Nanoparticle-mediated delivery of small RNA molecules in 
tumor therapy. Die Pharmazie, 71(1), 27–34. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/26867350 
Akhavantabasi, S., Sapmaz, A., Tuna, S., & Erson-Bensan, A. E. (2012). miR-125b targets 
ARID3B in breast cancer cells. Cell Structure and Function, 37(1), 27–38. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/22307404 
Alagaratnam, S., Lind, G. E., Kraggerud, S. M., Lothe, R. A., & Skotheim, R. I. (2011). The 
testicular germ cell tumour transcriptome. International Journal of Andrology, 34(4 Pt 2), 
e133-50; discussion e150-1. https://doi.org/10.1111/j.1365-2605.2011.01169.x 
Albany, C., Hever-Jardine, M. P., von Herrmann, K. M., Yim, C. Y., Tam, J., Warzecha, J. M., 
… Spinella, M. J. (2017). Refractory testicular germ cell tumors are highly sensitive to 
the second generation DNA methylation inhibitor guadecitabine. Oncotarget, 8(2), 2949–
2959. https://doi.org/10.18632/oncotarget.13811 
Alexander, M., Ramstead, A. G., Bauer, K. M., Lee, S.-H., Runtsch, M. C., Wallace, J., … 
O’Connell, R. M. (2017). Rab27-Dependent Exosome Production Inhibits Chronic 
Inflammation and Enables Acute Responses to Inflammatory Stimuli. The Journal of 
Immunology, 199(10), 3559–3570. https://doi.org/10.4049/jimmunol.1700904 
Amatruda, J. F., Ross, J. A., Christensen, B., Fustino, N. J., Chen, K. S., Hooten, A. J., … 
Poynter, J. N. (2013a). DNA methylation analysis reveals distinct methylation signatures 
in pediatric germ cell tumors. BMC Cancer, 13(1), 313. https://doi.org/10.1186/1471-
2407-13-313 
Amatruda, J. F., Ross, J. A., Christensen, B., Fustino, N. J., Chen, K. S., Hooten, A. J., … 
Poynter, J. N. (2013b). DNA methylation analysis reveals distinct methylation signatures 
in pediatric germ cell tumors. BMC Cancer, 13(1), 313. https://doi.org/10.1186/1471-
2407-13-313 
Ambros, V. (2000). Control of developmental timing in Caenorhabditis elegans. Current 
 
Opinion in Genetics & Development, 10(4), 428–433. https://doi.org/10.1016/S0959-
437X(00)00108-8 
Anding, A. L., & Baehrecke, E. H. (2015). Autophagy in Cell Life and Cell Death. In Current 
topics in developmental biology (Vol. 114, pp. 67–91). 
https://doi.org/10.1016/bs.ctdb.2015.07.012 
Andrews, P. W., Goodfellow, P. N., Shevinsky, L. H., Bronson, D. L., & Knowles, B. B. 
(1982). Cell-surface antigens of a clonal human embryonal carcinoma cell line: 
morphological and antigenic differentiation in culture. International Journal of Cancer, 
29(5), 523–531. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7095898 
Anglesio, M., Wang, Y., Yang, W., Senz, J., Wan, A., Heravi-Moussavi, A., … Morin, G. 
(2013). Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA 
processing and reverse-strand expression bias to predominantly mature 3p strands through 
loss of 5p strand cleavage. The Journal of Pathology, 229(3), 400–409. 
https://doi.org/10.1002/path.4135 
Arora, R. S., Alston, R. D., Eden, T. O. B., Geraci, M., & Birch, J. M. (2012). Comparative 
incidence patterns and trends of gonadal and extragonadal germ cell tumors in England, 
1979 to 2003. Cancer, 118(17), 4290–4297. https://doi.org/10.1002/cncr.27403 
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., … Sherlock, 
G. (2000). Gene Ontology: tool for the unification of biology. Nature Genetics, 25(1), 25–
29. https://doi.org/10.1038/75556 
Aslan, D., Garde, C., Nygaard, M. K., Helbo, A. S., Dimopoulos, K., Hansen, J. W., … 
Kristensen, L. S. (2016). Tumor suppressor microRNAs are downregulated in 
myelodysplastic syndrome with spliceosome mutations. Oncotarget, 7(9), 9951–9963. 
https://doi.org/10.18632/oncotarget.7127 
Atkin, N. B., & Baker, M. C. (1982, December). Specific chromosome change, i(12p), in 
testicular tumours? Lancet. ENGLAND. 
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The impact 
of microRNAs on protein output. Nature, 455(7209), 64–71. 
https://doi.org/10.1038/nature07242 
Balzeau, J., Menezes, M. R., Cao, S., & Hagan, J. P. (2017). The LIN28/let-7 Pathway in 
Cancer. Frontiers in Genetics, 8, 31. https://doi.org/10.3389/fgene.2017.00031 
Banzhaf-Strathmann, J., & Edbauer, D. (2014). Good guy or bad guy: the opposing roles of 
microRNA 125b in cancer. Cell Communication and Signaling, 12(1), 30. 
https://doi.org/10.1186/1478-811X-12-30 
Bartel, D. P. (2004a). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
 
116(2), 281–297. 
Bartel, D. P. (2004b). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
116(2), 281–297. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14744438 
Baskerville, S., & Bartel, D. P. (2005). Microarray profiling of microRNAs reveals frequent 
coexpression with neighboring miRNAs and host genes. RNA. 
https://doi.org/10.1261/rna.7240905 
BASKERVILLE, S., & Bartel, D. P. (2005). Microarray profiling of microRNAs reveals 
frequent coexpression with neighboring miRNAs and host genes. RNA, 11(3), 241–247. 
https://doi.org/10.1261/rna.7240905 
Bastien, S., Smallwood, A., & Kelsey, G. (2011). De novo DNA methylation: a germ cell 
perspective. Trends in Genetics, 28, 33–42. https://doi.org/10.1016/j.tig.2011.09.004 
Batool, A., Wang, Y.-Q., Hao, X.-X., Chen, S.-R., & Liu, Y.-X. (2018). A miR-125b/CSF1-
CX3CL1/tumor-associated macrophage recruitment axis controls testicular germ cell 
tumor growth. Cell Death & Disease, 9(10), 962. https://doi.org/10.1038/s41419-018-
1021-z 
Bergeron, J. M., Crews, D., & McLachlan, J. A. (1994). PCBs as environmental estrogens: 
turtle sex determination as a biomarker of environmental contamination. Environmental 
Health Perspectives, 102(9), 780–781. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9657710 
Bergström, R., Adami, H. O., Möhner, M., Zatonski, W., Storm, H., Ekbom, A., … Hakulinen, 
T. (1996). Increase in testicular cancer incidence in six European countries: a birth cohort 
phenomenon. Journal of the National Cancer Institute, 88(11), 727–733. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8637026 
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001). Role for a bidentate 
ribonuclease in the initiation step of RNA interference. Nature, 409(6818), 363–366. 
https://doi.org/10.1038/35053110 
Bhutra, S., Lenkala, D., LaCroix, B., Ye, M., & Huang, R. S. (2014). Identifying and Validating 
a Combined mRNA and MicroRNA Signature in Response to Imatinib Treatment in a 
Chronic Myeloid Leukemia Cell Line. PLoS ONE, 9(12), e115003. 
https://doi.org/10.1371/journal.pone.0115003 
Bi, Y., Jing, Y., & Cao, Y. (2015). Overexpression of miR-100 inhibits growth of osteosarcoma 
through FGFR3. Tumor Biology. https://doi.org/10.1007/s13277-015-3581-1 
Bian, K., Fan, J., Zhang, X., Yang, X.-W., Zhu, H.-Y., Wang, L., … Zhang, R. (2012). 
MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly 
targeting survivin. FEBS Letters, 586(6), 804–809. 
 
https://doi.org/10.1016/J.FEBSLET.2012.01.050 
Bobbs, A., Gellerman, K., Hallas, W. M., Joseph, S., Yang, C., Kurkewich, J., & Cowden Dahl, 
K. D. (2015). ARID3B Directly Regulates Ovarian Cancer Promoting Genes. PLOS ONE, 
10(6), e0131961. https://doi.org/10.1371/journal.pone.0131961 
Bohnsack, M. T., Czaplinski, K., & Gorlich, D. (2004). Exportin 5 is a RanGTP-dependent 
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA (New York, 
N.Y.), 10(2), 185–191. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14730017 
Brueckner, B., Stresemann, C., Kuner, R., Mund, C., Musch, T., Meister, M., … Lyko, F. 
(2007). The human let-7a-3 locus contains an epigenetically regulated microRNA gene 
with oncogenic function. Cancer Research, 67(4), 1419–1423. 
https://doi.org/10.1158/0008-5472.CAN-06-4074 
Bueno, M. J., & Malumbres, M. (2011). MicroRNAs and the cell cycle. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease, 1812(5), 592–601. 
https://doi.org/10.1016/J.BBADIS.2011.02.002 
Bussey, K. J., Lawce, H. J., Himoe, E., Shu, X. O., Suijkerbuijk, R. F., Olson, S. B., & Magenis, 
R. E. (2001). Chromosomes 1 and 12 abnormalities in pediatric germ cell tumors by 
interphase fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 125(2), 
112–118. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11369053 
Cai, X., Hagedorn, C. H., & Cullen, B. R. (2004). Human microRNAs are processed from 
capped, polyadenylated transcripts that can also function as mRNAs. RNA (New York, 
N.Y.), 10(12), 1957–1966. https://doi.org/10.1261/rna.7135204 
Caldwell, B. T., Wilcox, D. T., & Cost, N. G. (2017). Current Management for Pediatric 
Urologic Oncology. Advances in Pediatrics, 64(1), 191–223. 
https://doi.org/10.1016/j.yapd.2017.04.001 
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., … Croce, C. M. 
(2002). Nonlinear partial differential equations and applications: Frequent deletions and 
down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic 
lymphocytic leukemia. Proceedings of the National Academy of Sciences, 99(24), 15524–
15529. https://doi.org/10.1073/pnas.242606799 
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., … Croce, C. 
M. (2004a). Human microRNA genes are frequently located at fragile sites and genomic 
regions involved in cancers. Proceedings of the National Academy of Sciences, 101(9), 
2999–3004. https://doi.org/10.1073/pnas.0307323101 
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., … Croce, C. 
M. (2004b). Human microRNA genes are frequently located at fragile sites and genomic 
regions involved in cancers. Proceedings of the National Academy of Sciences, 101(9), 
 
2999–3004. https://doi.org/10.1073/pnas.0307323101 
Campaner, S., & Amati, B. (2012). Two sides of the Myc-induced DNA damage response: 
from tumor suppression to tumor maintenance. Cell Division, 7(1), 6. 
https://doi.org/10.1186/1747-1028-7-6 
Cao, Y., Song, J., Ge, J., Song, Z., Chen, J., & Wu, C. (2018). MicroRNA-100 suppresses 
human gastric cancer cell proliferation by targeting CXCR7. Oncology Letters, 15(1), 
453–458. https://doi.org/10.3892/ol.2017.7305 
Carvajal, L. A., Hamard, P.-J., Tonnessen, C., & Manfredi, J. J. (2012). E2F7, a novel target, 
is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. 
Genes & Development, 26(14), 1533–1545. https://doi.org/10.1101/gad.184911.111 
Casey, M.-C., Kerin, M. J., Brown, J. A., & Sweeney, K. J. (2015). Evolution of a research 
field-a micro (RNA) example. PeerJ, 3, e829. https://doi.org/10.7717/peerj.829 
Cecchetto, G. (2014). Gonadal germ cell tumors in children and adolescents. Journal of Indian 
Association of Pediatric Surgeons, 19(4), 189–194. https://doi.org/10.4103/0971-
9261.141995 
Cedar, H., & Bergman, Y. (2009). Linking DNA methylation and histone modification: 
Patterns and paradigms. Nature Reviews Genetics. https://doi.org/10.1038/nrg2540 
Chaganti, R. S., & Houldsworth, J. (2000). Genetics and biology of adult human male germ 
cell tumors. Cancer Research, 60(6), 1475–1482. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10749107 
Chang, H.-M., Martinez, N. J., Thornton, J. E., Hagan, J. P., Nguyen, K. D., & Gregory, R. I. 
(2012). Trim71 cooperates with microRNAs to repress Cdkn1a expression and promote 
embryonic stem cell proliferation. Nature Communications, 3, 923. 
https://doi.org/10.1038/ncomms1909 
Chang, T.-C., Yu, D., Lee, Y.-S., Wentzel, E. A., Arking, D. E., West, K. M., … Mendell, J. 
T. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. 
Nature Genetics, 40(1), 43–50. https://doi.org/10.1038/ng.2007.30 
Chen, D., Sun, Y., Yuan, Y., Han, Z., Zhang, P., Zhang, J., … Ma, L. (2014). miR-100 Induces 
Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and 
Invasion. PLoS Genetics, 10(2), e1004177. https://doi.org/10.1371/journal.pgen.1004177 
Chen, H., & Xu, Z. (2015). Hypermethylation-Associated Silencing of miR-125a and miR-
125b: A Potential Marker in Colorectal Cancer. Disease Markers, 2015, 1–7. 
https://doi.org/10.1155/2015/345080 
Chen, Y.-F., Liu, H., Luo, X.-J., Zhao, Z., Zou, Z.-Y., Li, J., … Liang, Y. (2017). The roles of 
 
reactive oxygen species (ROS) and autophagy in the survival and death of leukemia cells. 
Critical Reviews in Oncology/Hematology, 112, 21–30. 
https://doi.org/10.1016/j.critrevonc.2017.02.004 
Cheung, H.-H., Lee, T.-L., Rennert, O. M., & Chan, W.-Y. (2009). DNA methylation of cancer 
genome. Birth Defects Research Part C: Embryo Today: Reviews, 87(4), 335–350. 
https://doi.org/10.1002/bdrc.20163 
Chi, S. W., Hannon, G. J., & Darnell, R. B. (2012). An alternative mode of microRNA target 
recognition. Nature Structural & Molecular Biology, 19(3), 321–327. 
https://doi.org/10.1038/nsmb.2230 
Chorn, G., Klein-McDowell, M., Zhao, L., Saunders, M. A., Flanagan, W. M., Willingham, A. 
T., & Lim, L. P. (2012). Single-stranded microRNA mimics. RNA, 18(10), 1796–1804. 
https://doi.org/10.1261/rna.031278.111 
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., … Croce, C. 
M. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proceedings of the 
National Academy of Sciences, 102(39), 13944–13949. 
https://doi.org/10.1073/pnas.0506654102 
Cloonan, N. (2015). Re-thinking miRNA-mRNA interactions: intertwining issues confound 
target discovery. BioEssays : News and Reviews in Molecular, Cellular and 
Developmental Biology, 37(4), 379–388. https://doi.org/10.1002/bies.201400191 
Clouaire, T., Webb, S., Skene, P., Illingworth, R., Kerr, A., Andrews, R., … Bird, A. (2012). 
Cfp1 integrates both CpG content and gene activity for accurate H3K4me3 deposition in 
embryonic stem cells. Genes & Development, 26(15), 1714–1728. 
https://doi.org/10.1101/gad.194209.112 
Collinson, K., Murray, M. J., Orsi, N. M., Cummings, M., Shipley, J., Joffe, J. K., … Stark, D. 
(2014). Age-related biological features of germ cell tumors. Genes, Chromosomes and 
Cancer, 53(3), 215–227. https://doi.org/10.1002/gcc.22131 
Cui, L., Zhou, H., Zhao, H., Zhou, Y., Xu, R., Xu, X., … He, X. (2012). MicroRNA-99a 
induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. 
BMC Cancer, 12(1), 546. https://doi.org/10.1186/1471-2407-12-546 
Curtis, H. J., Seow, Y., Wood, M. J. A., & Varela, M. A. (2017). Knockdown and replacement 
therapy mediated by artificial mirtrons in spinocerebellar ataxia 7. Nucleic Acids 
Research, 45(13), 7870–7885. https://doi.org/10.1093/nar/gkx483 
Dai, E., Yu, X., Zhang, Y., Meng, F., Wang, S., Liu, X., … Jiang, W. (2014). EpimiR: a 
database of curated mutual regulation between miRNAs and epigenetic modifications. 
Database, 2014. https://doi.org/10.1093/database/bau023 
 
Danial, N. N., & Korsmeyer, S. J. (2004). Cell death: critical control points. Cell, 116(2), 205–
219. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14744432 
de Jong, J., Stoop, H., Gillis, A., van Gurp, R., van de Geijn, G.-J., Boer, M. de, … Looijenga, 
L. (2008). Differential expression of SOX17 and SOX2 in germ cells and stem cells has 
biological and clinical implications. The Journal of Pathology, 215(1), 21–30. 
https://doi.org/10.1002/path.2332 
Dehner, L. P. (1983). Gonadal and extragonadal germ cell neoplasia of childhood. Human 
Pathology, 14(6), 493–511. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/6343221 
Dhayalan, A., Rajavelu, A., Rathert, P., Tamas, R., Jurkowska, R. Z., Ragozin, S., & Jeltsch, 
A. (2010). The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and 
guides DNA methylation. Journal of Biological Chemistry. 
https://doi.org/10.1074/jbc.M109.089433 
Dobi, K. C., & Winston, F. (2007). Analysis of Transcriptional Activation at a Distance in 
Saccharomyces cerevisiae. Molecular and Cellular Biology, 27(15), 5575–5586. 
https://doi.org/10.1128/MCB.00459-07 
Drosten, M., Sum, E. Y. M., Lechuga, C. G., Simón-Carrasco, L., Jacob, H. K. C., García-
Medina, R., … Barbacid, M. (2014). Loss of p53 induces cell proliferation via Ras-
independent activation of the Raf/Mek/Erk signaling pathway. Proceedings of the 
National Academy of Sciences, 111(42), 15155–15160. 
https://doi.org/10.1073/pnas.1417549111 
Du, P., Kibbe, W. A., & Lin, S. M. (2008). lumi: a pipeline for processing Illumina microarray. 
Bioinformatics (Oxford, England), 24(13), 1547–1548. 
https://doi.org/10.1093/bioinformatics/btn224 
Eichhorn, S. W., Guo, H., McGeary, S. E., Rodriguez-Mias, R. A., Shin, C., Baek, D., … 
Bartel, D. P. (2014). mRNA Destabilization Is the Dominant Effect of Mammalian 
MicroRNAs by the Time Substantial Repression Ensues. Molecular Cell, 56(1), 104–115. 
https://doi.org/10.1016/J.MOLCEL.2014.08.028 
Einhorn, L. H., & Williams, S. D. (1979). Chemotherapy of disseminated testicular cancer. The 
Western Journal of Medicine, 131(1), 1–3. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/90432 
Ellwanger, D. C., Büttner, F. A., Mewes, H.-W., & Stümpflen, V. (2011). The sufficient 
minimal set of miRNA seed types. Bioinformatics, 27(10), 1346–1350. 
https://doi.org/10.1093/bioinformatics/btr149 
Emmrich, S., Rasche, M., Schöning, J., Reimer, C., Keihani, S., Maroz, A., … Klusmann, J.-
H. (2014). miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell 
 
homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes & 
Development, 28(8), 858–874. https://doi.org/10.1101/gad.233791.113 
Emmrich, S., Streltsov, A., Schmidt, F., Thangapandi, V., Reinhardt, D., & Klusmann, J.-H. 
(2014). LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic 
leukemia. Molecular Cancer, 13(1), 171. https://doi.org/10.1186/1476-4598-13-171 
Endo-Munoz, L., Dahler, A., Teakle, N., Rickwood, D., Hazar-Rethinam, M., Abdul-Jabbar, 
I., … Saunders, N. (2009). E2F7 can regulate proliferation, differentiation, and apoptotic 
responses in human keratinocytes: implications for cutaneous squamous cell carcinoma 
formation. Cancer Research, 69(5), 1800–1808. https://doi.org/10.1158/0008-
5472.CAN-08-2725 
Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs — microRNAs with a role in cancer. 
Nature Reviews Cancer, 6(4), 259–269. https://doi.org/10.1038/nrc1840 
Exelby, P. R. (1980). Testicular Cancer in Children. Cancer, 45, 1803–1809. 
https://doi.org/10.1002/cncr.1980.45.s7.1803 
Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P., … 
D’Eustachio, P. (2018). The Reactome Pathway Knowledgebase. Nucleic Acids Research. 
https://doi.org/10.1093/nar/gkx1132 
Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011). miRNAs in human cancer. The 
Journal of Pathology, 223(2), 102–115. https://doi.org/10.1002/path.2806 
Fazi, F., Racanicchi, S., Zardo, G., Starnes, L. M., Mancini, M., Travaglini, L., … Nervi, C. 
(2007). Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the 
AML1/ETO Oncoprotein. Cancer Cell, 12(5), 457–466. 
https://doi.org/10.1016/j.ccr.2007.09.020 
Fazi, F., Rosa, A., Fatica, A., Gelmetti, V., De Marchis, M. L., Nervi, C., & Bozzoni, I. (2005). 
A Minicircuitry Comprised of MicroRNA-223 and Transcription Factors NFI-A and 
C/EBPα Regulates Human Granulopoiesis. Cell, 123(5), 819–831. 
https://doi.org/10.1016/j.cell.2005.09.023 
Fontana, L., Pelosi, E., Greco, P., Racanicchi, S., Testa, U., Liuzzi, F., … Peschle, C. (2007). 
MicroRNAs 17-5p–20a–106a control monocytopoiesis through AML1 targeting and M-
CSF receptor upregulation. Nature Cell Biology, 9(7), 775–787. 
https://doi.org/10.1038/ncb1613 
Fujimoto, T., Miyayama, Y., & Fuyuta, M. (1977). The origin, migration and fine morphology 
of human primordial germ cells. The Anatomical Record, 188(3), 315–329. 
https://doi.org/10.1002/ar.1091880305 
Fujino, Y., Takeishi, S., Nishida, K., Okamoto, K., Muguruma, N., Kimura, T., … Takayama, 
 
T. (2017). Downregulation of microRNA-100/microRNA-125b is associated with lymph 
node metastasis in early colorectal cancer with submucosal invasion. Cancer Science, 
108(3), 390–397. https://doi.org/10.1111/cas.13152 
Fuks, F., Hurd, P. J., Wolf, D., Nan, X., Bird, A. P., & Kouzarides, T. (2003). The methyl-
CpG-binding protein MeCP2 links DNA methylation to histone methylation. Journal of 
Biological Chemistry. https://doi.org/10.1074/jbc.M210256200 
Galluzzi, L., & Kroemer, G. (2008). Necroptosis: A Specialized Pathway of Programmed 
Necrosis. Cell, 135(7), 1161–1163. https://doi.org/10.1016/J.CELL.2008.12.004 
Genovesi, L. A., Anderson, D., Carter, K. W., Giles, K. M., & Dallas, P. B. (2012). 
Identification of suitable endogenous control genes for microRNA expression profiling of 
childhood medulloblastoma and human neural stem cells. BMC Research Notes, 5, 507. 
https://doi.org/10.1186/1756-0500-5-507 
Ghazarian, A. A., Trabert, B., Devesa, S. S., & McGlynn, K. A. (2015a). Recent trends in the 
incidence of testicular germ cell tumors in the United States. Andrology, 3(1), 13–18. 
https://doi.org/10.1111/andr.288 
Ghazarian, A. A., Trabert, B., Devesa, S. S., & McGlynn, K. A. (2015b). Recent trends in the 
incidence of testicular germ cell tumors in the United States. Andrology, 3(1), 13–18. 
https://doi.org/10.1111/andr.288 
Gilam, A., Conde, J., Weissglas-Volkov, D., Oliva, N., Friedman, E., Artzi, N., & Shomron, 
N. (2016). Local microRNA delivery targets Palladin and prevents metastatic breast 
cancer. Nature Communications, 7, 12868. https://doi.org/10.1038/ncomms12868 
Gozuacik, D., Akkoc, Y., Ozturk, D. G., & Kocak, M. (2017). Autophagy-Regulating 
microRNAs and Cancer. Frontiers in Oncology, 7, 65. 
https://doi.org/10.3389/fonc.2017.00065 
Griffiths-Jones, S., Saini, H. K., Van Dongen, S., & Enright, A. J. (2008). miRBase: Tools for 
microRNA genomics. Nucleic Acids Research. https://doi.org/10.1093/nar/gkm952 
Gronbaek, Kirsten Hother, Christoffer Jones, P. A. (2007). Epigenetic changes in cancer. 
APMIS, 115(10), 1039–1059. https://doi.org/10.1111/j.1600-0463.2007.apm_636.xml.x 
Gu, L., Li, H., Chen, L., Ma, X., Gao, Y., Li, X., … Zhang, X. (2015). MicroRNAs as 
prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-
analysis. Oncotarget, 6(32), 32545–32560. https://doi.org/10.18632/oncotarget.5324 
Guillette, L. J., Gross, T. S., Masson, G. R., Matter, J. M., Percival, H. F., Woodward, A. R., 
& Woodward, A. R. (1994). Developmental abnormalities of the gonad and abnormal sex 
hormone concentrations in juvenile alligators from contaminated and control lakes in 
Florida. Environmental Health Perspectives, 102(8), 680–688. Retrieved from 
 
http://www.ncbi.nlm.nih.gov/pubmed/7895709 
Gulyaeva, L. F., & Kushlinskiy, N. E. (2016). Regulatory mechanisms of microRNA 
expression. Journal of Translational Medicine, 14(1), 143. 
https://doi.org/10.1186/s12967-016-0893-x 
Guo, F., Yan, L., Guo, H., Li, L., Hu, B., Zhao, Y., … Qiao, J. (2015). The Transcriptome and 
DNA Methylome Landscapes of Human Primordial Germ Cells. Cell, 161(6), 1437–1452. 
https://doi.org/10.1016/j.cell.2015.05.015 
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010a). Mammalian microRNAs 
predominantly act to decrease target mRNA levels. Nature, 466(7308), 835–840. 
https://doi.org/10.1038/nature09267 
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010b). Mammalian microRNAs 
predominantly act to decrease target mRNA levels. Nature, 466(7308), 835–840. 
https://doi.org/10.1038/nature09267 
Guo, Q., Zhang, J., Li, J., Zou, L., Zhang, J., Xie, Z., … Wu, Y. (2013). Forced miR-146a 
expression causes autoimmune lymphoproliferative syndrome in mice via downregulation 
of Fas in germinal center B cells. Blood, 121(24), 4875–4883. 
https://doi.org/10.1182/blood-2012-08-452425 
Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews Molecular 
Cell Biology, 15(8), 509–524. https://doi.org/10.1038/nrm3838 
Han, H., Sun, D., Li, W., Shen, H., Zhu, Y., Li, C., … Li, Y. (2013). A c-Myc-MicroRNA 
functional feedback loop affects hepatocarcinogenesis. Hepatology, 57(6), 2378–2389. 
https://doi.org/10.1002/hep.26302 
Hardell, L., van Bavel, B., Lindström, G., Carlberg, M., Dreifaldt, A. C., Wijkström, H., … 
Kolmert, T. (2003). Increased concentrations of polychlorinated biphenyls, 
hexachlorobenzene, and chlordanes in mothers of men with testicular cancer. 
Environmental Health Perspectives, 111(7), 930–934. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12782494 
Harrington, C. T., Lin, E. I., Olson, M. T., & Eshleman, J. R. (2013). Fundamentals of 
Pyrosequencing. Archives of Pathology & Laboratory Medicine, 137(9), 1296–1303. 
https://doi.org/10.5858/arpa.2012-0463-RA 
Hata, A., & Kashima, R. (2016). Dysregulation of microRNA biogenesis machinery in cancer. 
Critical Reviews in Biochemistry and Molecular Biology, 51(3), 121–134. 
https://doi.org/10.3109/10409238.2015.1117054 
Haugnes, H. S., Bosl, G. J., Boer, H., Gietema, J. A., Brydøy, M., Oldenburg, J., … Fosså, S. 
D. (2012). Long-term and late effects of germ cell testicular cancer treatment and 
 
implications for follow-up. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, 30(30), 3752–3763. 
https://doi.org/10.1200/JCO.2012.43.4431 
Haugnes, H. S., Wethal, T., Aass, N., Dahl, O., Klepp, O., Langberg, C. W., … Fosså, S. D. 
(2010). Cardiovascular risk factors and morbidity in long-term survivors of testicular 
cancer: a 20-year follow-up study. Journal of Clinical Oncology : Official Journal of the 
American Society of Clinical Oncology, 28(30), 4649–4657. 
https://doi.org/10.1200/JCO.2010.29.9362 
Hausser, J., Syed, A. P., Bilen, B., & Zavolan, M. (2013). Analysis of CDS-located miRNA 
target sites suggests that they can effectively inhibit translation. Genome Research, 23(4), 
604–615. https://doi.org/10.1101/gr.139758.112 
Hayashita, Y., Osada, H., Tatematsu, Y., Yamada, H., Yanagisawa, K., Tomida, S., … 
Takahashi, T. (2005). A Polycistronic MicroRNA Cluster, miR-17-92 , Is Overexpressed 
in Human Lung Cancers and Enhances Cell Proliferation. Cancer Research, 65(21), 
9628–9632. https://doi.org/10.1158/0008-5472.CAN-05-2352 
He, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., … Lin, J.-S. (2012). 
MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer 
cell growth in vitro and in vivo. Oncogene, 31(28), 3357–3369. 
https://doi.org/10.1038/onc.2011.500 
Heifetz, S. A., Cushing, B., Giller, R., Shuster, J. J., Stolar, C. J., Vinocur, C. D., & Hawkins, 
E. P. (1998). Immature teratomas in children: pathologic considerations: a report from the 
combined Pediatric Oncology Group/Children’s Cancer Group. The American Journal of 
Surgical Pathology, 22(9), 1115–1124. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9737245 
Henson, B. J., Bhattacharjee, S., O’Dee, D. M., Feingold, E., & Gollin, S. M. (2009). Decreased 
expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. 
Genes, Chromosomes and Cancer, 48(7), 569–582. https://doi.org/10.1002/gcc.20666 
Heo, I., Joo, C., Kim, Y.-K., Ha, M., Yoon, M.-J., Cho, J., … Kim, V. N. (2009). TUT4 in 
concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. 
Cell, 138(4), 696–708. https://doi.org/10.1016/j.cell.2009.08.002 
Hermeking, H. (2010). The miR-34 family in cancer and apoptosis. Cell Death & 
Differentiation, 17(2), 193–199. https://doi.org/10.1038/cdd.2009.56 
Herrington, C. S. (1999). Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and 
Broad Ligament. Atlas of Tumor Pathology. Third Series, Fascicle 23 Robert E. Scully, 
Robert H. Young and Philip B. Clement. Armed Forces Institute of Pathology, 
Washington, DC, 1998. No. of pages: 527. Price: $95.00. ISBN: 1 881041 43 3. The 
 
Journal of Pathology, 189(1), 145–145. https://doi.org/10.1002/(SICI)1096-
9896(199909)189:1<145::AID-PATH420>3.0.CO;2-F 
Höbel, S., & Aigner, A. (2013). Polyethylenimines for siRNA and miRNA delivery in vivo. 
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 5(5), 484–501. 
https://doi.org/10.1002/wnan.1228 
Hochstetter, A. R., & Hedinger, C. E. (1982). The differential diagnosis of testicular germ cell 
tumors in theory and practice. Virchows Archiv A Pathological Anatomy and Histology, 
396(3), 247–277. https://doi.org/10.1007/BF00431386 
Hoffman, B., & Liebermann, D. A. (2008). Apoptotic signaling by c-MYC. Oncogene, 27(50), 
6462–6472. https://doi.org/10.1038/onc.2008.312 
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., … Tschopp, J. (2000). 
Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase 
RIP as effector molecule. Nature Immunology, 1(6), 489–495. 
https://doi.org/10.1038/82732 
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., … Horwich, 
A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, 
treatment and follow-up. Annals of Oncology, 29(8), 1658–1686. 
https://doi.org/10.1093/annonc/mdy217 
Honecker, F., Stoop, H., Mayer, F., Bokemeyer, C., Castrillon, D. H., Lau, Y.-F. C., … 
Oosterhuis, J. W. (2006). Germ cell lineage differentiation in non-seminomatous germ 
cell tumours. The Journal of Pathology, 208(3), 395–400. 
https://doi.org/10.1002/path.1872 
Honorio, S., Agathanggelou, A., Wernert, N., Rothe, M., Maher, E. R., & Latif, F. (2003). 
Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular 
tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ 
cell tumours. Oncogene, 22(3), 461–466. https://doi.org/10.1038/sj.onc.1206119 
Horwich, A., Nicol, D., & Huddart, R. (2013). Testicular germ cell tumours. BMJ (Clinical 
Research Ed.), 347, f5526. https://doi.org/10.1136/BMJ.F5526 
Huang, G., Nishimoto, K., Zhou, Z., Hughes, D., & Kleinerman, E. S. (2012). miR-20a 
Encoded by the miR-17-92 Cluster Increases the Metastatic Potential of Osteosarcoma 
Cells by Regulating Fas Expression. Cancer Research, 72(4), 908–916. 
https://doi.org/10.1158/0008-5472.CAN-11-1460 
Huebner, R. J., & Todaro, G. J. (1969). Oncogenes of RNA tumor viruses as determinants of 
cancer. Proceedings of the National Academy of Sciences of the United States of America, 
64(3), 1087–1094. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/5264139 
 
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. 
(2011). MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a 
model of colon carcinoma. Cancer Research, 71(15), 5214–5224. 
https://doi.org/10.1158/0008-5472.CAN-10-4645 
Ioka, A., Tsukuma, H., Ajiki, W., & Oshima, A. (2003). Ovarian cancer incidence and survival 
by histologic type in Osaka, Japan. Cancer Science, 94(3), 292–296. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12824924 
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., … Croce, C. M. 
(2005). MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer 
Research, 65(16), 7065–7070. https://doi.org/10.1158/0008-5472.CAN-05-1783 
Iwakawa, H.-O., & Tomari, Y. (2015). The Functions of MicroRNAs: mRNA Decay and 
Translational Repression. Trends in Cell Biology, 25, 651–665. 
https://doi.org/10.1016/j.tcb.2015.07.011 
Jeyapalan, J. N., Noor, D. A. M., Lee, S.-H., Tan, C. L., Appleby, V. A., Kilday, J. P., … 
Scotting, P. J. (2011). Methylator phenotype of malignant germ cell tumours in children 
identifies strong candidates for chemotherapy resistance. British Journal of Cancer, 
105(4), 575–585. https://doi.org/10.1038/bjc.2011.218 
Jia, H.-Y., Wang, Y.-X., Yan, W.-T., Li, H.-Y., Tian, Y.-Z., Wang, S.-M., & Zhao, H.-L. 
(2012). MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma 
Cells. International Journal of Molecular Sciences, 13(7), 8762–8774. 
https://doi.org/10.3390/ijms13078762 
Jiang, Q., He, M., Guan, S., Ma, M., Wu, H., Yu, Z., … Wei, M. (2016). MicroRNA-100 
suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and 
inhibiting Wnt/β-catenin signaling pathway. Tumor Biology, 37(4), 5001–5011. 
https://doi.org/10.1007/s13277-015-4342-x 
Jin, H. Y., Gonzalez-Martin, A., Miletic, A. V, Lai, M., Knight, S., Sabouri-Ghomi, M., … 
Xiao, C. (2015). Transfection of microRNA Mimics Should Be Used with Caution. 
Frontiers in Genetics, 6, 340. https://doi.org/10.3389/fgene.2015.00340 
Jin, L., Zhang, Z., Li, Y., He, T., Hu, J., Liu, J., … Lai, Y. (2017). miR-125b is associated with 
renal cell carcinoma cell migration, invasion and apoptosis. Oncology Letters, 13(6), 
4512–4520. https://doi.org/10.3892/ol.2017.5985 
Johnson, C. D., Esquela-Kerscher, A., Stefani, G., Byrom, M., Kelnar, K., Ovcharenko, D., … 
Slack, F. J. (2007). The let-7 MicroRNA Represses Cell Proliferation Pathways in Human 
Cells. Cancer Research, 67(16), 7713–7722. https://doi.org/10.1158/0008-5472.CAN-
07-1083 
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., … Slack, F. J. 
 
(2005). RAS Is Regulated by the let-7 MicroRNA Family. Cell, 120(5), 635–647. 
https://doi.org/10.1016/j.cell.2005.01.014 
Jonas, S., & Izaurralde, E. (2013). The role of disordered protein regions in the assembly of 
decapping complexes and RNP granules. Genes & Development, 27(24), 2628–2641. 
https://doi.org/10.1101/gad.227843.113 
Jones, P. A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and 
beyond. Nature Reviews Genetics, 13(7), 484–492. https://doi.org/10.1038/nrg3230 
Kaatsch, P., Häfner, C., Calaminus, G., Blettner, M., & Tulla, M. (2015). Pediatric germ cell 
tumors from 1987 to 2011: incidence rates, time trends, and survival. Pediatrics, 135(1), 
e136-43. https://doi.org/10.1542/peds.2014-1989 
Kandori, S., Kawai, K., Fukuhara, Y., Joraku, A., Miyanaga, N., Shimazui, T., & Akaza, H. 
(2010). A case of metastatic testicular cancer complicated by pulmonary hemorrhage due 
to choriocarcinoma syndrome. International Journal of Clinical Oncology, 15(6), 611–
614. https://doi.org/10.1007/s10147-010-0092-3 
Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic 
Acids Research, 28(1), 27–30. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10592173 
Kao, C.-S., Idrees, M. T., Young, R. H., & Ulbright, T. M. (2012). Solid Pattern Yolk Sac 
Tumor. The American Journal of Surgical Pathology, 36(3), 360–367. 
https://doi.org/10.1097/PAS.0b013e31823c510b 
Katsube, Y., Berg, J. W., & Silverberg, S. G. (1982). Epidemiologic pathology of ovarian 
tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver 
Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 
December 1979. International Journal of Gynecological Pathology : Official Journal of 
the International Society of Gynecological Pathologists, 1(1), 3–16. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/7184889 
Kim, K. H., & Lee, M.-S. (2014). Autophagy—a key player in cellular and body metabolism. 
Nature Reviews Endocrinology, 10(6), 322–337. https://doi.org/10.1038/nrendo.2014.35 
Kim, V. N., Han, J., & Siomi, M. C. (2009). Biogenesis of small RNAs in animals. Nature 
Reviews Molecular Cell Biology, 10(2), 126–139. https://doi.org/10.1038/nrm2632 
Kimmins, S., & Sassone-Corsi, P. (2005). Chromatin remodelling and epigenetic features of 
germ cells. Nature, 434(7033), 583–589. https://doi.org/10.1038/nature03368 
Klein, U., Lia, M., Crespo, M., Siegel, R., Shen, Q., Mo, T., … Dalla-Favera, R. (2010). The 
DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to 
Chronic Lymphocytic Leukemia. Cancer Cell, 17(1), 28–40. 
 
https://doi.org/10.1016/j.ccr.2009.11.019 
Kloosterman, W. P., & Hochstenbach, R. (2014). Deciphering the pathogenic consequences of 
chromosomal aberrations in human genetic disease. Molecular Cytogenetics, 7(1), 100. 
https://doi.org/10.1186/s13039-014-0100-9 
Kollmannsberger, C., Kuzcyk, M., Mayer, F., Hartmann, J. T., Kanz, L., & Bokemeyer, C. 
(1999). Late toxicity following curative treatment of testicular cancer. Seminars in 
Surgical Oncology, 17(4), 275–281. 
Korkola, J. E., Houldsworth, J., Chadalavada, R. S. V, Olshen, A. B., Dobrzynski, D., Reuter, 
V. E., … Chaganti, R. S. K. (2006). Down-regulation of stem cell genes, including those 
in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human 
male germ cell tumors. Cancer Research, 66(2), 820–827. https://doi.org/10.1158/0008-
5472.CAN-05-2445 
Koster, R., Mitra, N., D’Andrea, K., Vardhanabhuti, S., Chung, C. C., Wang, Z., … Kanetsky, 
P. A. (2014). Pathway-based analysis of GWAs data identifies association of sex 
determination genes with susceptibility to testicular germ cell tumors. Human Molecular 
Genetics, 23(22), 6061–6068. https://doi.org/10.1093/hmg/ddu305 
Kota, J., Chivukula, R. R., O’Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-
W., … Mendell, J. T. (2009). Therapeutic microRNA delivery suppresses tumorigenesis 
in a murine liver cancer model. Cell, 137(6), 1005–1017. 
https://doi.org/10.1016/j.cell.2009.04.021 
Koul, S., Houldsworth, J., Mansukhani, M. M., Donadio, A., McKiernan, J. M., Reuter, V. E., 
… Murty, V. V. (2002). Characteristic promoter hypermethylation signatures in male 
germ cell tumors. Molecular Cancer, 1, 8. https://doi.org/10.1186/1476-4598-1-8 
Kraggerud, S. M., Skotheim, R. I., Szymanska, J., Eknaes, M., Fosså, S. D., Stenwig, A. E., … 
Lothe, R. A. (2002). Genome profiles of familial/bilateral and sporadic testicular germ 
cell tumors. Genes, Chromosomes and Cancer, 34(2), 168–174. 
https://doi.org/10.1002/gcc.10058 
Krakauer, D. C., & Plotkin, J. B. (2002). Redundancy, antiredundancy, and the robustness of 
genomes. Proceedings of the National Academy of Sciences of the United States of 
America, 99(3), 1405–1409. https://doi.org/10.1073/pnas.032668599 
Kristensen, D. G., Skakkebaek, N. E., Rajpert-De Meyts, E., & Almstrup, K. (2013). Epigenetic 
features of testicular germ cell tumours in relation to epigenetic characteristics of foetal 
germ cells. The International Journal of Developmental Biology, 57(2–4), 309–317. 
https://doi.org/10.1387/ijdb.130142ka 
Kristensen, D. G., Skakkebk, N. E., Rajpert-De Meyts, E., & Almstrup, K. (2013). Epigenetic 
features of testicular germ cell tumours in relation to epigenetic characteristics of foetal 
 
germ cells. The International Journal of Developmental Biology, 57(2-3–4), 309–317. 
https://doi.org/10.1387/ijdb.130142ka 
Kroemer, G., Mariño, G., & Levine, B. (2010). Autophagy and the Integrated Stress Response. 
Molecular Cell, 40(2), 280–293. https://doi.org/10.1016/J.MOLCEL.2010.09.023 
Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA 
biogenesis, function and decay. https://doi.org/10.1038/nrg2843 
Kuersten, S., Radek, A., Vogel, C., & Penalva, L. O. F. (2013). Translation regulation gets its 
“omics” moment. Wiley Interdisciplinary Reviews. RNA, 4(6), 617–630. 
https://doi.org/10.1002/wrna.1173 
Kumar, M. S., Erkeland, S. J., Pester, R. E., Chen, C. Y., Ebert, M. S., Sharp, P. A., & Jacks, 
T. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA 
family. Proceedings of the National Academy of Sciences of the United States of America, 
105(10), 3903–3908. https://doi.org/10.1073/pnas.0712321105 
Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R., & Jacks, T. (2007). Impaired microRNA 
processing enhances cellular transformation and tumorigenesis. Nature Genetics, 39(5), 
673–677. https://doi.org/10.1038/ng2003 
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., 
… Orum, H. (2010). Therapeutic Silencing of MicroRNA-122 in Primates with Chronic 
Hepatitis C Virus Infection. Science, 327(5962), 198–201. 
https://doi.org/10.1126/science.1178178 
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 843–854. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8252621 
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., … Kim, V. N. (2003). The nuclear RNase 
III Drosha initiates microRNA processing. Nature, 425(6956), 415–419. 
https://doi.org/10.1038/nature01957 
Lee, Y., Jeon, K., Lee, J.-T., Kim, S., & Kim, V. N. (2002). MicroRNA maturation: stepwise 
processing and subcellular localization. The EMBO Journal, 21(17), 4663–4670. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12198168 
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005a). Conserved Seed Pairing, Often Flanked by 
Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets. Cell, 
120(1), 15–20. https://doi.org/10.1016/j.cell.2004.12.035 
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005b). Conserved Seed Pairing, Often Flanked by 
Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets. Cell, 
120(1), 15–20. https://doi.org/10.1016/j.cell.2004.12.035 
 
Li, D., Liu, X., Lin, L., Hou, J., Li, N., Wang, C., … Cao, X. (2011). MicroRNA-99a inhibits 
hepatocellular carcinoma growth and correlates with prognosis of patients with 
hepatocellular carcinoma. The Journal of Biological Chemistry, 286(42), 36677–36685. 
https://doi.org/10.1074/jbc.M111.270561 
Li, H., Rauch, T., Chen, Z. X., Szabó, P. E., Riggs, A. D., & Pfeifer, G. P. (2006). The histone 
methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly 
and localize to promoters silenced in cancer cells. Journal of Biological Chemistry. 
https://doi.org/10.1074/jbc.M513249200 
Li, L.-C., & Dahiya, R. (2002). MethPrimer: designing primers for methylation PCRs. 
Bioinformatics (Oxford, England), 18(11), 1427–1431. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12424112 
Li, Y., Wang, Y., Fan, H., Zhang, Z., & Li, N. (2018). miR-125b-5p inhibits breast cancer cell 
proliferation, migration and invasion by targeting KIAA1522. Biochemical and 
Biophysical Research Communications, 504(1), 277–282. 
https://doi.org/10.1016/j.bbrc.2018.08.172 
Li, Z., Huang, H., Chen, P., He, M., Li, Y., Arnovitz, S., … Chen, J. (2011). miR-196b directly 
targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged 
leukaemia. Nature Communications, 2(1), 688. https://doi.org/10.1038/ncomms1681 
Li, Z., Owonikoko, T. K., Sun, S.-Y., Ramalingam, S. S., Doetsch, P. W., Xiao, Z.-Q., … Deng, 
X. (2012). c-Myc suppression of DNA double-strand break repair. Neoplasia (New York, 
N.Y.), 14(12), 1190–1202. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/23308051 
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., … Johnson, 
J. M. (2005). Microarray analysis shows that some microRNAs downregulate large 
numbers of target mRNAs. Nature, 433(7027), 769–773. 
https://doi.org/10.1038/nature03315 
Lin, K.-Y., Zhang, X.-J., Feng, D.-D., Zhang, H., Zeng, C.-W., Han, B.-W., … Chen, Y.-Q. 
(2011). miR-125b, a target of CDX2, regulates cell differentiation through repression of 
the core binding factor in hematopoietic malignancies. The Journal of Biological 
Chemistry, 286(44), 38253–38263. https://doi.org/10.1074/jbc.M111.269670 
Lin, R.-J., Lin, Y.-C., Chen, J., Kuo, H.-H., Chen, Y.-Y., Diccianni, M. B., … Yu, A. L. (2010). 
microRNA Signature and Expression of Dicer and Drosha Can Predict Prognosis and 
Delineate Risk Groups in Neuroblastoma. Cancer Research, 70(20), 7841–7850. 
https://doi.org/10.1158/0008-5472.CAN-10-0970 
Lind, G. E., Skotheim, R. I., & Lothe, R. a. (2007). The epigenome of testicular germ cell 
tumors. APMIS : Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 
 
https://doi.org/10.1111/j.1600-0463.2007.apm_660.xml.x 
Lindow, M., & Kauppinen, S. (2012). Discovering the first microRNA-targeted drug. The 
Journal of Cell Biology, 199(3), 407–412. https://doi.org/10.1083/jcb.201208082 
Linsley, P. S., Schelter, J., Burchard, J., Kibukawa, M., Martin, M. M., Bartz, S. R., … Lim, 
L. (2007). Transcripts targeted by the microRNA-16 family cooperatively regulate cell 
cycle progression. Molecular and Cellular Biology, 27(6), 2240–2252. 
https://doi.org/10.1128/MCB.02005-06 
Livak, K. J., & Schmittgen, T. D. (2001). Analysis of Relative Gene Expression Data Using 
Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods, 25(4), 402–408. 
https://doi.org/10.1006/meth.2001.1262 
Loedige, I., Gaidatzis, D., Sack, R., Meister, G., & Filipowicz, W. (2013). The mammalian 
TRIM-NHL protein TRIM71/LIN-41 is a repressor of mRNA function. Nucleic Acids 
Research, 41(1), 518–532. https://doi.org/10.1093/nar/gks1032 
Loginov, V. I., Rykov, S. V., Fridman, M. V., & Braga, E. A. (2015). Methylation of miRNA 
genes and oncogenesis. Biochemistry (Moscow), 80(2), 145–162. 
https://doi.org/10.1134/S0006297915020029 
Looijenga, L. H. (2009). Human testicular (non)seminomatous germ cell tumours: the clinical 
implications of recent pathobiological insights. The Journal of Pathology, 218(2), 146–
162. https://doi.org/10.1002/path.2522 
Looijenga, L. H., Gillis, A. J., Van Putten, W. L., & Oosterhuis, J. W. (1993). In situ numeric 
analysis of centromeric regions of chromosomes 1, 12, and 15 of seminomas, 
nonseminomatous germ cell tumors, and carcinoma in situ of human testis. Laboratory 
Investigation; a Journal of Technical Methods and Pathology, 68(2), 211–219. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/8382754 
Looijenga, L. H. J., Stoop, H., de Leeuw, H. P. J. C., de Gouveia Brazao, C. A., Gillis, A. J. 
M., van Roozendaal, K. E. P., … Oosterhuis, J. W. (2003). POU5F1 (OCT3/4) identifies 
cells with pluripotent potential in human germ cell tumors. Cancer Research, 63(9), 2244–
2250. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12727846 
Lopez-Serra, P., & Esteller, M. (2012). DNA methylation-associated silencing of tumor-
suppressor microRNAs in cancer. Oncogene, 31(13), 1609–1622. 
https://doi.org/10.1038/onc.2011.354 
Lorch, A., Kleinhans, A., Kramar, A., Kollmannsberger, C. K., Hartmann, J. T., Bokemeyer, 
C., … Beyer, J. (2012). Sequential versus single high-dose chemotherapy in patients with 
relapsed or refractory germ cell tumors: long-term results of a prospective randomized 
trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical 
 
Oncology, 30(8), 800–805. https://doi.org/10.1200/JCO.2011.38.6391 
Lorente, A., Mueller, W., Urdangarín, E., Lázcoz, P., von Deimling, A., & Castresana, J. S. 
(2008). Detection of methylation in promoter sequences by melting curve analysis-based 
semiquantitative real time PCR. BMC Cancer, 8, 61. https://doi.org/10.1186/1471-2407-
8-61 
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., … Golub, T. R. (2005). 
MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834–838. 
https://doi.org/10.1038/nature03702 
Lu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., … Coffey, R. J. (2017). lncRNA 
MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-
catenin signaling. Nature Medicine, 23(11), 1331–1341. https://doi.org/10.1038/nm.4424 
Lujambio, A., Ropero, S., Ballestar, E., Fraga, M. F., Cerrato, C., Setien, F., … Esteller, M. 
(2007). Genetic Unmasking of an Epigenetically Silenced microRNA in Human Cancer 
Cells. Cancer Research, 67(4), 1424–1429. https://doi.org/10.1158/0008-5472.CAN-06-
4218 
Luo, Y., Na, Z., & Slavoff, S. A. (2018). P-Bodies: Composition, Properties, and Functions. 
Biochemistry, 57(17), 2424–2431. https://doi.org/10.1021/acs.biochem.7b01162 
Luo, Y., Wang, X., Niu, W., Wang, H., Wen, Q., Fan, S., … Zhou, M. (2017). Elevated 
microRNA-125b levels predict a worse prognosis in HER2-positive breast cancer 
patients. Oncology Letters, 13(2), 867–874. https://doi.org/10.3892/ol.2016.5482 
Lytle, J. R., Yario, T. A., & Steitz, J. A. (2007). Target mRNAs are repressed as efficiently by 
microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proceedings of the National 
Academy of Sciences, 104(23), 9667–9672. https://doi.org/10.1073/pnas.0703820104 
M Dror Michaelson, MD, PhDWilliam K Oh, M. (2018). Epidemiology of and risk factors for 
testicular germ cell tumors - UpToDate. Retrieved September 9, 2018, from 
https://www.uptodate.com/contents/epidemiology-of-and-risk-factors-for-testicular-
germ-cell-tumors#H4 
Malumbres, M., & Barbacid, M. (2001). To cycle or not to cycle: a critical decision in cancer. 
Nature Reviews Cancer, 1(3), 222–231. https://doi.org/10.1038/35106065 
Manecksha, R. P., & Fitzpatrick, J. M. (2009). Epidemiology of testicular cancer. BJU 
International, 104(9b), 1329–1333. https://doi.org/10.1111/j.1464-410X.2009.08854.x 
Mann, J. R., Gray, E. S., Thornton, C., Raafat, F., Robinson, K., Collins, G. S., … UK 
Children’s Cancer Study Group Experience. (2008). Mature and Immature Extracranial 
Teratomas in Children: The UK Children’s Cancer Study Group Experience. Journal of 
Clinical Oncology, 26(21), 3590–3597. https://doi.org/10.1200/JCO.2008.16.0622 
 
Mann, J. R., Raafat, F., Robinson, K., Imeson, J., Gornall, P., Sokal, M., … Oakhill, A. (2000). 
The United Kingdom Children’s Cancer Study Group’s Second Germ Cell Tumor Study: 
Carboplatin, Etoposide, and Bleomycin Are Effective Treatment for Children With 
Malignant Extracranial Germ Cell Tumors, With Acceptable Toxicity. Journal of Clinical 
Oncology, 18(22), 3809–3818. https://doi.org/10.1200/JCO.2000.18.22.3809 
Matsuda, A., Chikashige, Y., Ding, D.-Q., Ohtsuki, C., Mori, C., Asakawa, H., … Hiraoka, Y. 
(2015). Highly condensed chromatins are formed adjacent to subtelomeric and 
decondensed silent chromatin in fission yeast. Nature Communications, 6(1), 7753. 
https://doi.org/10.1038/ncomms8753 
Matsui, Y., & Okamura, D. (2005). Mechanisms of germ-cell specification in mouse embryos. 
BioEssays, 27(2), 136–143. https://doi.org/10.1002/bies.20178 
Mattie, M. D., Benz, C. C., Bowers, J., Sensinger, K., Wong, L., Scott, G. K., … Haqq, C. 
(2006). Optimized high-throughput microRNA expression profiling provides novel 
biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer, 
5(1), 24. https://doi.org/10.1186/1476-4598-5-24 
McCabe, M. T., Brandes, J. C., & Vertino, P. M. (2009). Cancer DNA methylation: molecular 
mechanisms and clinical implications. Clinical Cancer Research : An Official Journal of 
the American Association for Cancer Research, 15(12), 3927–3937. 
https://doi.org/10.1158/1078-0432.CCR-08-2784 
McDougal, W. S. (William S. (2012). Campbell-Walsh urology tenth edition review. 
Elsevier/Saunders. 
McGlynn, K. A., & Cook, M. B. (2009). Etiologic factors in testicular germ-cell tumors. Future 
Oncology, 5(9), 1389–1402. https://doi.org/10.2217/fon.09.116 
McGlynn, K. A., & Trabert, B. (2012). Adolescent and adult risk factors for testicular cancer. 
Nature Reviews Urology, 9(6), 339–349. https://doi.org/10.1038/nrurol.2012.61 
McIntyre, A., Summersgill, B., Lu, Y. J., Missiaglia, E., Kitazawa, S., Oosterhuis, J. W., … 
Shipley, J. (2007). Genomic copy number and expression patterns in testicular germ cell 
tumours. British Journal of Cancer, 97(12), 1707–1712. 
https://doi.org/10.1038/sj.bjc.6604079 
Melo, S. A., Moutinho, C., Ropero, S., Calin, G. A., Rossi, S., Spizzo, R., … Esteller, M. 
(2010). A Genetic Defect in Exportin-5 Traps Precursor MicroRNAs in the Nucleus of 
Cancer Cells. Cancer Cell, 18(4), 303–315. https://doi.org/10.1016/j.ccr.2010.09.007 
Menck, K., Sönmezer, C., Worst, T. S., Schulz, M., Dihazi, G. H., Streit, F., … Gross, J. C. 
(2017). Neutral sphingomyelinases control extracellular vesicles budding from the plasma 
membrane. Journal of Extracellular Vesicles, 6(1), 1378056. 
 
https://doi.org/10.1080/20013078.2017.1378056 
Mestdagh, P., Lefever, S., Pattyn, F., Ridzon, D., Fredlund, E., Fieuw, A., … Vandesompele, 
J. (2011). The microRNA body map: dissecting microRNA function through integrative 
genomics. Nucleic Acids Research, 39(20), e136–e136. 
https://doi.org/10.1093/nar/gkr646 
Milne, T. A., Zhao, K., & Hess, J. L. (2009). Chromatin immunoprecipitation (ChIP) for 
analysis of histone modifications and chromatin-associated proteins. Methods in 
Molecular Biology. https://doi.org/10.1007/978-1-59745-418-6_21 
Mori, N., Yokobori, T., Mimori, K., Sudo, T., Tanaka, F., Shibata, K., … Mori, M. (2011). 
MicroRNA miR-125b is a prognostic marker in human colorectal cancer. International 
Journal of Oncology, 38(5), 1437–1443. https://doi.org/10.3892/ijo.2011.969 
Motzer, R. J., Cooper, K., Geller, N. L., Pfister, D. G., Lin, S. Y., Bajorin, D., … Morse, M. 
(1990). Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell 
tumors. Cancer, 65(11), 2465–2470. 
Mullany, L. E., Herrick, J. S., Wolff, R. K., & Slattery, M. L. (2016). MicroRNA Seed Region 
Length Impact on Target Messenger RNA Expression and Survival in Colorectal Cancer. 
PloS One, 11(4), e0154177. https://doi.org/10.1371/journal.pone.0154177 
Murphy, B. L., Obad, S., Bihannic, L., Ayrault, O., Zindy, F., Kauppinen, S., & Roussel, M. 
F. (2013). Silencing of the miR-17~92 cluster family inhibits medulloblastoma 
progression. Cancer Research, 73(23), 7068–7078. https://doi.org/10.1158/0008-
5472.CAN-13-0927 
Murray, M. J., Bailey, S., Raby, K. L., Saini, H. K., de Kock, L., Burke, G. A. A., … 
Tischkowitz, M. (2014). Serum levels of mature microRNAs in DICER1-mutated 
pleuropulmonary blastoma. Oncogenesis, 3(2), e87–e87. 
https://doi.org/10.1038/oncsis.2014.1 
Murray, M. J., Fern, L. A., Stark, D. P., Eden, T. O., & Nicholson, J. C. (2009). Breaking down 
barriers: improving outcomes for teenagers and young adults with germ cell tumours. 
Oncology Reviews, 3(4), 201–206. https://doi.org/10.1007/s12156-009-0030-7 
Murray, M. J., & Nicholson, J. C. (2010). Germ cell tumours in children and adolescents. 
Paediatrics and Child Health, 20(3), 109–116. 
https://doi.org/10.1016/j.paed.2009.10.006 
Murray, M. J., Nicholson, J. C., & Coleman, N. (2015a). Biology of childhood germ cell 
tumours, focussing on the significance of microRNAs. Andrology, 3(1), 129–139. 
https://doi.org/10.1111/andr.277 
Murray, M. J., Nicholson, J. C., & Coleman, N. (2015b). Biology of childhood germ cell 
 
tumours, focussing on the significance of microRNAs. Andrology, 3(1), 129–139. 
https://doi.org/10.1111/andr.277 
Murray, M. J., Nicholson, J. C., & Coleman, N. (2015c). Biology of childhood germ cell 
tumours, focussing on the significance of microRNAs. Andrology, 3(1), 129–139. 
https://doi.org/10.1111/andr.277 
Murray, M. J., Saini, H. K., Siegler, C. A., Hanning, J. E., Barker, E. M., van Dongen, S., … 
Coleman, N. (2013). LIN28 Expression in malignant germ cell tumors downregulates let-
7 and increases  oncogene levels. Cancer Research, 73(15), 4872–4884. 
https://doi.org/10.1158/0008-5472.CAN-12-2085 
Murray MJ, Fern LA, Stark DP, Eden TO, N. J. (2009). Breaking Down Barriers: Improving 
Outcomes for Teenagers and Young Adults with Germ Cell Tumours. Oncology Reviews, 
3, 201–206. 
Nagaraja, A. K., Creighton, C. J., Yu, Z., Zhu, H., Gunaratne, P. H., Reid, J. G., … Matzuk, 
M. M. (2010). A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer. 
Molecular Endocrinology, 24(2), 447–463. https://doi.org/10.1210/me.2009-0295 
Nettersheim, D., Westernströer, B., Haas, N., Leinhaas, A., Brüstle, O., Schlatt, S., & Schorle, 
H. (2012). Establishment of a versatile seminoma model indicates cellular plasticity of 
germ cell tumor cells. Genes Chromosomes and Cancer. 
https://doi.org/10.1002/gcc.21958 
Niu, M., Dai, X., Zou, W., Yu, X., Teng, W., Chen, Q., … Liu, P. (2017). Autophagy, 
Endoplasmic Reticulum Stress and the Unfolded Protein Response in Intracerebral 
Hemorrhage. Translational Neuroscience, 8, 37–48. https://doi.org/10.1515/tnsci-2017-
0008 
Nonaka, D. (2009). Differential Expression of SOX2 and SOX17 in Testicular Germ Cell 
Tumors. American Journal of Clinical Pathology, 131(5), 731–736. 
https://doi.org/10.1309/AJCP7MNCNBCRN8NO 
Noor, D. A. M., Jeyapalan, J. N., Alhazmi, S., Carr, M., Squibb, B., Wallace, C., … Scotting, 
P. J. (2016). Genome-wide methylation analysis identifies genes silenced in non-
seminoma cell lines. Npj Genomic Medicine, 1(1), 15009. 
https://doi.org/10.1038/npjgenmed.2015.9 
Norbury, C., & Nurse, P. (1992). ANIMAL CELL CYCLES AND THEIR CONTROL. Annu. 
Rev. Biochem (Vol. 61). Retrieved from www.annualreviews.org 
O’Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005). c-Myc-
regulated microRNAs modulate E2F1 expression. Nature, 435(7043), 839–843. 
https://doi.org/10.1038/nature03677 
 
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., … Kauppinen, S. 
(2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nature Genetics, 
43(4), 371–378. https://doi.org/10.1038/ng.786 
Ooi, S. K. T., Qiu, C., Bernstein, E., Li, K., Jia, D., Yang, Z., … Bestor, T. H. (2007). DNMT3L 
connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature. 
https://doi.org/10.1038/nature05987 
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008). MicroRNA-10a Binds the 5ʹ′UTR of 
Ribosomal Protein mRNAs and Enhances Their Translation. Molecular Cell, 30(4), 460–
471. https://doi.org/10.1016/j.molcel.2008.05.001 
Ottaviani, S., Stebbing, J., Frampton, A. E., Zagorac, S., Krell, J., de Giorgio, A., … Castellano, 
L. (2018). TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B 
controlling PDAC progression. Nature Communications, 9(1), 1845. 
https://doi.org/10.1038/s41467-018-03962-x 
Pallesen, G., & Hamilton-Dutoit, S. J. (1988). Ki-1 (CD30) antigen is regularly expressed by 
tumor cells of embryonal carcinoma. The American Journal of Pathology, 133(3), 446–
450. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2849300 
Palmer, R. D., Barbosa-Morais, N. L., Gooding, E. L., Muralidhar, B., Thornton, C. M., Pett, 
M. R., … Children’s Cancer and Leukaemia Group. (2008). Pediatric Malignant Germ 
Cell Tumors Show Characteristic Transcriptome Profiles. Cancer Research, 68(11), 
4239–4247. https://doi.org/10.1158/0008-5472.CAN-07-5560 
Palmer, R. D., Foster, N. A., Vowler, S. L., Roberts, I., Thornton, C. M., Hale, J. P., … 
Coleman, N. (2007). Malignant germ cell tumours of childhood: new associations of 
genomic imbalance. British Journal of Cancer, 96(4), 667–676. 
https://doi.org/10.1038/sj.bjc.6603602 
Palmer, R. D., Murray, M. J., Saini, H. K., van Dongen, S., Abreu-Goodger, C., Muralidhar, 
B., … Coleman, N. (2010). Malignant germ cell tumors display common microRNA 
profiles resulting in global changes in expression of messenger RNA targets. Cancer 
Research, 70(7), 2911–2923. https://doi.org/10.1158/0008-5472.CAN-09-3301 
Pasquinelli, A. E., Reinhart, B. J., Slack, F., Martindale, M. Q., Kuroda, M. I., Maller, B., … 
Ruvkun, G. (2000). Conservation of the sequence and temporal expression of let-7 
heterochronic regulatory RNA. Nature, 408(6808), 86–89. 
https://doi.org/10.1038/35040556 
Patricia M Baker, E. O. (2009). Germ Cell Tumors of the Ovary-Gynecologic Pathology. 
Elsevier. https://doi.org/10.1016/B978-0-443-06920-8.X5001-9 
Pauniaho, S.-L., Salonen, J., Helminen, M., Vettenranta, K., Heikinheimo, M., & Heikinheimo, 
 
O. (2012). The incidences of malignant gonadal and extragonadal germ cell tumors in 
males and females: a population-based study covering over 40 years in Finland. Cancer 
Causes & Control, 23(12), 1921–1927. https://doi.org/10.1007/s10552-012-0069-9 
Peng, Y., & Croce, C. M. (2016). The role of MicroRNAs in human cancer. Signal 
Transduction and Targeted Therapy, 1(1), 15004. https://doi.org/10.1038/sigtrans.2015.4 
Penn, A., Jenney, M. E. M., & Nicholson, J. C. (2014). Germ cell tumours in children and 
adolescents. Paediatrics and Child Health, 24(4), 148–154. 
https://doi.org/10.1016/j.paed.2014.01.003 
Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-
PCR. Nucleic Acids Research, 29(9), e45. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11328886 
Pierson, J., Hostager, B., Fan, R., & Vibhakar, R. (2008). Regulation of cyclin dependent 
kinase 6 by microRNA 124 in medulloblastoma. Journal of Neuro-Oncology, 90(1), 1–7. 
https://doi.org/10.1007/s11060-008-9624-3 
Pigazzi, M., Manara, E., Bresolin, S., Tregnago, C., Beghin, A., Baron, E., … Basso, G. (2013). 
MicroRNA-34b promoter hypermethylation induces CREB overexpression and 
contributes to myeloid transformation. Haematologica, 98(4), 602–610. 
https://doi.org/10.3324/haematol.2012.070664 
Portela, A., & Esteller, M. (2010). Epigenetic modifications and human disease. Nature 
Biotechnology, 28(10), 1057–1068. https://doi.org/10.1038/nbt.1685 
Poulos, C., Cheng, L., Zhang, S., Gersell, D. J., & Ulbright, T. M. (2006). Analysis of ovarian 
teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for 
teratomatous elements. Modern Pathology, 19(6), 766–771. 
https://doi.org/10.1038/modpathol.3800596 
Poynter, J. N., Amatruda, J. F., & Ross, J. A. (2010). Trends in incidence and survival of 
pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. 
Cancer, 116(20), 4882–4891. https://doi.org/10.1002/cncr.25454 
Preusse, M., Theis, F. J., & Mueller, N. S. (2016). miTALOS v2: Analyzing tissue specific 
microRNA function. PLoS ONE. https://doi.org/10.1371/journal.pone.0151771 
Puissegur, M. P., Eichner, R., Quelen, C., Coyaud, E., Mari, B., Lebrigand, K., … Brousset, P. 
(2012). B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a 
is a direct target of the oncomir microRNA-125b in progenitor B-cells. Leukemia, 26(10), 
2224–2232. https://doi.org/10.1038/leu.2012.95 
Qin, C., Huang, R.-Y., & Wang, Z.-X. (2015). Potential role of miR-100 in cancer diagnosis, 
prognosis, and therapy. Tumor Biology, 36(3), 1403–1409. 
 
https://doi.org/10.1007/s13277-015-3267-8 
Qin, D., Wang, X., Li, Y., Yang, L., Wang, R., Peng, J., … Fan, G.-C. (2016). MicroRNA-
223-5p and -3p Cooperatively Suppress Necroptosis in Ischemic/Reperfused Hearts. The 
Journal of Biological Chemistry, 291(38), 20247–20259. 
https://doi.org/10.1074/jbc.M116.732735 
Rabinowits, M., Souhami, L., Gil, R. A., Andrade, C. A., & Paiva, H. C. (1990). Increased 
pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations. American 
Journal of Clinical Oncology, 13(2), 132–138. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/1690503 
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011). 
A unique chromatin signature uncovers early developmental enhancers in humans. 
Nature, 470(7333), 279–283. https://doi.org/10.1038/nature09692 
Ramassone, A., Pagotto, S., Veronese, A., & Visone, R. (2018). Epigenetics and MicroRNAs 
in Cancer. International Journal of Molecular Sciences, 19(2), 459. 
https://doi.org/10.3390/ijms19020459 
Rashid, H.-O., Yadav, R. K., Kim, H.-R., & Chae, H.-J. (2015). ER stress: Autophagy 
induction, inhibition and selection. Autophagy, 11(11), 1956–1977. 
https://doi.org/10.1080/15548627.2015.1091141 
Reid, G., Kao, S. C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., … van 
Zandwijk, N. (2016). Clinical development of TargomiRs, a miRNA mimic-based 
treatment for patients with recurrent thoracic cancer. Epigenomics, 8(8), 1079–1085. 
https://doi.org/10.2217/epi-2016-0035 
Reid, G., Pel, M. E., Kirschner, M. B., Cheng, Y. Y., Mugridge, N., Weiss, J., … van Zandwijk, 
N. (2013). Restoring expression of miR-16: a novel approach to therapy for malignant 
pleural mesothelioma. Annals of Oncology : Official Journal of the European Society for 
Medical Oncology / ESMO, 24(12), 3128–3135. https://doi.org/10.1093/annonc/mdt412 
Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E., Bettinger, J. C., Rougvie, A. E., … 
Ruvkun, G. (2000). The 21-nucleotide let-7 RNA regulates developmental timing in 
Caenorhabditis elegans. Nature, 403(6772), 901–906. https://doi.org/10.1038/35002607 
Richiardi, L., Bellocco, R., Adami, H.-O., Torrång, A., Barlow, L., Hakulinen, T., … Akre, O. 
(2004). Testicular cancer incidence in eight northern European countries: secular and 
recent trends. Cancer Epidemiology, Biomarkers & Prevention : A Publication of the 
American Association for Cancer Research, Cosponsored by the American Society of 
Preventive Oncology, 13(12), 2157–2166. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/15598775 
 
Rijlaarsdam, M. A., Tax, D. M. J., Gillis, A. J. M., Dorssers, L. C. J., Koestler, D. C., de Ridder, 
J., & Looijenga, L. H. J. (2015). Genome wide DNA methylation profiles provide clues 
to the origin and pathogenesis of germ cell tumors. PloS One, 10(4), e0122146. 
https://doi.org/10.1371/journal.pone.0122146 
Rio, D. C., Ares, M., Hannon, G. J., & Nilsen, T. W. (2010). Purification of RNA using TRIzol 
(TRI reagent). Cold Spring Harb Protoc, 2010(6), pdb.prot5439. 
https://doi.org/10.1101/pdb.prot5439 
Ririe, K. M., Rasmussen, R. P., & Wittwer, C. T. (1997). Product Differentiation by Analysis 
of DNA Melting Curves during the Polymerase Chain Reaction. Analytical Biochemistry, 
245(2), 154–160. https://doi.org/10.1006/abio.1996.9916 
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015). 
limma powers differential expression analyses for RNA-sequencing and microarray 
studies. Nucleic Acids Research, 43(7), e47–e47. https://doi.org/10.1093/nar/gkv007 
Rivas, F. V, Tolia, N. H., Song, J.-J., Aragon, J. P., Liu, J., Hannon, G. J., & Joshua-Tor, L. 
(2005). Purified Argonaute2 and an siRNA form recombinant human RISC. Nature 
Structural & Molecular Biology, 12(4), 340–349. https://doi.org/10.1038/nsmb918 
Roberts, A. P. E., Lewis, A. P., & Jopling, C. L. (2011). miR-122 activates hepatitis C virus 
translation by a specialized mechanism requiring particular RNA components. Nucleic 
Acids Research, 39(17), 7716–7729. https://doi.org/10.1093/nar/gkr426 
Roden, C., Gaillard, J., Kanoria, S., Rennie, W., Barish, S., Cheng, J., … Lu, J. (2017). Novel 
determinants of mammalian primary microRNA processing revealed by systematic 
evaluation of hairpin-containing transcripts and human genetic variation. Genome 
Research, 27(3), 374–384. https://doi.org/10.1101/gr.208900.116 
Rodriguez, S., Jafer, O., Goker, H., Summersgill, B. M., Zafarana, G., Gillis, A. J. M., … 
Shipley, J. M. (2003). Expression profile of genes from 12p in testicular germ cell tumors 
of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. 
Oncogene, 22(12), 1880–1891. https://doi.org/10.1038/sj.onc.1206302 
Rosa, A., Ballarino, M., Sorrentino, A., Sthandier, O., De Angelis, F. G., Marchioni, M., … 
Bozzoni, I. (2007). The interplay between the master transcription factor PU.1 and miR-
424 regulates human monocyte/macrophage differentiation. Proceedings of the National 
Academy of Sciences of the United States of America, 104(50), 19849–19854. 
https://doi.org/10.1073/pnas.0706963104 
Rose, N. R., & Klose, R. J. (2014). Understanding the relationship between DNA methylation 
and histone lysine methylation. Biochimica et Biophysica Acta - Gene Regulatory 
Mechanisms. https://doi.org/10.1016/j.bbagrm.2014.02.007 
Rosen, A., Jayram, G., Drazer, M., & Eggener, S. E. (2011). Global Trends in Testicular Cancer 
 
Incidence and Mortality. European Urology, 60(2), 374–379. 
https://doi.org/10.1016/j.eururo.2011.05.004 
Ruby, J. G., Jan, C. H., & Bartel, D. P. (2007). Intronic microRNA precursors that bypass 
Drosha processing. Nature, 448(7149), 83–86. https://doi.org/10.1038/nature05983 
Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016). miRNA 
Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discovery, 6(3), 
235–246. https://doi.org/10.1158/2159-8290.CD-15-0893 
Sacconi, A., Biagioni, F., Canu, V., Mori, F., Di Benedetto, A., Lorenzon, L., … Blandino, G. 
(2012). miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. 
Cell Death & Disease, 3(11), e423. https://doi.org/10.1038/cddis.2012.160 
Saito, Y., & Jones, P. M. (2006). Epigenetic Activation of Tumor Suppressor MicroRNAs in 
Human Cancer Cells. Cell Cycle, 5(19), 2220–2222. https://doi.org/10.4161/cc.5.19.3340 
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. 
(2006a). Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 9(6), 
435–443. https://doi.org/10.1016/j.ccr.2006.04.020 
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. 
(2006b). Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 9(6), 
435–443. https://doi.org/10.1016/J.CCR.2006.04.020 
Sakai, E., Miura, Y., Suzuki-Kouyama, E., Oka, K., Tachibana, M., Kawabata, K., … 
Mizuguchi, H. (2017). A mammalian mirtron miR-1224 promotes tube-formation of 
human primary endothelial cells by targeting anti-angiogenic factor epsin2. Scientific 
Reports, 7(1), 5541. https://doi.org/10.1038/s41598-017-05782-3 
Saltzman, A. F., & Cost, N. G. (2018). Adolescent and Young Adult Testicular Germ Cell 
Tumors: Special Considerations. Advances in Urology, 2018, 1–8. 
https://doi.org/10.1155/2018/2375176 
Samuel, P., Mulcahy, L. A., Furlong, F., McCarthy, H. O., Brooks, S. A., Fabbri, M., … Carter, 
D. R. F. (2018). Cisplatin induces the release of extracellular vesicles from ovarian cancer 
cells that can induce invasiveness and drug resistance in bystander cells. Philosophical 
Transactions of the Royal Society B: Biological Sciences, 373(1737), 20170065. 
https://doi.org/10.1098/rstb.2017.0065 
Sanger, F., & Coulson, A. R. (1975). A rapid method for determining sequences in DNA by 
primed synthesis with DNA polymerase. Journal of Molecular Biology, 94(3), 441–448. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1100841 
 
Sarraf, S. A., & Stancheva, I. (2004). Methyl-CpG binding protein MBD1 couples histone H3 
methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. 
Molecular Cell. https://doi.org/10.1016/j.molcel.2004.06.043 
Sasidharan Nair, V., El Salhat, H., Taha, R. Z., John, A., Ali, B. R., & Elkord, E. (2018). DNA 
methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of 
PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer. 
Clinical Epigenetics. https://doi.org/10.1186/s13148-018-0512-1 
Sax, K., & Enzmann, E. V. (1939). The Effect of Temperature on X-Ray Induced Chromosome 
Aberrations. Proceedings of the National Academy of Sciences of the United States of 
America, 25(8), 397–405. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/16577923 
Schabel, F. M., Trader, M. W., Laster, W. R., Corbett, T. H., & Griswold, D. P. (1979). cis-
Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies 
with tumors of mice. Undefined. Retrieved from 
https://www.semanticscholar.org/paper/cis-Dichlorodiammineplatinum(II)%3A-
combination-and-Schabel-Trader/4c22a17b6f66012815be161945eba4bca70e4e84 
Schonberger, S., Okpanyi, V., Alemazkour, K., Looijenga, L. H. J., Nicholson, J., Borkhardt, 
A., & Schneider, D. T. (2010). Extracellular regulators of the Wnt signaling pathway in 
childhood germ cell tumors: Methylation of the SFRP2 promoter leads to Wnt activation 
and beta-catenin accumulation. Pediatric Blood & Cancer. 
Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., … Jenuwein, T. 
(2004). A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive 
heterochromatin. Genes & Development, 18(11), 1251–1262. 
https://doi.org/10.1101/gad.300704 
Schwarzenbach, H., da Silva, A. M., Calin, G., & Pantel, K. (2015). Data Normalization 
Strategies for MicroRNA Quantification. Clinical Chemistry, 61(11), 1333–1342. 
https://doi.org/10.1373/clinchem.2015.239459 
Scott, G. K., Goga, A., Bhaumik, D., Berger, C. E., Sullivan, C. S., & Benz, C. C. (2007). 
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA 
miR-125a or miR-125b. Journal of Biological Chemistry, 282(2), 1479–1486. 
https://doi.org/10.1074/jbc.M609383200 
Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008). 
Widespread changes in protein synthesis induced by microRNAs. Nature, 455(7209), 58–
63. https://doi.org/10.1038/nature07228 
Shen, H., Shih, J., Hollern, D. P., Wang, L., Bowlby, R., Tickoo, S. K., … Hoadley, K. A. 
(2018). Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell 
 
Reports, 23(11), 3392–3406. https://doi.org/10.1016/j.celrep.2018.05.039 
Shi, L., Zhang, J., Pan, T., Zhou, J., Gong, W., Liu, N., … You, Y. (2010). MiR-125b is critical 
for the suppression of human U251 glioma stem cell proliferation. Brain Research, 1312, 
120–126. https://doi.org/10.1016/J.BRAINRES.2009.11.056 
Sievers, S., Alemazkour, K., Zahn, S., Perlman, E. J., Gillis, A. J. M., Looijenga, L. H. J., … 
Schneider, D. T. (2005). IGF2/H19 imprinting analysis of human germ cell tumors 
(GCTs) using the methylation-sensitive single-nucleotide primer extension method 
reflects the origin of GCTs in different stages of primordial germ cell development. Genes 
Chromosomes and Cancer. https://doi.org/10.1002/gcc.20237 
Slap, G. B., Lehmann, C., & Biro, F. M. (2008). Testicular and Scrotal Disorders. Adolescent 
Medicine, 140–145. https://doi.org/10.1016/B978-032304073-0.10020-2 
Smiraglia, D. J., Rush, L. J., Frühwald, M. C., Dai, Z., Held, W. a, Costello, J. F., … Plass, C. 
(2001). Excessive CpG island hypermethylation in cancer cell lines versus primary human 
malignancies. Human Molecular Genetics. https://doi.org/10.1093/hmg/10.13.1413 
Smiraglia, D. J., Szymanska, J., Kraggerud, S. M., Lothe, R. A., Peltomäki, P., & Plass, C. 
(2002). Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular 
germ cell tumors. Oncogene, 21(24), 3909–3916. https://doi.org/10.1038/sj.onc.1205488 
Smith-Sørensen, B., Lind, G. E., Skotheim, R. I., Fosså, S. D., Fodstad, Ø., Stenwig, A.-E., … 
Lothe, R. A. (2002). Frequent promoter hypermethylation of the O 6 -Methylguanine-
DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene, 21(57), 8878–
8884. https://doi.org/10.1038/sj.onc.1205978 
Song, T., Xia, W., Shao, N., Zhang, X., Wang, C., Wu, Y., … Li, H. (2010). Differential 
miRNA expression profiles in bladder urothelial carcinomas. Asian Pacific Journal of 
Cancer Prevention. 
Srivastava, N., Manvati, S., Srivastava, A., Pal, R., Kalaiarasan, P., Chattopadhyay, S., … 
Bamezai, R. N. (2011). miR-24-2 controls H2AFX expression regardless of gene copy 
number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a 
potential for therapeutic intervention. Breast Cancer Research, 13(2), R39. 
https://doi.org/10.1186/bcr2861 
Stang, A., Trabert, B., Wentzensen, N., Cook, M. B., Rusner, C., Oosterhuis, J. W., & 
McGlynn, K. A. (2012). Gonadal and extragonadal germ cell tumours in the United States, 
1973-2007. International Journal of Andrology, 35(4), 616–625. 
https://doi.org/10.1111/j.1365-2605.2011.01245.x 
Stewart, M. D., Li, J., & Wong, J. (2005). Relationship between Histone H3 Lysine 9 
Methylation, Transcription Repression, and Heterochromatin Protein 1 Recruitment. 
Molecular and Cellular Biology, 25(7), 2525–2538. 
 
https://doi.org/10.1128/MCB.25.7.2525-2538.2005 
Stresemann, C., & Lyko, F. (2008). Modes of action of the DNA methyltransferase inhibitors 
azacytidine and decitabine. International Journal of Cancer, 123(1), 8–13. 
https://doi.org/10.1002/ijc.23607 
Su, Z., Yang, Z., Xu, Y., Chen, Y., Yu, Q., Su, Z., … Yu, Q. (2015). MicroRNAs in apoptosis, 
autophagy and necroptosis. Oncotarget, 6(11), 8474–8490. 
https://doi.org/10.18632/oncotarget.3523 
Sui, M., Jiao, A., Zhai, H., Wang, Y., Wang, Y., Sun, D., & Li, P. (2017). Upregulation of 
miR-125b is associated with poor prognosis and trastuzumab resistance in HER2-positive 
gastric cancer. Experimental and Therapeutic Medicine, 14(1), 657–663. 
https://doi.org/10.3892/etm.2017.4548 
Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., … Zheng, X. (2008). Downregulation of 
CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Letters, 582(10), 1564–
1568. https://doi.org/10.1016/j.febslet.2008.03.057 
Suzuki, H., Maruyama, R., Yamamoto, E., & Kai, M. (2012). DNA methylation and microRNA 
dysregulation in cancer. Molecular Oncology, 6(6), 567–578. 
https://doi.org/10.1016/j.molonc.2012.07.007 
Suzuki, S., Murakami, Y., & Takahata, S. (2017). H3K36 methylation state and associated 
silencing mechanisms. Transcription, 8(1), 26–31. 
https://doi.org/10.1080/21541264.2016.1246076 
Tagawa, H., & Seto, M. (2005). A microRNA cluster as a target of genomic amplification in 
malignant lymphoma. Leukemia, 19(11), 2013–2016. 
https://doi.org/10.1038/sj.leu.2403942 
Takahashi, R.-U., Miyazaki, H., & Ochiya, T. (2014). The role of microRNAs in the regulation 
of cancer stem cells. Frontiers in Genetics, 4, 295. 
https://doi.org/10.3389/fgene.2013.00295 
Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, H., Endoh, H., … Takahashi, 
T. (2004). Reduced Expression of the  let-7  MicroRNAs in Human Lung Cancers in 
Association with Shortened Postoperative Survival. Cancer Research, 64(11), 3753–
3756. https://doi.org/10.1158/0008-5472.CAN-04-0637 
Takeshige, K., Baba, M., Tsuboi, S., Noda, T., & Ohsumi, Y. (n.d.). Autophagy in Yeast 
Demonstrated with Proteinase-deficient Mutants and Conditions for its Induction. 
https://doi.org/10.1083/jcb.119.2.301 
Takeshita, F., Patrawala, L., Osaki, M., Takahashi, R., Yamamoto, Y., Kosaka, N., … Ochiya, 
T. (2010). Systemic Delivery of Synthetic MicroRNA-16 Inhibits the Growth of 
 
Metastatic Prostate Tumors via Downregulation of Multiple Cell-cycle Genes. Molecular 
Therapy, 18(1), 181–187. https://doi.org/10.1038/MT.2009.207 
Tamaru, H., & Selker, E. U. (2001). A histone H3 methyltransferase controls DNA methylation 
in Neurospora crassa. Nature. https://doi.org/10.1038/35104508 
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017). GEPIA: a web server for cancer 
and normal gene expression profiling and interactive analyses. Nucleic Acids Research, 
45(W1), W98–W102. https://doi.org/10.1093/nar/gkx247 
Tassano, E., Acquila, M., Tavella, E., Micalizzi, C., Panarello, C., & Morerio, C. (2010). 
MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in 
childhood B-Cell precursor acute lymphoblastic leukemia. Genes, Chromosomes and 
Cancer, 49(8), 682–687. https://doi.org/10.1002/gcc.20776 
Tay, Y., Zhang, J., Thomson, A. M., Lim, B., & Rigoutsos, I. (2008). MicroRNAs to Nanog, 
Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature, 
455(7216), 1124–1128. https://doi.org/10.1038/nature07299 
Teilum, G. (1965). Classification of endodermal sinus tumour (mesoblatoma vitellinum) and 
so-called &quot;embryonal carcinoma&quot; of the ovary. Acta Pathologica et 
Microbiologica Scandinavica, 64(4), 407–429. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/5318716 
Terashima, K., Yu, A., Chow, W.-Y. T., Hsu, W. J., Chen, P., Wong, S., … Lau, C. C. (2014a). 
Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in 
intracranial germ cell tumors. Pediatric Blood & Cancer, 61(4), 593–600. 
https://doi.org/10.1002/pbc.24833 
Terashima, K., Yu, A., Chow, W.-Y. T., Hsu, W. J., Chen, P., Wong, S., … Lau, C. C. (2014b). 
Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in 
intracranial germ cell tumors. Pediatric Blood & Cancer, 61(4), 593–600. 
https://doi.org/10.1002/pbc.24833 
Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., … Stallings, 
R. L. (2012). Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of 
MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles. PLoS ONE, 
7(5), e38129. https://doi.org/10.1371/journal.pone.0038129 
Torres, A. G., Fabani, M. M., Vigorito, E., Williams, D., Al-Obaidi, N., Wojciechowski, F., … 
Gait, M. J. (2012). Chemical structure requirements and cellular targeting of microRNA-
122 by peptide nucleic acids anti-miRs. Nucleic Acids Res, 40(5), 2152–2167. 
https://doi.org/10.1093/nar/gkr885 
Toyota, M., Suzuki, H., Sasaki, Y., Maruyama, R., Imai, K., Shinomura, Y., & Tokino, T. 
(2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is 
 
associated with CpG island methylation in colorectal cancer. Cancer Research, 68(11), 
4123–4132. https://doi.org/10.1158/0008-5472.CAN-08-0325 
Trama, A., & Berrino, F. (2017). The Epidemiology of Malignant Germ Cell Tumors: The 
EUROCARE Study. Pathology and Biology of Human Germ Cell Tumors. 
https://doi.org/10.1007/978-3-662-53775-6_2 
Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., … Slack, F. J. 
(2010). Regression of murine lung tumors by the let-7 microRNA. Oncogene, 29(11), 
1580–1587. https://doi.org/10.1038/onc.2009.445 
Travis, L. B., Fosså, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., … 
Gilbert, E. S. (2005). Second Cancers Among 40 576 Testicular Cancer Patients: Focus 
on Long-term Survivors. JNCI: Journal of the National Cancer Institute, 97(18), 1354–
1365. https://doi.org/10.1093/jnci/dji278 
Tyson, J. J., & Novak, B. (2014). Control of cell growth, division and death: information 
processing in living cells. Interface Focus, 4(3), 20130070. 
https://doi.org/10.1098/rsfs.2013.0070 
Ulbright, T. M. (2005). Germ cell tumors of the gonads: a selective review emphasizing 
problems in differential diagnosis, newly appreciated, and controversial issues. Modern 
Pathology, 18(S2), S61–S79. https://doi.org/10.1038/modpathol.3800310 
Vaksman, O., Hetland, T. E., Trope’, C. G., Reich, R., & Davidson, B. (2012). Argonaute, 
Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. 
Human Pathology, 43(11), 2062–2069. 
https://doi.org/10.1016/J.HUMPATH.2012.02.016 
Van Der Ree, M., de Vree, M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., … 
Reesink, H. (2015). LO7: A single subcutaneous dose of 2mg/kg or 4mg/kg of rg-101, a 
galnac-conjugated oligonucleotide with antagonist activity against mir-122, results in 
significant viral load reductions in chronic hepatitis C patients. Journal of Hepatology 
(Vol. 62). https://doi.org/10.1016/S0168-8278(15)30153-7 
van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, 
H. L., … Reesink, H. W. (2016). Miravirsen dosing in chronic hepatitis C patients results 
in decreased microRNA-122 levels without affecting other microRNAs in plasma. 
Alimentary Pharmacology & Therapeutics, 43(1), 102–113. 
https://doi.org/10.1111/apt.13432 
van der Zwan, Y. G., Rijlaarsdam, M. A., Rossello, F. J., Notini, A. J., de Boer, S., Watkins, 
D. N., … Looijenga, L. H. J. (2014). Seminoma and embryonal carcinoma footprints 
identified by analysis of integrated genome-wide epigenetic and expression profiles of 
germ cell cancer cell lines. PloS One, 9(6), e98330. 
 
https://doi.org/10.1371/journal.pone.0098330 
van Dongen, S., Abreu-Goodger, C., & Enright, A. J. (2008a). Detecting microRNA binding 
and siRNA off-target effects from expression data. Nature Methods, 5(12), 1023–1025. 
https://doi.org/10.1038/nmeth.1267 
van Dongen, S., Abreu-Goodger, C., & Enright, A. J. (2008b). Detecting microRNA binding 
and siRNA off-target effects from expression data. Nature Methods, 5(12), 1023–1025. 
https://doi.org/10.1038/nmeth.1267 
van Dongen, S., Abreu-Goodger, C., & Enright, A. J. (2008c). Detecting microRNA binding 
and siRNA off-target effects from expression data. Nature Methods, 5(12), 1023–1025. 
https://doi.org/10.1038/nmeth.1267 
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., … Reid, G. 
(2017a). Safety and activity of microRNA-loaded minicells in patients with recurrent 
malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation 
study. The Lancet Oncology, 18(10), 1386–1396. https://doi.org/10.1016/S1470-
2045(17)30621-6 
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., … Reid, G. 
(2017b). Safety and activity of microRNA-loaded minicells in patients with recurrent 
malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation 
study. The Lancet Oncology, 18(10), 1386–1396. https://doi.org/10.1016/S1470-
2045(17)30621-6 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & 
Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR data by 
geometric averaging of multiple internal control genes. Genome Biology, 3(7), 
RESEARCH0034. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12184808 
Vazquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008). The genetics of the p53 pathway, 
apoptosis and cancer therapy. Nature Reviews Drug Discovery, 7(12), 979–987. 
https://doi.org/10.1038/nrd2656 
Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: a review of 
regulation, deregulation and therapeutic targets in cancer. Cell Proliferation, 36(3), 131–
149. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12814430 
Viswanathan, S. R., & Daley, G. Q. (2010a). Lin28: A MicroRNA Regulator with a Macro 
Role. Cell, 140(4), 445–449. https://doi.org/10.1016/j.cell.2010.02.007 
Viswanathan, S. R., & Daley, G. Q. (2010b). Lin28: A MicroRNA Regulator with a Macro 
Role. Cell, 140(4), 445–449. https://doi.org/10.1016/j.cell.2010.02.007 
Viswanathan, S. R., Daley, G. Q., & Gregory, R. I. (2008). Selective blockade of microRNA 
 
processing by Lin28. Science (New York, N.Y.), 320(5872), 97–100. 
https://doi.org/10.1126/science.1154040 
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., … Croce, C. M. 
(2006). A microRNA expression signature of human solid tumors defines cancer gene 
targets. Proceedings of the National Academy of Sciences of the United States of America, 
103(7), 2257–2261. https://doi.org/10.1073/pnas.0510565103 
Volinia, S., Galasso, M., Costinean, S., Tagliavini, L., Gamberoni, G., Drusco, A., … Croce, 
C. M. (2010). Reprogramming of miRNA networks in cancer and leukemia. Genome 
Research, 20(5), 589–599. https://doi.org/10.1101/gr.098046.109 
Vrba, L., Muñoz-Rodríguez, J. L., Stampfer, M. R., & Futscher, B. W. (2013). miRNA Gene 
Promoters Are Frequent Targets of Aberrant DNA Methylation in Human Breast Cancer. 
PLoS ONE, 8(1), e54398. https://doi.org/10.1371/journal.pone.0054398 
Wahle, E., & Winkler, G. S. (2013). RNA decay machines: Deadenylation by the Ccr4–Not 
and Pan2–Pan3 complexes. Biochimica et Biophysica Acta (BBA) - Gene Regulatory 
Mechanisms, 1829(6–7), 561–570. https://doi.org/10.1016/J.BBAGRM.2013.01.003 
Walz, A. L., Ooms, A., Gadd, S., Gerhard, D. S., Smith, M. A., Guidry Auvil, J. M., … 
Perlman, E. J. (2015). Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations 
in Favorable Histology Wilms Tumors. Cancer Cell, 27(2), 286–297. 
https://doi.org/10.1016/j.ccell.2015.01.003 
Wang, B., Hsu, S., Wang, X., Kutay, H., Bid, H. K., Yu, J., … Ghoshal, K. (2014). Reciprocal 
regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and 
transcription factor dimerization partner 2. Hepatology, 59(2), 555–566. 
https://doi.org/10.1002/hep.26712 
Wang, F., Fu, X.-D., Zhou, Y., & Zhang, Y. (2009). Down-regulation of the cyclin E1 
oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. 
BMB Reports, 42(11), 725–730. https://doi.org/10.5483/BMBRep.2009.42.11.725 
Wang, S., Wu, J., Ren, J., Vlantis, A. C., Li, M., Liu, S. Y. W., … Chen, G. G. (2018). 
MicroRNA-125b Interacts with Foxp3 to Induce Autophagy in Thyroid Cancer. 
Molecular Therapy. https://doi.org/10.1016/j.ymthe.2018.06.015 
Warnefors, M., Liechti, A., Halbert, J., Valloton, D., & Kaessmann, H. (2014). Conserved 
microRNA editing in mammalian evolution, development and disease. Genome Biology, 
15(6), R83. https://doi.org/10.1186/gb-2014-15-6-r83 
Watanabe, K., Emoto, N., Hamano, E., Sunohara, M., Kawakami, M., Kage, H., … Takai, D. 
(2012). Genome structure-based screening identified epigenetically silenced microRNA 
associated with invasiveness in non-small-cell lung cancer. International Journal of 
Cancer, 130(11), 2580–2590. https://doi.org/10.1002/ijc.26254 
 
Weaver, K. E., Forsythe, L. P., Reeve, B. B., Alfano, C. M., Rodriguez, J. L., Sabatino, S. A., 
… Rowland, J. H. (2012). Mental and Physical Health-Related Quality of Life among 
U.S. Cancer Survivors: Population Estimates from the 2010 National Health Interview 
Survey. Cancer Epidemiology Biomarkers & Prevention, 21(11), 2108–2117. 
https://doi.org/10.1158/1055-9965.EPI-12-0740 
Weber, B., Stresemann, C., Brueckner, B., & Lyko, F. (2007). Methylation of Human 
MicroRNA Genes in Normal and Neoplastic Cells. Cell Cycle, 6(9), 1001–1005. 
https://doi.org/10.4161/cc.6.9.4209 
Wermann, H., Stoop, H., Gillis, A. J., Honecker, F., van Gurp, R. J., Ammerpohl, O., … 
Looijenga, L. H. (2010). Global DNA methylation in fetal human germ cells and germ 
cell tumours: association with differentiation and cisplatin resistance. The Journal of 
Pathology, 221(4), n/a-n/a. https://doi.org/10.1002/path.2725 
Westholm, J. O., & Lai, E. C. (2011). Mirtrons: microRNA biogenesis via splicing. Biochimie, 
93(11), 1897–1904. https://doi.org/10.1016/j.biochi.2011.06.017 
Wetherell, D., Weerakoon, M., Williams, D., Koonj Beharry, B., Sliwinski, A., Ow, D., … 
Lawrentschuk, N. (2014). Mature and Immature Teratoma: A Review of Pathological 
Characteristics and Treatment Options. Med Surg Urol, 3, 124. 
https://doi.org/10.4172/2168-9857.1000124 
Wiederschain, D., Wee, S., Chen, L., Loo, A., Yang, G., Huang, A., … Benson, J. D. (2009). 
Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle. 
https://doi.org/10.4161/cc.8.3.7701 
Williamson, S. R., Delahunt, B., Magi-Galluzzi, C., Algaba, F., Egevad, L., Ulbright, T. M., 
… Members of the ISUP Testicular Tumour Panel. (2017). The World Health 
Organization 2016 classification of testicular germ cell tumours: a review and update from 
the International Society of Urological Pathology Testis Consultation Panel. 
Histopathology, 70(3), 335–346. https://doi.org/10.1111/his.13102 
Winans, S., Flynn, A., Malhotra, S., Balagopal, V., & Beemon, K. L. (2017). Integration of 
ALV into CTDSPL and CTDSPL2 genes in B-cell lymphomas promotes cell 
immortalization, migration and survival. Oncotarget. 
https://doi.org/10.18632/oncotarget.19328 
Wittwer, C. T., Reed, G. H., Gundry, C. N., Vandersteen, J. G., & Pryor, R. J. (2003). High-
resolution genotyping by amplicon melting analysis using LCGreen. Clinical Chemistry, 
49(6 Pt 1), 853–860. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12765979 
Wojdacz, T. K., & Dobrovic, A. (2007). Methylation-sensitive high resolution melting (MS-
HRM): a new approach for sensitive and high-throughput assessment of methylation. 
Nucleic Acids Research, 35(6), e41–e41. https://doi.org/10.1093/nar/gkm013 
 
Wu, H., Wang, F., Hu, S., Yin, C., Li, X., Zhao, S., … Yan, X. (2012). MiR-20a and miR-106b 
negatively regulate autophagy induced by leucine deprivation via suppression of ULK1 
expression in C2C12 myoblasts. Cellular Signalling, 24(11), 2179–2186. 
https://doi.org/10.1016/j.cellsig.2012.07.001 
Wu, K., He, J., Pu, W., & Peng, Y. (2018). The Role of Exportin-5 in MicroRNA Biogenesis 
and Cancer. Genomics, Proteomics & Bioinformatics, 16(2), 120–126. 
https://doi.org/10.1016/j.gpb.2017.09.004 
Wu, N., Xiao, L., Zhao, X., Zhao, J., Wang, J., Wang, F., … Lin, X. (2012). miR-125b regulates 
the proliferation of glioblastoma stem cells by targeting E2F2. FEBS Letters, 586(21), 
3831–3839. https://doi.org/10.1016/J.FEBSLET.2012.08.023 
Xu, T., Zhu, Y., Xiong, Y., Ge, Y.-Y., Yun, J.-P., & Zhuang, S.-M. (2009). MicroRNA-195 
suppresses tumorigenicity and regulates G 1 /S transition of human hepatocellular 
carcinoma cells. Hepatology, 50(1), 113–121. https://doi.org/10.1002/hep.22919 
Yamakuchi, M., & Lowenstein, C. J. (2009). MiR-34, SIRT1, and p53: The feedback loop. 
Cell Cycle, 8(5), 712–715. https://doi.org/10.4161/cc.8.5.7753 
Yang, G., Gong, Y., Wang, Q., Wang, Y., & Zhang, X. (2015). The role of miR-100-mediated 
Notch pathway in apoptosis of gastric tumor cells. Cellular Signalling, 27(6), 1087–1101. 
https://doi.org/10.1016/j.cellsig.2015.02.013 
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003). Exportin-5 mediates the nuclear export 
of pre-microRNAs and short hairpin RNAs. Genes & Development, 17(24), 3011–3016. 
https://doi.org/10.1101/gad.1158803 
Ying, Y., Liu, X.-M., Marble, A., Lawson, K. A., & Zhao, G.-Q. (2000). Requirement of 
Bmp8b for the Generation of Primordial Germ Cells in the Mouse. Molecular 
Endocrinology, 14(7), 1053–1063. https://doi.org/10.1210/mend.14.7.0479 
Yu, X., Shi, W., Zhang, Y., Wang, X., Sun, S., Song, Z., … Qu, X. (2017). CXCL12/CXCR4 
axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through 
enhancing autophagy in colorectal cancer. Scientific Reports, 7(1), 42226. 
https://doi.org/10.1038/srep42226 
Yuan, M., Da Silva, A. C. A. L., Arnold, A., Okeke, L., Ames, H., Correa-Cerro, L. S., … 
Rodriguez, F. J. (2018). MicroRNA (miR) 125b regulates cell growth and invasion in 
pediatric low grade glioma. Scientific Reports, 8(1), 12506. 
https://doi.org/10.1038/s41598-018-30942-4 
Yuan, X., Liu, C., Yang, P., He, S., Liao, Q., Kang, S., & Zhao, Y. (2009). Clustered 
microRNAs’ coordination in regulating protein-protein interaction network. BMC 
Systems Biology. https://doi.org/10.1186/1752-0509-3-65 
 
Zhang, H., Li, Y., Huang, Q., Ren, X., Hu, H., Sheng, H., & Lai, M. (2011). MiR-148a 
promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death & Differentiation, 
18(11), 1702–1710. https://doi.org/10.1038/cdd.2011.28 
Zhang, J., Zhang, H., Yao, Y.-F., Zhong, S.-L., Zhao, J. H., & Tang, J. H. (2015). β-Elemene 
Reverses Chemoresistance of Breast Cancer Cells by Reducing Resistance Transmission 
via Exosomes. Cellular Physiology and Biochemistry : International Journal of 
Experimental Cellular Physiology, Biochemistry, and Pharmacology, 36(6), 2274–2286. 
https://doi.org/10.1159/000430191 
Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., … Coukos, G. 
(2006a). microRNAs exhibit high frequency genomic alterations in human cancer. 
Proceedings of the National Academy of Sciences, 103(24), 9136–9141. 
https://doi.org/10.1073/pnas.0508889103 
Zhang, L., Huang, J., Yang, N., Greshock, J., Megraw, M. S., Giannakakis, A., … Coukos, G. 
(2006b). microRNAs exhibit high frequency genomic alterations in human cancer. 
Proceedings of the National Academy of Sciences, 103(24), 9136–9141. 
https://doi.org/10.1073/pnas.0508889103 
Zhang, Y., Roccaro, A. M., Rombaoa, C., Flores, L., Obad, S., Fernandes, S. M., … Ghobrial, 
I. M. (2012). LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. 
Blood, 120(8), 1678–1686. https://doi.org/10.1182/blood-2012-02-410647 
Zhang, Y., Yan, L.-X., Wu, Q.-N., Du, Z.-M., Chen, J., Liao, D.-Z., … Shao, J.-Y. (2011a). 
miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 
Proto-oncogene in Human Invasive Breast Cancer. Cancer Research, 71(10), 3552–3562. 
https://doi.org/10.1158/0008-5472.CAN-10-2435 
Zhang, Y., Yan, L.-X., Wu, Q.-N., Du, Z.-M., Chen, J., Liao, D.-Z., … Shao, J.-Y. (2011b). 
miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 
Proto-oncogene in Human Invasive Breast Cancer. Cancer Research, 71(10), 3552–3562. 
https://doi.org/10.1158/0008-5472.CAN-10-2435 
Zhao, T., Liu, Y., Jiang, H., Zhang, H., & Lu, Y. (2016). Management of bilateral malignant 
ovarian germ cell tumors: Experience of a single institute. Molecular and Clinical 
Oncology, 5(2), 383–387. https://doi.org/10.3892/mco.2016.915 
Zheng, Y. S., Zhang, H., Zhang, X. J., Feng, D. D., Luo, X. Q., Zeng, C. W., … Chen, Y. Q. 
(2012). MiR-100 regulates cell differentiation and survival by targeting RBSP3, a 
phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene. 
https://doi.org/10.1038/onc.2011.208 
Zhou, H., & Rigoutsos, I. (2014). MiR-103a-3p targets the 5ʹ′ UTR of GPRC5A in pancreatic 
cells. RNA, 20(9), 1431–1439. https://doi.org/10.1261/rna.045757.114 
 
Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., Xi, Y., … Tan, M. (2010). MicroRNA-125b 
Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-
apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression. Journal of Biological Chemistry, 
285(28), 21496–21507. https://doi.org/10.1074/jbc.M109.083337 
 
  
  
 
  
2  
 
Some more appendix 
  
Error! No text of specified style in document. Error! No text of specified style 
in document. 
3 
 
And even more 
 
  
 
And some more text on a new page 
  
 
And even more text 
 
 
 
 
 

 
 
Error! No text of specified style in document. Error! No text of specified style 
in document. 
11 
 
References

  
  
 
  
2  
 
Some more appendix 
  
Error! No text of specified style in document. Error! No text of specified style 
in document. 
3 
 
And even more 

 
  
2  
 
And some more text on a new page 
  
Error! No text of specified style in document. Error! No text of specified style 
in document. 
3 
 
And even more text 
